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Abstract  
Background  
Invasive fungal infections (IFI) are opportunistic infections caused by yeast or 
filamentous fungi, typically presenting in immunocompromised patients (haemato-
oncology, intensive care, HIV, solid organ transplant settings). This research aims to 
comprehensively evaluate molecular diagnostics to address the current shortfall in IFI 
diagnosis and, where appropriate, embed molecular methods into routine clinical 
service.  
Methods  
Molecular methodologies, including PCR, MALDI-TOF MS and PNA-FISH, were 
evaluated on clinical sample cohorts from the Royal Free Hospital NHS Foundation 
Trust. Each method was critically appraised for: statistical performance, clinical utility 
and suitability for service adoption.  
Results  
MALDI-TOF MS improved yeast agar culture identification, demonstrating 97.4% 
(185/190) concordance with ITS rRNA sequencing, and time to identification was 
significantly reduced (p<0.01, 24 hrs. v’s 15 mins). Lower identification rates of 66% 
(33/50) were observed when applying MALDI-TOF MS directly to blood culture for 
yeast identification. In contrast PNA-FISH identified 98.5% (93/96, CI: 91.2, 98.9) of 
yeasts direct from blood culture within 30 minutes. Using PCP PCR a 60% (3/5) 
increase in the detection of PCP from BAL in non-HIV patients was demonstrated 
compared with GMS staining. Overall sensitivity was 100% (95% CI: 56.6, 100) and 
specificity was 97.9% (95% CI: 88.9, 99.6) for the diagnosis of PCP. Aspergillus PCR 
demonstrated a sensitivity of 100% (95% CI: 34.2, 100) and specificity of 93.8% (95% 
CI: 86.4, 97.3) for the diagnosis of IA but a low PPV of 28.6% (95% CI: 8.2, 64.1).  
Conclusions  
Molecular diagnostic assays can improve the diagnosis of IFI through improved 
accuracy of identification and increased detection of fungal pathogens from specimens. 
Results must be interpreted alongside clinical presentation, as false positivity occurs 
utilising highly sensitive molecular assays. Dual biomarker strategies may improve the 
performance of molecular diagnostics but the associated impact on healthcare 
economics must also be considered 
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**p<0.01, *p=0.02, NS = no significant difference. Red lines indicate 
thresholds of >1.7 for genus identification and >2.0 for species 
identification. 
4.3 a) Sections of MALDI-TOF MS spectra at acquisition for a) Candida 
albicans blood culture analysis with a log similarity score <1.6 indicating 
‘no identification’. 
4.3 b) C. albicans blood culture with a successful identification with a log 
similarity score >1.8. 
4.3 c) Candida albicans isolate identified by MALDI-TOF log similarity score 
2.312. 
4.3 d) Spectrum obtained from a negative blood culture by MALDI-TOF MS. 
The dotted line on both spectra indicates 600 absolute intensity. 
Chapter 5 Evaluation of MALDI TOF MS compared with conventional 
microscopic identification for the identification of filamentous 
mould isolates from clinical samples 
5.1 Example of an agarose gel for ITS rRNA amplicons. 
5.2 Varying inocula (light, moderate, and heavy) for Aspergillus fumigatus 
fungal ball preparation for MALDI-TOF MS. 
5.3 Box plot of log similarity scores obtained for four isolates (triplicate 
analyses) by MALDI-TOF MS using the pellet processing methods; a) 
drying in an incubator b) drying in a dry hot block c) no drying.  
Wilcoxon Signed Rank was used to calculate significance between the 
three methods. 
5.4 Histogram displaying the distribution of log similarity scores obtained 
for 147 isolates processed by MALDI-TOF MS. Grey bars indicate 
correct species, white indicates the correct genus and black indicates 
incorrect identification. Dashed lines indicate manufacturers log 
similarity score thresholds for genus and species identifications. 
5.5 Microscopic features for a) Scytalidium hyalinum and  
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b) Thanatephorus cucumeris demonstrating hyaline hyphae with 
arthroconidia. 
Chapter 6 Improving the diagnosis of Candidemia utilising microscopic 
techniques for the rapid identification of yeasts direct from 
positive blood cultures: evaluation of Gram’s stain analysis and 
PNA FISH  
6.1  
 
Example of an identification key used for Gram’s stain analysis of 
Candida albicans from blood cultures. 
6.2 Histogram detailing the proportion of clinical decisions that may have 
been impacted by the PNA-FISH result if it had been available to 
clinicians at the time of diagnosis. 
Chapter 7 Evaluation of a second generation PNA-FISH assay, QuickFISH™, 
for the rapid identification of yeasts direct from positive blood 
cultures 
7.1 Comparison of PNA-FISH and QuickFISH processing methods. 
7.2 QuickFISH slide demonstrating sample preparation area, negative and 
positive control areas on the pre-prepared slide. 
7.3 Fluorescence signal observed when analysing QuickFISH Candida 
slides with C. albicans (green), C. parapsilosis (yellow) and C. glabrata 
(red) demonstrated. A mixed culture representing a typical image of the 
positive control is also shown.  
7.4 Histogram displaying the frequency of yeast species isolated from 38 
blood cultures at the Royal Free Hospital microbiology laboratory over 
a twelve-month period from 1st January – 31st December 2013. 
Chapter 8 Evaluating the performance of P. jirovecii PCR alongside 
automated DNA extraction; a comparison of the Diasorin IXT and 
the BD MAX. 
8.1 Schematic of magnetic bead based DNA extraction. 
8.2 Linear regression of CT values for plasmid dilutions processed through 
the MycAssay Pneumocystis PCR. 
8.3 CT values obtained across the three methods processing DNA extracts 
from patients with proven PCP. 
8.4 Comparison of CT values obtained from MycAssay and Bristol 23S 
PCR from DNA extracts. 
8.5 a) Design of the smart cycler unit demonstrating the position of the 
thermal heating block. 
8.5 b) A BD MAX cartridge demonstrating the cylindrical reaction chambers 
which hold the 4μL reaction. 
8.6 Pipetting workflow for the BD MAX PCP PCR and IXT/Myconostica. 
Chapter 9 Evaluation of PCR for screening patients with hematological 
malignancy for the detection of Invasive Aspergillosis (IA) 
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9.1 Schematic of PCR-SERS amplification and detection. 
9.2 CT values for plasmid dilutions processed through the 28Asp PCR, with 
median values and IQR indicated. 
9.3 Demonstrating a standard curve of target plasmid dilutions processed 
through the 28Asp PCR for which the high, medium and low genomic 
DNA dilutions were measured against to estimate the equivalent 
plasmid copies.  
9.4 CT values for the A. fumigatus genomic DNA dilutions tested neat 
through both PCR assays and extracted from 1mL and 550µL of serum. 
9.5 ROC curve analysis for 28Asp PCR for A) POS PCR (using an average 
CT) and probable disease, B) POS (using an average CT) / PNC PCR 
with probable disease C) POS PCR (using an average CT) and 
probable/possible disease and D) POS (using an average CT) /PNC 
PCR and probable/possible disease. 
Chapter 10 Conclusion and Future Developments 
10.1 Correlation of (1-3)-β-D-glucan (pg/mL) and PCP qPCR (copies per μL) 
for the diagnosis of PCP in cases and controls. 
10.2 Routine Diagnostic Service in the new HSL microbiology laboratory – 
2017. 
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1. Chapter 1 Introduction 
1.1 Global incidence and mortality of invasive fungal disease  
Invasive fungal infection (IFI) is a collective term used to describe a range of 
opportunistic infections typically presenting in critically ill, immunocompromised 
patients (Enoch et al., 2017). The etiological agents may be either yeast or filamentous 
fungi. Patients at risk of IFI include those within haemato-oncology, intensive care, HIV, 
solid organ transplant settings and also patients who have undergone invasive surgery 
(Denning, 2005; Cooley et al., 2014; Shao et al., 2014; Alvaro-meca et al., 2015; 
Harrison et al., 2015; Enoch et al., 2017). However, IFI is not exclusive to the 
respective patient groups and can present in many patients with immunosuppression. 
The definition of IFI is described as the isolation of a yeast or mould from sterile sites or 
deep tissues by culture and or the detection of fungal infection through 
histopathological examination of clinical specimens (Ascioglu et al., 2002; De Pauw et 
al., 2008)  
 
The global burden of IFI is estimated to be in excess of 2 million cases per year 
globally (Brown et al., 2012). In figure 1.1 the most frequently occurring fungal diseases 
are detailed with their estimated annual incidence and associated mortality rates 
(adapted from Brown et al., 2012).  
 
 
Figure 1.1 Histogram detailing the estimated global incidences of Invasive Fungal Infections per 
annum with associated mortality rates shown as percentage values (Brown et al., 2012).  
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According to estimated data, the top four invasive fungal infections account for 96.4% 
of the total global burden and include; 1) cryptococcosis, accounting for approximately 
one million cases of life threatening infections per year (Park et al., 2009; Maziarz and 
Perfect, 2016), 2) pneumocystosis accounting for 400,000 life threatening infections 
per year  3) candidiasis accounting for 400,000 life-threatening infections per year and 
4) aspergillosis accounting for 200,000 life-threatening infections per year (Brown et al., 
2012). All IFIs are associated with significant morbidity and mortality rates ranging from 
20-95% (Pfaller and Diekema, 2007; Baddley et al., 2010; Brown et al., 2012; 
Armstrong-James, Meintjes and Brown, 2014; Bitar, Lortholary, Strat, et al., 2014; 
Kullberg and Arendrup, 2015). It is estimated that 1.5 million people die each year from 
IFI, with the top ten IFI accounting for more deaths per annum than TB or Malaria 
(Brown et al., 2012). 
 
The global incidence of IFI has increased over the last 30 years, as a consequence of 
the Human Immunodeficiency Virus (HIV) epidemic (Morse, 1995; Armstrong-James, 
Meintjes and Brown, 2014). The progression of HIV infected patients to development of 
acquired immunodeficiency syndrome (AIDS) allowed invasive fungal infections, 
including cryptococcosis and pneumocystosis, to present as opportunistic infections. 
The respective IFIs are recognised as AIDS defining diseases (Limper et al., 2017). In 
recent years the long-term prognosis of HIV infection has dramatically improved with 
the development of highly active antiretroviral therapy (HAART) (Rouet et al., 2006; 
Maggiolo and Leone, 2010; López-Sánchez et al., 2015). In developed countries HIV is 
no longer a terminal disease but rather a chronic condition controlled with HAART and 
routine screening of CD4 T-cell counts and viral loads. In developing countries where 
HAART is not readily available the incidence of cryptococcosis remains high, with sub-
Saharan Africa estimated to be carrying 75% of the global burden of cryptococcal 
meningitis (Ortblad, Lozano and Murray, 2013). In contrast, as HAART is the standard 
of care for HIV infected patients in developed countries it has been the catalyst for the 
dramatic decrease in the incidence of cryptococcosis. In the UK from 1996 to 2007, the 
incidence per 1000 persons in the UK fell from 3.0 to 0.2 (Garvey, 2011). In the UK 
estimates are now as low as <100 cases of cryptococcal meningitis diagnosed per 
annum (Pegorie, Denning and Welfare, 2017).  
However, not all IFI have shown the same trend in decreasing incidence in the UK, this 
is due to non-HIV associated factors driving their sustained, if not increasing incidence 
(Warnock, 2007; Cuenca-Estrella et al., 2008; Erjavec, Kluin-Nelemans and Verweij, 
2009; Meis and Chakrabarti, 2009; Bajwa and Kulshrestha, 2013). By considering the 
patients who develop IFI it becomes clear that a key factor is the advancement in 
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medical practices including in-hospital and outpatient management of severe diseases 
such as organ failure, cancers and leukaemia. The resultant immune deficient host 
environment arising from aggressive immunosuppressive pharmacological strategies 
used in the treatment of severe disease is a major contributing factor to the proliferation 
of IFI (Warnock, 2007). 
In the last twenty years advances in the treatment of haematological malignancies 
have included increasingly intensive chemotherapy regimens. As a consequence 
patients experience profound levels of immunosuppression for longer periods 
(Warnock, 2007). Advances in therapeutic techniques such as extracorporeal 
membrane oxygenation (ECMO), gastrointestinal surgery and solid organ 
transplantation have also improved the chance of survival for patients with life-
threatening diseases but often patients require care in an the intensive care setting, 
and are by proxy susceptible to IFI (Gautam, 2006; Brown, Denning and Levitz, 2012; 
Gardner et al., 2012). The use of corticosteroids in solid organ transplant patients is 
also associated with an increased risk of IFI (Rostaing and Malvezzi, 2016). The 
National Health Service (NHS) in the UK is a mature centrally managed health care 
system offering advance health care across the population; therefore IFI secondary to 
underlying diseases are expected to increase in incidence.  
 
1.2 Overview of Invasive fungal infections in the United Kingdom 
The incidence of IFI, other than cryptococcosis, in the UK is estimated to be much 
higher than 100 cases per annum. Invasive candidiasis (IC) was estimated at 4473 
cases in 2013, for invasive aspergillosis (IA) the burden was estimated to be 2912 per 
year and 587 cases of Pneumocystis infection were estimated to have been diagnosed 
(Pegorie, Denning and Welfare, 2017). Current trends from UK clinical surveillance 
data indicate that the incidence of IFI is increasing (Pegorie, Denning and Welfare, 
2017). However, there is a lack of robust multisite or national surveillance data to 
conclusively support this (Pegorie, Denning and Welfare, 2017). From voluntary 
reporting to Public Health England (PHE), the UK government body for monitoring 
national trends in infection, the reported rate of candidemia increased in the year 2015-
2016 from 2.7 per 100,000 to 3.1 per 100,000 population (PHE, 2016). Data published 
for 2016 shows a further increase to 3.5 per 100,000 population (PHE, 2017). The 
isolation of A. fumigatus and Fusarium sp from clinical specimens in the UK is detailed 
in figure 1.2. A marginal upward trend is described for both species from 2011-2015 but 
rates again remain low at 3 per 100,000 population for Aspergillus and 1.6 per 100,000 
for Fusarium sp (Public Health England, 2016) 
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Figure 1.2 Frequency of isolation of Aspergillus and Fusarium species in the UK from 2011-
2015. Data published by Public Health England.  
 
As the incidence of IFI is low in comparison to other infectious diseases the question 
posed is why there is a need to improve the diagnosis of IFI? In short, there are 
limitations in diagnostic testing for IFI and IFI are high mortality rates. This combination 
is in turn driving the overuse of antifungal drugs for the prophylaxis and treatment of 
IFI. The overuse of antifungal drugs in healthcare is additionally associated with a 
significant economic burden (Wilson et al., 1998, Desai, Cavanaugh and Guo, 2011). 
In 1998 Wilson et al reported the estimated total direct cost of systemic fungal infection 
in the USA to be $2.6 billion per annum and the average attributable cost per-patient 
was $31,200 (Wilson et al., 1998). A proportion of this cost is due to the overuse of 
antifungal therapies within the tertiary care setting. From September 2002 to 
September 2003 the annual hospital antifungal expenditure in the UK was £52.5M 
(‘Fungal Diseases in the UK’, 2006). Recent estimates in antifungal spend for the year 
2013 were £112M (PHE, 2015); more than doubling the amount of expenditure over a 
10-year period.  This trend is not unique to the UK health care system, with reports 
from the USA demonstrating a ten-fold increase in the utilisation of antifungal 
agents for IFI between 2001 and 2009 (Desai, Cavanaugh and Guo, 2011). The 
economic impact of fungal infection is high and measures to reduce the unnecessary 
use of antifungals is required, not only for expenditure management but also to 
preserve their efficacy  
1.3 Overview of Antifungal drugs 
Current therapeutic choices for invasive fungal disease are limited to four classes of 
antifungal agents (Denning and Hope, 2010; Campoy and Adrio, 2017). Table 1.1 
details the current armamentarium of antifungals and their cellular or molecular targets. 
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From the outset it is important to recognise that fungi are eukaryotes, with structural 
features including membrane bound organelles, a nucleus and they may be unicellular 
or multicellular in form (Vellai et al., 1999). Therefore, fungi are similar in structure to 
mammalian cells. The targets for antifungal agents are molecules that are similar in 
structure to those found within human cells. This makes the treatment of IFI 
challenging as antifungal therapies can be associated with host cellular toxicity (table 
1.1) (Denning and Hope, 2010). When choosing an antifungal regimen several factors 
require consideration. Antifungal agents, such as fluconazole have a narrow spectrum 
in their activity profile, whilst agents such as amphotericin B (Ambisome®) have a 
broader spectrum (Denning and Hope, 2010). If the causative fungus has not been 
identified this prohibits the use of narrow spectrum antifungal agents. Establishing both 
the source and site of infection is important as not all antifungals can be distributed to 
all sites within the body; more specifically the echinocandins are unable to penetrate 
the central nervous system (CNS), gastrointestinal (GI) and renal tract (table 1.1) 
(Denning and Hope, 2010; Campoy and Adrio, 2017). The toxicity profile of antifungal 
agents also requires consideration.  
Using liposomal amphotericin B (Ambisome®) in renal patients is challenging as this 
antifungal agent may contribute to additional renal damage. The drug ergosterol is 
similar in structure to cholesterol in mammalian cells (Laniado-Laborín and Cabrales-
Vargas, 2009). Amphotericin B (Ambisome®) can bind to cholesterol causing cellular 
damage (Milhaud et al., 2002). Using triazoles in HIV patients and patients receiving 
treatment for tuberculosis is also contraindicated due to the administration of drugs 
such as rifampicin which induce the cytochrome P450 pathway, significantly reducing 
the efficacy of triazoles (Brüggemann et al., 2009). 5-flucytosine is contraindicated in 
haematology patients due to a toxicity profile that includes bone marrow suppression 
(Navarro and Senior, 2006). In addition to chemical composition, the formulation of the 
antifungal also must be considered. Until 2014 posaconazole was only available in oral 
formulation therefore, could not be administered to patients unable to receive oral 
preparations (McKeage, 2015). Patients well enough to be treated as an outpatient 
may have to be admitted to hospital as often the only antifungal option is in an 
intravenous formulation (Brüggemann et al., 2009). Tailoring the correct antifungal for 
an infection in the right patient requires expertise. Clinical mycologists with such 
expertise are lacking in number within healthcare, therefore clinicians rely heavily on 
nationally steered published guidelines (often re-interpreted as local policy) to direct 
their choice of antifungal therapy. 
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Table 1.1 Antifungal drug classes for the treatment of invasive fungal disease, detailing mode of action, antifungal activity, toxicity, resistance 
mechanisms, formulations and penetration profile (adapted from Campoy and Kanafani 2017, Li et al., 2015). 
Drug class 
Mode of 
action 
Drug name Antifungal spectrum Toxicity Formulations Resistance Organ distribution 
Triazoles 
Inhibition of 
ergosterol 
synthesis, 
Cytochrome 
P450 
pathway 
Fluconazole 
Candida, Cryptococcus, 
dimorphic fungi 
Dose related: 
high levels 
associated 
with  
hepatotoxicity, 
renal toxicity, 
arrhythmia, 
and rash 
 
Oral and 
Intravenous 
 
Efflux pumps, 
several point 
mutations 
including: 
ERG11, 
cyp51A and 
cyp51B 
Good penetration 
including CNS 
Itraconazole Candida and Aspergillus 
Voriconazole Broad spectrum 
including yeasts, 
Aspergillus, Fusarium, 
Scedosporium,  
Mucorales 
Posaconazole 
Isavuconazole 
Polyenes 
Disruption of 
the fungal 
cell 
membrane  
Nystatin 
Candida, Cryptococcus, 
Aspergillus and 
Fusarium 
Not used 
systemically 
Topical 
Rare, ERG3 
defects 
Good penetration 
including CNS Liposomal 
Amphotericin B 
(Ambisome®) 
Broad spectrum 
including yeasts, 
Aspergillus, Fusarium, 
Scedosporium,  
Mucorales 
Kidneys, liver Intravenous 
Echinocandins 
Fungal cell 
wall 
synthesis  
(1-3)-β-D-
glucan 
Caspofungin 
Candida and 
Aspergillus 
None Intravenous 
Poorly 
understood - 
Mutations in 
Fks1 gene 
Does not penetrate 
GI tract, Renal and 
CSF. Good for 
biofilms 
Micafungin 
Anidulafungin 
5-flucytosine 
Inhibits 
nucleic acid 
synthesis 
5-flucytosine 
Candida and 
Cryptococcus  
Bone marrow 
suppression  
Intravenous 
Common in 
monotherapy, 
mutations in 
cysteine 
deaminase 
Good penetration 
including CNS 
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1.4 Guidelines for the definition, diagnosis and management of invasive 
fungal disease  
International guidelines provide the backbone for the clinical management of IFI. 
Evidence-based guidance defines criteria for diagnosing and treating patients 
suspected of having IFI. In the past decade four major groups (including two scientific 
societies) have published guidelines and criteria including: the European Society of 
Clinical Microbiology and Infectious Diseases (Ullmann et al., 2012; Cornely et al., 
2014) and the Infectious Diseases Society of America (IDSA) (Pappas et al., 2015; 
Patterson et al., 2016) the European Conference on Infection in Leukaemia (ECIL) 
(Tissot et al., 2016) and the European Organisation for the Treatment and Research of 
Cancer (De Pauw et al., 2008) Table 1.2 summarises, in brief, the grading used for 
recommendations made within the respective guidelines. Recommendations are 
produced first by evaluating the evidence base, grading the quality of the evidence on 
the level the study. In principle randomised control trials are rated as high quality, well-
designed clinical trials are considered moderate quality and low quality evidence is 
considered to be expert opinion, observational and clinical case studies. The quality of 
the evidence base is paired with a ‘strength of recommendation’, calculated from 
principles including: quality of evidence, the balance between benefit/harm and 
burdens, resource and cost and also patient’s values and preferences (Ullmann et al., 
2012; Cornely, Cornely et al., 2014;, Cuenca-Estrella, et al., 2014; Pappas et al., 2015; 
Patterson et al., 2016; Tissot et al., 2016). Recommendations for diagnosis and 
treatment of IFI will be considered throughout chapter 1 alongside the specific IFI, with 
reference to the strength and grade of the recommendation as detailed in table 1.2. 
 
Table 1.2 Grading utilised by guidelines for recommendations made for the 
diagnosis and treatment of invasive fungal disease.   
Strength of recommendation Quality of evidence 
ECIL IDSA ESCMID ECIL IDSA ESCMID 
A = Good  Strong A= Strong I ≥ 1 RCT High I ≥ 1 RCT 
B = Moderate  Weak  B = Moderate 
II ≥ 1 
WDCT 
Moderate  
II ≥ 1 
WDCT 
C = Poor   C = Marginal  
III = expert 
opinion  
Low 
III = expert 
opinion  
RCT = randomised controlled trial, WDCT= well designed clinical trial 
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Where guidelines provide recommendations on treatment and diagnosis, the 
EORTC/MSG criteria provides a strategy by which patients can be classified into 
categories of proven, probable and possible IFI based on clinical presentation, 
underlying immunosuppression and pathological findings from the investigation of 
clinical specimens. The EORTC/MSG criteria published standard definitions for IFI for 
clinical and epidemiologic research (De Pauw et al., 2008). These definitions were 
developed to facilitate the identification of reasonably homogeneous cohorts of patients 
(De Pauw et al., 2008). Clinical trials designed to evaluate new drugs; diagnostics and 
patient management strategies also use the EORTC/MSG criteria to analyse data. The 
criteria also help to standardise analysis across studies internationally allowing 
communication between international researchers (De Pauw et al., 2008). For the 
purpose of this research the EORTC/MSG criteria will be considered in chapter 9. 
 
1.5 Overview of Immunity to fungal infection  
The innate and adaptive immune system protect against IFI (Jiang, 2016). Physical 
barriers of the skin and mucosa provide non-specific protection (Jiang, 2016). If fungi 
invade past skin and mucosal barriers the specific innate and adaptive immune 
response is activated. Circulating white blood cells provide the innate response 
including neutrophils, macrophages, and dendritic cells (Jiang, 2016) that phagocytose 
and inactivate infecting fungal cells. If fungi evade this first line of defence the adaptive 
immune response is activated and T-cells (th1, th2 and th17, t-Reg) and B-cells secrete 
an array of cytokines and antibodies to target fungal pathogens (Jiang, 2016). The 
scope of the immune response to fungi is complex and breaches the scope of this 
research however; there are key immune components that are classified as risk factors 
when diagnosing fungal infection. 
Skin and mucosal barrier integrity 
The skin and mucosal barriers protect hosts from fungal infection. Candida are 
commensal organisms of the gastrointestinal tract (Ohmit et al., 2003; Southern et al., 
2008). In healthy individuals colonisation is without consequence as protective mucosal 
barriers prevent translocation of Candida into the blood stream. A breakdown in the 
integrity of the mucosal barrier, through surgery or chemotherapies, is a primary risk 
factor for invasive candidiasis (Moyes and Naglik, 2011; Netea et al., 2015). Another 
major risk factor for IC is through a breach in the skin by the insertion of central venous 
catheters (CVC) and other intra-venous (IV) lines used for the administration of 
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treatment. In mucoraceous fungal infections skin/soft tissue trauma or trauma to the 
gastrointestinal tract can predispose patients to invasive infection (Spellberg, Edwards 
and Ibrahim, 2016; Ghuman and Voelz, 2017). Wounds become colonised from fungi in 
the environment and subsequent IFI develops. The ingestion of mucoraceous fungi 
with food sources, such as fruit and vegetables, in patients with damage to the integrity 
of the GI tract is also a risk factor for developing mucoraceous IFI, although the latter is 
a rarely occurring infection (Spellberg, Edwards and Ibrahim, 2016; Ghuman and 
Voelz, 2017). If fungi evade protective barriers and invade sterile sites immune cells 
are recruited to the site of infection, through signalling molecules inflammatory 
cytokines, chemokines and complement factor, to destroy the invading fungi (Eberyl 
and Davy, Immunology.org). When considering patients at risk of IFI the role of 
neutrophils is crucial for protection against fungal infection.  
Neutrophil role in the innate immune response to fungi 
Neutrophil cells are the first immune cells recruited to site of inflammation during fungal 
infection (Eberyl and Davy, Immunology.org). Fungi are engulfed by neutrophils 
through the process of phagocytosis. Fungal cells are internalized in a phagosome 
inside the neutrophil where antimicrobial molecules and reactive oxygen species bind 
to the phagasome and damage and/or kill fungal cells (Diamond and Clark, 1982; 
Levitz and Farrell, 1990; Hohl and Feldmesser, 2007; Dagenais and Keller, 2009). In 
vitro studies have demonstrated this killing action of neutrophils against Aspergillus 
hyphae (Diamond and Clark, 1982; Levitz and Farrell, 1990). In Candida infection 
neutrophils are crucial for early recognition and clearance of the fungus, but also 
prevent the morphological switch from yeast to filamentous forms (Duggan et al, 2015). 
In Fusarium infection studies have demonstrated damage to hyphae, primed by 
gamma interferon and granulocyte stimulating factor, through neutrophil attack (Gaviria 
et al., 2017). In mucroaceous mould infection increased neutrophil recruitment in the 
nasal tissues has been demonstrated in animal models (Ghuman and Voelz, 2017). 
Neutrophils and soluble mediators also play a role in facilitating clearance of PCP 
during infection (Gigliotti and Wright, 2005; Krajicek, Thomas and Limper, 2009; Kelly 
and Shellito, 2010). Therefore, neutrophils are crucial for the prevention of fungal 
infection. Having low levels of neutrophils (neutropenia) is a primary risk factor for 
developing invasive fungal disease. In particular prolonged periods of neutropenia are 
associated with an increased risk of fungal disease. Factors that reduce neutrophil 
levels and function include myeloablative chemotherapy, steroid therapy, 
myelodysplastic syndromes, HIV infection, sepsis and severe autoimmune conditions.  
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Whilst prolonged neutropenia is recognised as a primary risk factor of IFI, and is 
included in the EORTC definitions of IFI (de Pauw et al., 2008), overall defects in a 
patients’ immune system is a key predisposing factor for development of IFI. The type 
of IFI a patient develops is co-associated with the patients underlying disease and 
mode of immune suppression.  
 
1.6 Invasive fungal infections  
IFIs can be broadly divided into two clinical categories: invasive yeast and invasive 
mould infections. The morphology and cellular structure of the two different forms of 
fungi facilitate the identification the infection resulting from the different fungal 
pathogens. Before attempting to diagnose IFI it is crucial to understand the clinical 
features of each disease (White, 2017). Pathogenesis and risk factors associated with 
different IFI allow for the selection of specimens most suitable for investigation. 
Considering what tests are available for a given disease and the performance 
characteristics of specific methods determines how specimens are prepared for 
analysis. It is important to appreciate that the choice of specimen itself introduces 
variables into the diagnostic process (White, 2017). The optimal specimen type will be 
determined by the disease manifestation or testing strategy employed.  
 
1.7 Invasive Candidiasis 
Candida spp are unicellular organisms that replicate asexually via the process of 
budding (Calderone and Fonzi, 2001). Some species, such as Candida albicans can 
switch from a unicellular state to a complex multicellular filamentous organism, this 
feature is thought to have developed to convey an opportunistic evolutionary 
advantage compared with other yeast species (Calderone and Fonzi, 2001). Figure 1.3 
demonstrates a) unicellular blastoconidia of yeasts, b) pseudohyphae formations of 
tubular filaments c) hyphae with septa. The morphological characteristics of yeasts 
allow for dispersion through the blood stream, as unicellular blastospores in fungemia, 
but also dissemination into deep-seated organs where some yeast species then invade 
tissues forming multifocal lesions in the hyphal form (Calderone and Fonzi, 2001).  
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Figure 1.3 Morphological characteristics of yeasts, as a) blastospores b) pseudohyphae and c) 
true hyphae/mycelia. 
 
Candida are also very competent at forming biofilms within tissues and on plastics that 
become heavily resistant to antifungal agents (Vila and Rozental, 2016). The biofilm 
starts with adhesion of blastospores to a surface that then develops, through hyphal 
production into a mature biofilm surrounded by extracellular matrix. Daughter cells are 
then dispersed from the biofilm into the surrounding environment, fig 1.4 (Vila and 
Rozental, 2016) 
 
 
Figure 1.4 Candida adhesion and biofilm formation through hyphal production and extracellular 
matrix (Vila and Rozental, 2016). 
 
Invasive candidiasis is a well-recognised nosocomial infection affecting hospitalised 
patients in developed countries (Pfaller et al., 2011; Kaye et al., 2014; Wisplinghoff et 
al., 2014). Mortality is high, reaching up to 40% in some settings despite the 
administration of antifungal therapy (Kullberg and Arendrup, 2015). With increasing 
incidence of IC new insights into diagnostic and therapeutic strategies are required to 
improve the incidence and outcome of IC.  
 
1.7.1 Epidemiology of invasive candidiasis 
Invasive candidiasis incidence rates in the general population are very low. Recent 
surveillance data reports incidence rates of 2.9-6.3 per 100,000 population in the UK 
(Odds et al., 2007; Oeser et al., 2014) and 10.4 per 100,000 populations in Denmark 
a b c 
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(Arendrup et al., 2011). Candida is reportedly the fourth most common cause of blood 
stream infection (BSI) in the United States however, source data is mainly derived from 
ICU where patients are at a higher risk of IC (Pfaller et al., 2001). When focusing on 
the specific patient groups at risk of IC, incidence rates increase one hundred-fold, to 
an incidence of 2-6.9 per 1000 patients in the intensive care setting (Eggimann, Bille 
and Marchetti, 2011; Kett et al., 2011). Other patient groups at higher risk of IC include 
haemato-oncology, surgical and other immunocompromised patient groups such as 
HIV/AIDS (Fraser et al., 1992; Ascioglu et al., 2002; Arendrup et al., 2010; Ullmann et 
al., 2012) 
Several risk factors are associated with IC. Mucous membrane colonisation of the GI 
tract is a risk factor in immunosuppressed patients. The fungal burden is higher than 
normal due to overgrowth of Candida as the bacterial flora is reduced due to broad 
spectrum antimicrobial therapy (Fraser et al., 1992; Alonso-Valle et al., 2003; Pauw et 
al., 2008; Arendrup, 2010). Gastrointestinal surgery and chemotherapy-induced injury 
to the lower gastrointestinal tract are also major risk factors for IC (Calderone and 
Fonzi, 2001; Dellinger, Levy and Rhodes, 2013; Wisplinghoff et al., 2014). Damage to 
the protective integrity of the gut mucosal surface allows colonising Candida to 
translocate into tissues and the bloodstream resulting in IC (Janum and Afshari, 2016). 
Once translocation has occurred into the bloodstream Candida is capable of forming 
biofilms on plastic surfaces. Vascular catheterisation is a significant risk factor in the 
development of Candidemia as the catheter becomes the direct source of infection 
(Janum and Afshari, 2016). The extremes of age also present a risk as the patient’s 
immune system is either underdeveloped in neonates or is declining in the elderly 
(Arendrup, 2013; Kaye et al., 2014). Parenteral nutrition is also a risk factor for IC, 
mainly in neonates, but most likely reflects the severity of the patient’s condition rather 
than being a true source of IC (Widmer et al., 1997). It is often the case that a patient 
will experience a combination of the respective risk factors prior to developing IC.   
Although Candidemia is the most common presentation, deep-seated infection of 
tissues such as the liver, spleen and kidney can also arise from dissemination during 
blood stream infection (Clancy et al 2013). Both candidemia and deep seated 
candidiasis can present in isolation or overlap as a consequences of each other 
(Clancy and Nguyen, 2013; Kullberg and Arendrup, 2015). Disseminated candidiasis, 
in the absence of blood stream infection, presents a diagnostic challenge. Recent 
advancements in radiological techniques are allowing for more accurate diagnosis. 
Figure 1.5 demonstrates micro abscesses in the liver and spleen due to Candida 
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infection (Cornely et al, 2015). These Candida lesions are non-specific as differential 
diagnoses could be lymphoma of the liver, leukemic infiltrates or metastases (Cornely, 
Bangard and Jaspers, 2015). Despite radiology being non-specific positive imaging can 
be used to prompt further pathological investigations. Chronic disseminated 
(hepatosplenic) candidiasis can occur in patients at risk of IC with prolonged 
neutropenia (Cornely, Bangard and Jaspers, 2015). Chronic infection of the blood 
stream can also lead to more complicated infections of sites such as ocular infection or 
infection of the central nervous system (Calderone and Fonzi, 2001; Kullberg and 
Arendrup, 2015). Disseminated invasive Candida infections are more commonly 
associated with virulent species of Candida such as C. albicans and C. tropicalis 
(Calderone and Fonzi, 2001; Kullberg and Arendrup, 2015) but several species have 
been implicated in invasive disease (Deorukhkar, Saini and Mathew, 2014). 
 
Figure 1.5 CT scan with multiple hypodense Candida micro abscesses in the liver and spleen. 
The arrow indicates peripheral contrast uptake of the small abscess (Cornely, Bangard and 
Jaspers, 2015). 
The distribution of species implicated in IC globally has remained relatively consistent 
with 90-95% of all candidemia attributed to five main species (Kullberg and Arendrup, 
2015). C. albicans remains the primary etiological agent (Tortorano et al., 2006; Pfaller 
et al., 2011; Guinea, 2014; PHE report, 2016) with C. parapsilosis, C. tropicalis, C. 
glabrata and C. krusei making up the five top species implicated in IC (Pfaller et al., 
2011; Kullberg and Arendrup, 2015). Some species are more prevalent in certain 
clinical settings, for example in the haematology setting the incidence of C. krusei is 
relatively high causing 12-16% of candidemia (Pfaller, Diekema, et al., 2008). Recent 
surveillance data from Denmark has highlighted a shift towards increased incidence of 
azole resistant Candida species (Arendrup et al., 2011) which has been associated 
with the prophylactic use of azole antifungal agents such as fluconazole (Hope, Morton 
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and Eisen, 2002). The increasing incidence of azole-resistant species is a key factor for 
driving guidelines to recommend echinocandins as empirical therapy for candidemia 
(Ullmann et al., 2012; Pappas et al., 2015; Tissot et al., 2016). It is important to note 
that a small proportion of IC cases are caused by rare non-Candida yeast species, e.g. 
Blastoschizomyces capitatus and Trichosporon sp. Guinea (2014) reported, from the 
ARTEMIS DISK Global Antifungal Surveillance Study, a decrease in incidence of C. 
albicans with increasing incidence of ‘other’ yeast species implicated in fungemia from 
1997-2007, as shown in figure 1.6 (Guinea, 2014).  
Therefore, determining the species of yeast implicated in IC is of increasing importance 
in order to guide antifungal therapy. Until the species has been determined, treatment 
of invasive candidiasis relies on broad-spectrum antifungal agents as empirical therapy 
(Garey et al., 2006; Farmakiotis et al., 2015). As improved outcome for patients is 
reliant on administering the correct antifungal agents, early diagnosis is essential. 
 
 
Figure 1.6 Frequency distribution of Candida species isolated from candidemia (adapted from 
Guinea, 2014). 
 
1.7.2 Clinical presentation of invasive Candidiasis 
Invasive candidiasis presents with non-specific symptoms such as pyrexia and signs of 
sepsis, which is often undistinguishable from bacterial sepsis (Hollenbach, 2008; 
Bassetti et al., 2017). Suspicion of IC usually arises when a patient’s fever is refractory 
to broad-spectrum antibacterial therapy. As a result, candidemia and other forms of IC 
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can go undiagnosed for 3-4 days before being suspected and follow-up diagnostic 
investigations are initiated. Despite the administration of antifungal therapy, chronic 
disseminated candidiasis and intra-abdominal infection often present as refractory 
infection as the source of infection can be difficult for antifungal drugs to penetrate and 
often requires source control through drainage or surgical intervention (Cornely, 
Bangard and Jaspers, 2015). Chronic Candida infection can often be associated with 
chorioretinitis which presents as blurred vision of floating black spots caused by 
Candida fungal balls within the eye (Lashof et al., 2011; Kauffman, 2015). 
Chorioretinitis is associated with poor outcome if diagnosed and occurs in 8-16% of 
patients with Candidemia (Shah et al., 2008; Clancy and Nguyen, 2013). Candida 
endocarditis is rare, accounting for less than 2% of all endocarditis cases. However, 
Candida endocarditis can occur in patients with risk factors such as valvular prosthesis, 
congenital heart disease, history of infective endocarditis and other prosthetics such as 
pace makers (Kauffman, 2015). In a review of 44 patients who developed candidemia 
with prosthetic heart valves 16% had evidence of endocarditis at the time of 
presentation and 9% developed endocarditis after candidemia (Melgar et al., 1997). 
 
1.7.3 Laboratory diagnosis of Invasive Candidiasis 
1.7.3.1 Blood cultures 
The diagnosis of IC is heavily dependent on laboratory investigation. The current gold 
standard for the diagnosis of IC is a positive blood culture sample, despite being 
associated with a low test sensitivity of only 21-75% (Kami et al., 2002; Thorn et al., 
2010; Clancy and Nguyen, 2013). The limitation of blood culture for the diagnosis of IC 
is in the poor detection of deep-seated disseminated candidiasis where blood cultures 
are often negative (Clancy and Nguyen, 2013). Despite this lack of sensitivity blood 
culture is still recommended as an essential investigation for IC (Schelenz et al., 2009; 
Pappas et al,. 2016). If a patient is suspected to have IC current guidelines recommend 
daily collection of blood cultures, aspirating a total volume of 40-60mL to be distributed 
across 4-6 bottles in 10mL aliquots to optimise the sensitivity of the culture process 
(Pappas et al., 2015). Additional blood cultures should be collected during febrile 
episodes to maximise the chance of recovering yeasts from blood stream infection. 
Improved performance has been shown with the inclusion of Mycosis bottles into the 
blood culture pathway (Chiarini et al., 2008) but they are not routinely used in clinical 
practice. Most laboratories in the developed world incubate blood cultures on 
automated blood culture systems providing an electronic positive flag. Although 
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automated systems have been shown to be more effective in the speed of recovery of 
microorganisms from blood cultures (Wilson et al., 1999) there is still a delay in the 
time to diagnosis, reportedly on average 25.9 hours for Candida (±24.9h) (Lai et al., 
2012).  
The availability of other clinical specimens such as sterile fluids and tissue biopsies 
from patients with suspected IC relies heavily on the patient’s condition and therefore 
invasive specimens are not commonly taken. If tissue and fluid samples are collected 
the standard of care is to perform microscopy and culture on specialised fungal media 
(Schelenz et al., 2009).   
1.7.3.2 Microscopy and culture  
When a blood culture is detected as positive or when performing direct microscopy on 
a specimen the most important diagnostic test used is the Gram’s stain from which 
yeasts can be detected (Thairu, Usman and Nasir, 2014), figure 1.7. Yeasts stain Gram 
positive, owing to the capture of the crystal violet between the cell wall layers as it 
complexes with iodine (Henrici, 1914). In 1919 the scientist Arthur T Henrici described 
his studies on the staining characteristics of yeasts declaring ‘’So far as I know, all of 
the yeasts are Gram-positive, and they stain so deep and solid a black that it seemed 
to me not unlikely that they would retain the stain even more firmly than the ordinary 
Gram-positive bacteria’’ (Henrici, 1914). 
 
 
 
 
 
 
 
 
 
 
 Figure 1.7 Candida sp stained Gram Positive (Gorton et al., 2015).  
 
To this day Gram’s stain still provides a rapid result available to clinicians in less than 
15 minutes providing valuable information for targeted management of patients with 
antifungal agents. Gram’s stain is limited to generalising the identification to that of 
‘yeasts seen’ (Beveridge, 2001). The next step in the diagnostic pathway is to 
subculture the yeast onto specialised media, either Candida chromogenic media or 
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Sabouraud’s agar which requires an additional incubation time of at least 18-24 hours 
to culture yeasts for identification (Ainscough and Kibbler, 1998).  
The clinical microbiology laboratory is required to identify yeast cultures to species 
level when isolated from patients with suspected IC (Schelenz et al., 2009). If 
chromogenic media are used for subculture C. albicans can be identified as apple 
green colonies with a high degree of accuracy of >99% (Odds and Bernaerts, 1994). 
For non-albicans species the conventional method of yeast identification is phenotypic 
testing through biochemical profiling with a variety of assimilation reactions of 
carbohydrates such as glucose and lactose (Davey et al., 1995; Sheppard et al., 1998; 
Romney et al., 2000). Candida cultures grown on cornmeal agar supplemented with 
Tween 80 are performed alongside biochemical assays for the characterisation of 
morphological characteristics such as hyphae, pseudohyphae and chlamydospores 
(figure 1.8). After an additional 24-48 hours incubation the reaction profile can be 
determined as positive or negative through colorimetric or turbidity readings alongside 
the cornmeal agar morphology (Davey et al., 1995; Sheppard et al., 1998; Romney et 
al., 2000). The resulting profile/score is then matched to a database and the most likely 
identification assigned (Davey et al., 1995; Sheppard et al., 1998; Romney et al., 
2000).  
The most utilised commercial assays are the Auxacolor system (Sanofi Diagnostics 
Pasteur, Paris, France), the Vitek 2 system (Biomerieux, Marcy-l’Etoile France) and the 
API Candida (BioMerieux, Marcy-l’Etoile France). In a recent meta-analysis of assay 
performance, across 26 published studies, the accuracy of three biochemical 
identification systems’ were reportedly 89% for the Auxacolor, 80% for the API ID32C, 
and 93% for the Vitek 2 (Posteraro et al., 2015).  
 
Figure 1.8 Cornmeal agar culture of Candida albicans demonstrating chlamydospore production 
and true hyphae (Hardy Diagnostics). 
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Misidentifications were most common with rarer yeast species as they were either not 
included in the assay databases or could not be distinguished from profiles of more 
commonly isolated species (Posteraro et al., 2015). In total, the identification pathway 
can equate to a turnaround time of 4 days before the identification can be reported.  
 
1.7.3.3 Antifungal susceptibility of Candida  
With accurate species identification it is possible to predict the susceptibility of Candida 
species to antifungal agents. A global survey published in 2011 reported 98% of C. 
albicans isolates from IC infection measured susceptible to fluconazole (Pfaller et al., 
2011). Susceptibility to fluconazole was lower for C. tropicalis (91%) and C. 
parapsilosis (93.2%) isolates but still remained high above 90% (Pfaller et al., 2011). In 
contrast identification of C. glabrata or C. krusei from IC would contraindicate the use 
of fluconazole with a high proportion C. glabrata (31.3%) being resistant resistant to 
fluconazole and C. krusei being intrinsically resistant (Pfaller et al., 2011). Therefore, 
accurate species identification can contribute to the antifungal management.  
Diagnosrtic guidelines recommend that antifungal susceptibility testing (AST) should be 
performed on all yeasts isolated from sterile sites or blood cultures (Schelenz 2012). 
The minimum inhibitory concentration (MIC) of yeasts can be determiend using 
gradient MIC strips (Barnes et al., 1996) or microdilution methods (Arendrup et al., 
2017). For the interpratation of MIC breakpoints it is essential to obtain an accurate 
species identification (Espinel-Ingroff et al., 1999; Cantón et al., 2005; Pfaller, 
Chaturvedi, et al., 2008). Susceptibility breakpoints for Candida species are different 
dependent on the species therefore, misidentification of isolates can in turn result in 
misinterpretation of susceptibility results (Borman et al., 2012). This is currently a 
limitation for laboratories using biochemical methods to identify yeasts from blood 
cultures (Posteraro et al., 2015). 
With up to 88.9% of candidemia patients reportedly receiving inappropriate antifungal 
therapy for 24 hours or more until culture and AST results are known reducing the time 
to identification and increasing the accuracy of identification could have a significant 
clinical impact on morbidity and mortality of IC through the administration of appropriate 
targeted antifungal therapy (Sutepvarnon et al., 2008; Arnold et al., 2010; Zilberberg et 
al., 2010).  
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1.7.3.4 (1-3)-β-D-glucan and PCR for the diagnosis of invasive candidiasis 
Non-culture techniques including PCR and serological testing for the detection of 
fungal antigens have the potential to improve the diagnosis of invasive candidiasis 
(Clancy and Nguyen, 2013). The detection of DNA or antigens from specimens may aid 
in the diagnosis of 40% of invasive candidiasis that is undetected by blood culture 
(Clancy and Nguyen, 2013).  
PCR is a rapid technique, reducing the TAT to results by an average of 2.2 days 
compared to culture and provides a species level identification as much as 4 days 
earlier than culture based techniques (Lau et al., 2010). However, use of PCR for 
candidemia is limited with only select clinical services choosing to adopt this method for 
diagnosis of IC. The main prohibiting factor preventing clinical diagnostic services from 
developing PCR for invasive candidiasis is assay sensitivity, as less than 1 cfu/mL is 
known to be present in blood during candidemia infection (Pfeiffer et al., 2011). Large 
blood volumes are required for extraction to enable detection. Reichard et al (2012) 
recently reported intra-laboratory inconsistency when detecting Candida from blood 
using PCR, and the limit of detection determined to be between 10 and 100 cfu/ml 
(Reichard et al., 2012). The use of Candida PCR is therefore still experimental or 
utilised in highly specific clinical scenarios and by specialist service laboratories with 
experienced mycologists. 
Antigen detection, specifically the detection of (1-3)-β-D-glucan, is becoming more 
frequently utilised to assist in the diagnosis of IC. In the last decade (1-3)-β-D-glucan 
has become an established biomarker for the investigation of invasive fungal infection. 
(1-3)-β-D-glucans are a group of β-D glucose polysaccharides contained within the cell 
wall of most fungi (excluding mucoraceous fungi) (Brown and Gordon, 2003; Synytsya 
and Novák, 2013) plants and bacteria. Many fungi produce (1-3)-β-D-glucan and during 
the infection process it is possible to detect the antigen within serum. Two 
commercially available assays, the Fungitell (Cape Cod) and Fungus (1-3)-β-D-glucan 
assay (Dynamiker, Tianjin) tests are available and have shown comparable 
performance (White et al., 2017). Due to the commonality of the target across species 
positive results are non-specific and do not differentiate between fungal infections at 
the species level. A recent meta-analysis reported a pooled sensitivity and specificity of 
78% and 81% respectively for the diagnosis of IC (He et al., 2015). Improved 
performance was noted in a systematic review by ECIL in 2012 when two consecutive 
positive tests were used for diagnosis with a sensitivity and specificity of 49.6% and 
98.9% respectively (Lamoth et al., 2012). The PPV and NPV was predicted to be 
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83.5% and 94.6% respectively, at a disease prevalence level of 10%, which is high 
compared to actual prevalence rates in the UK and Europe (Lamoth et al., 2012). The 
PPV and NPV are likely to be reduced in lower prevalence settings (Bentley, Catanzaro 
and Ganiats, 2012). The performance of (1-3)-β-D-glucan assays for the diagnosis of 
IC is limited as a stand-alone test but is a useful negative screen for several fungal 
infections.  
 
1.7.3.5 Prophylaxis and treatment of invasive candidiasis 
In table 1.3 recommendations from the three major guidelines are compared for the 
treatment of invasive candidiasis; ECIL (2016), IDSA (2016) and ESCMID (2012)           
(Tissot et al., 2016, Pappas et al., 2015; Ullmann et al., 2012). Encouragingly all 
guidelines appear to consistently recommend the same approach to the management 
of IC in both general and haemato-oncology patients. The empirical therapy of choice 
is an Echinocandin, with step down to fluconazole after 5 days of therapy if an azole 
susceptible species is identified. For C. krusei voriconazole is recommended as a step 
down alternative and for C. parapsilosis isolates fluconazole is suggested as a more 
effective alternative due to reports of high MIC to echinocandins (Ullmann et al., 2012; 
Pappas et al., 2015; Tissot et al., 2016). For clinically stable patients where the species 
is known to be azole susceptible fluconazole can be used empirically, but is only 
recommended in this specific scenario. The length of treatment is 2 weeks after 
clearance of candidemia, determined by a negative blood culture (Ullmann et al., 2012; 
Pappas et al., 2015; Tissot et al., 2016). The removal of central venous catheters 
(CVC) and indwelling lines is recommended as early as possible. For disseminated 
Candida infection Liposomal Amphotericin B is recommended with the inclusion of 5-
flucytosine for ocular or CNS infection (Ullmann et al., 2012; Pappas et al., 2015; Tissot 
et al., 2016).  
Prophylaxis in high-risk patients is usually through the administration of fluconazole, 
which in guidelines received a weak recommendation; moderate-quality evidence from 
the IDSA (Mossad, 2004; Uko et al., 2006; Weitkamp et al., 2008; Springer et al., 2012; 
Eschenauer et al., 2015; Pappas et al., 2015). In neonates non-absorbable nystatin is 
recommended as an oral agent for decolonisation of the GI tract but also oral 
fluconazole to be assessed on a case by case basis (Hope et al., 2012).
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Table 1.3. Comparison of recommendations from guidelines for the management of invasive candidiasis; ECIL, IDSA and ESCMID 
 
  
ECIL 2017  
(Tissot et al., 2016) 
IDSA (Haematology)  
(Pappas et al., 2015) 
ESCMID  
(Ullmann et al 2012) 
Intervention Recommendation General Haem General Haem General Haem 
First line empirical Echinocandin AI AII Strong High Strong Moderate AI AI 
Alternative empirical 
Liposomal AmpB 
(Ambisome) 
AI AII Strong Moderate Strong Moderate BI AI 
Non-critical patient 
once species is 
known 
Fluconazole AI CIII Strong High Weak Low - -  
Step down >5 days Fluconazole AI CIII Strong High Weak Low BII ns 
C. krusei step down Voriconazole BI CIII Strong Low - - - - 
Catheter removal Rapid removal AII BII Strong Moderate - - AIII AII 
Length of antifungal 
treatment 
2 weeks after 
clearance 
- - Strong Moderate Strong Low BII BI 
Chronic 
disseminated 
candidiasis 
Liposomal AmpB or 
an echinocandin with 
fluconazole step 
down 
- - Strong Low - - BII - 
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1.8 Pneumocystis pneumonia (PCP) 
Pneumocystis jirovecii is the etiological agent responsible for an acute, severe 
pneumonia in immunosuppressed patients, known as Pneumocystis pneumonia or 
PCP. Prior to the advent of whole genome sequencing P. jirovecii was thought to be 
protozoan but was reclassified as a yeast after whole genome sequencing aligned P. 
jirovecii with the fungal kingdom (Frenkel, Bartlett and Smith, 1990). P. jirovecii is 
unique as a fungus with a multiphasic life cycle that occurs within the alveolar space of 
the host, figure 1.9 (www.tulane.edu). The cystic form of Pneumocystis, namely the 
ascus, is circular or ovoid in shape and measures 4–7 μm in diameter (Aliouat-Denis et 
al., 2009; Skalski, Kottom and Limper, 2015). A thick outer wall made of abundant (1-
3)-β-D-glucan contains ascospores that mature and are released from the ascus 
through a small pore. The Pneumocystis cells then mature to become the more 
metabolically active trophic forms of P. jirovecii (Finkelman, 2010; Skalski, Kottom and 
Limper, 2015). In the infective process the trophic cells are the replicative form of P. 
jirovecii which, unlike other yeast species that replicate via asexual budding; replicate 
through the process of binary fission (Aliouat-Denis et al., 2009; Skalski, Kottom and 
Limper, 2015). 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 The replicative life cycle of P. jirovecii showing ascus formation, troph maturation and 
release with replication through binary fission (www.tulane.edu). 
Cysts 
 
Trophs 
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1.8.1 Epidemiology of P. jirovecii infection 
Pneumocystis jirovecii is distributed worldwide and is known to colonise the lungs of 
healthy individuals, with up to 75% of children testing sero-positive by the age of 4 
years old (Vargas et al., 2001; Respaldiza et al., 2004). Transmission of P. jirovecii 
from person to person has been documented (de Boer et al., 2007; Yazaki et al., 
2009). More recently hospital acquired infection has been described in outbreaks on 
renal and ICU units (Chapman et al., 2013; Robin et al., 2017). Genotypically distinct 
mixtures of organisms have been reported in more than 90% of cases, reinforcing the 
hypothesis that P. jirovecii is consistently inhaled from different environmental sources 
over time (Alanio et al., 2017). Patients at risk of developing PCP were, until recently, 
mainly HIV infected patients, with PCP presenting as an AIDS associated disease. In 
HIV positive patients PCP is associated with 15-30% mortality rates (Helweg-Larsen, 
2004; Teshale et al., 2007). In the last decade, with the advent of HAART therapy and 
cotrimoxazole prophylaxis, the incidence of PCP in the HIV positive population has 
decreased significantly. Increasing incidence of PCP infection is reported in patients 
with acute and chronic leukaemia, dexamethasone treated patients (such as those with 
brain tumours), other corticosteroid treated patients (especially SLE, Wegener’s, 
glomerulonephritis), transplant recipients who are not receiving cotrimoxazole, 
hypogammaglobinaemia and those patients on anti-TNF therapy (Yale and Limper, 
1996; Pareja, Garland and Koziel, 1998; Enomoto et al., 2010; Bitar, Lortholary, Le 
Strat, et al., 2014). In the respective patient groups mortality is reported to be higher 
than in HIV positive patients, in some reports >50% mortality is described (Yale and 
Limper, 1996; Pareja, Garland and Koziel, 1998; Enomoto et al., 2010; Bitar, 
Lortholary, Le Strat, et al., 2014) 
 
1.8.2 Clinical presentation of PCP 
P. jirovecii pneumonia typically presents as a severe respiratory infection, which may 
precipitate rapidly into life-threatening pneumonia. The classical presentation of a 
patient with PCP is low-grade fever, a dry cough and dyspnoea. When listening to the 
lungs, through auscultation, fine crackles are common at presentation in patients with 
PCP. Oxygen saturation is typically low with patients describing drowning sensations 
and severe difficulty in breathing. It is important to acknowledge that this presentation 
is classical for a HIV positive patient presenting with PCP (Tasaka, 2015). In non-HIV 
patients’ low-grade respiratory infection is indistinguishable from the presentation of 
other atypical respiratory infections. Clinical diagnosis in HIV-negative patients is more 
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challenging as PCP can be more acute and fulminant with high grade dyspnoea, fever, 
and chills (Catherinot et al., 2010; A. Alanio et al., 2016; Cordonnier et al., 2016). HIV-
negative patients are more likely to require mechanical ventilation (Pathak et al., 2012). 
Table 1.4 details the patient groups that are associated with Pneumocystis infection 
and (seperatley) the therapeutic agents associated with a risk of infection (Catherinot et 
al., 2010; Hayes and Denning, 2013; Roux et al., 2014; Tasaka, 2015; A. Alanio et al., 
2016; Cordonnier et al., 2016).  
Table 1.4. Clinical conditions and therapeutic agents associated with PCP  
Conditions associated with PCP 
Therapeutic agents associated with PCP (mode 
of immune suppression) 
HIV Corticosteroids (T-lymphocyte suppression) 
Hematological malignancy Alkylating agents such as cyclophosphamide) 
Solid tumors Chemotherapeutics (e.g. methotrexate) (DNA, 
RNA, proteins) 
Autoimmune disease TNF inhibitors (such as infliximab) 
Solid organ transplant Rituximab (targets CD20; B cells) 
Severe combined immune deficiency Cyclosporine (decreases lymphocyte function) 
Hyper IgM syndrome Azanthioprine (transplant immunosuppressant) 
Wegener’s granulomatosis Sirolimas/tacrolimas (intracellular lymphocyte 
messaging) 
Inflammatory bowel disease - 
Collagen vascular disorders - 
 
As health care advances there is an ever-increasing range of therapies with varying 
mechanisms of immunosuppression that predispose patients to PCP infection. 
Targeted diagnosis and treatment of PCP is challenging and many disciplines within 
primary healthcare may be affected. 
 
1.8.3 Radiological diagnosis of PCP 
Radiological investigation of PCP can be highly specific if classical presentations are 
observed. Chest X-rays will display bilateral peri-hilar interstitial infiltrates (or ground 
glass opacification), described as having the appearance of ‘bats wings’ infiltrates 
(Hardak, Brook and Yigla, 2010), (as shown in figure 1.10 a). Radiology may not 
always present with typical features of PCP during infection. Figure 1.10 b 
demonstrates a patient with a right sided pneumothorax, which was diagnosed to be 
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due to P. jirovecii infection (Mu et al., 2016). In early infection patients’ radiological 
investigations (mainly X-ray) may be negative.  
 
 
 
 
 
 
a) b) 
Figure 1.10 a) Bilateral diffuse ground glass opacification in PCP b) Atypical presentation of a 
right side pneumothorax in PCP (Mu et al., 2016). 
 
A CT scan may be required to observe features of infection. Mu et al described the 
varying presentations at different stages of disease progression, detailed in table 1.5. 
Chest CT detected progression of disease earlier than X-ray (Mu et al., 2016). 
 
 
 
 
1.8.3.1 Laboratory diagnosis of PCP 
GGO = ground glass opacification, CXR = chest X-ray 
 
1.8.4 Microscopy for the detection of P. jirovecii 
Pneumocystis is non-cultivable in the diagnostic laboratory and highly specialized 
manipulation in lung cell lines is required for isolation (Schildgen, Mai and Khalfaoui, 
2014). The current gold standard for diagnosis of PCP is direct visualization of 
Pneumocystis cells using microscopy. Historically several stains have been utilised 
including; toluidine blue O stain, the Gram-Weigert stain and Grocott's adaptation of 
Gomori's methenamine silver nitrate (MSN) stain (Newman, 1964). The toluidine blue 
Table 1.5 Radiological presentations in PCP patients on X-ray and CT at early, 
mid and late stages of infection (adapted from Mu et al., 2016) 
Stage of PCP 
Manifestation (bilateral) 
CXR Chest CT 
Early Normal Diffuse GGO 
Mid Infiltrates GGO/patchy consolidations 
Late Consolidations Predominant consolidations 
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O stain and Gram-Weigert stain have several limitations; staining the cyst form only 
whilst also staining the background material, or co-staining other cells such as yeasts 
and red blood cells, making it difficult to distinguish P. jirovecii (Newman, 1964). 
Grocott's MSN stain shows the greatest contrast between the organism and its 
environment. Staining the cyst dark brown/black, as demonstrated in figure 1.11, and 
the background material light green, it is considered to be the best stain for identifying 
P. jirovecii and has remained the stain of choice to date by cytologists. 
 
Figure 1.11 Grocott’s staining of P. jirovecii in a broncho-alveolar lavage sample from a HIV-
infected patient presenting with PCP (http://medicine.academic.ru/140233). 
Despite demonstrating high specificity, the sensitivity of Grocott's MSN stain is highly 
variable ranging from 53% to 83.5% (Cruciani et al., 2002a), influenced by sample type 
with detection from BAL being more sensitive than induced sputum (Silva, Bazzo and 
Borges, 2007). In our centre Grocott's MSN stain is utilised for the detection of P. 
jirovecii. An internal audit demonstrated that the provision of this service was affected 
by the working hours of our cytology department with a median turnaround time of 7 
days (range 3-16) from the sample being taken to provision of results (in-house vertical 
audit, 2014). As PCP often requires rapid medical intervention, patients were almost 
always diagnosed clinically with radiological assistance. Grocott's MSN stain results 
served to confirm or rule out infection after treatment had been administered some 
days earlier.  
An alternative technique to Grocott's MSN stain is a direct immunofluorescent (IF) 
method utilising fluorescein-conjugated monoclonal antibodies targeting P. jirovecii 
(Procop et al., 2004). This stain is commercially available in several formats (Hauser et 
al., 2011; Tia et al., 2012; Choe et al., 2014) and is used mainly in laboratories with a 
specialist mycology service. When compared with Grocott’s staining IF is more 
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sensitive (Arasteh et al., 1998) with a meta-analysis reporting sensitivities ranging from 
79-94.4% (Cruciani et al., 2002). The advantage of IF is that it can detect both cystic 
and trophic forms of Pneumocystis. The fluorescent signal, demonstrated in figure 
1.12, most likely contributes to increased detection of P. jirovecii at lower 
concentrations. IF can also be performed in microbiology laboratories, making out-of-
hours testing possible. 
 
Figure 1.12 Immunofluorescence staining for the detection of Pneumocystis jirovecii in BAL fluid 
(Weinstein., 2014). 
However, implementing the immunofluorescence-based assay requires careful 
consideration. Processing samples can be time-consuming, and analysis can be 
complicated by nonspecific background staining or auto-fluorescence from structures 
such as red blood cells or eosinophilic granules which if misinterpreted can lead to 
false positive results (Procop et al., 2004). When considering immunofluorescence as a 
diagnostic assay there is a requirement to have a fully trained health care scientist to 
perform processing and microscopic analysis. There is also a need to consider the limit 
of detection when using fluorescence microscopy for P. jirovecii, reportedly 1.5 x 103 
cfu/mL from BAL (Mühlethaler et al., 2012). This LOD may not be sensitive enough to 
diagnose PCP in the atypical patient groups presenting with symptoms of PCP. 
Specific patient groups including: haemato-oncology, renal transplant and those with 
complex immunological disorders are at risk of P. jirovecii infection, typically present 
with low grade disease (Bollée et al., 2007; Roux et al., 2014). In the respective patient 
groups the burden of P. jirovecii in infection has been shown to be lower than that of 
HIV patients (Hauser et al., 2011; Seah et al., 2012). Sample type can also affect 
sensitivity. The most frequently utilised specimen for diagnosis of PCP is broncho-
alveolar lavage (BAL), which involves irrigating patient’s lungs with 60-200mL of saline 
to sample the alveolar lung spaces (Svensson et al., 2017). This inevitably has a 
dilution effect on the cfu/mL of organisms within the sample, which may further affect 
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the sensitivity of detection using microscopy. To give context, the significance of 
microorganisms such as Streptococcus pneumoniae in infection is considered to be 
upwards of >106 cfu/mL from a sputum whereas BAL utilises a cut off >103 cfu/mL 
which is accepted as significant from direct culture of the specimen (SMI B55, 2015). 
Utilising microscopy for the diagnosis of PCP may lead to infections in non-HIV patients 
being missed through lack of sensitivity.  
 
1.8.5 Serological diagnosis of PCP – (1-3)-β-D-glucan 
The detection of (1-3)-β-D-glucan is not specific for the diagnosis of PCP infection but, 
unlike some other fungal infections, the level of (1-3)-β-D-glucan detected during PCP 
infection can exceed >500pg/mL, even when IF microscopy is negative. These high 
concentrations of (1-3)-β-D-glucan are characteristic of PCP infection (Koga et al., 
2011; Damiani et al., 2013). Studies have demonstrated that (1-3)-β-D-glucan 
negativity can be used to exclude a diagnosis of PCP with NPV > 99% as the assays 
show a high degree of sensitivity (Onishi et al., 2012; Karageorgopoulos et al., 2013). A 
positive result cannot be used to definitively diagnose PCP as other fungi such as 
Aspergillus to which the patient is also susceptible, contain (1-3)-β-D-glucan. Specificity 
of (1-3)-β-D-glucan detection ranged between 75%-86.3% in three meta analyses 
(Onishi et al., 2012; Karageorgopoulos et al., 2013; Li et al., 2015). Specificity can also 
be impacted by false positive reactions, which have been documented for IVIG 
infusions (Ramsay et al., 2016). The (1-3)-β-D-glucan assay has a positivity threshold 
>80pg/mL. If a higher threshold of >300pg/mL is used for defining a positive (1-3)-β-D-
glucan result for the diagnosis of PCP it can further improve the specificity as 
demonstrated by Damiani et al (2015) reporting a sensitivity of 91% and a specificity of 
92% (Damiani et al., 2015). Due to the lack of specificity a positive (1-3)-β-D-glucan 
result should always be interpreted alongside a specific assay, such as IF or PCR, and 
radiological findings (White et al., 2017) for the diagnosis of PCP. 
 
1.8.6 PCR for the diagnosis of PCP 
Recently published ECIL guidelines for PCP diagnosis, which included 34 studies of 
PCR testing in the report, gave the highest rating of AII (AI was not possible as 
randomized control trials are lacking in literature) for the use of PCR in the diagnosis of 
PCP (Alanio et al, 2016). The use of Immunofluorescence for PCP diagnosis was also 
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given the same AII recommendation (Alanio et al, 2016). A negative PCR result was 
given an AII rating for its ability to rule out PCP infection when testing BAL samples 
(Alanio et al, 2016). This is owing to the high negative predictive value and sensitivity of 
PCP PCR. Across three recent meta-analyses PCR was shown to have an NPV of 
≥99% (Lu et al., 2011; Fan et al., 2013; Summah et al., 2013; White, Backx and 
Barnes, 2017). The pooled sensitivity was 97-99%, demonstrating the strength of PCR 
in its ability to detect P. jirovecii in clinical specimens. As P. jirovecii is known to 
colonise the lungs, this can complicate the use of PCR as a diagnostic test for PCP 
(Davis et al., 2008). The PPV was reported to be 66-85% and specificity 90-94%, as 
false positive PCR results occur when colonization is detected but the patient is not 
clinically diagnosed as having PCP (Lu et al., 2011; Fan et al., 2013; Summah et al., 
2013; White, Backx and Barnes, 2017. False positive PCR results (thought to be as a 
result of colonization) are of constant debate as a patient must be considerably sick to 
warrant taking a BAL for the investigation of their lung infection PCR is the only 
diagnostic test that can specifically detect P. jirovecii at low levels and it is clear that 
further research is required to understand the role of P. jirovecii when detected by PCR 
in cases of lung infection not thought to be PCP. This confounding issue prevents the 
use of PCR routinely in most diagnostic laboratories.  
 
1.8.7 Prophylaxis and treatment of PCP  
Due to the severity of PCP infection and the risk in HIV infected individuals and 
immunosuppressed patients’, prophylaxis is routinely given to prevent infection. 
Several guidelines are available detailing criteria for selecting patients requiring 
prophylaxis from ECIL, the American Society of Transplantation and CDC, NIH and 
HIVMA/IDSA (Mofenson et al., 2009; Martin and Fishman, 2013; Alexandre Alanio et 
al., 2016). For HIV positive patients prophylaxis is recommended with a CD4 count 
<200 cells/µL or <14% if the patient is being routinely monitored, this increases to a 
threshold of 200-250 cells/µL in the absence of quarterly monitoring (Mofenson et al., 
2009; Martin and Fishman, 2013; Alexandre Alanio et al., 2016). In haemato-oncology 
patients’ prophylaxis should be given to acute lymphocytic leukaemia patients, 
allogenic HSCT patients with steroids or those receiving some forms of immune 
depleting therapy (e.g. Rituximab). In solid organ transplant patients all are considered 
at risk and requiring prophylaxis especially with graft rejection-prevention therapies, 
prolonged corticosteroids or neutropenia (Martin and Fishman, 2013). The length of 
prophylaxis is considerable, from 3-12 months across these groups and may be life-
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long in some instances. A standard prophylactic regimen across all at-risk groups of 
oral trimethoprim/sulfamethoxazole, with dapsone or pentamidine as alternatives when 
trimethoprim/sulfamethoxazole is not an option therapeutically (Mofenson et al., 2009; 
Martin and Fishman, 2013; Alexandre Alanio et al., 2016). For patients diagnosed with 
PCP who require treatment, intravenous trimethoprim/sulfamethoxazole is 
recommended as empirical therapy. The alternative therapy of primaquine and 
clindamycin is recommended in HIV and haemato-oncology patients. For SOT patients 
IV pentamidine is recommended as an alternative (Mofenson et al., 2009; Martin and 
Fishman, 2013; Alexandre Alanio et al., 2016).  
1.9 Invasive mould infection 
In contrast to Candida and Pneumocystis, moulds or filamentous fungi are exogenously 
aquired from the environment as most fungi exist within the environment as saprophytic 
organisms (Carris and Little, 2012). Filamentous fungi liberate their conidia (spores) 
into the environment. Germination of conidia occurs when conidia enters an 
environment suitable to the growth requirements of that mould i.e. temperature and 
nutrients (Carris and Little, 2012). Once germinated a mycelial network forms and 
grows into a complex multicellular organism (Carris and Little, 2012). Figure 1.13 
demonstrates the life cycle of a mould.  
 
Figure 1.13 Life cycle of a mould from conidia to mycelium with fruiting structures and spore 
production (www.blackmould.me.uk). 
Mycelium 
Conidia 
Germination 
Spore 
production 
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Non-endemic filamentous fungi implicated in invasive mould infections are harmless to 
the immunocompetent population who breathe in in excess of 2000 conidia per day 
without any risk of infection (Boddy, 2016). For immunocompromised patients this 
inoculum can be deadly. Invasive Aspergillosis (IA) accounts for the main burden of 
invasive mould disease with greater than 95% of invasive mould infections being due to 
this genus (Brown et al., 2012). The Prospective Antifungal Therapy registry (PATH) 
reported Aspergillus as the cause of 13.3% of all invasive fungal infections (Azie et al., 
2012) Non-Aspergillus invasive moulds infections are rare but have been reported to 
include fusariosis, mucormycosis and scedosporiosis (Slavin et al., 2015). 
 
1.10 Invasive Aspergillosis 
More than a hundred species of Aspergilli have been identified to date, despite this, 
greater than 70% of IA results from infection by a single species, Aspergillus fumigatus 
(Ascioglu et al., 2002; Kibbler, 2005; De Pauw et al., 2008; Shoham and Marr, 2012). 
A. fumigatus is one of the most abundant species of fungus in the environment. Its 
spores are small measuring 1-2µm in size, therefore are small enough to penetrate the 
alveolar lung spaces when inhaled (Deacon et al., 2009). A. fumigatus is also thermo-
tolerant and is able to thrive at 37°C (Rhodes, 2006). These two factors contribute to 
the dominance of A. fumigatus as a cause of invasive fungal infection.  
 
1.10.1 Epidemiology of Invasive Aspergillosis 
Patients at risk of IA include haemato-oncology patients, [especially hematopoietic 
stem cell transplant (HSCT) recipients], solid tumour oncology patients, solid organ 
transplant (SOT) patients and ICU patients (Kontoyiannis et al., 2010). Recent data 
reported from the Transplant-Associated Infection Surveillance Network (TRANSNET) 
collected from 16,200 HSCT patients reported a cumulative incidence of 1.6% over a 
12 month period with the highest incidence rates in the mismatched related and 
unrelated matched donor transplant recipients (Kontoyiannis et al., 2010). In the adult 
intensive care setting incidence rates of 6.1 per 1000 are experienced (Tortorano, Dho, 
et al., 2012). Unsurprisingly in the SOT patient group lung transplant recipients are 
most at risk of developing IA with a cumulative incidence of 2.4% compared to 0.8%, 
0.3% and 0.1% for heart, liver and kidney transplants respectively (Morgan et al., 
2005).  
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Mortality rates in the haemato-oncology setting, amongst HSCT patients and in the ICU 
are greater than 40% (Morgan et al., 2005; Nicolle et al., 2011; Pacholczyk et al., 
2011). In the paediatric haematology/ICU setting mortality rates are much higher (Azie 
et al., 2012). Associated risk factors include haematological malignancy, allogeneic 
bone marrow transplantation, immuno-suppressive therapies, granulocytopenia, 
corticosteroids and solid organ transplant (Fukuda et al., 2003; Baddley, 2011; 
Kosmidis and Denning, 2015; Miceli et al., 2017).  
Although A. fumigatus causes more than 95% of cases of invasive aspergillosis, other 
species are rarely implicated in IA including, A. niger, A. flavus and A. terreus 
(Krishnan, Manavathu and Chandrasekar, 2009; Xavier et al., 2009; Risslegger et al., 
2017). Aspergillus sp are generally susceptible to most antifungal agents but in the last 
decade increased levels of resistance have been reported (van der Linden et al., 
2015), in particular to azole antifungal agents. The high use of antifungal therapy and 
the agricultural use of azoles for crop control are contributing factors for the emergence 
of resistant strains (Vermeulen, Lagrou and Verweij, 2013; Verweij et al., 2013). Recent 
studies have demonstrated that up to 13% of infections are caused by azole resistant 
strains of Aspergillus in the Netherlands, whereas in the UK resistance rates of 6.8 – 
28% have been reported within clinical strains of Aspergillus fumigatus (Vermeulen, 
Lagrou and Verweij, 2013; Verweij et al., 2013; Meis et al., 2017, Howard et al, 2009, 
Mortensen et al, 2011).  
 
1.10.2 Clinical presentations of Invasive Aspergillosis  
IA is primarily a pulmonary infection resulting from inhalation of spores into the lung 
accounting for >90% of primary infection (Ascioglu et al., 2002; Kibbler, 2005; De Pauw 
et al., 2008; Shoham and Marr, 2012). Infection is defined by invasion of the pulmonary 
parenchyma by the growing hyphae of Aspergillus (Chabi et al., 2015). Invasive 
Aspergillosis can be further described as being ‘angio-invasive’ demonstrating vascular 
invasion as described by radiological imaging (Chabi et al., 2015). The clinical 
symptoms of IA are non-specific, including fever that is refractory to broad-spectrum 
antibiotics (Ascioglu et al., 2002; Kibbler, 2005; De Pauw et al., 2008; Shoham and 
Marr, 2012). Cough, chest pain and haemoptysis are documented symptoms, but not 
common to all infections (Ascioglu et al., 2002; Kibbler, 2005; De Pauw et al., 2008; 
Shoham and Marr, 2012). As part of the diagnostic pathway a patient who is at risk of 
IFI should receive a HRCT scan of the lungs to detect signs of an invasive infection 
(Misch and Safdar, 2016; Patterson et al., 2016). Figure 1.14 demonstrates the typical 
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presentation of a lesion surrounded by ground glass appearance, described as the halo 
sign. This characteristic presentation is caused by hyphae invading new tissue inducing 
haemorrhage during an angio-invasive process (Georgiadou et al, 2011). When seen 
on histopathological presentation there is a strong indication for the diagnosis of 
Invasive Aspergillosis (Greene et al., 2007; Verweij, van Die and Donnelly, 2007). 
However, the halo sign is transient; and has been shown to be present in 68% of 
patients at day 3 reducing to 19% of patients after two weeks of infection (Caillot et al., 
2001). IA may also present as invasive sinusitis, central nervous system infections, 
osteomyelitis, endophthalmitis and endocarditis resulting from dissemination or direct 
inoculation (Levin et al., 1996; Schwartz and Thiel, 1997; Koehler, Tacke and Cornely, 
2014). Symptoms of disseminated infection are related to the location of the infection 
with deteriorating organ function in cases of liver or renal disease. Seizures or other 
focal neurological signs are noted that could indicate cerebral dissemination 
(Kourkoumpetis et al., 2012). With a lack of specific symptoms to aid diagnosis and 
variable radiological interpretation the diagnosis of IA also relies on clinical laboratory 
methodologies to detect Aspergillus from a variety of clinical specimens. 
 
 
 
 
 
 
 
Figure 1.14 Lung lesions with the halo appearance typical of pulmonary invasive aspergillosis 
due to a defined circumscribed lesion surrounded by ground glass shadowing (Sheetal Shroff et 
al, 2014). 
 
1.10.3 Laboratory diagnosis of Invasive aspergillosis 
Conventional microbiological methods for diagnosing IA include serological based 
testing, specifically Galactomannan Enzyme Immune Assay (GM-EIA), direct 
microscopy from clinical specimens and culture (de Pauw et al., 2008). 
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1.10.4 Histopathology of tissue sections 
The current gold standard and most specific diagnostic method is histopathological 
assessment demonstrating hyphae within tissue (de Pauw et al., 2008). Haematoxylin 
and eosin (H&E) staining will reveal the presence of Aspergillus hyphae whereas more 
specific stains such as periodic acid Schiff (PAS) and Grocott’s methenamine silver 
(GMS) will increase sensitivity and should be carried out whenever a fungal infection is 
suspected (Barton, 2013). In addition to fungal hyphae the PAS staining method 
detects polysaccharides, glycoproteins, glycolipids and mucins in tissues (Alturkistani, 
Tashkandi and Mohammedsaleh, 2016). This stain is only effective with living fungi (at 
time of biopsy or resection) as cell walls contain high levels of carbohydrate which stain 
PAS-positive (Alturkistani, Tashkandi and Mohammedsaleh, 2016). In contrast the 
GMS stain can detect both living and dead fungi in tissues. Polysaccharides within the 
cell walls are oxidized to release aldehyde groups (Alturkistani, Tashkandi and 
Mohammedsaleh, 2016). The aldehyde groups then react with the silver nitrate, 
reducing it to metallic silver staining fungal elements black in colour, figure 1.16 
although histopathological investigation is high in specificity in determining that a 
fungus is present in tissue, refining the fungal identification further is challenging. It is 
possible to distinguish between Ascomycetes (septate) and the Mucoromycotina (non-
septate) but histopathology cannot be used to identify fungal species in most cases of 
infection (Vyzantiadis, Johnson and Kibbler, 2012). 
 
 
 
 
 
 
 
Figure 1.15 PAS stain for Invasive candidiasis (Mohammadi et al, 2015). 
A limiting factor is that a high degree of interpretative skill is required for the accurate 
identification of the different fungal infections in histopathological sections. Figure 1.16 
demonstrates the varying appearance of fungi in Grocott’s stain from two different IFI of 
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Mucor and Aspergillus. Measuring the hyphae may assist interpretation as Aspergilli 
typically have hyphae with a diameter of 1-3µm (Barton, 2013). As IFI is rare, exposure 
to histopathological cases is limited and in centres without skilled histopathologists 
misidentification of fungi from sections can often occur (Vyzantiadis, Johnson and 
Kibbler, 2012). For this reason reports are often limited to stating ‘hyphae’ or 
‘filamentous fungi seen’.   
 
 
 
 
 
 
 
a)                                                                  b)  
Figure 1.16 Grocott’s staining for fungi in histopathological sections of tissue, from left to right 
showing Mucor sp and Aspergillus fumigatus (Cho et al., 2007; Chow et al., 2015).  
 
1.10.5 Microscopy and culture of Aspergillus sp from clinical specimens  
If a fresh biopsy is available specimen culture is the conventional approach for the 
recovery of Aspergillus. Other specimen types such as sputum, BAL aspirates and 
sterile fluids such as CSF may also be sent for investigation.  
Direct microscopy should always be performed on sterile specimens and BAL 
(Schelenz et al., 2009, 2015). Direct microscopy can also be performed on sputum, 
although this is not routinely practiced, as the analysis of sputum using fluorescent 
microscopy may lead to false positive results. Commonly a fluorescent brightener, 
calcofluor, is added to the specimen on a slide and analysed using fluorescence 
microscopy (Harrington and Hageage, 2003). Direct microscopy lacks specificity as the 
fruiting structures required for identification of Aspergillus rarely occur in vivo. 
Specimen quality also can have an impact on the results (Kozel and Wickes, 2014). If 
hyphae are seen they may be from any number of filamentous fungi. Dichotomous 
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branching has been used to try and distinguish Aspergillus from other mould species 
as in figure 1.16 b. The accuracy of histology for the identification of fungi when 
compared with culture was reported to be 83% (Kozel and Wickes, 2014). 
Culture for Aspergillus in suspected infection should always be undertaken. Isolating 
Aspergillus from infection is the only clinical investigation that enables vital 
susceptibility testing to be performed, guiding targeted antifungal therapy. Aspergillus 
sp are relatively rapid in growth (typically will grow within 48 hr) and will culture on most 
microbiology media including selective Sabouraud’s agar but also on standard bacterial 
agar such as blood agar. However, the sensitivity of culture is less than optimal. Table 
1.6 details culture rates based on specimen type, overall sensitivity does not exceed 
62%, and from sputum can be as low as 8% (Denning, 2005). 
 
 
 
 
 
The sensitivity of culture for Aspergillus is most likely affected by a lack of standardised 
laboratory sample preparation methods, with standards for microbiological 
investigations (PHE Surveillance Services, 2015) unsuitable for fungal workup. The 
current SMI of sputum in the U.K recommends a 1µL loop of sputum to be inoculated 
onto a Sabouraud’s agar slope. Fungal elements within sputum are not as abundant as 
bacteria so it is likely that a much larger volume of sputum is required for optimal fungal 
recovery. A recent study by Fraczek et al (2014) improved sensitivity of culture from 
respiratory specimens was reported by using higher volume cultures, with 44% of 
sputum samples positive for Aspergillus compared with 0% using the SMI 
methodology. Higher volume cultures resulted in the x100 fold increase in the number 
of fungal colonies isolated from clinical specimens. This alone suggests the culture of 
Aspergillus from clinical specimens requires significant improvement and 
standardisation to enhance its reproducibility, clinical accuracy and ultimately its 
usefulness in diagnosing IA (Fraczek et al., 2014). 
If Aspergillus is isolated from clinical specimens the interpretation and identification of 
most Aspergillus species is straightforward (de Hoog and Guarro, 1995). Macroscopic 
and microscopic characteristics, including colony forming morphology, growth rate and 
Table 1.6 Sensitivity of culture for Aspergillus from clinical 
specimens (Denning, 2005) 
Specimen Culture rate 
Sputum 8 – 34% 
BAL 45 – 62 % 
Blood/CSF Rarely positive 
Tissue 56% 
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morphology of fruiting structures such as the vesicles are used to accurately determine 
identification. Occasionally atypical forms of A. fumigatus may be encountered, 
particularly in patients who have been exposed to mould active antifungal agents 
(Brandt et al., 2009). However, the epidemiology of IA is changing as molecular 
methods have led to the description of infections with de novo species A. lentulus, A. 
novofumigatus, and A. fumigatiaffinis. These species cannot be distinguished 
morphologically from A. fumigatus and require DNA based sequence analysis to 
reliably confirm their identification (Peláez et al., 2013; Ola et al., 2014; de Azevedo 
Bastos et al., 2015). Most diagnostic laboratories do not routinely sequence their 
Aspergillus isolates therefore species remain undetected until a method with higher 
resolution in identification that is applicable in the routine diagnostic setting is 
developed.  
 
1.10.6 Serological diagnosis of Aspergillosis 
The cell walls of Aspergillus spp. contain the carbohydrate molecule Galactomannan 
(GM), which is released from the cell wall during fungal growth (Morelle et al., 2005). 
During invasive infection the release of GM has been correlated with Aspergillus 
invasion of the endothelial compartment (Hope et al., 2007). Therefore, GM detection 
should be a strong indicator of angioinvasion. The Platelia Aspergillus galactomannan 
antigen sandwich enzyme immunoassay (GM-EIA) (Bio-Rad, California, USA) is used 
globally as a screening method for prospective surveillance of invasive aspergillosis 
(IA), usually through twice weekly testing of serum samples, in patients at high-risk of 
disease. BAL specimens can also be processed. The GM-EIA assay is now well 
established, reflected by its recommendation in European Organisation for Research 
and Treatment of Cancer (EORTC) MSG consensus criteria for defining invasive fungal 
disease (de Pauw et al., 2008).   
Despite this the diagnostic performance of the GM-EIA is variable, with meta-analyses 
showing combined sensitivity and specificity ranges of 71%-78% and 81%-89% 
respectively (Pfeiffer, Fine and Safdar, 2006; Leeflang et al., 2008). False positivity 
experienced using the GM-EIA has been associated with antimicrobial preparations 
involving Penicillium (e.g. piperacillin-tazobactam) as well as ingestion of ice pops and 
when testing patients with histoplasmosis infection (Pfeiffer, Fine and Safdar, 2006; 
Gerlinger et al., 2012; Tortorano, Esposto, et al., 2012; Guigue, Menotti and Ribaud, 
2013). The assessment of compounds classified as interfering substances is part of the 
In Vitro Diagnostic (IVD) regulations to bring a commercial assay to market. These 
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substances should be tested as part of the assay validation and findings reported to 
users within the assay interpretation guidelines. Laboratories are required to work 
directly with clinical teams to ensure where possible interfering substances are limited. 
Although initially, the GM-EIA assay reproducibility was reported to have high inter-
laboratory reproducibility (Pedroza et al., 2013), recent reports document a lack of 
precision when repeat testing positive samples (Furfaro et al., 2012). In particular, 
samples with an optical density index (ODI) value on or around the positivity threshold 
of the assay (0.5) are regularly found to be negative on repeat testing (Upton et al., 
2005; Kimpton, White and Barnes, 2014). The storage conditions of the primary 
specimen appears to impact on reproducibility with a significant decline in sample ODI 
values reported after storage at -80C (Kimpton, White and Barnes, 2014). IA diagnosis 
also appears to be important, with a lack of reproducibility more frequently observed 
when retesting false positive samples from patients without IA (Furfaro et al., 2012; 
Kimpton, White and Barnes, 2014). A significant correlation between serum albumin 
concentration and difference in ODI value on retesting has also recently been reported 
(Upton et al., 2005). Improved standardisation of the GM EIA has been demonstrated 
by automating the assay on an ELISA processing platform (Gorton et al., 2015). 
However, due to the respective performance limitations the GM-EIA cannot be used as 
a stand-alone diagnostic test but is an important component of the diagnostic testing 
strategy for IA.   
 
1.10.7 PCR for the diagnosis of Invasive Aspergillosis  
The use of PCR for the diagnosis of invasive aspergillosis remains a debated issue 
despite recent advances in standardisation, primarily through the work of the European 
Aspergillus PCR Initiative (EAPCRI) (White et al., 2010). Performance of PCR is 
heavily dependent on the specimen type being investigated. The main two specimens 
used for the detection of Aspergillus from patients suspected of having IA are BAL and 
blood. PCR testing on BAL was first published in 1993 with multiple studies showing 
consistent performance with sensitivity and specificity rates ranging between 76.8-
79.7% and 93.7-94.5% respectively (Tuon, 2007; Sun et al., 2011; Avni et al., 2012). 
PCR from BAL is clinically useful for ruling out infection with a high NPV. When 
considering PCR from blood specimens these must be broken down into whole blood, 
serum and plasma. The performance of PCR from the different fractions of blood 
varies. When comparing whole blood to serum the sensitivity is 85% compared with 
79% respectively, but the specificity is lower for whole blood 65% compared with 84% 
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for serum (Springer et al., 2016). The investigation of plasma as an alternative to 
serum shows superior sensitivity 95% compared with 68% for serum (White et al., 
2015). As serum or plasma can be processed using simplified extraction methods, as 
opposed to whole blood that can be complicated due to the requirement of 
centrifugation, red cell lysis and washing stages, serum and plasma present as the 
more optimal sample types for Aspergillus PCR. In a recent meta-analysis Mengoli et al 
reported that a single positive PCR reaction alone was not sufficient for the diagnosis 
of IA as the sensitivity and specificity were reported as 0.88 (95% CI 0.75-0.94) and 
0.75 (95% CI 0.63-0.84), respectively (Mengoli et al., 2009). Aspergillus PCR is not 
used routinely by most laboratories for this reason and is confined to use in specialist 
mycology laboratories.   
 
1.10.8 Prophylaxis and treatment of invasive aspergillosis  
The use of prophylaxis for patients at risk of developing IA is in part due to the 
aforementioned lack of robust diagnostic testing pathways to rapidly detect an 
infection. Currently empirical treatment of invasive aspergillosis as the first line 
recommendation is IV voriconazole, table 1.7. Isavuconazole, a recently released 
broad spectrum azole, was also given the highest rating by the ECIL-6 (2016) and 
IDSA guidelines (2016) as the first line therapy (Thomas F Patterson et al., 2016; 
Tissot et al., 2016). An alternative first line option is liposomal Amphotericin B but only 
in patients unable to receive azoles or in the rare instance of knowing an isolate is 
resistant to azole antifungals.  
 
Table 1.7 ECIL and IDSA recommendations for the management of invasive 
Aspergillosis (Thomas F Patterson et al., 2016; Tissot et al., 2016) 
 ECIL-6 IDSA 
First line 
treatment 
voriconazole (AI*) voriconazole (strong high quality*) 
Alternative Isavuconazole (AI*) Isavuconazole (strong moderate*) 
Alternative 
Liposomal Amphotericin B 
(BI*) 
Liposomal Amphotericin B  
(strong moderate*) 
*see table 1.2 for overview of evidence ratings  
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The main stay of prophylaxis, as recommended by 2008 consensus antifungal 
guidelines is Itraconazole or posaconazole (Slavin et al., 2008). Both antifungals can 
be administered orally providing an advantage in the management of this patient group. 
 
1.11 Non-Aspergillus invasive mould infection  
There are many species of fungi reported in the literature as etiological agents of IFI. 
Immuno-compromised patients are susceptible to any mould that presents a risk of 
infection. Some fungi are more commonly encountered than others in IFI. The 
incidence of non-Aspergillus invasive mould infection is difficult to define, as the 
incidence is very low in comparison to other invasive fungal diseases. Two of the most 
common infections are mucoraceous mould infections, with an estimated annual 
incidence of >10,000 cases globally (Brown et al., 2012), and fusariosis for which an 
estimated global incidence has not been reported. In the high-risk haemato-oncology 
setting fusariosis cases range from 0.8-3.1 per 1000 patients (Garnica et al., 2015) and 
are responsible for 3-5% of all invasive fungal disease (Rostaing and Malvezzi, 2016). 
The majority of non-Aspergillus fungi are found in the environment either within 
compost heaps and decaying vegetation (Mucoraceous mould) (CDC, 2011) or are wet 
moulds found within sewers or ponds/lakes (Scedosporium/Fusarium) or other 
environments of this type (Luplertlop et al., 2016).  
 
1.11.1 Epidemiology of non-Aspergillus invasive mould infection 
A small number of studies have been published on the epidemiology of non-Aspergillus 
IFI. The largest study by Slavin et al (2015) details infections reported across a six-year 
time span in Australia (Slavin et al., 2015). Over 23 fungal species were reported from 
180 proven/probable invasive fungal infections (Slavin et al., 2015). The most common 
fungi included those of the Mucoromycotina, Scedosporium sp and Fusarium sp. In two 
similar studies published on data generated from the USA a similar distribution of 
fungal species was also reported (Park et al., 2011), table 1.8. The respective species 
are the commonest non-Aspergillus species implicated in IFI and will be considered as 
a representation of the diverse group of non-Aspergillus invasive fungal infections. 
In a recent report by Guinea et al there was a significant increase in the incidence of 
mucormycosis from 1.2 cases/100,000 hospital admissions between 1988-2006 to 3.3 
cases/100,000 hospital admissions between 2007-2015 (Guinea et al., 2017) 
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Mucormycosis accounts for the greatest proportion of non-Aspergillus mould infections 
in the USA and Australia (Slavin et al., 2015) and globally (Lass-Flörl and Cuenca-
Estrella, 2017). In the adult population mortality rates associated with non-Aspergillus 
mould infection can range from 20-50% (Lass-Flörl and Cuenca-Estrella, 2017). The 
most commonly reported risk factor for Mucormycosis being uncontrolled diabetes 
mellitus (Vijayabala et al., 2013). Other risk factors for mucormycosis IFI include 
haematological disorders, solid organ transplant and trauma patients (Wu, Zhang and 
Jiang, 2010; Petrikkos et al., 2012; Lelievre et al., 2014; Mitchell et al., 2014; Kermani 
et al., 2016; Moreira et al., 2016; Zahoor, Kent and Wall, 2016) amongst other 
immunosuppressive conditions. The most commonly implicated fungi include Mucor sp, 
Rhizopus sp and Lichthemia sp accounting for 70-80% of mucormycosis (Wu, Zhang 
and Jiang., 2010; Petrikkos et al., 2012; Leiievre et al, 2014; Mitchell et al., 2014; 
Kermani et al,. 2016; Moreira et al., 2016; Zahoor, Kent and Wall., 2016). 
 
Table 1.8. Documented proven and probable cases of non-
Aspergillus infections from two large multi-center surveillance 
studies in Australia and the USA.  
Organism 
2004-2012 
(Slavin et al., 2015) 
2001-2006 
(Park et al., 2011) 
 
Australia USA 
Mucoromycotina 74 105 
Scedosporium sp 54 27 
Fusarium spp 13 37 
 
Fusariosis is more frequently described as an emerging fungal infection with increasing 
incidence (Nucci et al., 2015) but infection remains rare. Fusariosis is associated with 
48-90% mortality (Lass-Flörl and Cuenca-Estrella, 2017) but can be lower with 44% 
survival as reported from a review of 65 cases (Horn et al., 2014). Patients at risk of 
fusariosis are the same at-risk patient group as for IA, including neutropenia, 
corticosteroids, HIV, haematological malignancies, transplant and patients with 
prosthetic devices (Dabas, Bakhshi and Xess, 2016). As this genus of moulds are 
commonly associated with wet environments further risk factors include working in or 
exposure to contaminated wet environments (Peman and Salavert, 2014). Over 300 
Fusarium species have been described with the most frequently implicated species in 
infection being F. solani, F. oxysporum and F. moniliforme (Horn et al., 2014). The 
most important factor clinically when treating Fusariosis is the choice of antifungal 
therapy. There is a wide range of variability across species with regards to 
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susceptibility to antifungal agents, presenting a challenge for the selection in clinical 
practice. Identifying the Fusarium species causing an infection is crucial for optimal 
management of infection (Muhammed et al., 2011) 
Scedosporium sp, like Fusarium, are wet moulds found in sewage, soil, water and 
other areas mostly with decaying vegetation. Acquisition of infection is either through 
contact with contaminated environments or inoculation of inhalation/ingestion of the 
fungus (Tadros et al., 1998; Nesky, McDougal and Peacock Jr, 2000). Primary sources 
of infection are the lungs and open wounds. Patients at risk of being infected by 
Scedosporium are the same patients as Fusarium and Aspergillus. In a review by 
Johnson et al (2014) of 57 cases in solid organ transplant patients the mortality rate 
was 54%. Scedosporiosis is generally caused by two species, S. apiospermum and S. 
prolificans (Johnson, Shields and Clancy, 2014). S. apiospermum reportedly causes a 
greater proportion of infections than S. prolificans (Johnson, Shields and Clancy, 
2014). Both species are intrinsically resistant to Amphotericin B (Ambisome®) but 
infection with S. prolificans is complicated as this species conveys greater intrinsic 
resistance to most antifungal agents (Wang et al., 2015; Goldman et al., 2016). Choice 
of effective therapy is again reliant on accurate diagnosis of infection through 
speciation of the fungus. A wide range of infections have been reported including bone 
and joint infections and also haematogenous spread and dissemination (Peman and 
Salavert, 2014). 
 
1.11.2 Clinical presentation of Non-Aspergillus invasive mould infection 
Spores of mucoraceous moulds are large in comparison to other fungi, measuring 7-
10μm in diameter compared with Aspergillus conidia measuring 1-3μm in diameter 
(Wang et al., 2018). Infection presents commonly as rhino-cerebral disease, as the 
spores are lodged inside the nasal cavity. Pulmonary infection can occur and has a 
higher incidence in haemato-oncology patients. Wound infection post trauma is a 
recognised complication in scenarios such as road traffic accidents, military personal 
and in the aftermath of natural disasters such as tornado (Wu, Zhang and Jiang, 2010; 
Binder, Maurer and Lass-Flörl, 2014; Riley et al., 2016). Infections with mucoraceous 
fungi are aggressive and tissue damage is characterised by severe necrosis, becoming 
black as the infection progresses (Wu, Zhang and Jiang, 2010; Binder, Maurer and 
Lass-Flörl, 2014; Riley et al., 2016). Patients present with fever and sore sinus and 
within hours this will have progressed to proptosis and cerebral pain, blurred vision and 
a breakdown in the facial tissue. In pulmonary or wound infection disseminated disease 
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via haematogenous spread is more likely to develop; with characteristic blackened skin 
lesions often present at the source of infection (Wu, Zhang and Jiang, 2010; Binder, 
Maurer and Lass-Flörl, 2014; Riley et al., 2016).  
 
Figure 1.17. Survival curve for non-Aspergillus fungal infection from 180 cases recorded over 6 
years in Australia (Slavin et al., 2015). 
Fusariosis and scedosporiosis presents typically as a pulmonary infection (cough and 
dyspnoea), with a sepsis like syndrome and fever refractory to antimicrobials (Husain 
et al., 2005; Cortez et al., 2008; Peman and Salavert, 2014). Hypotension has been 
noted in HCST patients (Husain et al., 2005; Cortez et al., 2008; Peman and Salavert, 
2014). Haematogenous spread is more likely in HCST patients, and was noted in 33% 
of HSCT patient compared with 11% in SOT patients for Scedopsorium infection 
(Hussein, rodriguez-tudela). In disseminated infection, skin lesions are commonly 
reported with 36% of HSCT recipients reported to have cutaneous involvement with 
scedosporiosis (Husain et al., 2005). Infection through inoculation is commonly 
reported in patients with a wound at the site of infection. The infecting species can 
impact on the clinical presentation, with S. prolificans being significantly more 
associated with fungaemia compared with S. apiospermum infection (P = .009) (Husain 
et al., 2005). Central nervous system involvement is common and patients will present 
with sign of cerebral infection (Rodriguez-Tudela et al., 2015). In figure 1.17 the 
survival rates of patients with non-Aspergillus invasive infection are plotted over days. 
Mucoraceous infection, scedosporiosis and fusariosis have similar survival rates with 
40% mortality at 20 days reducing to 45-50% mortality after day 50 (Slavin et al, 2015).  
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1.11.3 Laboratory diagnosis of Non-Aspergillus invasive mould infection 
1.11.4 Microscopy for the detection of non-Aspergillus IFI 
Direct miscopy on clinical specimens can be performed using a fluorescent brightener 
such as Calcofluor on tissue, fluid and respiratory specimens. This test is usually 
performed if there is a high degree of suspicion for fungal infection. Performance data 
for direct microscopy is lacking in the literature. There is a single key difference in the 
appearance of mucoraceous fungi compared to ascomycete fungi in direct microscopy 
preparations, that being the size of the hyphae (Hageage and Harrington, 1984). Figure 
1.18 illustrates images of mucoraceous fungi stained with calcofluor compared with 
Aspergillus. Hyphae of mucoraceous fungi are wide ribbon like hyphae, septa are 
infrequent and the hyphae appear irregular. Ascomycetes have thinner hyphae, septa 
are clearly visible and branching is defined with regular lines of the hyphae (Hageage 
and Harrington, 1984). If a mucoraceous infection is suspected the ability to distinguish 
the presence of hyphae direct from specimen is crucial to rapid diagnosis (Hageage 
and Harrington, 1984).  
 
 
 
 
 
 
 
Figure 1.18 Calcafluor staining of a mucoraceous mould versus an ascomycete mould 
(x40 objective) (Kalkanci and Ozdek, 2011; Vanzzini Zago, Alcantara Castro and 
Naranjo Tackman, 2012).  
 
1.11.5 Fungal culture 
The performance of fungal culture for the diagnosis of non-Aspergillus fungal infections 
is a standard of care within diagnostic microbiology laboratories (Barnes et al., 1996; 
Schelenz et al., 2015). Specimens are inoculated onto Sabouraud’s agar, either on 
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plates or slopes and cultured typically at 30°C for up to 3 weeks. In general, cultures 
are insensitive, but data are lacking on the performance characteristics for the isolation 
of non-Aspergillus species. For mucoraceous infection it is estimated that <25% of 
sputum specimens will be positive by culture for these fungi (Denning, 2005). As 
cultures typically grow within 24 hours a rapid identification can be achieved if cultures 
are positive (Denning, 2005). There is also some utility in the use of blood cultures for 
the isolation of Fusarium, with 40-60% sensitivity reported (Denning, 2005). All cultures 
from specimens with a suspicion of invasive fungal infection should be treated as 
significant and where possible full species identification achieved to enable the correct 
antifungal therapy to be administered. Identification is performed using microscopy and 
stains such as lactophenol cotton blue (Campbell, 2013). Macro- and micro-
morphological characteristics are utilised for species identification. The accuracy of 
identification for some fungal species is currently sub-optimal, especially for Fusarium 
species. This is reflected in recent studies reporting the accuracy of conventional 
identification by microscopy to be between 61.5%-80.1% (Becker et al., 2014; Gautier 
et al., 2014; Ranque et al., 2014). For non-Aspergillus isolates successful identification 
to the species level can be as low as 31% in the laboratory when compared with gold 
standard molecular identification (Ranque et al., 2014). Due to the inaccuracies in 
identification of fungi from culture using microscopy, laboratories often turn to 
molecular methods for accurate identification of the fungal species.  
 
 
 
 
 
 
1.11.6 PCR for the detection and identification of non-Aspergillus fungi  
The use of PCR for the identification of fungal isolates or fungi direct from clinical 
specimens is not routinely performed in most laboratories. In general this remains a 
function of highly specialised laboratories and reference facilities. Pan-fungal PCR 
provides an opportunity to test specimens where fungal culture is negative but hyphae 
have been observed microscopically, or to identity fungal colonies more accurately.  
Table 1.9 Sensitivity of culture for non-Aspergillus IFI  
(Denning, 2005) 
Genus Specimen  Positivity rate 
Fusarium sp Blood  40 - 60% 
Mucor sp Sputum <25% 
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There are many studies investigating the use of pan-fungal PCR, with 80-100% 
concordance with histopathology reported direct from tissue (Paterson et al., 2003; 
Bialek, 2005; Coura, 2005). Real-time PCR has been used to identify fungi from tissue 
biopsies with a sensitivity of 100% (Springer, Lackner, et al., 2016). The choice of 
target is important as 18S ribosomal PCR assays are specific to the genus level only, 
whereas, assays that target the intergenic spacer region (ITS) of the ribosomal genes 
are more specific and can identify fungi to the species level (Borman et al., 2008). The 
identification of Fusarium species can be more complicated and a combination of 
targets are usually utilised (Geiser et al., 2004). The use of pan-fungal PCR to identify 
fungi can take up to 3 days for a result as amplicons require sanger sequencing, 
however faster turnaround times have been demonstrated using pyrosequencing 
techniques. Both modes of sequencing come with additional cost in terms of laboratory 
labor and time therefore; the use of these methods for the identification of fungi should 
be clinically justified with a degree of control. There is a need of a more accurate, rapid 
and routine method for the identification of non-Aspergillus moulds isolated from clinical 
specimens.  
 
1.11.7 Antifungal therapy and management of non-Aspergillus invasive 
fungal infection  
The optimal treatment for non-Aspergillus fungal infection has yet to be defined, as 
there are wide variations in the antifungal susceptibility of non-Aspergillus fungi. For 
mucoraceous fungal infection surgical debridement is an essential intervention, in an 
attempt to remove as much of the infected tissue to prevent spread of the infection 
(Cornely, Arikan-Akdagli, et al., 2014; Tissot et al., 2016). As infections are often rhino-
cerebral in presentation this treatment is not always possible. Antifungal therapy is 
usually IV high dose liposomal amphotericin B (Ambisome®). posaconazole (IV) has 
shown some potential as an alternative agent. In reality when faced with mucoraceous 
fungal infection combination therapy is often administered. The treatment of 
scedosporiosis and fusariosis is heavily dependent on the causative species and in the 
absence of identification voriconazole if often administered as first line antifungal 
therapy.  
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1.12 Molecular diagnostic tool box 
There are a variety of molecular techniques that can be applied to the diagnosis of 
infectious diseases. Strengths and limitations of these techniques should be 
considered when selecting which method is best suited to the disease being 
diagnosed. In essence a molecular toolbox is available to scientists that can be used to 
improve the detection of microbial pathogens from clinical specimens.  
1.12.1 Parameters used to determine the performance of a diagnostic test 
When developing or selecting a method for use as a diagnostic test several parameters 
need to be considered; a) the assessment of the method’s ability to provide an 
accurate diagnostic result, b) the reproducibility and complexity of the test and c) cost. 
Diagnostic accuracy is measured against a gold standard. 
1. Gold standard; the gold standard can be a test (or a combination of tests) that 
is considered the current preferred method of diagnosing a particular disease 
either offered within an existing service or performed elsewhere (e.g. in the 
context of centres of clinical excellence or specialist referral laboratories). 
Alternatively clinical classification of patients according to defined and agreed 
criteria can also be utilised as the gold standard, this approach is typically used 
for measuring performance of fungal diagnostics as there is a lack of a series of 
gold standard analytical tests for comparison (Altman and Bland, 1994; Lalkhen 
and McCluskey, 2008).  
 
  
Presence of disease  
(Gold standard) 
  Positive Negative 
Test 
outcome 
Positive 
True positive 
(A) 
False 
Positive (B) 
PPV A/A+B 
Negative 
False 
negative (C) 
True 
negative (D) 
NPV C/C+D 
  Sensitivity Specificity   
  A/A+C D/B+D   
 
Figure 1.19 four by four table for the calculation of test performance parameters 
against a gold standard, including sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV). 
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2. Analytical Sensitivity and Limit of detection (LOD); the sensitivity of a test is 
its ability to correctly detect a disease. To calculate sensitivity you must divide 
the true positive result by the true positive plus the false negative results 
(Altman and Bland, 1994; Lalkhen and McCluskey, 2008).  
 
3. Specificity: is a measure of a test’s ability to correctly determine that control 
patients as not having disease. To calculate specificity you must divide the true 
negatives by the true negatives plus the false positives (Altman and Bland, 
1994; Lalkhen and McCluskey, 2008).  
 
4. Positive predictive value; is essentially a percentage of the patients with a 
positive test who have the disease. To calculate the PPV you must divide true 
positive result by the true positive plus the false positive results (Altman and 
Bland, 1994; Lalkhen and McCluskey, 2008). 
 
5. Negative predictive value; is the ability of the test to determine the percentage 
of patients who do not have the disease. This value is obtained by dividing true 
negatives by false negatives plus true negatives (Altman and Bland, 1994; 
Lalkhen and McCluskey, 2008). 
 
6. Accuracy and precision; the accuracy of a test is its ability to reproduce the 
same result repeatedly without variation irrespective of the value. Precision 
relates to the ability of a test to obtain the expected result. In figure 1.20 
accuracy and precision are represented in bull’s eye diagrams, demonstrating 
how accuracy can be high but the result could be imprecise (Altman and Bland, 
1994; Lalkhen and McCluskey, 2008).  
 
 
 
 
 
 
Figure 1.20 Diagrammatic representations of precision and accuracy. 
Highly precise, 
highly accurate 
Highly precise, 
inaccurate 
Unprecise, 
inaccurate 
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1.12.2 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was first referenced in 1985 (Strauss, 1985) and 
over the last 30 years has developed exponentially in utility. The implementation of 
thermostable polymerases and advances in thermal cycler technology have allowed 
PCR to embed as a routine technique used throughout diagnostic laboratories. This 
technique supports a myriad of clinical applications in areas such as infection, acquired 
and hereditary malignancies cancer and pediatric and adult genetic disorders 
(Kaltenboeck and Wang, 2005). Despite considerable development in PCR technology, 
both in terms of instrumentation and chemistry, the basic principles to date still include 
formulation of a master mix consisting of primers, buffer (e.g. MgCl
2
), nucleotides and 
DNA polymerase to which the DNA template is added. PCR occurs through reaction 
cycles (35-50) consisting of DNA denaturation (95°C), primer annealing (60°C) and 
extension of the amplicons (72°C) eventually resulting in the exponential amplification 
of the target. Two PCR methods are routinely used within laboratories, conventional 
and real-time PCR (Kolmodin and Williams, 1997; Raeymaekers and Raeymaekers, 
2000; Gualberto, 2004). The latter was first developed in the late 1990’s. The 
fundamental difference between the two methods is the process of detecting 
amplification. Conventional PCR uses end point detection through visualising 
amplicons in solid phase, most commonly by gel electrophoresis, see figure 1.21 a) 
(Gualberto, 2004). The reaction mix is transferred into an agarose gel containing 
reagents that enable the amplicon to fluoresce, such as ethidium bromide. An electrical 
current is passed through the gel and the amplicons migrate according to their size. 
Detection occurs by placing the gel into an imaging platform and ultra violet (UV) light 
is passed through the gel whilst a camera images the result, figure 1.21 a) (Gualberto, 
2004). This method of detection adds an additional 1-2 hours onto the turnaround time 
for a PCR result.  
In contrast real-time PCR amplification does not require any post PCR product 
manipulation as the amplification is visualised in real time as a measure of 
fluorescence emitted from labeled probes complementary to the target being amplified 
(Raeymaekers and Raeymaekers, 2000; Arya et al., 2005). As the amount of amplified 
target increases more probe binds to its target in real time and the fluorescent signal 
increases, figure 1.21 b).  
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Figure 1.21. a) Detection of amplification for conventional PCR (gel electrophoresis) and b) real-
time PCR (fluorescence detection in real time). 
 
Both methods are still utilised in routine diagnostics. However, real time PCR has 
become the method of choice in most diagnostic laboratories, in part because of the 
ability to also quantify target within a specimen (Raeymaekers and Raeymaekers, 
2000; Arya et al., 2005). Real time PCR amplification allows a positivity threshold to be 
assigned which defines the detection point of amplification. As fluorescence increases 
and crosses the threshold a quantification cycle, Cq, is assigned to the result [figure 
1.21 b)] (Raeymaekers and Raeymaekers, 2000; Arya et al., 2005). The Cq value 
relates directly to the amount of target present within the sample. It is generally 
accepted that a change in Cq of 3 cycles is equal to a ten-fold change in concentration 
of the target (Raeymaekers and Raeymaekers, 2000; Arya et al., 2005). By generating 
a calibration curve, determined from known concentrations of target, the number of 
copies of the target within the specimen can be calculated. Therefore real-time PCR 
can be qualitative or quantitative dependent on the format results are reported in, 
whereas conventional PCR in general is qualitative only.  
One of the main strengths of PCR as a molecular diagnostic tool is very high 
sensitivity. Sensitivity of PCR is directly related to limit of detection (LOD) of the assay. 
The LOD of PCR is determined through analysis of serial dilutions of biological 
replicates and the higher dilution that achieves 95% positivity is deemed to be the LOD 
(Raeymaekers and Raeymaekers, 2000; Gualberto, 2004; Bustin, A et al., 2009). In 
theoretical analyses the LOD of PCR was reported to be equal to or greater than three 
copies of the nucleic acid targets. However, studies have demonstrated PCR assays 
such as those using digital droplet PCR methodologies that are capable of detecting a 
single copy of target DNA molecule from a variety of specimens (Hassan et al., 2006). 
The high sensitivity of PCR is made possible through specificity in the design of the 
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assay primers complementary to the target gene sequence of known pathogens. Loci 
for taxonomic identification (such as multi-copy ribosomal coding regions) are generally 
used for detection of pathogens but other targets can include phenotypic traits (such as 
antimicrobial resistance determinants), or virulence factors (Mackay, 2004; Mothershed 
and Whitney, 2006). Primer sequences are short oligonucleotide sequences designed 
to complement target genes encoding species-specific targets. The binding of primers 
to the target sequence enables the polymerase recognition and subsequent replication 
in the 5’-3’ direction (Gualberto, 2004). The choice of target determines the specificity 
of the PCR both in its ability to be unique to the species of the pathogen being 
investigated but also inclusive enough to detect all strains of that species. Primer 
design has to satisfy several parameters including; primer length (optimally 18-22 
nucleotides), a melting temperature between 52-58°C, similar annealing temperatures, 
GC content between 40-60% and avoidance of secondary structure formation whereby 
the primer loops back and sticks to itself (Gualberto, 2004). Several software packages 
are available now that can analyse a target sequence and generate primer sequences. 
In support of development of in-house or commercially available assays these include 
but are not limited to Primerdesign, Primer BLAST, Primer3. It is a requirement of 
commercial assays that the manufacturer should demonstrate specificity as part of the 
assay validation, which must be verified by the end user before clinical use in the 
diagnostic laboratory (ISO:15189., 2012).  
The highly sensitive and highly specific features of PCR have transformed the 
diagnosis of infectious diseases. The first field in the infection sciences to develop 
services utilising PCR was virology (Mackay, Arden and Nitsche, 2002; Gunson, 
Collins and Carman, 2006; Gunson et al., 2008). Viruses were difficult to detect, 
requiring culture in cell lines, such as monkey kidney cells, a process which is 
extremely time consuming and technically impossible in some instances (Mackay, 
Arden and Nitsche, 2002; Gunson, Collins and Carman, 2006; Gunson et al., 2008). 
Diagnosis of viral infection relies heavily on serological based testing for the detection 
of the host response to viruses through antibody or viral antigen detection, this process 
is still employed as front line screening but due to sensitivity and specificity issues 
antigen and antibody testing has been replaced in some instances by PCR based 
methods (Mackay, Arden and Nitsche, 2002; Gunson, Collins and Carman, 2006; 
Gunson et al., 2008). Molecular methods have since been introduced as confirmatory 
and in some cases front line detection methods. The implementation of PCR for the 
amplification of RNA and DNA viral targets advanced diagnostic virology into what is 
now a leading edge PCR based diagnostic service (Mackay, Arden and Nitsche, 2002; 
69 
 
Gunson, Collins and Carman, 2006; Gunson et al., 2008). In some circumstances 
established PCR and sequencing based methods are now being replaced by whole 
genome sequencing using next generation technology (Parikh et al., 2017). 
Bacteriology is now following the footsteps of virology with PCR based detection being 
the method of choice for hard-to-culture microorganisms. Atypical pneumonia caused 
by Mycoplasma pneumoniae, Chlamydophila pneumoniae and Legionella pneumophila 
relied heavily on serological methods to diagnose infection but increasingly PCR is 
being used to detect the atypical bacteria from respiratory specimens (Oosterheert et 
al., 2005; Ling and McHugh, 2013). The detection of Mycobacterium tuberculosis 
(MTB) by culture requires up to 6 weeks, which has now resulted in PCR becoming 
established as a rapid method for early detection of MTB in developed and developing 
countries (Rodrigues and Vadwai, 2012; McNerney and Zumla, 2015). Rapid screening 
for sexually transmitted diseases by PCR for Chlamydia trachomatis and Neisseria 
gonorrhoeae has been the front line testing strategy for over 10 years (Lee, Vigliotti 
and Pappu, 2009; Centers for Disease Control and Prevention., 2014). Recent 
developments in the diagnosis of sexually transmitted infections now include PCR for 
the detection of the flagellate parasite Trichomonas vaginalis (Šoba, Skvarč and 
Matičič, 2015) and difficult to culture bacterium Mycoplasma genitalium (Ross and 
Jensen, 2006). Probably the most recent transformation in the routine diagnostic 
laboratory is the detection of enteric pathogens from stool, with PCR replacing culture 
as the front line test in some laboratories (Koziel et al., 2013). It is fair to conclude that 
bacteriology is now undergoing a baseline shift in the methods used to routinely 
diagnose infection by incorporating PCR into both primary and secondary workflows.  
So why are fungal diagnostics lagging behind in the introduction of molecular methods 
in support of the diagnosis of fungal infections?  
What is known is that generally there is a very low burden of fungal DNA within clinical 
specimens; therefore PCR stands out as the most appropriate method to use when 
trying to detect fungi direct from these specimens (Loeffler et al., 2002). The main 
challenge faced by mycologists is the risk of environmental contamination, mainly with 
filamentous moulds (Alanio and Bretagne, 2014) but also Candida. False positives 
through the detection of colonising endogenous fungi are also of concern when using 
highly sensitive PCR assays. False positivity in Aspergillus PCR is a well-recognised 
complication when utilising PCR for the diagnosis of IFI (Alanio and Bretagne, 2014). 
Despite these complications PCR is being utilised in specialized mycology and 
reference laboratories for the diagnosis of fungal disease. In the Netherlands a survey 
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of 16 hospitals reported 12.5% (2/16) centers using PCR for fungal identification. In the 
UK a survey of 21 laboratories in 2004 reported that 28.6% (6/21) provided PCR as 
part of their diagnostic service (van der Linden et al., 2015). However, the respective 
survey was most likely subject to bias as the region surveyed has a concentration of 
specialist microbiology centers. A much larger survey of the UK published in 2008 
revealed that the proportion of laboratories offering PCR as part of their routine 
diagnostic service was proportionally considerably lower, at 14% (9/64) reporting the 
use of PCR routinely (Barnes et al., 1996). An updated survey on the diagnostic 
landscape is now underway and it is anticipated publication will reveal an increase in 
the use of PCR for the diagnosis of IFI. The main utility across centers adopting PCR 
for diagnosis of IFI is for the detection of invasive aspergilllosis, invasive candidiasis 
and Pneumocystis pneumonia (PCP). PCR is also used as a pan-fungal approach for 
the identification of fungi from a variety of clinical specimens after fungal elements are 
detected following microscopic examination, most frequently from histopathological 
assessment of tissue sections. In a recent publication in Lancet Infectious Diseases the 
British Society for Medical Mycology (BSMM) published recommendations for the 
diagnosis of serious fungal infection and included PCR as diagnostic tests for patients 
at high risk of invasive fungal disease (Schelenz et al., 2015). It is clear that the 
challenge faced is taking PCR from being a specialist test offered from regional or 
national centres to one that can be used by most routine diagnostic laboratories as a 
standard of care. In the last decade the EAPCRI has worked to standardise PCR for 
the diagnosis of invasive aspergillosis from blood and BAL specimens. The same 
group is now applying this approach in an international effort called the Fungal PCR 
Initiative (FPCRI) for the standardization of PCR for the diagnosis of invasive 
candidiasis, Pneumocystis pneumonia, mucoraceous fungal infection and PCR for the 
identification of fungi from tissues.  
 
1.12.3 Matrix assisted laser desorption ionisation time of flight mass 
spectrometry (MALDI-TOF MS) 
The term ‘matrix assisted’ laser desorption ionization mass spectrometry was first 
described by Hillenkamp et al in 1990 for the analysis of peptides and proteins 
(Hillenkamp and Karas, 1990). MALDI-TOF MS is capable of analysing a variety of 
cellular components including lipids, proteins and polysaccharides. The basic principles 
of MALDI-TOF MS are demonstrated in figure 1.22 (Vestal and Hayden, 2007; 
Carbonnelle et al., 2011; Croxatto, Prod’hom and Greub, 2012; Bourassa and Butler-
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Wu, 2015);  
1. Matrix: a chemical (suitable to the molecules being targeted) that is stable 
under normal atmospheric conditions that can be applied to an analyte and co-
crystalizes, in the process charging the analyte by donating protons. 
2. Laser desorption/ionisation; a laser is fired, inside a vacuum, at the matrix-
analyte complex which liberates molecules into a vacuum chamber 
3. Time of flight; based on the mass to charge ratio, molecules migrate through 
the vacuum chamber, directed by an electric field generator, towards the 
detector.  
4. Mass spectrometry; as the analyte passes the detector a signal is created 
which is then interpreted by software to produce a mass spectrum that 
represents the analyte.  
 
 
 
 
Figure 1.22 MALDI-TOF MS analysis demonstrating laser desorption of an analyte/matrix 
complex, with vaporisation into a vacuum chamber and time of flight of molecules based on 
their mass to charge (m/z) ratio through to a detector (slideshare.com). 
In the early 1990’s MALDI-TOF MS had evolved as a technology and its application in 
medical microbiology was underway. In 1996 Claydon and colleagues described the 
use of MALDI-TOF MS for the identification of bacteria from solid agar cultures 
(Claydon et al., 1996). The discriminatory power of MALDI-TOF MS was clearly 
demonstrated with the correct identification of several Escherichia coli and 
Staphylococcus aureus strains. Claydon described unique peaks for the respective 
Electric field 
generator  
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species, which allowed subsequent identification and established the basic principle of 
using mass spectra obtained by MALDI-TOF MS and peak selection for microbial 
identification (Claydon et al., 1996).  
Up until this point the use of MALDI-TOF MS for microbial identification relied on the 
manual analysis of peak positions. The final leap in the development of this technology 
as a routine diagnostic tool came from the development of software capable of 
analysing and processing spectra and matching these unknown spectra to those 
contained within a reference database (Claydon et al., 1996). The proof of principle 
was established through initial studies that developed algorithmic approaches for 
matching MALDI-TOF MS spectral fingerprints to reference spectra in small databases 
initially containing five species represented by a single strain (Wunschel et al., 2005) or 
multiple strains of one species, E. coli (Arnold and Reilly, 1998). In both studies it was 
demonstrated that unknown isolates could identify against the reference database with 
high accuracy. In 2002 Bright and colleagues developed MUSE (Manchester 
Metropolitan University Search Engine), a reference database containing 35 strains, 
representing 20 species and 12 genera (Bright et al., 2002). This study was the first to 
demonstrate the use of software employing a spectral matching algorithm, enabling 
unknown spectra to be analyzed alongside a database containing several species and 
the correct identification be returned in the majority of analyses, in this case for 84% of 
the isolates. Other groups also demonstrated successful identification using in-house 
spectral databases (Bright et al., 2002).  
In 2007, the first commercial bench top MALDI-TOF system, the Microflex alongside 
the first Biotyper database, was released by Bruker Daltonics. The Biotyper system 
was and still is centred on the analysis of whole cell and extorted proteins, mostly 
abundant ribosomal proteins, for the identification of microorganisms. The sentinel 
publication investigating the Biotyper system detailed the analysis of 1116 bacterial 
isolates, comparing identification with phenotypic bacterial identification systems and 
16S rDNA sequencing to resolve discrepancies. 95.2% of the isolates were correctly 
identified with the MALDI-Biotyper. Differences in the identification rates for different 
groups of bacteria were noted with 95.5% success for enterobacteriaceae and 100% 
for staphylococci (Mellmann et al., 2008). The turnaround time to identification was 
reduced significantly from 18-24 hours to 12 minutes from culture. Over the last decade 
the application of MALDI-TOF MS for the identification of bacterial isolates has 
established itself as a conventional method used in many laboratories in developed 
countries with the financial resources to afford the technology. Over 200 studies are 
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now published (pubmed search parameters ((MALDI[TITLE]) OR MATRIX-
ASSISTED[TITLE]) AND BACTERIA[TITLE]. Despite these advances, the use of 
MALDI-TOF MS for the identification of fungi is lagging behind with 34 studies listed for 
yeast identification (Pubmed search parameters ‘MALDI[TITLE]) OR MATRIX-
ASSISTED[TITLE]) AND YEAST[TITLE]’) and 22 studies for the identification of 
filamentous fungi (Pubmed search parameters ‘(MALDI[TITLE]) OR MATRIX-
ASSISTED[TITLE]) AND FUNGI[TITLE’]. Hettick and colleagues published the first 
proof of principle study in 2008 created a reference database for 12 Aspergillus species 
(Hettick et al., 2008). Proteins were extracted using mechanical lysis in a trifluoracetic 
acid/acetonitrile suspension. Spectra obtained from the 12 species were cross 
analysed and no misidentifications occurred providing spectra contained a minimum of 
28 significant peaks (Hettick et al., 2008). Some two years later an in-house reference 
database was created utilising a novel processing method to generate reference 
spectra known as the ‘colony scrape’ technique (Marinach et al., 2009). Retrospective 
analysis of 140 isolates matched against the database demonstrated a 98.6% 
identification success rate (Marinach et al., 2009). De Carolis and colleagues created 
an in-house database representing 55 fungal species of Aspergillus, Fusarium and 
Mucorales, using the same colony scrape method (De Carolis et al., 2012). The 
analysis of 103 blind-coded fungal isolates against this expanded database 
demonstrated 96.8% accuracy when identifying species contained within the reference 
database (De Carolis et al., 2012). All respective studies have demonstrated the 
strength of MALDI-TOF MS lies within its specificity when applied to fungal 
identification. This is in contrast to other molecular methods currently used for fungal 
identification, such as pan-fungal sequencing with the 18S rRNA gene, which lack in 
specificity (Balajee et al., 2009). The turnaround time to identification is an attractive 
feature as identifications can be achieved within 20 minutes from a colony compared 
with up to 2 days for pan-fungal sequencing methods. MALDI-TOF MS methodology is 
also more cost effective when amortised over a prolonged period, with an average 
MALDI-TOF MS analysis costing less than £1.00 per analysis (Ge et al., 2017). The 
development of MALDI-TOF MS methods is required as many studies detail the use of 
in-house databases, which limits the routine use of MALDI-TOF MS, as the databases 
are not made freely available. Processing methods are not standardised with several 
different approaches to protein extraction published.  
1.12.4 Peptide nucleic acid fluorescence in situ hybridization (PNA-FISH) 
In 1977 Cheung and colleagues described a novel method for the mapping of 
mammalian genes, utilising In situ hybridization of mRNA to chromosomal DNA 
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(Cheung et al., 1977). By applying DNA probes to immobilized mammalian cell 
preparations on a slide the resultant mRNA/DNA hybridization product could be 
visualized by fluorescence microscopy in situ. This was the first description of FISH for 
visualization of nucleic acid. Over 40,000 publications have now detailed the use of this 
technique for a variety of applications, most commonly in the study of chromosomes in 
cytogenetic applications.  
Fluorescence in situ hybridisation (FISH) for the identification of yeasts was first 
described by Lishchewski and colleagues who used a 20-nucleotide DNA probe 
complementary to a region of the 18S ribosomal gene labeled with a 5(6)-carboxy- 
fluorescein-A-hydroxysuccinimide ester The probe targeted C. albicans and C. 
tropicalis. Both species could be differentiated from other commonly encountered 
Candida species using the probe and in the presence of human epithelial cells cross- 
reaction did not occur with human DNA (figure 1.23). The turnaround time to results 
was less than one day, far quicker than other molecular methods available at this time 
(Lischewski et al., 1996). This preliminary work led to the successful application of 
FISH for the identification of yeasts within paraffin embedded sections of tissue from 
murine kidney and brain infected with C. albicans (Lischewski et al., 1996)  
 
 
 
 
 
 
Figure 1.23 (a) Phase contrast micrograph showing the round C. albicans and the oval-shaped 
C. krusei adhering to the endothelial cells. (b) The same section viewed by fluorescence 
microscopy. (c) Double exposure of the phase contrast and fluorescence micrographs. Note 
that only the round C. albicans cells, but not the longer C. krusei cells are stained by the 
fluorescently labelled probe 020 (Lischewski et al., 1996). 
Some two years later Kempf and colleagues demonstrated the first application of FISH 
for the identification of microorganisms direct from positive blood cultures (Kempf et al., 
2000). Using a panel of DNA probes targeting bacterial and fungal pathogens, known 
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to cause 95% of blood stream infections in their setting, they demonstrated that 96.5% 
of microorganisms within blood cultures could be identified in less than 2.5 hours of 
blood cultures becoming positive (Kempf et al., 2000). Probes for C. albicans, C. 
glabrata, C. krusei and C. parapsilosis were included with no reported cross-reaction of 
probes and the successful identification of two C. albicans fungaemia episodes in real 
time (Kempf et al., 2000). DNA probes had been shown to be successful yet efficiency 
of probe hybridization is reliant on optimal sample preparation. DNA probes have a 
negative charge and are therefore subject to repulsion from negatively charged, or 
adherence to positively charged molecules, that may be present within the cell wall of 
microorganisms. It is necessary to use ethanol fixation, plus enzymes such as 
lysozyme for S. aureus, to make the cell membrane permeable whilst retaining 
morphological features, to allow successful hybridization of the probe (Lischewski et 
al., 1996; Kempf et al., 2000). Researchers working in this field realized that 
neutralization of the negative charge associated with probes would enable more 
efficient probe hybridisation.  
In 1993 Egholm and colleagues described the design of a novel DNA analogue, 
peptide nucleic acid (PNA), in which the phosphate backbone of DNA is replaced with 
a structurally homomorphous backbone consisting of N-(2-aminoethyl) glycine units to 
which nucleotides are attached, figure 1.24. The resulting PNA molecules carrying a 
neutral charge, bound to complementary nucleotides with greater stability compared to 
the DNA probes (Nielsen, Egholm and Buchardt, 1994).  
 
 
Figure 1.24 Peptide nucleic acid (PNA) molecule bound to DNA demonstrating the 
neutrally charged peptide substitution in the backbone replacing the negatively charged 
phosphate molecule (Mateo-Mart and Pradier, 2010).  
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The neutrally charged backbone of PNA molecules no longer affected by repulsion 
between two negatively charged DNA molecules facilitated stronger bonding of the 
probe to its target inside the cell (Nielsen, Egholm and Buchardt, 1994; Mateo-Mart and 
Pradier, 2010). Figure 1.25 demonstrates the PNA binding process to RNA molecules 
within whole cells, in this example staphylococcus cells, and the overall fluorescence 
omitted from cells where a red fluorescing probe has bound to the target RNA molecule 
(Jensen et al., 2014). Oliveria et al designed the first PNA probes for the identification 
of yeasts from liquid culture. In this study two probes targeting the 26S rRNA were 
designed for the closely related species C. albicans and C. dubliniensis. Processing 
time was 1-3 hours dependent on the fixing method utilised and 100% sensitivity and 
specificity of the two PNA probes was observed when tested against multiple isolates 
of the two respective species (Oliveira et al., 2001). In a further study the same group 
then applied the C. albicans probe to the prospective analysis of positive blood cultures 
and further tested the probe for cross reaction with other Candida species. Again 100% 
sensitivity and 100% specificity was observed when testing the probe against 18 
different species across 229 analyses in the presence of human blood (Rigby et al., 
2002).  
 
Figure 1.25 Intracellular fluorescent In situ hybridisation using PNA probes 
complementary to ribosomal RNA molecules (Jensen et al., 2014).  
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1.12.5 Clinical laboratory mycology diagnostic service 
At the time of study the diagnostic service at the Royal Free Hospital microbiology 
department included tests outlined in figure 1.26. The workflows are a fair 
representation of many clinical diagnostic laboratories to date (Barnes et al., 1996, 
Schelenz et al., 2015). Blood cultures, if positive, were processed with Gram’s stain, 
culture and biochemical identification using the AuxaColor 2 assay. Galactomannan 
was performed twice weekly for patients at high risk of IA and also as a diagnostic test 
for patients with a high suspicion of IA. BAL for Pneumocystis pneumonia was 
processed by cytology using GMS staining. For the investigation of Invasive mould 
infection Calcofluor was performed on BAL or tissue followed by extended culture (3 
weeks) for filamentous moulds. If positive, conventional identification of moulds was 
performed using microscopy. If identification was unsuccessful isolates were referred to 
the reference laboratory.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.26 Routine Diagnostic Service at the Royal Free Hospital diagnostic microbiology 
laboratory – 2009. 
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1.13 Research Aims 
The aims of this research are to comprehensively evaluate the use of molecular 
diagnostics to address the current shortfall in the diagnosis of IFI and where 
appropriate embed new methods and technology into the clinical service.  
IFI targeted in the research are invasive candidiasis, invasive aspergillosis, 
Pneumocystis pneumonia and other non-Aspergillus invasive mould infections. The 
respective invasive fungal infections have diagnostic challenges unique to the 
pathology of each disease and the patient cohorts who are susceptible to each IFI. The 
limitations of current diagnostic techniques were assessed so that the most appropriate 
molecular techniques could be applied to the diagnostic scenario for each IFI to 
investigate if diagnosis could be improved.  
A range of molecular methodologies, including polymerase chain reaction (PCR) and 
matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass 
spectrometry (MS) and peptide nucleic acid fluorescence In situ hybridisation (FISH), 
were evaluated on clinical sample cohorts established from pathology samples surplus 
to diagnostic requirements from the Royal Free Hospital clinical pathology archive. 
Each method evaluated was critically appraised for; statistical performance, clinical 
utility and suitability for service adoption.  
This research was undertaken as part of the National Institute for Health Research 
NIHR/Chief Scientific Officer (CSO) Healthcare Science Research Fellowship. The aim 
of the program was to support the development of research infrastructure, capacity and 
capability in healthcare science. The intention of research undertaken throughout the 
time of the award was to support this research in the NHS setting bridging the gap 
between clinical/service careers and research at doctoral level through translational 
research. 
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2 Chapter 2 General methods  
2.1 Culture based methods  
2.1.1 Subculture of yeast isolates 
Yeasts stored in water were vortexed for 10 seconds prior to subculture to re-suspend 
the isolate. A 10µL loop of the Candida suspension was streaked out onto 
CHROMagar and incubated at 36°C for 24 h. Subcultures were passaged twice to 
ensure purity. (Becton Dickinson, Franklin Lakes, NJ, and USA).  
2.1.2 Biochemical identification of yeasts 
Apple green colonies on CHROMagar Candida (Becton Dickinson, New Jersey) were 
identified as C. albicans. All non-albicans Candida species were subject to testing with 
the AuxaColor 2 assay (Bio-Rad, California) as per manufacturer’s instructions. 
Cornmeal agar slide preparations (supplemented with 1% Tween 80 and a sterile cover 
slip placed on the agar square) were used to establish morphological characteristics for 
the complete species profile. 
2.1.3 Simulated blood cultures  
The spiking inoculum was prepared by making a 0.5 McFarland suspension of the 
yeast isolates in saline, representing approximately 108 cfu/mL. 10µL of the suspension 
was added to 10mL of saline and vortexed to make suspension 2. 100µL of suspension 
2 was transferred to 900µL saline to make suspension 3.  
 
Anonymised blood culture bottles, determined to be negative after 5 days incubation on 
the BacTec, were spiked with 10µL of suspension 3 of each yeast isolate containing 
approximately 100–200 cfu. Spiked blood cultures were re-incubated on the BacTec 
system (Becton Dickenson, New Jersey) until positivity was detected. An inoculum of 
10µL was plated onto CHROMagar Candida medium to obtain an approximate colony 
count. Bottles were spiked in batches of 10. At the point of positivity blood cultures 
were subjected to Gram’s stain and CHROMagar Candida subculture to confirm purity.  
 
2.1.4 Mycelial mat culture for filamentous moulds 
To create mycelial mats for DNA extraction 3cm microtiter plates were used. One plate 
per isolate was prepared. 5mL of Sabouraud’s broth was inoculated into the wells of 
the microtiter plate. Using a wet cotton swab the fungal colony was gently brushed then 
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the harvested spores were transferred into a microtiter well containing Sabouraud’s 
broth. The lid was fixed into position and plates were incubated in a shaking incubator 
at 30°C for 24 hours, or until a flat mycelium mat had formed. The mycelial mat was 
transferred into a 5mL bijou tube and frozen at -20°C until required for DNA extraction. 
2.1.5 Miles and Misra 
Miles and Misra counts on positive blood cultures were prepared from serial dilutions of 
the blood culture. 100µL of positive blood culture was aspirated and added to 900µL of 
saline. The tube was vortexed for 10 seconds. Using a fresh pipette tip 100µL of the  
10-1 dilution was transferred to another 900µL of saline and vortexed to make the 10-2 
dilution. The dilution process was repeated to obtain serial dilutions up to a 10-7 
dilution. 100µL of each dilution was plated out onto a CHROMagar Candida plate and 
incubated at 35°C for 24 hours. Colony counts were performed from the two dilutions 
that had distinct colonies. An average cfu/mL was calculated from a mean of the two 
counts, i.e. if the 10-4 count was 180 and the 10-5 count was 16 the mean = 1.7 x106 
2.2 Molecular based methods 
2.2.1 DNA extraction from yeasts and mycelial mats 
For yeast isolates a 4.0 McFarland suspension of each isolate was prepared in 
molecular grade water. For the mycelial mats a small pea sized piece of mycelium was 
added to 300ul of sterile distilled water. Acid washed glass beads (~50µL equivalent) 
were added to the fungal suspensions. Ribolysis was performed for 3 minutes at 
6.5m/s speed using a MP Fast-prep 24 platform. Lysates were processed using the 
Wizard genomic DNA kit (Promega, Wisconsin, USA) as per manufacturer’s 
instructions for yeast cells (omitting the lyticase treatment step as mechanical lysis was 
adequate for fungal cell wall lysis). 
2.2.2 Gel electrophoresis for detection of PCR amplification 
PCR products were separated on a 1.5 % agarose gel and DNA bands were visualized 
with ethidium bromide. A 100bp ladder was used to size products. 
2.2.3 Big dye terminator sequencing 
PCR amplicon clean up was performed using a kit as per manufacturers instructions 
(Qiagen) designed to remove excess nucleotides and primers from the amplified DNA. 
Sequencing was performed in duplicate in the forward and reverse direction. The 
reaction mix consisted of 5µL template DNA, 2µL of PCR primer, 8µL water, 2µL 
BigDye buffer and 2µL BigDye Terminator v3.1 Ready Reaction Mix (Applied 
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Biosystems). Reaction cycling was as follows: 96°C for 1 minute, 25 cycles of 96°C for 
10 seconds, 50°C for 5 seconds and 60°C for 4 seconds. Ethanol precipitation clean up 
was used to purify sequencing products. The pellet of DNA was air-dried and 
rehydrated in 15µL formamide. Analysis was performed on a 3130 Genetic Analyser 
Capillary Array for detection (Applied Biosystems). Bionumerics v5.1 (Applied Maths) 
was used to obtain a composite sequence. Fungi were identified for each assay by 
comparing consensus sequences to a database library of known ITS rRNA gene 
sequences in GenBank (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) by multiple 
sequence alignment (Jenkins et al., 2012).  
2.2.4 Ribosomal rRNA ITS amplification and sequencing 
Amplification of the ITS1-5.8S-ITS2 region was performed using previously described 
ITS primers ITS1 (5' TCC GTA GGT GAA CCT GCG G 3') and ITS4 (5' TCC TCC GCT 
TAT TGA TAT GC 3 (Innis MA, Gelfand DH, 1990). PCR was performed in 50µl 
reactions in the presence of 2U Hotstar Taq polymerase, 1.5mM MgCl2, 0.3mM of 
each deoxynucleoside triphosphate, 0.5mM of each primer and 5ul of template DNA. 
Following enzyme activation at 94ºC for 15 minutes reactions were subject to 40 
thermal cycles of 94ºC (60s), 50ºC (60s) and 72ºC (180s) on a GeneAmp® PCR 
system 9700 thermocycler. DNA amplification was detected by electrophoresis of a 
fraction of the amplification product on a 0.5% (wt/vol) agarose gel run for 30 minutes 
at 170V in 0.5 x Tris-borate buffer. Sequencing was performed as detailed by Jenkins 
et al (2012). 
 
2.3 MALDI-TOF MS methods  
2.3.1 Conventional formic acid extraction 
A 1 µL loop full of yeast colony was suspended in 300µL of HPLC grade water then 
900µL of absolute ethanol was added. After centrifugation the supernatant was 
removed and the pellet air-dried for 10 minutes. Pellets were re-suspended in 40µL of 
70% formic acid and incubated for 2 minutes. 40µL of acetonitrile was added and the 
solution was thoroughly vortexed before a final centrifugation at 8000g for two minutes. 
1µL of supernatant was used for analysis and spotted in duplicate. 1µL α-Cyano-4-
hydroxy-cinnamic-acid matrix was immediately added to each spot once dry. Time to 
result was measured for a single isolate for the whole identification process including 
software analysis. 
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2.3.2 MALDI-TOF analysis  
Spectra acquisition was performed on a Microflex™ LT platform (Bruker Daltonics) with 
Flex Control software (version 3.0) using default settings. Spectra analysis was 
performed using MALDI Flex analysis™ software analysing spectra in the 2000-20,000 
m/z range. Log similarity score thresholds for the MALDI Biotyper identifications were 
defined as; no reliable ID 0-1.699, probable genus 1.7-1.999, secure genus, secure 
species >2.0. Re-analysis of spectra was also performed lowering the species 
acceptable log similarity score threshold to >1.9.  
 
2.3.3 Bruker log similarity score calculation 
The number of peaks matched between the sample and the reference spectra divided 
by the overall number of peaks in the samples to gives a score out of 10. Followed by 
the number of peaks matched in the unknown sample is divided by the number of 
peaks in the reference sample to give a score out of 10. Finally the relative intensities 
of the matching peaks are calculated to give a score out of ten. These three values are 
multiplied in sequence to give a score out of 1000 and the log of that score if then 
calculated to give a score out of 3. In the example below the calculation is as follows: 
1. There are six reference peaks in the unknown spectra containing 20 peaks = 
6/20  
2. There are six peaks matched in the unknown spectra divided by the 10 peaks in 
the reference spectra = 6/10 
3. Then the score of the relative intensities of the matched peaks is calculated  
 
The final score = 6 x 3 x 7 = 126 = log similarity score 2.1 
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Figure 2.1 example of spectral matching with unknown spectra (top) matched against reference 
spectra (bottom). Peak matching and unmatched peaks are used to calculate the log similarity 
score.  
 
2.3.4 Reference laboratory identification of fungi 
Isolates requiring further identification were referred to Bristol PHE MRL for processing 
on SAB slopes. ITS pyrosequenced based identification is utilised to identify fungi 
(Borman et al., 2010).  
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3 Chapter 3 Evaluation of solid agar culture processing methods 
and MALDI-TOF MS for the identification of clinically relevant 
yeast isolates 
3.1 Introduction 
Phenotypic and biochemical identification methods for yeast isolates, including sub-
culture onto chromogenic media and biochemical profiling, are the conventional 
methods of choice in many diagnostic laboratories in the UK and globally (Davey et al., 
1995; Romney et al., 2000; Meletiadis et al., 2011). Using chromogenic agar the 
turnaround time (TAT) for identification is 24 hours for C. albicans. An additional 48-72 
hours is required to achieve identification for all other yeast species using biochemical 
assays, such as the AuxaColor 2 (Bio-Rad, California) (Meletiadis et al., 2011). One 
fundamental drawback is that commercially available biochemical assays are 
supported by databases that are limited in their species coverage leading to 
misidentification of rare yeasts such as C. famata, C. guilliermondii, C. lusitaniae 
(Posteraro et al., 2013), as discussed in section 1.5.5 of the introduction (Massonet et 
al., 2004; Kullberg and Arendrup, 2015). Some yeasts, such as Candida famata, may 
also remain unidentified, as their standard biochemical profiles obtained using 
commercially available assays cannot be interpreted. This contributes to a delay in 
achieving a full diagnosis which may have a subsequent impact on the clinical 
management of the patient (Sheppard et al., 1998;; Ullmann, et al., 2011). A meta-
analysis evaluating the accuracy of biochemical tests for yeast identification concluded 
the pooled identification ratio at the species level to be 0.89 (95% CI: 0.8-0.98) 
(Posteraro et al., 2013). Commercially available identification systems for bacterial 
identification have demonstrated similar rates of identification, 92.5% using the Phoenix 
and 88.8% using the Vitek system (Chatzigeorgiou et al., 2010). Therefore, there is a 
requirement across microbiology to improve the accuracy of identifying 
microorganisms. As more than 100 yeast and yeast-like species are known to be 
human pathogens (Ashbee et al., 2010) the identification of rarer yeast species 
presents a challenge for non-specialist diagnostic laboratories. The incidence of rare 
yeast species causing fungaemia is estimated at 1.8-3% (Arendrup et al., 2008; 
Chitasombat et al., 2012)  
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The Biotyper version 3.1 database (Bruker Daltonics, Germany) is a comprehensive 
data repository, containing reference spectra for >100 yeast species used in 
conjunction with MALDI-TOF spectroscopy. Prior to MALDI-TOF MS analysis it is 
recommended that yeasts undergo formic acid protein extraction (Bruker protocols). 
This is necessary as fungi have a robust fungal cell wall, comprised of glucan, mannan 
and chitins (Bowman and Free, 2006). The extraction process extends the turnaround 
time to results by 10-15 minutes (Bruker protocols) On an individual sample basis the 
increase in TAT is not significant but in a high throughput diagnostic setting it could 
contribute to a significant increase in the turn around time of results. A reduction in the 
time for this step may be achieved by application of formic acid directly onto yeast 
analytes applied onto the MALDI-TOF MS target plate, termed ‘on-plate extraction’, 
prior to the addition of matrix. At the time of study this was suggested by Bruker as an 
alternative method for yeast identification but was unpublished. The aim of this study 
was to evaluate the Microflex (Bruker Daltonics, Germany) and Biotyper V3.1 software 
(Bruker Daltonics, Germany) for the identification of clinical yeast isolates from solid 
agar cultures. Both conventional and on-plate formic acid extraction methods were 
investigated and compared with a gold standard ITS rRNA sequence analysis (Innis 
MA, Gelfand DH, 1990) and previously obtained biochemical identifications using the 
AuxaColor 2 (Bio-Rad, California) assay.   
 
3.2 Methods 
3.2.1 Yeast isolates 
Clinical isolates classified as surplus to diagnostic requirements were selected from the 
clinical archive of isolates stored by the UK CMN regional laboratory at the Royal Free 
Hospital NHS microbiology department (Pond Street, Hampstead, London) and were 
accessed under local clinical service improvement guidelines; isolates were stored in 
water away from light (Borman et al., 2006).  
3.2.2 Subculture of isolates 
See general methods section 2.1.1 
3.2.3 Biochemical identification 
See general methods section 2.1.2 
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3.2.4 DNA extraction 
See general methods section 2.2.1 
 
3.2.5 Ribosomal rRNA ITS amplification and sequencing 
See general methods section 2.2.2 - 2.2.4 
 
3.2.6 Conventional direct analysis 
For direct analysis a small amount of a single yeast colony was inoculated in duplicate 
spots onto the target plate in thin smears using a wooden mixing stick (without 
returning to the culture for the second spot to enable a lighter smear). 1 µL of α-cyano-
4-hydroxy-cinnamic-acid matrix was pipetted onto each spot. For yeasts failing to 
identify on first attempt a repeat analysis was performed.  
3.2.7 On-plate FA extraction 
For on-plate FA extraction a small amount of a single yeast colony was inoculated in 
duplicate spots onto the target plate in thin smears using a wooden applicator (without 
returning to the culture for the second spot so enable a lighter smear). 1µL of 100% FA 
was pipetted onto each spot, allowed to dry then 1µL of α-cyano-4-hydroxy-cinnamic-
acid matrix was immediately added to each spot. 
3.2.8 Conventional Formic Acid extraction 
See general methods 2.3.1 
3.2.9 MALDI-TOF MS analysis 
See general methods 2.3.2 
3.2.10 Log similarity score manipulation  
Stepwise reduction in the log similarity score was investigated to assess the impact on 
the rate of identification using the different identification methods, measures of >2.0, 
>1.9, >1.8 and >1.7 were evaluated as acceptable thresholds for species identification. 
Lowering the log similarity score was previously described by Van Herendaelan and 
colleagues (2012) as an effective method for increasing the success of MALDI-TOF for 
yeast identification (Van Herendael et al., 2012). Identifications were only considered 
accurate if complete agreement was obtained with ITS rRNA sequenced based 
identification for the top three identifications returned by the biotyper software. 
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3.2.11 Statistical analysis 
Calculation of the log similarity score by the Biotyper 3.1 software (Bruker Daltonics, 
Germany) can be found in section 2.5 of the general methods section. To calculate if 
the difference between the rates of identification was significant or not across the 
different processing methods an "N-1" Chi-squared test was applied as recommended 
by Campbell (2007) and Richardson (2011). MedCalc (medcalc.org, Belgium) software 
was used to perform this test.  
3.2.12 Time to identification 
The time to identification of a single yeast isolate was measured by timing the same 
operator performing on plate formic acid extraction and conventional formic acid 
extraction, from the start of the process to the final identification. 
3.2.13 Prospective yeast identification performance 
Yeast identification by MALDI-TOF MS in the clinical diagnostic service was 
implemented in January 2012. Figure 3.3 demonstrates the workflow for yeast MALDI-
TOF MS analysis. On-plate formic acid extraction was used as first attempt processing 
for yeast isolates, with conventional formic acid extraction being performed on isolates 
failing to identify. A species log similarity score threshold of >1.9 was used for 
identification.  
 
3.3 Results 
3.3.1 Yeast isolates 
Clinical yeast isolates (n=190) were collected over a 12-month period from 1st January 
2012 to 31st December 2012. Table 3.1 details the ITS rRNA sequence based 
identifications from the cohort. In total, 19 yeast species were represented. Commonly 
encountered species C. albicans, C. parapsilosis, C. krusei, C. glabrata, C. tropicalis 
and C. guilliermondii accounted for 87.9% (167/190) whilst 12.1% (23/190) of the yeast 
isolates were rarely encountered yeast species.  
3.3.2 Performance of MALDI-TOF MS processing methods 
The performance of each processing method for the identification of yeasts was 
calculated from the first attempt at identification using each method.  
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Repeat analysis was performed for yeast isolates that hadn’t identified on first attempt 
using conventional formic acid extraction. The overall identification rate, after repeat 
analysis, is presented in table 3.2.  
 
 
 
3.3.3 Direct on-plate analysis from culture 
One isolate was identified by direct preparation, as C. guilliermondii (log similarity score 
2.04). For 21.6% (41/190) of the isolates a result of ‘no reliable identification’ was 
retuned. The median log similarity score for isolates returning either identification or a 
result of ‘no reliable identification’ was 1.332 (IQR: 1.281, 1.421), figure 3.1. For 77.9% 
(148/190) of the isolates no peaks were detected by MALDI-TOF therefore no log 
similarity score was generated.   
3.3.4  Direct on-plate formic acid extraction 
Using direct on plate formic acid extraction 41% (78/190) of yeast isolates were 
identified to species level with a log similarity score >2.0. A genus level identification 
was obtained for a further 33.7% (64/190) of the isolates with a log similarity score 1.7-
1.999. A result of ‘no reliable identification’ was obtained for 25.3% (48/190) of the 
Table 3.1. ITS rRNA sequenced based identifications for 190 yeast isolates 
included within the study 
Species % n Species % n 
Candida parapsilosis 29.5 56 
Saccharomyces 
cerevisiae 
1.1 2 
Candida albicans 26.3 50 Pichia fermentans 0.5 2 
Candida glabrata 14.7 28 Candida lipolytica 0.5 1 
Candida tropicalis 6.3 12 Cryptococcus neoformans 0.5 1 
Candida guilliermondii 6.3 12 Candida nivariensis 0.5 1 
Candida krusei 4.7 9 Pichia cactophila 0.5 1 
Candida lusitaniae 1.6 3 Candida dubliniensis 0.5 1 
Candida kefyr 1.6 3 Magnusiomyces capitatus 0.5 1 
Pichia caribica 1.6 3 Cyberlindnera fabianii 0.5 1 
Candida orthopsilosis 1.1 2 
Debaryomyces 
nepalensis 
1.1 1 
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isolates with a log similarity score <1.7. The overall median log similarity score 
obtained using direct on plate formic acid extraction was 1.97 (IQR: 1.84, 2.1), figure 
3.1. 
 
3.3.5 Conventional formic acid extraction  
Using conventional formic acid extraction 83.7% (159/190) of yeasts were identified at 
species level with a log similarity score >2.0 and 13.7% (26/190) at the genus level with 
a log similarity score between 1.7-1.99 on first attempt. A result of ‘no reliable 
identification’ was returned for 2.6% (5/190) of analytes with a log similarity score <1.7. 
The overall median log similarity score obtained using conventional formic acid 
extraction was 2.19 (IQR: 2.07. 2.33), figure 3.1. 
 
 
Figure 3.1 Log similarity scores obtained for 190 yeast isolates processed by direct 
smear, on plate and conventional formic acid extraction. 
 
3.3.6 Log similarity score reduction for on plate formic acid extraction 
By reducing the log similarity score species threshold to >1.9 a significant increase in 
the rate of identification (p<0.001) was observed for yeasts at the species level 63.7% 
(121/190). Further reducing the log similarity score to >1.8 increased the identification 
rate to 71% (135/190) but this was not a significant increase (p=0.13) compared to 
accepting a log similarity score >1.9. By further reducing the log similarity score 
threshold for identification to >1.7 the rate of identification increased further to 74.7% 
(142/190) but was not significantly different from the rate of identification with a log 
similarity score threshold of >1.9 (p=0.02) (table 3.2).  
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3.3.7 Log similarity score reduction for conventional formic acid extraction 
By lowering the species log similarity score threshold to >1.9 the success rate for 
conventional FA extraction the identification rate increased to 90% (171/190) but was 
not significantly different (p=0.07) to the identification rate with a log similarity score 
>2.0. By lowering the species threshold to >1.8 the identification rate increased 
significantly (p<0.01) to 96.3% (183/190) compared with a log similarity score of >2.0 
with no misidentifications compared to ITS rRNA sequencing. By reducing the log 
similarity score to >1.7 the identification rate increased to 97.4% (185/190) but was not 
statistically significant (p=0.54) compared with a log similarity score of >1.8.  
 
*Auxacolor 2 identification (Biorad, California) 
 
3.3.8 Unidentified yeasts by MALDI-TOF MS 
After repeat analysis 2.6% (5/190) of the yeast isolates returned a result of ‘no 
identification’ with a log similarity score <1.7. Analysis of the MALDI-TOF MS spectra 
for these isolates demonstrated high quality spectra with a significant number of peaks 
at the peak intensity expected of an analysis that would have provided isolate 
identification. This is exemplified in figure 3.2 where 3.2a shows the spectra for a yeast 
that failed to identify compared with the spectra of a yeast in figure 3.2b, which 
Table 3.2. MALDI-TOF MS and biochemical yeast identification success rates 
compared with ITS rRNA sequence analysis 
Processing method Species Genus No ID Incorrect 
Conventional formic acid  % n % n % n % n 
Log similarity score >2.0 83.7%  159 13.7%  26 2.6%  5 0  
Log similarity score >1.9 90% 171 7.4%  14 2.6%  5 0  
Log similarity score >1.8 96.3%  183 1.1%  2 2.6%  5 0  
Log similarity score >1.7 97.4%  185 0%  0 2.6%  5 0  
On-plate formic acid          
Log similarity score >2.0 41.1%  78 33.7%  64 25.3%  48 0  
Log similarity score >1.9 63.7%  121 11%  21 25.3%  48 0  
Log similarity score >1.8 71%  135 3.7%  7 25.3%  48 0  
Log similarity score >1.7 74.7%  142 0%  0 25.3%  48 0  
Overall success          
Conventional formic acid  97.4%  185 0  2.6%  5 0  
Biochemical identification*  94.2%  179 0  0  5.8%  11 
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achieved a successful identification.   
 
Figure 3.2 MALDI-TOF MS spectra obtained for a yeast isolate with a result of ‘no-
identification’. The threshold for peak acceptance is indicated by the dotted line. Peak 
intensity and abundance indicates this MS spectra should have resulted in a successful 
identification if a matching spectra was present in the reference spectral database.  
 
3.3.9 Time to results  
On-plate FA extraction had a turnaround time to result of 6 minutes for a single isolate. 
Conventional FA extraction had a turnaround time of 13 minutes for a single isolate. 
3.3.10 Agreement between methods 
Agreement between the three methods for the 190 isolates is detailed in table 3.3. The 
agreement between MALDI-TOF MS and ITS rRNA sequencing was 97.4% (185/190). 
Agreement between Biochemical identification and ITS rRNA sequencing was 94.2% 
(179/190). Agreement between MALDI-TOF and biochemical identification was 94.2% 
(179/190) agreement was achieved when compared with conventional identification 
methods. The difference in the rate of agreement was not statistically significant 
(p=0.12) across the three analyses.  
 
Table 3.3 Agreement between MALDI-TOF, ITS rRNA and Biochemical 
methods for the identification of 190 yeast isolates  
Methods % n 
MALDI-TOF & ITS rRNA 97.4% 185/190 
Biochemical & ITS rRNA 94.2% 179/190 
MALDI-TOF & Biochemical 94.2% 179/190 
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3.3.11 Misidentification of yeast isolates 
For the purpose of this study misidentification was defined as a result which differed to 
that of the ITS rRNA sequence result. Misidentification was not observed using MALDI-
TOF MS. Table 3.4 represents yeast misidentification observed for 5.8% (11/190) of 
yeast isolates using biochemical methods. 6 misidentified isolates were successfully 
identified by MALDI-TOF MS and 5 isolates returned a result of ‘no identification’, as 
shown in table 3.4 Misidentifications were categorised in to two groups. Major 
misidentification occurred for 4 isolates, where the identification given by biochemical 
methods has no taxonomic relatedness to that of the ITS rRNA identification. Minor 
misidentification occurred for 7 isolates; where the species ITS rRNA identification 
represents a sub-species within the clade identified by biochemical methods, table 3.4. 
 
*Level of clinical impact assigned to the disagreement between the identification 
methods 
 
 
3.3.12 Prospective yeast identification 
Over a 12 months period MALDI-TOF MS successfully identified 99.7% (296/297) of 
the isolates from culture. Table 3.5 details the species distribution of the 296 isolates 
identified by MALDI-TOF MS. A single (n=1) isolate did not identify by MALDI-TOF MS 
despite obtaining excellent quality spectra. This isolate was identified as Cyberlindnera 
fabianii by ITS rRNA sequence analysis.   
Table 3.4 Results for eleven isolates correctly identified or not identified by 
MALDI-TOF MS and misidentified by biochemical analysis compared with ITS 
rRNA analysis 
Biochemical MALDI-TOF –MS ITS rRNA n Class 
Candida krusei Pichia fermentans Pichia fermentans 2 Major 
Candida krusei Pichia cactophila Pichia cactophila 1 
Candida pelliculosa No ID Cyberlindnera fabianii 1 
Candida famata No ID Debaryomyces 
nepalensis 
1 
Candida glabrata Candida nivariensis Candida nivariensis 1 Minor 
Candida parapsilosis Candida orthopsilosis Candida orthopsilosis 2 
Candida guilliermondii No ID Candida fermentati 3 
93 
 
 
Table 3.5 Prospective identification of 296 clinical yeast isolates by MALDI-TOF 
MS and Biotyper version 3.1  
Identification % n Identification % n 
Candida albicans 48.1 143 Candida orthopsilosis 0.7 2 
Candida glabrata 21.2 63 Candida krusei 0.7 2 
Candida parapsilosis 9.4 28 Candida lusitaniae 0.3 1 
Candida tropicalis 8.1 24 Candida lipolytica 0.3 1 
Saccharomyces cerevisiae 3.0 9 Candida nivariensis 0.3 1 
Candida guilliermondii 1.7 5 Candida inconspicua 0.3 1 
Candida kefyr 1.7 5 Candida pelliculosa 0.3 1 
Cryptococcus neoformans 1.3 4 Trichosporon asahii 0.3 1 
Candida dubliniensis 1.3 4 Candida famata 0.3 1 
 
 
3.4 Discussion 
This study has demonstrated that MALDI-TOF MS in conjunction with Bruker Biotyper 
v3.1 software is a highly accurate method for the identification of clinical yeast isolates 
identifying 97.4% (185/190) of yeast isolates compared with the gold standard of ITS 
rRNA sequencing. This is comparable to identification rates of 92 - 97.7% published in 
other similar studies (Dhiman et al., 2011; Rosenvinge et al., 2013; Sendid et al., 
2013). When identifying yeasts prospectively in a real-time diagnostic laboratory 
scenario the identification rate was improved to 99.7% (296/297) as the impact of 
selecting out rarer yeast species was not observed. This demonstrates that in the 
diagnostic setting, where the unidentified yeast species are rarely encountered, almost 
all clinically significant yeasts are identified by MALDI-TOF MS. The agreement 
between identifications achieved in this study using MALDI-TOF and ITS rRNA 
sequencing is due to both methods targeting the ribosomal protein components of the 
yeast cells for identification, similar agreement between these two methods has been 
reported in other studies, with Sendid et al reporting 97.4% (1179/1208) agreement 
(Seyfarth et al., 2012; Sendid et al., 2013). Yeast misidentification was not observed 
using MALDI-TOF MS in our study and has not previously been reported when utilising 
the manufacturer’s recommended thresholds (Cassagne et al., 2012; Seyfarth et al., 
2012; Rosenvinge et al., 2013; Sendid et al., 2013) 
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Yeast misidentification was observed using biochemical methods for 5.8% (11/190) 
isolates during the study. This is an important factor for diagnostic microbiology 
laboratories to consider. Rarely encountered yeast species have similar biochemical 
profiles to commonly encountered yeasts leading to misidentification. In this study the 
identifications obtained for 4 isolates were considered to be major misidentifications. In 
one example C. lambica was misidentified as C. krusei. This misidentification has 
previously been described in a fungaemia case report and is clinically relevant as the 
two species have different susceptibility patterns, particularly to the azole class of 
antifungal agents (Vervaeke et al., 2008). Minor misidentifications occurred for 7 
isolates in that the species identified by ITS rRNA sequencing were cryptic species 
contained within the clade identified by biochemical methods. MALDI-TOF MS was 
able to correctly identify 4 of these isolates demonstrating that MALDI-TOF MS has the 
resolution power to identify cryptic species within clades. The limitation of MALDI-TOF 
MS highlighted in this study was that not all species were represented in the Biotyper 
v3.1 database. Three C. fermentati isolates, belonging to the C. guilliermondii clade, 
were not identified by MALDI-TOF MS despite obtaining high quality spectra.  
The Biotyper v3.1 database contains >100 yeast species within its database but is not 
yet fully comprehensive. Obtaining identification by MALDI-TOF MS is dependent on 
highly robust reference spectra being present within the database (Carrasco et al., 
2016). It is also possible that the database may not contain reference spectra for all 
strains of a species contributing to low identification log similarity scores. This was 
highlighted in a recent study investigating MALDI-TOF specifically for the identification 
of only rarely encountered yeast species (Dhiman et al., 2011). An overall success rate 
of 84.5% was reported, with authors concluding that a result of ‘no identification’ 
indicated the yeast species was not contained within the MALDI-TOF database 
(Dhiman et al., 2011). If MALDI-TOF MS fails to identify an organism biochemical 
methods must not be utilised and isolates should be referred for molecular 
identification.  
This study has also demonstrated reducing the species log similarity score threshold 
alongside on plate formic acid extraction can decrease turnaround time to results for a 
significant proportion of yeasts in the diagnostic setting, as seen for 63.7% (121/190) of 
isolates in this study using a log similarity score of >1.9. Yeast misidentification was not 
observed as a result of reducing the log similarity score threshold for species 
identification. Similar approaches have been utilised in three recent studies using 70% 
FA on-plate extraction and a species log similarity score threshold of ≥1.7 (Cassagne 
et al., 2012; Theel et al., 2012; Van Herendael et al., 2012). In two of the studies the 
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mean log similarity score thresholds for on-plate FA extraction (1.78 and 1.941) were 
significantly lower than those obtained using conventional FA extraction (2.0 and 
2.223) but all log similarity score values associated with misidentification by MALDI-
TOF MS were below 1.7 (Cassagne et al., 2012; Theel et al., 2012). If utilising on-plate 
FA extraction it is necessary to reduce the species log similarity score threshold to 
increase the identification success rate (Bader, 2013; Posteraro et al., 2013). Within 
our local diagnostic service the species log similarity score threshold was set at >1.9 
when using on plate formic acid extraction as statistically this was shown to be the 
most significant improvement in the identification rate. When using conventional formic 
acid extraction the most significant impact on the identification rate was seen by 
reducing the log similarity score threshold further to >1.8 with 96.3 (183/190) of the 
isolates identifying accurately on first attempt. A recent inter laboratory comparison 
study involving 11 diagnostic centres and 5460 MALDI-TOF spectra obtained using a 
yeast test panel demonstrated 88.6% of isolates identifying using a log similarity score 
of >1.7 for acceptable species identification with the conventional formic acid extraction 
method (Vlek et al., 2014). The difference between the performance of on-plate formic 
acid extraction and conventional extraction can be explained through the methods used 
to compose the reference spectral database.   
 
The Biotyper v3.0 reference database was developed using conventional FA 
extraction. The lower log similarity scores obtained using on-plate FA extraction is a 
result of the reduction in peak frequency and intensity compared with conventional FA 
extraction (Bader, 2013). The overall effect is a reduced log similarity score as fewer 
peaks are matched between the analyte and reference spectra. In this study 36.3% 
(69/190) isolates failed to identify to species level with on-plate FA extraction despite 
obtaining spectra. In two studies using the Vitek MS system success rates of 95.8% 
and 96.1% were achieved for yeast identification using the manufacturers 
recommended 25% FA on-plate extraction method (Iriart et al., 2012; Westblade et al., 
2013). This can be explained by the fact that the Vitek MS database is built from 
reference spectra obtained using the same 25% FA on-plate extraction procedure 
therefore there is improved consistency between MS spectra obtained from clinical 
isolates and those contained within the Vitek MS reference database (Iriart et al., 2012; 
Westblade et al., 2013). This is also supported by a recent study analysing 4232 yeast 
isolates against an in-house database created using a unique fast sample preparation 
method (De Carolis et al., 2012). In this study 99.5% of the isolates were correctly 
identified on first attempt owing to the fact that the database was constructed from 
reference spectra created using the same sample preparation technique used to 
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identify unknown clinical isolates (Elena De Carolis et al., 2012). When the sample 
processing method is consistent between the unknown test isolate and isolate used to 
create reference spectra the performance MALDI-TOF systems is enhanced (Jamal et 
al., 2014) 
 
Based on data from this study our centre routinely tests yeast smears prepared from 
primary culture using on-plate FA extraction, and conventional FA extraction is 
performed on isolates failing to identify. The overall workflow for yeast identification in 
our laboratory is indicated in figure 3.3. Molecular identification is infrequently required 
and in this study was only required for 2.6% (5/190) of the isolates included in the 
validation and 0.3% (1/297) of isolates encountered in our routine practice over a 12 
month period, but is the most appropriate option when MALDI-TOF MS fails to identify 
yeast. Molecular identification confirmed that the original identifications obtained using 
biochemical profiling were incorrect (unpublished data). This is a recognized limitation 
when using biochemical identification methods to identify rare yeast species (Bader, 
2013; Posteraro et al., 2013). One example, a Cyberlindnera fabianii isolate, was 
originally identified as C. pelliculosa using biochemical profiling. A second 
Cyberlindnera fabianii isolate was identified by ITS rRNA sequencing during the 12 
month prospective evaluation after failing to identify with MALDI-TOF MS. Historically 
the isolation of rare yeast species was not detected in previous years due to 
misidentification by biochemical methods. This is an important consideration for clinical 
isolates in culture collections used for biotechnology applications or as a resource for 
reference strains in the clinical setting. Re-analysis of isolates within a Brazilian culture 
collection demonstrated 15% discordance between the original biochemical 
identification and those obtained using MALDI-TOF MS which were subsequently 
confirmed by ITS sequenced based identification (Lima-neto et al., 2014). Using 
MALDI-TOF MS the isolation of rare species is now indicated by a failure to identify 
despite obtaining spectra. This prompts the correct application of molecular methods. 
The incidence of rare yeast species implicated in infections will inevitably increase as a 
factor of the increased accuracy of MALDI-TOF. The introduction of MALDI-TOF into 
the diagnostic setting has the potential to contribute to improvement in healthcare 
economic models and ultimately healthcare savings. The consumables cost of 
biochemical testing in the UK is £3.80 per sample (based on manufacturers costs 
within our centre). The estimated cost of MALDI-TOF is £0.50 per isolate for 
conventional formic acid extraction and would be less for on plate formic acid extraction 
(Dhiman et al., 2011). A recent cost evaluation of MALDI-TOF MS for the identification 
of bacterial and yeast isolates reported 87.8% reagent costs savings equivalent to just 
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under £54,176 in one year at a large university hospital in the USA. When total costs 
were calculated to include technologist’s time this reduced to a 51.7% cost saving of 
just over £56,498 (Tran et al., 2015). As the turn-around time (TAT) for yeast 
identification is reduced from 48-72 hours using biochemical methods to under 15 
minutes using conventional formic acid extraction and MALDI-TOF MS from a primary 
culture this will contribute to an overall cost saving for the service (Verweij et al., 1999). 
In summary, MALDI-TOF MS is a highly accurate method for the identification of 
yeasts, which may contribute to a positive impact on patient management as accurate 
yeast susceptibility patterns can be obtained from the identification. The increased 
awareness of rarer yeast species implicated in fungal infection strengthens 
epidemiological understanding. Furthermore maintaining a streamlined diagnostic 
service is essential in a modern microbiology service. Any modification that can 
maintain diagnostic accuracy and reduce sample-processing time has operational 
benefits and the addition of an on-plate formic acid extraction reference spectral 
database would further improve and enhance this process. This study has resulted in 
the discontinuation of conventional methods in our diagnostic service setting, with the 
introduction of MALDI-TOF as the new conventional method for yeast identification.  
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Figure 3.3 Diagrammatic representation of the yeast identification workflow in our laboratory. 
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4 Chapter 4 Improving the diagnosis of Candidemia through the 
application of MALDI-TOF MS for the identification of yeasts direct 
from positive blood cultures 
4.1 Introduction  
In the previous chapter MALDI-TOF MS was demonstrated to be an accurate method for 
the identification of clinically significant yeasts from solid agar culture, Solid agar cultures 
typically contain upwards of 1010 cells per colony therefore, have an abundance of proteins 
measurable by the MALDI-TOF process. This is crucial as MALDI-TOF is reliant on a 
concentration greater than 105 cfu/mL of biomass being present for successful 
identification (Lay, 2001). Identification of microorganisms direct from clinical specimens is 
restrictive as specimens often contain less than 105 cfu/mL. Blood cultures are the 
exception as, when positive, they contain greater than 106 colony forming units per 
millimetre of blood (Christner et al., 2010). This makes the identification of yeasts direct 
from blood culture a feasible approach when using MALDI-TOF MS as cultures may 
contain high enough concentrations of proteins to enable detection and identification. 
Using MALDI-TOF MS direct on blood cultures would reduce the time to identification of 
yeasts by 18-24 hours, as yeasts no longer require sub-culture onto solid media and 
subsequent incubation prior to MALDI-TOF MS analysis. However, identification of 
pathogens direct from clinical specimens presents some challenges.  
MALDI-TOF MS is a non-specific technique that detects all protein signatures present in 
an analyte regardless of origin. When analysing clinical specimens’ abundant human 
proteins present in the sample may interfere with the analysis. The removal of human 
cellular components through pre-processing of the specimen is recommended prior to 
MALDI-TOF MS analysis to maximise the successful detection and identification of 
microorganisms (Bruker protocols). Specific to blood cultures, removal of erythrocytes and 
other blood components is necessary (Morgenthaler and Kostrzewa, 2015). Prior to this 
study the processing of blood cultures for MALDI-TOF MS analysis was conducted using a 
variety of in-house sample preparation techniques. The most frequently utilised approach 
is a lysis/centrifugation method. In brief, preferential lysis of erythrocytes and leucocytes 
occurs with reagents such as saponin, followed by washing and centrifugation to obtain 
pellet containing cellular debris and intact microorganisms. At the point of undertaking this 
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study the identification of microorganisms directly from blood culture had been performed 
with varied success rates ranging between 40-90% using in-house lysis/centrifugation 
techniques (Christner et al., 2010; Ferreira et al., 2010; Moussaoui et al., 2010; Stevenson 
et al., 2010; Romero-Gómez and Mingorance, 2011). Only one study chose to investigate 
yeast identification specifically, reporting only 5.6% (1/19) success compared with 60% 
overall success for bacterial isolates (Ferreira et al., 2010). Furthermore, from centre to 
centre in-house developed methods were not standardised, with varying volumes, 
centrifugation speeds and reagents used. In early 2010, the Sepsityper kit (Bruker 
Daltonics, Germany) was launched into the diagnostic setting (Bruker Daltonics). The kit 
was developed for the pre-processing of blood cultures and consisted of two buffers, the 
first a red cell lysis buffer and the second a detergent wash buffer. Through centrifugation 
and treatment with the buffers the process was designed to remove the blood fraction of 
the culture leaving behind a pellet of concentrated microorganisms that could then be 
carried forward for MALDI-TOF MS analysis. The processing time was claimed to less 
than 10 minutes for a single blood culture, making this a rapid method for identifying 
organisms direct from blood cultures. The aim of this study was to evaluate and optimise 
blood culture processing using Sepsityper (Bruker Daltonics, Germany) specifically for 
yeast identification from blood cultures to reduce the time to diagnosis of candidemia. 
This study first focused on optimisation of the blood culture processing method using the 
Sepsityper assay (Bruker Daltonics, Germany) with several modifications to the method 
accounting for the change in microorganism detection. Once optimised, the blood culture 
processing method was applied to a larger set of yeast blood cultures to evaluate 
performance.  
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4.2 Methods 
4.2.1 Yeast isolates 
The optimisation arm of the study contained ten yeast isolates from confirmed cases of 
fungaemia, as detailed in table 4.1. For the final method of evaluation, fifty yeast isolates 
were selected from proven cases of fungaemia. Isolates were stored and passaged as 
detailed in general methods 2.1. 
4.2.2 Conventional phenotypic identification 
See general methods 2.1 
4.2.3 Formic acid extraction of proteins from solid agar yeast cultures 
See general methods 2.3  
4.2.4 Simulated blood cultures 
 See general methods 2.1 
4.2.5 Miles and Misra cfu/mL counts 
See general methods 2.1 
4.2.6 Standard Sepsityper blood culture processing  
200µL Sepsityper lysis solution (Bruker Daltonics, Germany) was added to a 1mL aliquot 
of blood and vortexed for 10 seconds. After incubation for 2-3 minutes at room 
temperature the suspension was centrifuged at 8000g for 2 minutes. The supernatant was 
discarded (avoiding disturbance of pellet) and the pellet re-suspended in 1mL of 
Sepsityper washing solution (Bruker Daltonics, Germany) by vortexing for 30 seconds. 
Centrifugation was repeated at 8000g for two minutes and the supernatant discarded. The 
pellet was re-suspended into 300µL of water by vortexing and 900µL absolute ethanol was 
added, vortexed, and a centrifuged again at 8000g for two minutes. The supernatant was 
discarded completely and the pellet was air dried for 20 minutes. 30µL of 70% formic acid 
was added to the pellet, vigorously mixed (including washing the acid along the side of the 
tube repeatedly to reconstitute any adhered cellular material) pulse centrifuged, pellet re-
suspended, then incubated for 3 minutes. To this 30µL of acetonitrile was added, mixed 
well, and after a second centrifugation at 8000g for two minutes, the final supernatant was 
used for analysis. 
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4.2.7 Optimisation of Sepsityper blood culture processing 
Several variables were identified within the bacterial Sepsityper assay procedure, listed 
below as experiments a) – f). Figure 4.1 illustrates the stage at which each variable was 
evaluated within procedure. If a modification was found to be beneficial to the yeast assay 
development it was retained within the method in a cumulative approach. 
a) Increasing blood volume to 5mL  
b) Increasing 100% Formic acid volume from 30µL to 70µL. 
c) Additional pellet wash with solution 2  
d) Water pre-wash; 1 mL of the blood culture fluid was centrifuged at 8000g for 2 
minutes, and the cell pellet was washed twice with 1mL of water 
e) Glass bead disruption of pellet; approximately 50µL equivalent volume of glass 
beads added to the cell pellet with the formic acid and vortexed for 5 minutes 
f) Vortexing the blood culture; gentle vortexing of the BacTec bottle at 1400rpm for 30 
seconds. Further vortexing of the 1ml blood aliquot for five minutes at 1400rpm prior 
to processing. 
 
4.2.8 Final optimised Sepsityper blood culture processing method  
All centrifugation steps were performed for 2 minutes at 8000g. Blood culture bottles were 
vortexed gently for 30 seconds, 1mL aspirated and transferred to a Sepsityper tube and 
vortexed for 5 minutes. After vortexing, 200µL of Sepsityper lysis buffer (LB) was added, 
vortexed for 10 seconds and incubated for 2 minutes. The suspension was centrifuged, 
supernatant discarded (avoiding disturbance of pellet) and the pellet re-suspended in 1mL 
of Sepsityper washing buffer (WB). Centrifugation was repeated, the supernatant 
discarded and the pellet was re-suspended into 300µL water and 900µL of absolute 
ethanol and re-centrfuged as previous. The supernatant was discarded and the pellet air-
dried for 5 minutes at room temperature. If a blood culture analysis did not return the 
identification on first attempt repeat analyses was undertaken 
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4.2.9 Formic acid extraction of blood culture pellets  
70µL of 70% formic acid was added to the dry pellet. The pellet was completely re-
suspended by pipetting (washing the formic acid along the side of the tube) and incubated 
for 5 minutes at room temperature. An equal volume of acetonitrile was added, mixed well, 
and then centrifuged. The target plate was inoculated with 1µL of the supernatant in 
triplicates and once dried, immediately overlaid with 1µL α-Cyano-4-hydroxy-cinnamic-acid 
matrix.  
4.2.10 MALDI-TOF spectral analysis  
See general methods 2.6 for standard identification protocol. For the amended blood 
culture analysis Spectra were cropped to exclude the mass range 0-4000 kDa and log 
similarity scores were lowered to >1.6 for genus identification and >1.8 for species 
identification. In a second analysis ‘adjusted log similarity score parameters’ were 
investigated to accept all identifications at species level with log similarity scores >1.5 
providing the top three matches were the same species. 
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Figure 4.1 Diagrammatic representation of Sepsityper processing with modifications indicated from A-F at the point of the process 
where they were introduced; a) increased blood volume, b) formic acid volume increase to 70µL c) additional wash solution 2 step d) 
water pre wash e) glass bead disruption of the pellet f) vortexing of the blood culture bottle and 1mL aliquot.
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4.3 Results 
4.3.1 Yeast identification from CHROMagar® Candida cultures  
ITS rRNA analysis from CHROMagar cultures returned the following identifications; C. 
albicans (17/50), C. glabrata (9/50), C. tropicalis (4/50), C. krusei (4/50), C. parapsilosis 
(7/50), C. orthopsilosis (1/50), C. metapsilosis (1/50), C. guilliermondii (2/50), C. 
lusitaniae (1/50), Cryptococcus neoformans (2/50), Magnusiomyces capitatus (1/50), 
Cyberlindnera fabianii (1/50). MALDI-TOF MS analysis identified 98% (49/50) of yeast 
isolates from CHROMagar culture. A Cyberlindnera fabianii isolate was not identified by 
MALDI-TOF MS, table 4.1. 
 
4.3.2 Optimisation of Sepsityper blood culture processing  
Miles and Misra counts demonstrated 100% (10/10) of the blood cultures used for 
method optimisation flagged positive > 106 cfu/mL.  
Using the standard Sepsityper methodology 20% (2/10) of the blood cultures were 
identified at genus level including one C. albicans isolate (log similarity score 1.942) and 
one C. parapsilosis isolate (log similarity score 1.93). Increasing blood volume led to 
complete failure of detection across all blood cultures with no yeasts being identified. 
Table 4.1 Yeast identifications by MALDI-TOF and ITS rRNA sequencing from 
CHROMagar® Candida cultures 
MALDI-TOF % n  ITS 1&2 % n 
C. albicans 34 17 (3) C. albicans 34 17  
C. tropicalis 8 4 (2) C. tropicalis 8 4  
C. glabrata 18 9 (1) C. glabrata 18 9  
C. krusei 8 4  C. krusei 8 4  
C. parapsilosis 14 7 (1) C. parapsilosis 14 7  
C. orthopsilosis 2 1 C. orthopsilosis 2 1 
C. metapsilosis 2 1 C. metapsilosis 2 1 
C. guilliermondii 4 2 (1) C. guilliermondii 4 2  
C. lusitaniae 2 1 C. lusitaniae 2 1 
C. neoformans 4 2 (1) C. neoformans 4 2 
M. capitatus 2 1 (1) M. capitatus 2 1 
NO ID 2 1 Cyberlindnera fabianii  2 1 
Total 100 50  100 50 
() Brackets indicate the isolates used in the optimisation arm of the study 
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Increasing the volume of formic acid applied to the pellet (70µL) during protein extraction 
increased the success rate to 10% (1/10) for species identification of one C. albicans 
(log similarity score 2.08), and a genus identification success rate of 50% (6/10) with four 
further isolates being identified including C. tropicalis (2) (log similarity scores 1.936, and 
1.866), M. capitatus (log similarity score 1.971) and a second C. albicans isolate (log 
similarity score 1.823).  
The positive impact of increased FA volume is demonstrated in figure 4.2 with a 
significant shift (p=0.02) in the median log similarity score obtained across the ten 
analyses. The addition of a second wash step using Sepsityper wash solution 2 did not 
significantly increase the success rate further nor did the addition of a water pre-wash 
step, which had a negative impact reducing the overall success rate to 50% (5/10). No 
improvement was seen with the addition of vortexing with glass beads to the formic acid 
incubation stage. Vortexing of the blood culture bottle and 1mL aliquot prior to 
processing increased the overall success rate to 70% (7/10) and also improved the 
species identification rate from 10% (1/10) to 40% (4/10) for those yeasts detected from 
the blood cultures.  
4.3.3 Modification of MALDI-TOF MS spectra prior to identification 
Re-analysis of the mass spectra obtained using the optimised SepsityperTM method was 
performed using the amended blood culture spectral analysis protocol that cropped 
spectra at 4000kda. The overall identification success rate doubled to 80% (8/10) with 
60% (6/10) identified to the species level (log similarity score >2.0) and 20% (2/10) blood 
cultures identified to the genus level (log similarity score >1.8). Figure 4.2 and table 4.2 
demonstrate the significant shift in the median log similarity score after adjustment of 
spectral analysis. By lowering the acceptable log similarity scores for identification to 
>1.8 as per the blood culture spectral analysis protocol all eight yeasts were now 
classified at the species level. Two yeasts remained unidentified from blood culture, one 
C. neoformans isolate and one C. glabrata isolate.  
Whilst vortexing the blood did not significantly impact the median log similarity score 
value it contributed to two additional blood cultures being identified with a log similarity 
score >2.0 so was retained as a modification in the method. No other modification had a 
statistically significant impact on the log similarity scores obtained, as shown in table 4.2 
and figure 4.2.  
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Figure 4.2 Scatter plot of average log similarity scores obtained from triplicate analyses 
of ten yeast blood cultures processed by Sepsityper with the addition of modifications: B 
= Increased formic acid to 70µL, C = Extra solution 2 wash, D = Pre water wash, E = 
Bead beating pellet, F = vortexing blood culture bottle and 1mL aspirate. Adjusted 
spectral analysis included cropping out the 0-4000kDa range from MS spectra. **p<0.01, 
*p=0.02, NS = no significant difference. Red lines indicate thresholds of >1.7 for genus 
identification and >2.0 for species identification. 
 
Table 4.2. Median log similarity scores obtained through modifications to the 
Sepsityper processing method 
Modification to Sepsityper processing Log similarity score  Significance 
  Median IQR  
A No modification 0 1.23 1.55 - 
B Increased volume formic acid 1.8 1.33 1.95 *P=0.02 
B+C Second buffer 2 wash 1.75 1.24 1.9 0.84 
B+D Water pre wash 1.63 1.44 1.98 0.78 
B+E Glass bead beating 1.78 1.58 2.0 0.49 
B+F Vortexing 1.9 1.54 2.0 0.54 
70µL formic acid, vortexing with spectral 
processing 
2.1 1.84 2.245 **P<0.01 
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4.3.4 Application of the final optimised blood culture processing method and 
MALDI-TOF MS spectral analysis protocol to blood cultures 
The optimised blood culture processing method was applied to a set of 50 blood cultures 
to evaluate its performance. MALDI-TOF MS identified 56% (28/50) of the yeasts from 
blood cultures at the species level on first attempt. Of the remaining blood cultures, 20% 
(10/50) returned a genus only identification of Candida sp with a log similarity score >1.6 
but <1.8 and the remaining 24% (12/50) returned a log similarity score <1.6 with a result 
of ‘no reliable identification’.  
92% (46/50) of spiked blood cultures flagged positive with a concentration greater than 
1x106 cfu/mL and the remaining four cultures contained greater than 1x105. No 
correlation was seen with cfu/mL and failure to identify yeasts within blood cultures, 
shown in figure 4.3. 
 
 
Figure 4.3 Graph plotting cfu/mL concentrations for 50 blood cultures included in the 
blood culture processing evaluation, grouped into those blood cultures which yeasts 
were detected from versus those that yeasts were not detected from. No significant 
difference was observed between the two groups (p=0.36). 
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Re-analysis of MALDI-TOF spectra using ‘adjusted’ parameters (including the lowered 
species log similarity score threshold of >1.5) for the 20% (10/50) of the blood culture 
strains identified to genus level, re-classified these results to acceptable species 
identification with no observed misidentification, increasing the overall success rate to 
76% (38/50).  
Re-analysis of spectra for the 24% (12/50) of blood cultures with a log similarity score 
<1.5 with adjusted parameters had no effect. Repeat processing of these blood cultures 
was performed and 8% (4/50) were resolved, all returning a correct identification. 16% 
(8/50) of yeast from blood cultures still remained undetected. Figure 4.4 demonstrates 
spectra from a C. albicans blood culture where yeasts failed to identify (B) alongside a 
spectrum from a C. albicans blood culture where yeasts were successfully identified (A) 
demonstrating a lack of intensity for peaks obtained from yeast proteins. No correlation 
was observed between yeast species and unsuccessful identification. 
110 
 
            
 
 
         
Figure 4.4 Sections of MALDI-TOF MS spectra at acquisition for a) Candida albicans blood culture analysis with a log similarity <1.6 
indicating ‘no identification (b) C. albicans blood culture with a successful identification with a log similarity score >1.8 (c) a Candida 
albicans isolate identified by MALDI-TOF log similarity score 2.312 (d) spectrum obtained from a negative blood culture by MALDI-TOF 
MS. The dotted line on both spectra indicates 600 absolute intensity. 
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4.4 Discussion 
This study has demonstrated that MALDI-TOF MS is capable of identifying yeasts 
direct from blood cultures, with 76% (38/50) accuracy compared with MALDI-TOF MS 
identification from solid agar. This success rate was achieved after optimisation of 
blood culture processing and spectral analysis. In a recent meta-analysis of Sepsityper 
performance, this success rate is supported by a recent meta analysis including 21 
studies which reported a success of 66% for MALDI-TOF MS yeast identification from 
blood cultures (Nils G Morgenthaler and Kostrzewa, 2015). The authors acknowledged 
the challenges faced when identifying yeasts specifically from blood cultures. Prior to 
optimisation Sepsityper processing was completely unsuccessful for the identification 
of yeasts at species level assuming a log similarity score of >2.0, despite blood 
cultures having a cfu/mL concentration >105, which is considered sufficient for MALDI-
TOF MS detection (Yan et al., 2011). In a recent study Yan et al reported complete 
failure to identify yeast with direct application of Sepsityper to yeast blood cultures. In a 
similar study, utilising an in house lysis centrifugation-processing method, Garci et al ( 
2010) demonstrated poor performance identifying only 5.6% (1/19) yeasts from blood 
cultures by MALDI-TOF MS (Garcı, 2010), with other studies also demonstrating 
poorer performance for yeasts (Chien et al., 2016; Jeddi et al., 2016) This indicates 
strongly that the standard methods used for bacteria are not appropriate for yeast 
identification from blood culture.   
 
4.4.1 Optimisation of blood culture processing and spectral analysis 
Failure to detect yeasts by MALDI-TOF MS is associated with two factors. The intensity 
of the peak represented in the MS spectra for yeast proteins are far less than the 
intensity seen with bacterial analysis. This in part is due to the robust cell wall of the 
yeast cells resisting lysis by formic acid. The second factor is the carryover of 
unwanted proteins from blood during processing. Three clusters of high intensity 
peaks, common across all analyses are visible within blood culture spectra (Figure 3.7 
D). The Sepsityper assay is designed to remove cellular blood components by lysis. 
However, carry-over free blood proteins are not removed by the processing. This study 
investigated a variety of modifications to blood processing with the aim of optimising 
Sepsityper processing for yeast blood cultures. Additional steps found to be beneficial 
to the success of identification included: increased volume of formic acid and 
subsequently the volume of acetonitrile applied to the pellet, vortexing the blood 
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culture, adjustment of spectral analysis with cropping from 0-4000 kDa and finally a 
reduction in the log similarity scores thresholds applied to the level of identification.  
 
4.4.2 Modification to blood culture processing 
4.4.2.1 Formic acid volume 
The volume of 100% formic acid applied to the yeast pellets varies across studies 
utilising the Sepsityper assay between 2µL to 70µL (Haigh et al., 2011; Jamal, Saleem 
and Rotimi, 2013; Nonnemann, Tvede and Bjarnsholt, 2013; Tadros and Petrich, 2013; 
Martinez et al., 2014). In the majority of studies the volume was determined by pellet 
size. In an earlier study 30µL of FA was added to a pellet obtained from 8mL of blood 
(Spanu et al., 2012) and an overall success rate of 91.8% was achieved, although in 
this study identifications were accepted with a log similarity score >1.2 providing all 
matches were the same species. Conversely in this study 70µL of formic acid was 
found to be more successful when applied to a pellet obtained from a blood culture 
volume of 1mL, increasing the success rate from 20% (2/10) to 60% (6/10). The 
reasons for the conflicting observations are not clear. Improved detection when 
increasing the volume of FA in this study may have been due to a dilution effect on 
blood proteins allowing yeast proteins to be detected or may have contributed to more 
efficient lysis of the yeast cells.  
 
4.4.2.2 Vortexing 
The addition of vortexing steps both for the blood culture prior to aspiration and the 
aspirated 1mL aliquot slightly improved the overall success rate but most notably had a 
positive impact on identification at the species level with two additional blood cultures 
achieving a log similarity score >2.0. This is the only study to describe vortexing as a 
modification to optimise the success of Sepsityper. Morphology of yeasts in blood 
culture may be an important factor. Hyphae and blastospores aggregate in blood 
cultures. By vortexing the blood culture it may liberate blastospores and hyphae into a 
unicellular state, allowing for a more consistent distribution of yeasts when aspirating 
the blood culture from the bottle and may also increase the surface area accessible by 
the FA, allowing for more efficient extraction of proteins.   
 
No other modifications to the blood culture processing were found to be beneficial in 
this study, although it is acknowledged that we used a small sample size of ten blood 
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cultures. Increasing the blood culture volume processed to 2mL resulted in complete 
failure of detection, most likely due to an increase in the human protein component of 
the analyte. By doubling the blood culture volume the amount of human protein 
extracted through the process is doubled in concentration. The yeast protein peaks 
were not visible in the MALDI-TOF MS spectra. As all blood cultures were found to 
contain a concentration of organisms within the published limit of detection (LOD) for 
MALDI-TOF MS analysis we did not consider it necessary to increase the blood 
volume any further (Drancourt et al., 2016) as this would have also required excessive 
reagents from the Sepsityper kit. It is important to acknowledge that increased blood 
volume may have contributed to the increased success rates observed in two similar 
studies. Ferroni et al demonstrated a success rate of 95.2% from 21 blood cultures 
using 1.8mL of blood (Ferroni et al., 2010). In a recent report a success rate of 91.8% 
was achieved with 8mL of blood culture (Spanu et al., 2012) however, using almost 
exactly the same processing method and 8mL of blood a second study reported a 
poor success rate of 9.3% (5/54) for the identification of yeasts (Rodríguez-Sánchez 
et al., 2013). Aspirating 8mL of blood for centrifugation has considerable health and 
safety considerations and is not a desirable approach for the routine diagnostic setting.  
 
Additional wash steps prior to lysis and a second buffer 2 wash were also investigated.  
Additional wash steps did not improve success any further after the increased volume 
of FA was added and again led to the utilisation of more Sepsityper reagents. In 
contrast 100% success has been observed with the addition of two wash steps prior to 
the red cell lysis. However, in this study the authors also used a larger than 
recommended volume of FA (50µL) which could have contributed to the increased 
success rate (Yan et al., 2011). In a more recent study, an in-house approach utilising 
SDS as the primary lysis solution, with a secondary water wash step, was found to be 
superior to Sepsityper processing, improving the identification rate by 8% across 107 
yeast blood cultures (Bidart et al., 2015). This suggests that adjusting the reagents 
used to process yeast blood cultures could contribute to increased success. Despite all 
of this a significant proportion of yeast remains undetectable from blood cultures, due 
to endogenous blood proteins remaining present in the analyses. Other factors may be 
important during blood culture processing. Increasing the number of protein extract 
replicates spotted onto the target plate may increase the success rate. In this study 
extracts were spotted in triplicate whereas in the more successful study protein 
extracts were spotted in quadruplicate (Yan et al., 2011). The culture medium used 
may also serve to increase the success of MALDI-TOF MS. Spanu et al utilised 
BACTEC Mycosis-IC/F culture vials that are optimised for fungal cultures and contain 
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saponin, a red blood cell lysing agent. This effectively added an extra red cell lysis 
step, which may have contributed to the increased success rate (Spanu et al., 2012). 
Despite all of these modifications to blood culture processing the identification of 
yeasts is still negatively affected by the presence of human protein peaks in spectra.  
It is important to acknowledge that any modification would deviate from using a CE-IVD 
regulated assay, which in a diagnostic service laboratory may have regulatory and 
quality control implications and would require a validation study. In-house developed 
methodologies require significantly more validation data to support claims for 
introduction into diagnostic practice. These processes can be counter intuitive and can 
often be costly for the laboratory to maintain analytical performance both in on-going 
supply of reagent and assay components and in terms of the increasing complexity of 
regulatory systems which govern the use of in vitro diagnostics in clinical practice 
systems (Morgenthaler and Kostrzewa, 2015)  
4.4.3 Spectral analysis and adjusted log similarity scores 
The blood culture analysis program in the Biotyper software is designed to exclude the 
spectral range 0-4000 kDa from the identification-matching algorithm. The purpose of 
this is to remove the cluster of blood protein peaks with the highest intensity, which has 
a peak position around 3500 m/z (mass to charge ratio). This resulted in increased 
identification success rate detection and increased log similarity scores across 
analyses. The log similarity score is in part calculated from the intensity of peaks within 
the unknown spectra, a full explication of the log similarity score can be found in the 
general method section 2.3. The principle is the higher the intensity the greater the 
score for a peak. If a peak is matched between the unknown and reference spectra it is 
given a positive score, whereas unmatched peaks are given a negative score. By 
removing the high intensity blood protein peaks from the analysis it removes the 
negative impact of these unmatched peaks on the log similarity score and allows the 
positive scores from lower intensity yeast proteins to have more weight. Figure 4.4 
demonstrates spectra acquired from two blood cultures containing C. albicans. In figure 
4.4 (A) a result of ‘no identification’ was achieved, as the intensity of yeast proteins are 
a fraction of those obtained from the blood whereas. In figure 4.4 (B) successful 
species identification was achieved as the yeast proteins have greater intensity within 
the spectrum and cross the acceptable threshold for peak intensity despite the 
presence of highly abundant human proteins in figure 4.4 (C) highly abundant protein 
with strong peak intensities match those of blood proteins and the presence of the 
blood peaks is neutralised. 
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4.4.4 Evaluation of optimised methodology 
Using the optimised blood culture processing method and adjusted spectral analysis 
MALDI-TOF MS demonstrated a first attempt success rate of 56% (28/50). Several 
recent studies have reported much higher success rates between 91.8% and 100% 
(Ferroni et al., 2010; Yan et al., 2011; Spanu et al., 2012; Pulcrano et al., 2013). There 
are several factors that may have contributed to the lower success rate of MALDI-TOF 
MS in this study compared with these other studies. Processing error was accounted 
for by repeating analysis of blood cultures when identification was not achieved, but 
from a workflow perspective in the diagnostic laboratory high proportions of repeat 
analyses would not be ideal. The success rate increased to 64% (32/50) with four 
further cultures achieving identification. Loss of pellet during processing was the likely 
factor leading to no identification in these cultures. However, 36% (18/50) cultures 
remained unidentified.  
This study has demonstrated that applying an adjusted set of parameters, including 
lowering the acceptable species log similarity score threshold further to >1.5, increases 
the success rate to 76% (38/50) on first attempt without misidentification, and 84% 
(42/50) when including repeat analysis. Lowering the score thresholds was justified 
through observing that when yeasts were detected only the correct yeast species, 
compared against ITS rRNA sequencing, were returned as identifications with log 
similarity scores above and below the acceptable species threshold. In all instances at 
least the top 3 differential identifications were of the same species. This approach has 
also been demonstrated in a previous study with similar success rates (Schubert et al., 
2011). Whilst lowering log similarity scores and cropping spectra improves the success 
of MALDI-TOF MS identification it is evident that the quantity of protein from blood 
components far outweighs yeast proteins. The high concentration of human protein 
may have an impact during matrix co-crystallisation (Drancourt et al., 2016). Highly 
abundant human protein could overwhelm any yeast proteins present which in turn 
then fail to co-crystallise. The success rate of MALDI-TOF MS for the identification of 
yeast from blood cultures may be improved if total human protein can be eliminated 
during processing prior to formic acid extraction of the yeast pellet.  
 
The outstanding factor not investigated in our study was the blood and its associated 
components. The use of five-day negative blood for spiking development experiments 
may have impacted on the overall success rate. It is possible that older blood contains 
larger amounts of free human protein released during haemolysis however, as the time 
to a positive blood culture is reportedly up to 120 hours for some C. glabrata isolates 
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(George, Horvath and Hospenthal, 2005), ‘older’ blood will inevitably be analysed using 
MALDI-TOF MS for yeast identification. Furthermore the use of five-day negative blood 
did not affect the viability of the yeast cultures on sub-culture. As the negative impact of 
using five day negative blood was not universal across analyses it may be better 
explained by the fact that blood from different patient may have a variable impact on 
MALDI-TOF MS analysis. The study of specific properties within the blood is an 
important consideration for further work. 
 
In summary, whilst Sepsityper alongside MALDI-TOF MS analysis is applicable in its 
current format for bacterial identification from blood cultures, improvement and 
standardisation of the processing method for Yeast identification is required to achieve 
the success rate required by a routine diagnostic laboratory. Methods to reduce the 
impact of human components within the analyte also require further refinement to 
progress these methods for diagnostic use.  
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5 Chapter 5 Evaluation of MALDI TOF MS compared with 
conventional microscopic identification of filamentous mould 
isolates from clinical samples 
5.1 Introduction 
The ability to accurately identify fungi to species level using macro- and microscopic 
features requires skill and expertise. This comprehensive process is challenging for 
general microbiology laboratories that have a high diagnostic mycology workload. This 
is reflected in recent studies reporting the accuracy of conventional identification of 
filamentous fungi by microscopy to be between 61.5%-80.1% (Becker et al., 2014; 
Gautier et al., 2014; Ranque et al., 2014). For non-Aspergillus isolates the successful 
identification to the species level can be as low as 31% in the diagnostic setting when 
compared with gold standard molecular identification (Ranque et al., 2014).  
There are several limitations to conventional identification that contribute to 
misidentification. To date over 100,000 fungi have been taxonomically classified, yet 
many more remain unknown. Many environmental fungi share similar 
macro/microscopic characteristics with pathogenic fungi when cultured under 
laboratory conditions; therefore misidentification of rarely encountered fungi is always a 
risk. The laboratory also relies on published material to aid the fungal identification 
process but literature can rapidly become out of date as fungal taxonomy is changing 
constantly through whole genome sequencing reclassifying species that were 
previously classified using morphological characteristics (de Hoog and Guarro, 1995; 
Campbell, 2013). In the laboratory environment some fungal strains fail to produce 
fruiting structures, making it impossible to identify them phenotypically. This instance 
the laboratory is reliant on molecular identification techniques, such as sequence-
based analysis of rRNA regions (Borman et al., 2008). Most diagnostic laboratories do 
not have direct access to molecular facilities; therefore isolates are referred to a 
reference laboratory. This process extends the turnaround time of identification. The 
other major consideration for most laboratories providing a comprehensive mycology 
service is that laboratory scientists require several months of training to become 
competent in fungal identification. Trained scientists need frequent rotation through the 
mycology laboratory to maintain their competency assessment profiles. As a result 
laboratories often have a single scientist who is relied upon for the provision of their 
mycology service. This is not a robust approach to providing a comprehensive 
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mycology service in modern health care environment. If Mycology is to sustain itself 
within pathology a new approach to fungal identification is required.  
Maier and colleagues recognised this when they published the first standardised 
method for fungal identification using MALDI-TOF MS (Maier and Kostrzewa, 2009). 
The authors proposed a new method for cultivating fungi in liquid medium encouraging 
the growth of mycelia to form ‘fungal balls’ with an absence of fruiting structures and 
conidia. The production of high quality reproducible spectra was possible through 
applying a standard formic acid extraction protocol to the mycelial cultures (Maier and 
Kostrzewa, 2009). In 2011 a filamentous fungal v1.0 (FFv1.0) database became 
commercially available (Bruker Daltonics, Germany). The database contained MS 
spectra representing 104 species (365 spectra) as generated using the novel liquid 
cultivation method. Subsequently this was recommended as the processing method for 
fungal isolates when using the FFv1.0 database is the liquid cultivation method (Maier 
and Kostrzewa, 2009).  
The aim of this study was to evaluate the FFv1.0 database, (Bruker Daltonics, 
Germany) utilising the liquid cultivation method for the identification of fungi. Gold 
standard ITS rRNA analysis and conventional identifications were compared to those 
obtained by MALDI TOF MS.  
 
5.2 Materials and Methods 
5.2.1 Sample selection 
Filamentous fungi surplus to diagnostic requirements were selected from a clinical 
archive at the UK CMN regional mycology laboratory, Royal Free Hospital microbiology 
laboratory. A range of species was selected to represent a diverse collection of fungi 
encountered in the diagnostic setting. All fungi had previously been isolated from 
clinical specimens and were considered to be pathologically significant. Isolates were 
passaged as detailed in general methods section 2.1.2.    
5.2.2 Microscopic identification 
Microscopic identification was performed by the ‘advanced’ scientist experienced in 
fungal identification with the aid of two identification keys (de Hoog and Guarro, 1995; 
Campbell Colin K, 2013). Sellotape and needle mount preparations were prepared as 
per published methods with Lactophenol cotton blue (Campbell Colin K, 2013). 
 119 
Phenotypic identification was based on macro-morphological criteria including; growth 
on different media and at different temperatures, colour, and growth rate of the colony, 
and on micro-morphological criteria, e.g. conidiogenesis, shape of conidia and conidia, 
and mycelial structures, (Campbell Colin K, 2013). 
5.2.3 Culture of mycelial mats for DNA extraction 
To minimise the potential for cross contamination of DNA extracts, each fungal isolate 
was cultured as a non-sporing filamentous ‘pancake like’ mycelial mat. All processing 
was performed in a laminar flow cabinet to protect cultures from environmental 
contamination. To produce the mycelial mats conidia were harvested from each fungal 
colony and a suspension was prepared in saline. 100μL of each conidial suspension 
was inoculated into a 96-well microtitre plate containing 5mL of Sabouraud’s liquid 
media. The microtitre plates were incubated for 1-3 days under daily observation. Once 
a complete mycelia mat had formed, each culture was harvested onto a sterile 
Whatman filter paper (grade 3) and transferred to a 5mL bijou. The mycelia mats were 
stored at -70C until required for DNA extraction. 
5.2.4 DNA extraction from mycelia mats 
See general methods 2.2.1  
5.2.5 PCR amplification and sequencing of the ITS rRNA 
See general methods 2.2.2 - 2.2.4 
5.2.6 Referral of unidentified isolates to reference facilities for further 
molecular identification  
See general methods 2.4 
5.2.7 Cultivation of mycelia balls  
Fungal culture plates were manipulated inside plastic sample bags to control the 
dispersion of conidia into the environment. Using a moistened cotton swab the top of 
the petri dish was lifted slightly and the cotton swab was gently rolled over the surface 
of the fungal culture to harvest conidia. The swab was immediately transferred to a 
15mL falcon tube containing 10mL of Sabouraud’s liquid. The conidia were released 
from the swab by pressing it against the side of the tube. The falcon tube was then 
sealed and inverted to mix. Broths were incubated for 24 hours on a SB2 rotator at 
30°C.  
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Optimisation of the fungal inoculum was undertaken in a crude approach by inoculating 
a very light, light and moderate quantity of conidia into the Sabouraud’s liquid broth to 
establish which spore inoculum warranted the best sporulation of fungal mycelium. 
Throughout processing a control tube of Sabouraud’s liquid agar was placed in the 
preparation area and left open to control for contamination events. 
 
5.2.8 Harvesting the mycelia balls and protein extraction 
The Falcon tubes were removed from the incubating rotator and centrifuged for 10 
minutes at 4000g. Using a fat tip pastette the pellet and approximately 1.5mL of SAB 
broth was transferred into a 1.5mL microfuge tube. The eppendorf was centrifuged at 
8000g for 2 minutes. The supernatant was discarded carefully using a fine tip pastette. 
The pellet was re-suspended in 1mL of distilled water then centrifuging again at 8000g 
for 2 minutes. The supernatant was removed using a fine tip pastette. The respective 
water wash step was repeated once more. 
  
5.2.9 Formic acid extraction 
See general methods 2.3.1 with the exception of the ethanol-drying step as detailed in 
section 5.3.13. 
5.2.10 Optimisation of pellet dehydration  
Four fungal isolates were selected, for method optimization representing species 
commonly encountered: Aspergillus fumigatus (1), Aspergillus oryzae (1), Mucor 
heimalis (1) and Fusarium oxysporum (1). Three replicates of each isolate were 
prepared as fungal balls and processed in parallel using the three pellet treatment 
steps a) – c) below. The protein extracts were spotted in quadruplicates. 
a) Pellets were placed in a hot block for 20 minutes at 60°C.  
b) Pellet was left to dry in an incubator at 37°C for 2 hours.  
c) No drying of the pellet.  
 
5.2.11 MALDI-TOF analysis of protein extracts and identification with the 
Biotyper 3.1 software 
See general methods 2.3.2 and 2.3.3.  
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5.3 Results 
5.3.1 Sample selection 
In total 147 clinical isolates were included in the sample cohort representing 24 genera 
and 47 species as determined by iTS rRNA sequenced based identification. Table 5.1 
details the ITS rRNA identifications for the 147 strains. Aspergilli represented 49% 
(72/147) of the isolates with the remaining 51% (75/147) being non-Aspergillus 
species.  
5.3.2 ITS rRNA identification of fungal isolates 
In-house ITS rRNA sequenced based identification was achieved for 87.8% (129/147) 
fungal isolates. The remaining 12.2% (18/147), all Aspergillus species, were referred to 
Bristol Mycology reference laboratory for molecular identification as per published 
protocol (Borman et al., 2010). Figure 5.1 shows a gel image of ITS rRNA fragments 
amplified using the ITS rRNA PCR as published by White et al (Innis MA, Gelfand DH, 
1990). All reactions had an input of 100ng template. Reduced amplification efficiency 
was observed for the Aspergillus species, with 25% (18/72) of the isolates failing to 
produce ITS rRNA products using the published primer sets. In figure 5.1 this is 
exemplified for several amplicons generated from Aspergillus isolates (figure 5.1), low 
intensity bands on gel electrophoresis indicate inefficient amplification in lanes 5, 7, 11 
and 17.  
 
Figure 5.1 Example of an agarose gel for ITS rRNA amplicons obtained from fungal 
isolates using published primers by White et al (Innis & Gelfand, 1990).  
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5.3.3 Microscopic identification of fungal isolates 
The overall identification rate compared with ITS rRNA sequenced based analysis was 
80.3% (118/147) at the species level and 91.8% (135/147) at the genus level. Sub 
analysis demonstrated identification rates of 95.8% (71/73) at species level and 100% 
(73/73) at genus level for the Aspergillus species, table 5.1. For non-Aspergillus 
species the identification rates were 63%% (47/74) at species level and 84% (62/74) at 
the genus level, table 5.2.  
Of the 19.7% (29/147) isolates not identified correctly to species level 5.4% (8/147) 
were identified at the genus level correctly but the investigator did not return the 
species level identification. For 6.1% (9/147) isolates the correct genus but incorrect 
species identification was reported, table 5.3. For 8.1% (12/147) of the isolates the 
genus was misidentified by the investigator, as detailed in table 5.3. The respective 
isolates misidentified at genus level included: Myrothecium sp, Neofusicoccum sp, 
Pheosphaeriopsis sp, Pleosporales sp, Bionectria ochroleuca, Basidiomycete fungus 
(2), Alternaria alternata, Botryosphaeria stevensii, Mucor circinelloides, Mucor heimalis 
and Epicocum nigrum.  
 
 
 
Table 5.1 Concordance between Microscopy and ITS rRNA identifications for 
Aspergillus isolates included in the study 
  Concordance (%) 
  Microscopy MALDI TOF MS 
Species n Species Genus Species Genus 
Aspergillus fumigatus 25 96 100 92 96 
Aspergillus niger 19 100 100 100 100 
Aspergillus oryzae/ flavus 9 100 100 100 100 
Aspergillus terreus 5 80 100 80 100 
Aspergillus versicolor /sydowii 5 100 100 80 100 
Aspergillus nidulans 4 100 100 50 100 
Aspergillus candidus 2 100 100 100 100 
Aspergillus pseudoflectus/ustus/calidoustus 2 100 100 100 100 
Aspergillus sclerotiorum 1 100 100 0 100 
Total 73 95.9 100 90.4 98.6 
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Table 5.2 Concordance between Microscopy and ITS rRNA identifications for non-Aspergillus isolates included in the study 
  Concordance (%)   Concordance (%) 
Species  Microscopy MALDI TOF MS Species  Microscopy MALDI TOF MS 
 n Species Genus Species Genus  n Species Genus Species Genus 
Acremonium kiliense 1 0 100 0* 0* Mucor racemosus 1 0 100 0* 100 
Acremonium strictum/alternatum 3 66.6 100 0 0 Mucor circinelloides 3 66.6 66.6 0 0 
Alternaria alternate 2 50 50 100 100 Myrothecium sp 1 0 0 0* 0* 
Unknown Basidomycete 2 0 0 100 100 Neofusicoccum sp 1 0 0 0* 0* 
Bionectria ochroleuca 1 0 0 0* 0* Paecilomyces lilacinus 1 100 100 100 100 
Cladosporium cladosporioides 1 100 100 0 0 Paecilomyces variotti 1 100 100 0 0 
Cochliobolus hawaiiensis 3 100 100 66.6 66.6 Penicillium chrysogenum 2 0 100 100 100 
Botryosphaeria stevensii 1 0 0 0* 0* Penicillium polonicium 1 0 100 0* 100 
Engyodontium album 3 100 100 0* 0* Pleosporales sp 1 0 0 0* 0* 
Epicoccum nigrum 1 0 0 0* 0* Pleosporales sp 1 0 0 0* 0* 
Exophiala spinifera 1 100 100 0* 0* Rhizopus oryzae/arrhizus 3 100 100 100 100 
Fusarium intermedius/proliferatum 2 0 100 50 50 Scedosporium apiospermum 6 100 100 100 100 
Fusarium moniliforme 1 100 100 100 100 Scedosporium prolificans 1 100 100 100 100 
Fusarium oxysporum 12 74.9 100 74.9 81.8 Scytalidium hylinum 1 100 100 0* 0* 
Fusarium solani 6 83.3 100 100 100 Scytalidium dimidiatum 2 100 100 0* 0* 
Fusarium sp 2 0 100 50* 50 Scopulariopsis brevicaulis 1 100 100 100 100 
Lichtheimia ramose 2 100 100 100 100       
Mucor hiemalis 2 0 50 0* 0       
Mucor indicus 1 100 100 0* 0 Total  74 63% 
(47/74) 
84% 
(62/74) 
54% 
(40/74) 
58% 
(43/74) 
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Table 5.3 Misidentification by microscopy compared with ITS rRNA 
sequenced based identification for 23 fungal isolates 
ITS rRNA identification  Microscopic identification  n 
Species misidentification 
Aspergillus terreus Aspergillus alliaceus 1 
Aspergillus fumigatus Aspergillus candidus 1 
Mucor racemosus Mucor circinelloides 1 
Fusarium proliferatum Fusarium oxysporum 1 
Fusarium solani Fusarium oxysporum 3 
Fusarium sp Fusarium oxysporum 1 
Acremonium sp/sclerotigenum Acremonium kiliense 1 
Total  9 
Genus misidentification  
Myrothecium sp Acremonium spinosum 1 
Neofusicoccum sp Scytilidium sp 1 
Pheosphaeriopsis sp Fusarium sp 1 
Pleosporales sp Scylalidium lignicola 1 
Bionectria ochroleuca Acremonium strictum 1 
Basidiomycete fungus Scytalidium hyalinum 2 
Alternaria alternate Ulocladium spp 1 
Botryosphaeria stevensii Scytilidium dimidiatum 1 
Mucor circenelloides Rhizopus stolonifer 1 
Mucor heimalis Rhizomucor variabilis 1 
Epicocum nigrus Aspergillus niger 1 
Total  12 
 
 
5.3.4 Optimisation of SAB broth inoculation for MALDI-TOF MS 
Prior to performing MALDI-TOF MS analysis on fungal cultures it was necessary to 
optimise the fungal concentration inoculated into Sabouraud’s broth as over inoculation 
led to poor germination of the conidia. To optimize the inoculum three different cultures 
were prepared by taking a light, moderate and heavy sweep of the fungal colony 
surface. Figure 5.2 shows the results of this experiment after 24 hours incubation at 
30°C on the rotating platform. The moderate inoculum produced optimal fungal 
biomass for analysis with well-developed fungal balls in suspension. The biomass in 
the light inoculum was not sufficient for protein extraction. The heavy sweep inoculum 
of conidia fungal balls was poorly developed and some un-germinated conidia were 
present that could interfere with the spectral consistency.  
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Figure 5.2 varying inocula (light, moderate, and heavy) for Aspergillus fumigatus fungal 
ball preparation for MALDI-TOF MS. 
 
5.3.5 Optimisation of protein extraction for MALDI-TOF MS 
Table 5.4 details MALDI-TOF MS results for four isolates processed using the three 
pellet drying methods detailed in section 5.2.10. Table 5.3 details the log similarity 
scores obtained for four isolates processed in triplicates through the three pellet drying 
conditions. In figure 5.3 log similarity scores are plotted for the three drying conditions.  
 
Table 5.3: MALDI TOF MS log similarity scores results obtained for four fungal 
isolates processed using three pellet drying conditions during protein extraction 
 Hot block  Incubator No drying  
 n Identification Score Identification Score Identification Score 
1 
A. oryzae/flavus 2.413 A. oryzae/flavus 2.283 A. oryzae/flavus 2.378 
A. oryzae/flavus 2.345 A. oryzae/flavus 2.347 A. oryzae/flavus 2.388 
A. oryzae/flavus 2.355 A. oryzae/flavus 2.279 A. oryzae/flavus 2.344 
2 
 
Aspergillus sp 1.926 A. fumigatus  2.32 A. fumigatus  2.487 
A. fumigatus 2.073 A. fumigatus  2.327 A. fumigatus  2.392 
No peaks found < 0 A. fumigatus  2.2 A. fumigatus  2.3 
3 
S. apiospermum 2.1 no reliable ID 1.6 S. apiospermum 2.1 
S. apiospermum 2.127 Scedosporium sp 1.935 Scedosporium sp 1.859 
Scedosporium sp 1.998 Scedosporium sp 1.982 S. apiospermum 2.217 
4 
 
 
F. oxysporum 2.311 F. oxysporum 2.185 F. oxysporum 2.218 
F. oxysporum 2.233 F. oxysporum 2.189 F. oxysporum 2.331 
F. oxysporum 2.277 F. oxysporum 2.318 F. oxysporum 2.295 
Median      2.18 (2.02, 2.34) 2.26 (2.03, 2.31) 2.34 (2.21, 2.38) 
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Figure 5.3 Box plot of log similarity scores obtained for four isolates (triplicate 
analyses) by MALDI-TOF MS using the pellet processing methods; a) drying in an 
incubator b) drying in a dry hot block c) no drying. Wilcoxon Signed Rank was used to 
calculate significance between the three methods.  
 
No significant difference was observed between log similarity scores obtained for 
pellets that were not dried (condition c) compared with pellets dried in a hot block 
(condition a), with all isolates achieving species identification in condition a and c. A 
significant increase in log similarity scores was observed if pellets were not dried 
(condition c) compared to pellets being dried in an incubator (condition b), with one 
isolate not achieving species identification for condition b. As not drying the pellet 
(condition c) was shown to be most successful all subsequent analysis of fungi was 
performed without a drying step after ethanol dehydration. 
 
5.3.1 MALDI TOF MS identification of fungal isolates 
The overall identification rate by MALDI-TOF MS for the identification of fungal isolates 
was 71.4% (105/147) at species level and 78.9% (116/147) at the genus level. A result 
of ‘no identification’ with log similarity scores <1.7 was reported for 19% (28/147) of the 
isolates. 2.7% (4/147) isolates were misidentified at the species level with log similarity 
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scores >2.0 but all were identified to the correct genus level which was significantly 
lower than the misidentification rate of microscopy (p<0.01); One isolate was 
misidentified at the genus level with a log similarity score of 1.933 (table 5.4). Two 
isolates failed to produce MS spectra with a result of ‘no peaks found’ despite repeat 
analysis. 
When limiting the analysis to species contained within the MALDI-TOF MS database 
the success rate was 83.3% (105/126) at species level, 92.1% (116/126) at genus 
level. Four of the isolates with a log similarity score >1.7 but <2.0 were correctly 
identified at the species level. 6.4% of the isolates with representative spectra in the 
database (10/127) had a result of ‘no identification’ with log similarity scores <1.7.  
 
5.3.1.1 Identification of Aspergillus species by MALDI-TOF MS 
Sub analysis of MALDI-TOF MS identifications for the genus Aspergillus demonstrated 
90% (67/73) success for identification at species level and 98.6% (72/73) at genus 
level, table 5.1. Four Aspergillus isolates with a genus only identification, log similarity 
score >1.7 but <2.0 returned the correct species identification. One A. fumigatus isolate 
identified as A. sydowii with a log similarity score of 1.793. This isolate phenotypically 
was identified as A. candidus by microscopy and was on further investigation shown to 
be a non-sporing variant of A. fumigatus. One A. fumigatus isolate by ITS rRNA 
analysis, obtained a result of ‘no identification’ log similarity score <1.7. Repeat 
analysis did not resolve this result despite representative spectra being present in the 
MALDI-TOF MS database. 
5.3.1.2 Identification of non-Aspergilus species by MALDI-TOF MS 
The success rate for non-Aspergillus species was 54% (40/74) at the species level and 
58% (43/74) to the genus level. A result of ‘no identification’ was returned for 37.8% 
(28/74) of the isolates, table 5.2. 6.76% (5/74) of the non-Aspergillus isolates were 
misidentified, and for 2.7% (2/74) of the isolates no peaks could be obtained during 
analysis despite repeat protein extractions being performed, including one Curvularia 
hawaiiensis and one Engydontium sp isolate.  
 
5.3.1.3 Isolates with a result of ‘no identification’ by MALDI TOF MS 
Of the 28 non-Aspergillus isolates not identified by MALDI TOF MS 71.4% (20/28) did 
not have representative reference spectra present within the Biotyper database, 
indicated by the asterisk in table 5.2. The remaining 28.6% (8/28) were species for 
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which spectra were present in the reference database and remained unidentified 
including Acremonium strictum (2), Cladosporium cladosporoides (1), Fusarium 
oxysporum (2), Mucor circineloides/rassimosis (2) and Paecilomyces varotii (1).  
 
5.3.1.4 Misidentification of non-Aspergillus species by MALDI TOF MS 
Table 5.4 details misidentifications of non-Aspergillus isolates by MALDI TOF MS. 
When applying manufacturers log similarity score thresholds, of >1.7 for genus 
identification and >2.0 for species identification, 6.8% (5/74) of non-Aspergillus isolates 
were misidentified in this study. Four isolates were correctly identified at genus level 
but misidentified at species level. One isolate was misidentified at genus level with a 
log similarity score >1.7, the respective isolate was identified as Mucor sp by ITS rRNA 
sequencing and Rhizopus microsporus by MALDI-TOF MS, both are mucoraceous 
fungi. If the acceptable species log similarity score was lowered to >1.7 three more 
isolates would have been misidentified, as detailed in section b) of table 5.4. All would 
have been correct at the genus level but incorrect at the species level. 
LS score = log similarity score, ITS = intergenic spacer reigon 
 
5.3.2 Applicability of log similarity score thresholds for MALDI TOF MS 
identification 
The manufacturer’s log similarity scores thresholds indicate identifications are 
acceptable at the genus level with log similarity scores 1.7-1.999 and to the species 
level with log similarity scores >2.0. Anything <1.7 is considered to be an unreliable 
Table 5.4. Misidentifications by MALDI-TOF MS when a) applying log similarity score 
thresholds as recommended by the manufacturer b) accepting all identifications above a 
log similarity score of 1.7 
 ITS identification n MALDI TOF MS identification n LS score 
a) Curvularia hawaiiensis  2 Curvularia pallescens 2 2.147/2.198 
 Penicillium polonicium 1 Penicillium chrysogenum/verrucosum 1 2.469 
 Mucor hiemalis 1 Rhizopus microspores 1 1.933 
 Mucor racemosus 1 Mucor circinelloides/ramosissimus 1 2.11 
b) 
Aspergillus fumigatus 1 Aspergillus sydowii 1 1.793 
Lichtheimia ramose 2 Lichtheimia corymbifera 2 1.83/1.854 
 Total 8  8  
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identification by the manufacturer. Table 5.5 details log similarity scores obtained 
across the genera included in this study alongside the frequency of reference spectra 
in the FFv1.0 database. Species that identify with high accuracy, such as the 
Aspergillus sp. are well represented in the reference database with the greatest 
proportion of reference spectra compared with non-Aspergillus, which are under 
represented, table 5.5. Four of the genera included in this study did not have 
representative reference spectra in the filamentous fungi library supplied by Bruker. 
The median log similarity score for correct identifications was 2.23 (IQR: 2.09-2.37). 
The median log similarity score for incorrect identifications was 1.31 (IQR 1.24-1.54). 
Figure 5.4 demonstrates the results obtained for the 147 isolates in this study 
according to their log similarity score and classified by colour according to the 
identification listed as the highest spectral match. Grey bars indicate the optimal 
spectral correlation that was correct at the species level and white bars indicate 
identifications that were correct at the genus level. Black bars indicate results where 
the best spectral match was a misidentification. 96.8% (92/95) of the isolates above 2.0 
obtained the correct species identification. A further nine isolates would have been 
identified correctly if log similarity scores had been lowered to accept identifications 
>1.7 however, eleven isolates would have been misidentified at the species level. 
  
 
Figure 5.4 Histogram displaying the distribution of log similarity scores obtained for 147 isolates 
processed by MALDI-TOF MS. Grey bars indicate correct species, white indicates the correct 
genus and black indicates incorrect identification. Dashed lines indicate manufacturers log 
similarity score thresholds for genus and species identifications. 
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Table 5.5. Log similarity score classification for 147 strains analysed by 
MALDI-TOF MS alongside the frequency of reference spectra for each genus 
contained within the FFv1.0 filamentous fungi Biotyper database 
Genus n 
Species 
>2.0 
Genus 
1.7-2.0 
No ID 
<1.7 
Mis-ID 
No 
peaks 
Reference 
Spectral (n) 
Other 5 1 1 1   165 
Aspergillus sp 73 66 6 1   90 
Penicillium sp 3 2   1  67 
Fusarium sp 23 16 2 5   36 
Rhizopus sp 3 2 1    15 
Paecilomyces sp 2 1  1   11 
Lichthemia sp 2  2    11 
Scopulariopsis sp 1 1     9 
Scedosporium sp 7 7     6 
Alternaria sp 2 2     5 
Mucor sp 7  1 5 2  5 
Cladosporium sp 1   1   1 
Acremonium sp 4   4   1 
Bionectria sp 1   1   1 
Curvularia sp 3    2 1 1 
Cladosporium sp 1   1   1 
Myrothecium sp 1     1 0 
Neofusicoccum sp 1   1   0 
Engydontium sp 3   3   0 
Exophila sp 1   1   0 
Total 147 98  
(66.7) 
13 
(8.8) 
29 
(19.7) 
5  
(3.4) 
2  
(1.4) 
365 
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5.4 Discussion 
This study has demonstrated that the MALDI-TOF MS and the FFv1.0 database can be 
utilised to identify fungi accurately with 71.4% (105/147) of isolates identified at species 
level and 78.9% (116/147) at the genus level. Identification was dependent on the 
database containing representative spectra for the species being identified. This 
identification rate is comparable with microscopy, which had an identification rate of 
76.2% (112/147) at the species level in this study. However, significantly more isolates 
(p<0.01) 15.6% (23/147), were misidentified by microscopy compared with 3.4% 
(5/147) misidentified by MALDI-TOF MS. The FFv1.0 database was the first 
commercially available database for use in the diagnostic laboratory setting. 
Schulthess and colleagues (2014) recorded 78.3% and 54.2% success for the 
identification of fungi to the genus and species level respectively using the FFv1.0 
database (Schulthess et al., 2014). In a smaller study analysing non-Aspergillus 
isolates including; Penicillium marneffei, Paecilomyces sp, Fusarium solani, Rhizopus 
sp and Pseudallescheria boydii all isolates returned a result of ‘no identification’ with 
log similarity scores <1.7 despite some of the species being listed in the FFv1.0 
database (Chen et al., 2015). There are several factors that contributed to the lower 
success of fungal identification in the respective studies.  
The success of MALDI-TOF MS for the identification of microorganisms is reliant on a 
robust reference database. In this study 19.7% (29/147) of isolates returned a result of 
‘no identification’ despite repeat analysis. In the majority of cases the species being 
identified did not have representative spectra within the FFv1.0 database. Five isolates 
were not identified despite representative spectra being included in the database. This 
suggests that the reference spectra are not diverse enough to identify all strains of 
particular species. This has been observed in similar studies utilising databases known 
to contain representative spectra for isolates being analysed (Tam et al., 2014; Chen et 
al., 2015). The current FFv1.0 database is not comprehensive enough (in terms of 
breadth of reference spectra available) to suit the needs of a clinical mycology 
laboratory. By expanding the reference database the performance of MALDI-TOF MS 
will be significantly improved (Lau et al., 2013; Becker et al., 2014; Gautier et al., 2014; 
Tam et al., 2014). This is evident from studies choosing to utilise in-house collated 
databases for fungal identification. By far the most substantial in-house database to be 
created was the work of Gautier et al (2014). In a multi-centre approach genotypically 
characterized isolates were used to create a database consisting of 2832 spectra 
representing 347 species and 708 strains of fungi (Gautier et al., 2014). The 
prospective identification of fungal isolates over a 16 month time frame demonstrated 
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98.8% (1094/1107) success for the identification of fungi in the routine diagnostic 
laboratory (Gautier et al., 2014). In a second study utilising an in-house database 
containing 760 strains representing 472 species, prospective identification of clinical 
isolates demonstrated 95.4% success at the species level in the routine diagnostic 
setting (Becker et al., 2014). Several other studies have also published relatively high 
success rates ranging between 87-100% using in house databases (Alanio, Beretti, et 
al., 2011; Cassagne et al., 2011; E De Carolis et al., 2012; Ranque et al., 2014; Sitterle 
et al., 2014). Not surprisingly the performance of MALDI-TOF MS is improved for 
Aspergillus species, 81.5-100% (Sanguinetti and Posteraro, 2014), compared with non-
Aspergillus species 0%-87.3% (Cassagne et al., 2011; Lau et al., 2013; Becker et al., 
2014; Ranque et al., 2014; Chen et al., 2015), confirming the observations in this study 
with 90% of Aspergillus isolates and 54% of non-Aspergilius isolates being identified. 
This is most likely a result of increased availability, interest in and access to Aspergillus 
strains during database construction which results in an over representation of 
reference spectra for Aspergillus isolates compared with non-Aspergillus species 
(Cassagne et al., 2011; Lau et al., 2013; Ranque et al., 2014).  
Building a comprehensive spectral reference database can also provide diagnostic 
laboratories with a method of identification with the accuracy and resolution similar that 
that of molecular identification methods. Studies have shown that MALDI-TOF MS was 
able to discriminate between the commonly isolated A. flavus and closely related rare 
cryptic species A. nomius and A. tamari, which in the laboratory cannot be 
distinguished phenotypically and would be misidentified. When A. nomius and A. 
tamari were analysed by MALDI-TOF MS these two cryptic species remained 
unidentified whilst A. flavus was identified. This demonstrates the spectral matching 
algorithm is powerful enough to distinguish between closely related cryptic fungal 
species and only provide an identification in the presence of representative spectra in 
the MALDI-TOF MS database for a given species (Tam et al., 2014). This was further 
demonstrated by the discrimination between phenotypically identical species 
Stachybotrys chartarum and S. chlorohalonata (Gruenwald et al., 2015) and A. lentulus 
from A. fumigatus (Verwer et al., 2014) using MALDI-TOF MS. This means that if the 
MALDI-TOF database is comprehensively developed over time the laboratory will 
seldom have to rely on molecular methods or even the reference laboratory service to 
obtain an accurate identification of moulds from invasive infections. Ultimately both the 
epidemiology of fungal infection and the understanding of the pathogenesis of fungal 
disease and treatment regimens will be enhanced through accurate identification. 
Collaboration between networks of centres in establishing a comprehensive national 
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collection of spectra may be one way of rapidly improving and standardising local 
mycology services.  
There are several other parameters that contribute to the improved success of 
identification using MALDI-TOF MS databases for fungal identification. Accurate 
identifications are obtained by MALDI-TOF MS when the processing method used to 
create the reference database entries is also used to process unknown cultures (Lau et 
al., 2013; Becker et al., 2014; Chalupová et al., 2014). Consistency between the 
reference spectra and unknown isolates provides the best conditions for a match. The 
FFv1.0 database is composed of reference spectra created using the liquid cultivation 
method (Maier and Kostrzewa, 2009). In this study the liquid cultivation method was 
adhered to with the exception of one variation, the removal of pellet drying after ethanol 
dehydration. The standard operating procedure published by the manufacturer 
recommends that the pellet should be dried completely in a vacuum concentrator or at 
37°C for 5-10 minutes prior to formic acid extraction, and emphasizes the importance 
of completely drying the pellet. In our centre we do not have access to a vacuum 
concentrator. In our experience when pellets were incubated for 5-10 minutes at 37°C 
very little moisture evaporated and pellets were not dry. Two alternative approaches 
were investigated, extending the incubation at 37°C to two hours or using a dry hot 
block to evaporate the remaining moisture from pellets. The performance of MALDI-
TOF MS was not enhanced by either of these approaches. When drying was omitted 
from processing a significant increase in log similarity scores was observed and 93.8% 
(15/16) of the technical replicates were identified with log similarity scores >2.0.  
In one study utilising vacuum centrifugation after ethanol dehydration, lower success 
rates of 78.3% at the genus level and 54.2% at species level were observed despite 
the majority of species in this study being represented in the FFv1.0 database. 
Schulthess et al observed 13.3% (38/285) of their analyses obtaining a log similarity 
score between 1.7-2.0 (Schulthess et al., 2014) compared with 8.8% (13/147) in this 
study. Log similarity scores are in part determined by peak frequency and intensity 
within spectra. Higher intensity and increased frequency of matched peaks contributes 
to a higher log similarity score. If protein extraction is optimal it would be expected that 
isolates with representative spectra in the reference database would achieve an 
identification with a log similarity score >2.0. Poor spectral quality through sub optimal 
protein extraction could explain why isolates are not identified despite the species 
being covered by the highest number of reference entries in the reference database 
(Becker et al., 2014; Schulthess et al., 2014). It is possible that the drying of pellets so 
intensely is having a negative impact on analysis. In written communication with the 
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manufacturer it was disclosed that vacuum centrifugation is being performed so 
vigorously in some laboratories that fungal biomass is being transformed into hardy dry 
pellets that are difficult to re-suspend when formic acid is added. The rationale behind 
drying the pellets is to reduce the size so that a reasonable amount of formic acid can 
be added, i.e. 50µL. In our study this was resolved by adding 100µL of formic acid and 
the same volume acetonitrile for large fungal pellets which on analysis led to log 
similarity scores >2.0. Cassagne et al do not report using a drying step during the 
preparation of protein extracts from colony scrapes of fungal biomass with high 
success and log similarity scores >2.0 across the majority of analyses (Cassagne et 
al., 2011). Additionally a further recommendation made by the manufacturer is that 
fungal identifications are only accepted if the log similarity score falls within thresholds 
set by the manufacturer (as detailed in section 2.3). Thresholds are applied to the log 
similarity score to ensure a match is sufficiently powerful enough to be accepted at the 
genus or species level. Often log similarity scores for fungal analysis fall below those 
thresholds despite the correct fungus being indicated as the best match in the 
reference database.  
An alternative approach for validating identifications is to disregard the use of log 
similarity scores and instead measure concordance of spectral matching across 
replicates of the same protein extract. By analysing protein extracts in quadruplicate 
identifications can be accepted if three out of four results give the same spectral match 
with the reference database. Cassagne et al pioneered this approach reporting 98.7% 
success for isolates contained within their in-house reference database (Cassagne et 
al., 2011). Becker and colleagues adopted this rationale in a subsequent study and 
reported 95.4% success to the species level with log similarity scores ranging from 
1.22-2.62. Notably in the respective study only 85.6% success would have been 
achieved utilising a log similarity score threshold of >1.7 for species identification 
(Becker et al., 2014). In 2014 Gautier et al adapted this identification rule slightly to 
accept an identification if three of four analyses had the same spectral match and at 
least one of the matches had a log similarity score of >1.9 (Gautier et al., 2014). The 
respective study reported the most successful identification rate with 98.8% of isolates 
being identified to species level. In our study protein extracts were analysed in 
duplicates and only one result with a log similarity score >2.0 was required for the 
identification to be accepted. Decreasing the log similarity score to >1.9 for species 
identification would have led to the misidentification of twelve isolates including two 
Lichthemia ramosa isolates as Lichthemia corymbifera. The function of the log 
similarity score threshold for species identification (>2.0) is to prevent misidentification 
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when the match between reference spectra and an unknown isolate is not optimal. The 
anti-log of genus thresholds (log similarity score 1.7-2.0) only equates to an actual 
score between 50-100 out of a possible 1000, derived in part from matched peaks and 
their relative intensity to unmatched peaks within the spectra. Lowering the log 
similarity score for species identification allows fewer or less intense peaks to be 
required for a match and thus weakens the power of identification. By maintaining the 
log similarity score thresholds set by the manufacturer stringency is maintained and 
limits the number of misidentifications, as demonstrated in this study. The ultimate goal 
should not be to discontinue use of log similarity scores but to optimize protein 
extraction to obtain high log similarity scores for those species represented in the 
database. Across all published MALDI-TOF MS fungal studies the protein extraction 
methods are less than standardised and may be contributing to lower log similarity 
scores obtained using the Biotyper software.  
When a fungal processing method is used other than the method used to create the 
reference database it leads to poor performance of MALDI-TOF MS. This was 
demonstrated in two studies utilising the FFv1.0 database. Lau et al processed fungal 
colonies by excising biomass from agar and placing in 100% ethanol with zirconia silica 
beads and vortexing for 15 minutes (Lau et al., 2013). The suspension was centrifuged 
and pellet suspended in 70% formic acid and again vortexed for 5 minutes. Acetonitrile 
was added and the supernatant was utilised for analysis. Analysis of 421 clinical 
isolates demonstrated 0.7% success at the species level (log similarity score >2.0) 
using the FFv1.0 database. When spectra were analysed against the Lau in-house 
database created using the same processing method to create reference spectra and 
to prepare isolates 88.9% success was achieved at species level (log similarity scores 
>2.0) (Lau et al., 2013). Chen et al utilised the colony scrape method for transferring 
biomass into 75% ethanol. Conidial suspensions were centrifuged then washed with 
ethanol then dried for 1 hour prior to formic acid extraction (Chen et al., 2015). Using 
the respective method all analyses returned log similarity scores <1.7 when analysed 
against the FFv1.0 database however, the correct identification was listed as the best 
match by the Biotyper software for all isolates indicating that the spectra from the 
conidial suspensions were of limited similarity to reference spectra in the Biotyper 
database but the software was still able to match the isolates with the correct species 
identification. The creation of an in-house database using the colony scrape method 
also led to the successful identification of 28 Penicillium marneffii isolates with log 
similarity scores ranging from 1.83-2.45 (Chen et al., 2015).  
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The colony scrape method, especially when being used for hazard group 3 fungi, has 
some limitations. Scraping colonies with a loop or other inoculating device will liberate 
conidia into the environment. This task must be conducted within an isolated 
environment within a biological safety cabinet. Conidia can also be hydrophobic 
making them difficult to centrifuge (Wosten and de Vocht, 2000; Grunbacher et al., 
2014) and as with any other microbial suspension the vortexing of conidial suspensions 
presents a health and safety risk, especially in the instance of hazard group 3 fungi. 
When creating mass spectrum profiles from fungal colonies variation in the protein 
profiles is apparent (Chalupová et al., 2014). Young and mature colonies produce 
different spectra (Alanio, Beretti, et al., 2011), presumably due to the production of 
fruiting structures and conidia in mature colonies, with the most reproducible spectra 
being obtained from cultures grown for 120h compared with those at 48, 72 and 96 
hours (Del Chierico et al., 2012). If the age of the colony being analysed is not similar 
to the age of the colony used to create the reference spectra it will contribute to a 
poorer match. The respective issues are partially resolved with the use of liquid 
cultivation.  
In this study we have demonstrated that only a light inoculum of conidia/fungal biomass 
needs to be harvested onto a wet cotton swab, which was conducted inside a plastic 
bag to reduce the spread of conidia. Manipulating cultures inside a biological safety 
cabinet is desirable but not essential as the sample bag can be used as an alternative. 
The swab was then directly inoculated into SAB broth, expressed and the culture 
sealed. After 24 hours of incubation the resulting biomass manifests as mycelial balls, 
as the production of fruiting structures and conidia are suppressed through the rotation 
of the cultures preventing an aerobic interface from forming. Although this extends the 
turnaround time by 24 hours, mycelial balls are of much lower risk throughout 
processing than conidial suspensions. One observation made throughout the study 
was that not all fungal species produce classic fungal balls. Mucoraceous fungi 
produce large mycelial masses, much larger than what is required for analysis, thus 
need some degree of division prior to analysis. There may also be an opportunity to 
shorten the incubation time for mucoraceous fungi to achieve and identification earlier. 
Wet fungi such as Fusarium sp produce a hazy suspension that at first analysis 
appears to be contamination of the SAB broth, however on analysis this is germinated 
conidia of wet fungi. One potential drawback is that SAB liquid cultures may become 
contaminated at the point of inoculation that is only realised upon obtaining the MALDI-
TOF MS identification, typically Aspergillus fumigatus contamination of a non-
Aspergillus preparation. In our centre we observed very little contamination by 
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manipulating the fungal cultures inside a sample bag, using careful technique and 
ensuring fungal cultures were pure.  
It has also been demonstrated that fungal pigments, including endogenous melanin, 
inhibit MALDI TOF MS analysis (Buskirk et al., 2011). An absence of peaks was 
observed through spectra obtained from Aspergillus niger preparations extracted from 
a typical mature sporing colony. If pigmented fungi are sub-cultured onto specialist 
media such as malt extract agar in the instance of Stachybotrys (Gruenwald et al., 
2015) or a media containing tricylazole (Buskirk et al., 2011) non-melanised colonies 
can be cultured and analyzed by MALDI TOF MS. However, these sub cultures require 
several days to develop. The alternative is liquid cultivation. If A. niger is grown in liquid 
culture abundant peaks are obtained from protein extracts, as preparations do not 
contain the highly melanised conidia (Buskirk et al., 2011). The analysis of 
dematiaceous fungi was not inhibited with almost all protein extracts from pigmented 
fungi achieving quality spectra were obtained with the exception of one Curvularia 
hawiiensis isolate. Failure to identify dematiaceous fungi using the colony scrape 
method is documented in several studies presumably due to the presence of highly 
melanised fungal elements (Cassagne et al., 2011; Becker et al., 2014). In this study 
we followed the prescribed processing and analysis methods as recommended by the 
manufacturer so that the performance of the FFv1.0 database for use in the routine 
diagnostic setting could be fully evaluated. Despite adhering to all recommended 
parameters several isolates were misidentified.  
Four isolates were misidentified all achieving log similarity scores >2.0. For the 
respective isolates the correct genus was indicated but the species identification was 
incorrect. This has been previously described using MALDI-TOF MS when identifying 
closely related bacterial species such as Streptococcus pneumoniae and the 
Streptococcus mitis group or Escherichia coli and Shigella sp (Werno et al., 2012; 
Schaumann et al., 2013). These species cannot be discriminated at the species level 
using the current Biotyper database (v3.1). The same may be true for some fungal 
species. The misidentification at the species level for fungi has been described across 
studies utilising MALDI-TOF MS (Cassagne et al., 2011; Becker et al., 2014; 
Schulthess et al., 2014). The impact of misidentification cannot be fully estimated until 
the use of this technology advances in mycology laboratories and a comprehensive 
reference database is developed for fungal identification. Despite limited 
misidentifications there was a significant improvement in accuracy of the identification 
in this study using MALDI-TOF MS compared with conventional microscopic 
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techniques, which was also demonstrated in several other studies (Becker et al., 2014; 
Gautier et al., 2014). Fungal identification in our routine diagnostic setting is not 
satisfactory with 15.6% (23/147) of isolates misidentified by microscopy. 60.7% (14/23) 
of the misidentifications were isolates identified correctly at the genus level but an 
incorrect species reported. For the remaining 39.3% (9/23) rarely encountered fungi 
were misidentified as common pathogenic species.  
The misidentification of fungi by conventional microscopy has been reported in several 
other studies to be between 19.9-38.5% (Ferreira et al., 2013; Becker et al., 2014; 
Gautier et al., 2014; Ranque et al., 2014) overall when compared against gold standard 
molecular identification. With the advent of molecular diagnostic assays species, such 
as A. fumigatus, are being classified into multiple distinct genotypically different 
species that also demonstrate varying susceptibility patterns to front line antifungal 
agents (Verwer et al., 2014). Therefore the accurate identification of the new species is 
important both pathogenically and pharmacologically to the patient.  
When reanalysing isolates identified with conventional microscopy up to 24% of A. 
fumigatus isolates were reclassified as A. lentulus and up 51% of A. niger isolates were 
shown to have been misidentified (Balajee et al., 2006; Hendrickx, Beguin and 
Detandt, 2012). In this study rare fungi including Myrothecium sp were misidentified as 
commonly encountered fungi that are microscopically similar. One striking observation 
was the misidentification of two Thanatephorus cucumeris isolates as Scytalidium 
hyalinum. Microscopy images are demonstrated in figure 5.5 for a) S. hyalinum and b) 
Thanatephorus cucumeris. 
 
The two Thanatephorus cucumeris isolates when cultured under laboratory conditions 
rapidly grew as spreading white colonies with aerial mycelium and arthroconidia seen 
Figure 5.5 Microscopy features for a) Scytalidium hyalinum and  
Thanatephorus cucumeris b) demonstrating hyaline hyphae with arthroconidia. 
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on microscopy, similar to colonies of S. hyalinum. In our laboratory we do not 
frequently encounter S. hyalinum. Upon suspicion of isolating this species we now rely 
on molecular methods for accurate identification, as the clinical consequences of a 
misdiagnosis of onychomycosis from this fungus are considerable, including possible 
surgical debridement of infected tissue. In this study MALDI TOF MS was able to 
identify these two isolates as Thanatephorus cucumeris and would have been a faster 
and cheaper alternative to molecular methods.  
The implementation of MALDI-TOF MS for fungal identification is now reliant on the 
expansion of commercially accessible databases by the manufacturer or by referral to 
experienced clinical mycology centres. It is essential that reference spectra meet 
quality criteria for inclusion in the database being utilised for routine use. Until this 
happens implementation of the current FFv1.0 database is not possible due to the high 
rate of isolates that are unidentified (Schulthess et al., 2014). A result of ‘no 
identification’ could be used as a mechanism to prompt the use of molecular 
techniques for identification but this approach warrants further prospective 
investigation. Reference spectra would then be created for the isolates for inclusion in 
either a local or national database collection. In summary MALDI-TOF MS has clearly 
demonstrated the potential to revolutionize clinical mycology services in the near future 
as efforts are directed towards utilising this technology for fungal identification.  
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6 Chapter 6 Improving the diagnosis of Candidemia: evaluation 
of Gram’s stain and PNA FISH for the rapid identification of 
yeasts from blood culture 
6.1  Introduction 
The most important diagnostic test applied to a positive blood culture is a Gram’s stain 
from which yeasts can be detected (Thairu, Usman and Nasir, 2014). Yeasts stain 
Gram positive owing to the selective capture of the crystal violet between the layers of 
the cell wall as it complexes with the iodine component of the staining process (Henrici, 
1914). Gram’s stain is rapid with results available to clinicians in less than 15 minutes 
from the point at which a blood culture is known to be positive. This provides clinicians 
with essential information allowing targeted management of patients with antifungal 
agents but is limited to generalising the identification to that of ‘yeasts seen’. In the last 
century the utility of Gram’s stain for yeast identification has not advanced. The size 
and shape of yeasts are easily distinguished from those of bacterial cells, as they are 
almost ten times larger with distinctive morphological characteristics such as 
blastospores, hyphae and pseudohyphae.  
These morphological characteristics of yeasts are distinctive and may offer an 
opportunity to further identify yeast cells within a Gram’s stain preparation. Harrington 
et al detailed the use of yeast morphology in Gram’s stain to identify C. albicans from 
non-albicans species (Harrington et al., 2007). The investigators utilised aggregates of 
pseudohyphae, a common feature within blood cultures from patients with Candida 
albicans fungemia, to achieve C. albicans/non-albicans identification. Authors 
demonstrated a sensitivity, specificity, positive predictive value and negative predictive 
value of 85%, 97%, 96%, and 89% respectively for C. albicans identification from 
Gram’s stain (Harrington et al., 2007). This study is the only published work 
investigating this method of speciation from Gram’s stain for yeasts. It may be possible 
to further utilise morphological feature of yeasts within Gram’s stain preparations for 
species identification and this technique may not just be limited to the gross 
differentiation of C. albicans from other species. However, in recent years an 
alternative approach to Grams stain has been advancing which may offer more 
specificity through genotypic identification of yeasts direct within microscopy sample 
preparations.  
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Fluorescence in situ hybridisation (FISH) utilises target -specific probes coupled with 
wavelength-specific fluorogenic molecules allowing for visualisations using a 
fluorescence microscope. In-house developed FISH methods can be complex and 
require specialist training and expertise to perform (Bisha, Kim and Brehm-Stecher, 
2011). For diagnostic laboratories standardization of the process is desirable. The 
release of a commercially available C. albicans PNA FISH assay 12 years ago allowed 
for the translation of FISH into the diagnostic setting (AdvanDX). In 2005 Wilson and 
colleagues published the first evaluation of the assay in a multi-centre study analysing 
244 yeast blood cultures (Wilson et al., 2005). The overall performance of the assay 
was 99%, 100% 100% and 99.3% for sensitivity, specificity, positive and negative 
predictive values respectively. Only one C. albicans isolate was undetected on first 
attempt out of 97 isolates and on repeat the blood culture was correctly reported 
positive (Wilson et al., 2005). The PNA FISH single target assay was also 
demonstrated to be beneficial economically by enabling targeted antifungal therapy. 
Alexander et al (2006) et al demonstrated a cost saving of $1837 per patient after 
implementation for the C. albicans probe in their patient care pathway. Savings were 
realised by switching to fluconazole instead of caspofungin (Alexander et al., 2006).  
In the second version of the assay PNA FISH was further developed to include 
multiplex probes combined with different fluorophores, a green fluorescing PNA probe 
complementary to C. albicans and red fluorescing PNA probe complementary to C. 
glabrata. The probe multiplex demonstrated 98.7% (78/79) and 100% (37/37) 
sensitivities for the identification of C. albicans and C. glabrata respectively (Shepard et 
al., 2008). Specificity for both probes was 100% (82/82). The PNA probe multiplex was 
tested against 80 reference strains encompassing 33 yeast species (Shepard et al., 
2008). Cross-reaction of the PNA probes was only reported with closely related 
species within the C. glabrata clade (C. nivariensis and C. bracariensis). Only one false 
negative result was reported for a C. albicans blood culture, which on repeat was 
positive (Shepard et al., 2008). In a third version of the YTL PNA FISH assay the 
multiplexing capabilities of the assay were further expanded to include five PNA probes 
labelled with three fluorophores targeting C. albicans/C. tropicalis (green), C. 
parapsilosis (yellow) and C. glabrata/krusei (red). At the time of study the third version 
of the assay had not been evaluated for its diagnostic utility in the laboratory. In this 
study Gram’s stain analysis and PNA FISH YTL V.3.0 will be evaluated for the 
identification of yeasts direct from blood culture.  
 142 
6.2 Methods 
6.2.1 Study design 
My role in this study was as the principal investigator, having the technical 
responsibility for artificial inoculation of blood cultures and distribution of positive 
samples to three investigators who were blind to the yeast identification within the 
blood culture samples.  
 Investigator 1 was trained to an advanced level (four months training) for the 
identification of yeasts from Gram’s stain through analysis of yeast morphology 
in blood culture smears. The respective investigator performed Gram’s stain 
analysis with the aid of identification keys (see figure 6.1 for an example 
identification key).  
 Investigator 2, with no experience in Gram’s stain analysis for yeast 
identification, analysed the slides using the identification keys.  
 Investigator 3, who had received three days training prior to the study, 
performed PNA FISH Yeast Traffic Light (YTL) analysis.  
Results were submitted to the principal investigator for analysis. When discrepancies 
with PNA FISH YTL were observed the investigator repeated the PNA FISH YTL 
analysis on the original preparation.  
 
6.2.2 Yeast isolates 
Yeast isolates from previous cases of fungaemia were selected to represent a diverse 
collection of clinical isolates. Isolates were stored at the Royal Free Hospital NHS 
microbiology laboratory. Isolates had previously been identified by Auxacolor2 
biochemical analysis by the diagnostic laboratory. 
6.2.3 Simulated blood cultures: 
See general methods 2.1.3. Blood cultures were prepared as mono-fungal cultures 
(n=50) with the exception of two mixed cultures prepared as an additional analysis to 
assess the performance of each method for mixed cultures.  
6.2.4 ITS rRNA sequenced based identification of yeasts 
 See general methods 2.2. 
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Figure 6.1 Example of an identification key used for Gram’s stain analysis of Candida 
albicans from blood cultures  
 144 
6.2.5 Gram’s stain 
Blood smears were fixed with absolute ethanol and Gram’s stain (Sigma Aldrich, USA) 
method was applied (26). The principal investigator created identification keys for the 
seven most commonly isolated yeast species including: C. albicans, C. glabrata, C. 
tropicalis, C. krusei, C. neoformans, C. guilliermondii and C. parapsilosis, see figure 
6.1 for the C. albicans example. Identification keys were generated from analysis of 
spiked blood cultures. For each of the seven species included in the identification keys 
an American Type Culture Collection (ATCC) control strain and five clinical isolates 
were used to create simulated blood cultures, with the exception of C. dubliniensis, as 
no ATCC control strain could be acquired in suitable timescale. For this species a C. 
dubliniensis strain characterized by the Public Health England reference laboratory 
was utilised. Two sets of Gram’s stain slides were prepared from each positive blood 
culture, totalling 12 slides from 6 blood cultures per species. The resulting 12 slides 
(per species) were analysed and consistent morphological characteristics were 
determined for each species. Images were captured at varying magnifications. Each 
identification key included colour images plus descriptive terminology to aid 
identification. Identification characteristics included the presence or absence of pseudo 
hyphae, clustering or branching of pseudo hyphae and the size and shape of the 
blastospores compared against the size of the red blood cells within the smear. If a 
yeast could not be identified the reviewer was instructed to report this as ‘unknown’. 
Each analysis was timed by the reviewer from the start of preparing the Gram’s stain to 
reporting the result.  
 
6.2.6 PNA FISH  
One drop of blood was added to each PNA FISH slide and heat fixed with fixation 
solution for 20 minutes on a slide station at 55°C. A drop of PNA Traffic Light probe 
was added to each slide and hybridised at 55°C for 30 minutes. The slides were then 
washed for 30 minutes in a buffered wash solution in a water bath set to 55°C to 
remove excess unbound probe. Slides were air-dried and mounting medium was 
added and then a coverslip applied. For each round of analysis a control slide, supplied 
by the manufacturer, was prepared. The slides were analysed using fluorescent 
microscopy. Visualisation of green fluorescence indicated the presence of C. albicans 
or C. parapsilosis, red fluorescence indicated C. glabrata or C. krusei and yellow 
fluorescence indicated C. tropicalis.  
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6.2.7 Antifungal impact assessment 
The clinical registrar collaborating in this study carried out a retrospective review of 
clinical notes of patients from whom the yeasts included in this study had been 
isolated. Predicted choice of antifungal therapy was estimated on the basis of the 
yeasts susceptibility to fluconazole in that identifying C. albicans, C. parapsilosis, or C. 
tropicalis would have resulted in commencing fluconazole therapy, and identifying C. 
glabrata or C. krusei would have prompted the use of Caspofungin as initial therapy 
(Stone et al., 2013). The actual antifungal therapies the patient received versus the 
antifungal that may have been selected based on the PNA FISH results were 
compared and an impact on antifungal choice estimated from the comparison.  
 
6.2.8 Evaluation of assay parameters 
The cost per test was determined based on reagent cost alone per sample (labour and 
indirect costs not included in analysis). Turnaround time (TAT) was measured across 
three repetitions of processing, one sample for each method and the mean TAT 
calculated. Technical ability (as defined by the level of training required to perform the 
assay) was assessed for each method based on the qualitative data produced. For 
PNA FISH analysis a scientist with 3 days training provided by the principal investigator 
undertook the testing. This scientist had no previous experience with the PNA FISH 
assay. Training was considered to be minimal. For the Gram’s stain the technical ability 
was determined from comparing the performance of the ‘advanced’ scientist using the 
key cards to that of the ‘inexperienced scientist’.  
 
6.3 Results 
6.3.1 Yeast identification from CHROMagar® Candida cultures;  
Table 6.1 details yeast identifications obtained by ITS rRNA analysis from CHROMagar 
cultures for yeasts selected for inclusion in the study including; C. albicans (17/50), C. 
glabrata (9/50), C. tropicalis (4/50), C. krusei (4/50), C. parapsilosis (7/50), C. 
orthopsilosis (1/50), C. metapsilosis (1/50), C. guilliermondii (2/50), Cryptococcus 
neoformans (2/50), Magnusiomyces capitatus (1/50), Cyberlindnera fabianii (1/50). 
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Table 6.1. ITS rRNA identifications for yeasts spiked into blood 
cultures 
Species % n Species % n 
C. albicans 34 17 Cryptococcus neoformans 4 2 
C. glabrata 18 9 Magnusiomyces capitatus 2 1 
C. parapsilosis 14 7 Cyberlindnera fabianii 2 1 
C. krusei 8 4 C. metapsilosis 2 1 
C. tropicalis 8 4 C. orthopsilosis 2 1 
C. guilliermondii 4 2    
 
 Table 6.2 displays the results for Gram’s stain and PNA FISH analysis for the 50 
monofungal blood cultures. Analysis of performance is displayed in three categories, a) 
overall success b) success of identifying those species only contained within the assay 
database and c) success of identifying those species only contained within the assay 
database including unknown as the correct result.  
 
MisID = misidentification 
 
Table 6.2 Performance of Gram’s stain and PNA FISH for the identification of yeasts 
direct from blood cultures with sub analyses based on species contained within the 
assay formats/databases 
  Subset description  Classification results 
  Species 
n 
Total 
n 
%  Correct MisID
$ 
Unknown Success 
% 
(a) Performance total 
 Gram’s stain 10 50 100  36 13 1 72 
 PNA FISH 10 50 100  43 2 5 86 
(b) Performance only on species in respective method database 
 Gram’s stain 7 47 94  36 10 1 76.6 
 PNA FISH 5 43 86  43 0 0 100 
(c) Performance on species in respective method database (including ‘unknown’ as the 
correct identification) 
 Gram’s stain 10 50 100  36 13 1 72 
 PNA FISH 10 50 100  48 2 0 96 
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6.3.2 Gram’s stain 
Overall correct identifications, when compared with ITS rRNA sequencing, for Gram’s 
stain analysis by the advanced investigator was 72% (36/50), which remained relatively 
unchanged across the three analyses, table 4.1. A slight increase in the success rate 
was observed when parameters were limited to more common species that were 
contained in both databases. Table 4.2 details the misidentifications made by the 
advanced investigator in 26% (13/50) of the cultures. Of the misidentifications 75% 
(3/4) of the C. krusei isolates were misclassified as C. parapsilosis. C. albicans was 
misidentified twice as C. tropicalis and once as C. parapsilosis. ‘Missed’ yeast was 
reported for one blood culture. Mixed culture analysis led to further misidentification 
with both mixed cultures being reported as C. parapsilosis. The correct species was 
not reported from either bottle and the mixed culture was undetected. Gram’s stain 
analysis performed by the second inexperienced investigator returned a success rate 
of 40% (20/50). 
 
6.3.3 PNA FISH  
Of the monofungal yeasts blood cultures 86% (43/50) of the yeast isolates were 
identified by the PNA FISH YTL assay. 100% (43/43) success was observed for the 
identification of yeast species contained within the assay’s database and 96% (48/50) 
success when including ‘unknown’ as the correct result for yeasts not included in the 
PNA FISH YTL assay format table 4.1.  
From the analysis of mixed cultures one C. glabrata isolate was not detected in a 
mixed culture with the C. tropicalis isolate being missed. The second mixed culture was 
correctly identified to contain C. albicans and C. tropicalis.  
Misidentifications by PNA FISH are displayed in table 6.3. Two false positives for the 
C. glabrata/C. krusei (red) probe were observed one with Cryptococcus neoformans 
isolate and the other with a Blastoschizomyces capitatus isolate. On repeat both 
cultures were recorded as negative. The C. metapsilosis and C. orthopsilosis isolates 
were identified as C. albicans/C. parapsilosis with green fluorescence seen on 
microscopy.  
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Results by probe are summarized in Table 6.4. The sensitivity for the C. albicans/C. 
parapsilosis probe was 100% (27/27), for the C. glabrata/C. krusei probe was 92.3% 
(13/14), and for the C. tropicalis probe was 100% (6/6). The specificity for the C. 
albicans/C. parapsilosis probe was 100% (27/27), for the C. glabrata/C. krusei probe 
was 95% (38/40), and for the C. tropicalis probe was 100% (48/48).  
 
 
Table 6.3 Isolates misidentified or not identified from blood cultures by Gram’s 
stain, PNA FISH and MALDI-TOF compared with the expected result. 
  Misidentifications / blood cultures not identified 
Expected result n Gram’s stain n PNA FISH n 
C. albicans 17 C. tropicalis 2 -  
  C. parapsilosis 1 -  
  Not seen 1 -  
C. tropicalis 4 C. albicans 1 -  
C. glabrata 9 C. parapsilosis 1 -  
C. krusei 4 C. parapsilosis 3 -  
C. parapsilosis 7 C. albicans 1 -  
C. metapsilosis 1   C. albicans/parapsilosis 1 
C. orthopsilosis 1   C. albicans/parapsilosis 1 
C. guilliermondii 2 C. glabrata 1 -  
C. lusitaniae 1 C. glabrata 1 -  
C. pelliculosa 1 C. glabrata 1 -  
C. neoformans 2 -  C. glabrata/krusei 1 
B. capitatus 1 -  C. glabrata/krusei 1 
Total 50  13  4 
Mixed blood cultures   
C. glabrata/tropicalis 1 C. parapsilosis 1 C. glabrata/krusei only 1 
C. albicans/tropicalis 1 C. parapsilosis 1 -  
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6.3.3.1 Cost, turnaround time and technical requirement  
The reagent cost of PNA FISH YTL was £44.00 per test, exceeding that of Gram’s 
stain at £0.13. When measuring the turnaround time for processing a single blood 
culture, which would be expected in a routine setting as Candida cultures are 
infrequent, the Gram’s stain analysis was more rapid for 15 minutes per sample 
compared with an average time of 90 minutes for PNA FISH YTL analysis. When 
assessing the technical requirement a scientist with only 3 days training was able to 
complete all analyses without any error of further assistance which was considered 
minimal technical requirement for PNA FISH YTL. In contrast Gram’s stain required a 
considerable amount of experience, four months experience in this study, and even 
with this experience the performance of this method was not optimal. The 
inexperienced scientist demonstrated poor performance when identifying yeasts by 
Gram stain analysis therefore this method couldn’t be performed with limited technical 
experience.  
Table 6.4 PNA FISH results for 52 yeast blood cultures displaying performance for each 
individual probe 
 PNA FISH result 
Blood cultures n 
C. albicans 
C. parapsilosis 
(green) 
C. tropicalis 
(yellow) 
C. glabrata 
C. krusei 
(red) 
Negative 
Candida albicans 17 17 - - - 
Candida parapsilosis 7 7 - - - 
Candida orthopsilosis 1 1 - - - 
Candida metapsilosis 1 1 - - - 
Candida tropicalis 4 - 4 - - 
Candida krusei 4 - - 4 - 
Candida glabrata 9 - - 9 - 
Candida 
glabrata/tropicalis 
1 
- 1 - - 
Candida 
albicans/tropicalis 
1 1 1 
- - 
Candida guillermondii 2 - - - 2 
Candida lusitaniae 1 - - - 1 
Candida fabianii 1 - - - 1 
Blastoschizomyces 
capitatus 
1 
- - 
1 - 
Cryptococcus 
neoformans 
2 
- 
_ 1 1 
Specificity  100%  100%  92.9%  71.4% 
Sensitivity  100%  100% 95%  97.9% 
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6.3.4 Antifungal impact assessment 
When analysing the antifungal impact through case note review data suggested that 
using PNA-FISH a switch from caspofungin to fluconazole could have been made in 
21.2% (11/52) cases, and a switch from fluconazole to caspofungin could have been 
made in 7.7% (4/52) cases, figure 6.2. There would have been no change in antifungal 
therapy for 61.5% (32/52) of the cases of candidemia. For 5 cases there was 
insufficient data to indicate which antifungal decision may have been made. 
 
 
 
 
 
 
 
Figure 6.2 Histogram detailing the proportion of clinical decisions that may have been 
impacted by the PNA FISH result if it had been available to clinicians at the time of 
diagnosis. 
6.4 Discussion 
The aim of this study was to evaluate the utility of two rapid microscopic techniques for 
the identification of yeasts direct from blood culture. The method returning the highest 
number of correct identifications, compared with ITS rRNA sequenced based analysis, 
was the PNA FISH YTL assay achieving 96% (48/50) success. These findings are 
supported by two further studies publishing 96% and 99.3% success rates (Hall et al., 
2005; Farina et al., 2015) Gram’s stain analysis identified 72% (36/50) of the yeasts 
isolates. Several factors led to the lower success rate of Gram’s stain. 
Previous work has investigated the use of Gram’s stain for the differentiation of           
C. albicans from non-albicans species from blood cultures (Harrington et al., 2007) but 
to my knowledge this study is the first to investigate the use of yeast morphology in 
Gram’s stain for identification of several Candida species. Misidentification was the 
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primary reason for the lower success rate, with 26% (13/50) of the yeast cultures being 
misidentified, despite an experienced health care scientist analysing the slides. Both 
commonly encountered yeasts and rare species were misidentified Only one result of 
‘unknown’ was recorded despite five of the yeast species in this study being absent 
from the identification keys, indicating a bias to identify rare yeasts as commonly 
encountered species. This could also be bias against perceived ‘failure’ to identify by 
the scientist analysing the slides, in that giving an identification is perceived to be 
better than not giving one at all (Rousseau et al., 1998; Chancey et al., 2017). A report 
of ‘no yeasts seen’ for one blood culture was likely to be an examination error as all 
blood cultures exceeded the estimated limit of detection (LOD) for Gram’s stain of 
1x105 cfu/mL (Branda, Ferraro and Kratz, 2007).  
The misidentification of fluconazole resistant C. krusei isolates as C. parapsilosis was 
noted as of particular concern. This would have had a negative clinical impact 
assuming that an identification of C. parapsilosis, a species commonly fluconazole 
susceptible, would have influenced a switch in empirical therapy from an echinocandin 
to fluconazole. However, 83% (14/17) of the C. albicans isolates were identified 
correctly. Three C. albicans misidentifications included two as C. tropicalis and one as 
C. parapsilosis. Both species are considered to be azole susceptible and a switch to 
fluconazole would not have been inappropriate in both instances in an uncomplicated 
patients (Ullmann, et al., 2011). The inclusion of pseudohyphal clustering in the 
identification keys for C. albicans was the likely factor contributing to this higher 
success rate for this species. This finding is supported by the previous study which 
also utilised pseudohyphal clusters to identify C. albicans from blood cultures 
demonstrating 97% specificity, with a single false positive result reported as C. 
tropicalis (Harrington et al., 2007). There is a potential role for the use of Gram’s stain 
to differentiate C. albicans from other Candida species in a centre where an 
experienced health care scientist is available. This approach could be useful in a low 
technology diagnostic setting. It should be noted that only a small proportion of other 
pseudohyphal species were included in this study but may explain the misidentification 
of C. albicans as pseudohyphal forming species C. tropicalis and C. parapsilosis.  
The success of the PNA FISH YTL assay was attributed to the minimal technical 
expertise necessary to perform the assay and the high specificity of the PNA probes for 
their target molecule, exceeding 95% across all published studies (Hall et al., 2005; 
Heil et al., 2012; Farina et al., 2015; Radic et al., 2016). The highly visible fluorescent 
signals seen using microscopy enable accurate results interpretation and only require a 
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limited amount of training and hands on time to be competent in interpreting results. 
Non-specific fluorescence or cross-reaction of the PNA probes with human blood 
components was not observed. Overall 86% (43/50) of the yeasts included in this study 
were identified. The species distribution included in this study does not reflect the 
normal distribution experienced in the clinical setting. Greater than 95% of fungaemia 
is attributed to the 5 yeast species contained within the assays database (Odds et al., 
2007; Ullmann, et al., 2011) and 100% (43/43) of the species contained within the 
assays database were identified correctly. Using the PNA FISH YTL assay routinely 
only a small proportion of yeasts implicated in Candidemia would require an additional 
24 hours before identification is achieved. Two misidentifications occurred using the 
PNA FISH YTL assay, one C. neoformans and one M. capitatus isolate, both cross 
reacting with the red C. krusei/C. glabrata probe.  
Assuming the respective C. glabrata/C. krusei results would have prompted the 
administration of an echinocandin, in both instances an echinocandin would have been 
an inappropriate therapy choice. Until phenotypic identification had been achieved 24-
72 hours later the fungal infections would have remained untreated. Although             
C. neoformans fungaemia is encountered infrequently in the laboratory, the unique 
morphology of this yeast in Gram’s stain often provides an indication of 
Cryptococcaemia. If this had been detected prior to performing PNA FISH YTL it could 
have prevented this misidentification from occurring, therefore in the routine laboratory 
setting this misidentification may have been avoided. M. capitatus is rarely 
encountered in fungaemia and should have been reported as negative by the PNA 
FISH assay. It is likely that a negative PNA FISH YTL result would have prompted the 
use of an echinocandin as empirical therapy until the yeast identification was achieved 
from culture, thus the treatment course would have remained unchanged. When 
repeated both analyses were reported as negative, which may indicate insufficient 
washing of the slide during analysis to be the likely cause of the false positive 
misidentifications or background debris reported as fluorescence. One other study  
reported misidentifications with the C. glabrata/C. krusei PNA FISH YTL probe cross 
reacting with the rarely encountered yeast Candida bracarensis (Hall et al., 2012).   
This study has shown that Gram’s stain analysis is inexpensive and rapid. However, 
Gram’s stain did not achieve the required diagnostic performance for yeast 
identification to species level. It was able to divide Candida species into C. albicans 
and species other than C. albicans which could in turn be used to drive the choice of 
antifungal therapy as Candida abicans are in the majority of isolates fully susceptible to 
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azoles (Castanheira et al., 2016). The PNA FISH YTL assay is rapid, successful and 
requires limited technical expertise but may be considered expensive at a list price of 
£44.00 per analysis. The initial cost could be offset by influencing a switch in antifungal 
therapy from an echinocandin to fluconazole in a proportion of patients. For yeasts 
included in this study a retrospective analysis of antifungal therapy at the time of 
fungaemia estimated a change in antifungal therapy could have been made in 29% of 
patients. This was based on a retrospective review of clinical notes, which as an 
approach has its limitations, as records are often not complete. Clinical records of 
when or which antifungal was administered were not always clear, and the information 
for some patients was not available. Additionally, the number of isolates tested was 
small, particularly those of species that the assay states it is unable to identify (n =7).  
However, a recent prospective study conducted in the USA calculated cost savings of 
$415 per patient through direct influence on targeted antifungal therapy using the 
results of the YTL assay (Heil et al., 2012). A significant decrease in time to targeted 
therapy and higher rate of culture clearance was also demonstrated (Heil et al., 2012). 
With the frequency of blood cultures growing yeasts remaining low, in our 900-bed 
hospital we experience 12-20 cases of fungemia per year (BSMM, 2003), the financial 
burden of the YTL PNA FISH assay is not substantial and could ultimately lead to 
financial savings (and improved clinical outcome) if clinical management can be 
influenced by the diagnostic results.  
In summary, Gram’s stain analysis of blood cultures will remain essential in the 
laboratory as a first line test to determine the presence of yeasts within a blood culture, 
and as shown in this study may serve as a means of discriminating non-albicans 
species in a low technology environment. This study has demonstrated that the PNA 
FISH YTL assay is highly sensitive and specific, with a short turnaround time. 
Favourable outcomes in prospective, randomized trials of clinical utility could lead to 
more widespread adoption of this assay in routine clinical laboratories.  
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7 Chapter 7 Evaluation of a second generation PNA-FISH assay, 
QuickFISH™, for the rapid identification of yeasts direct from 
positive blood cultures. 
7.1 Overview 
Peptide nucleic acid fluorescence In situ hybridisation (PNA-FISH) has demonstrated a 
high degree of accuracy, 100% (43/43), for the identification of yeasts direct from blood 
culture films (chapter 6). The processing of PNA-FISH YTL slides had a turnaround 
time of 90 minutes for one blood culture. The World Health Organisation (WHO, 2017) 
considers a ‘rapid’ test as a test that provides a result within 10 minutes – 2 hours 
(WHO, 2017). Therefore, the YTL PNA-FISH assay can be classified as a rapid test 
according to these criteria. However, for the PNA-FISH result to be effective, clinicians 
would have to wait 90 minutes to report out the result, withholding the grams stain 
result in the interim. This is a difficult position clinically as studies have shown 
candidemia mortality can increase hour on hour and guidelines recommend the earliest 
possible opportunity for intervention should be taken to administer antifungal therapy 
(Fraser et al., 1992; Alonso-Valle et al., 2003; Colombo et al., 2007). For PNA-FISH to 
truly meet the rapid test criteria and for the result to be actionable the result needs to 
be available as close as possible to the time the Gram’s stain result is available 
In 2012 a second-generation PNA FISH assay, QuickFISH™ (AdvanDX, Woburn, MA, 
USA), was developed for routine diagnostic use. The PNA-FISH assay processing was 
reformatted, removing the lengthy hybridisation and slide washing steps in the protocol, 
into a simple two-step approach incorporating a fixation step, probe application to the 
fixed blood smear and a final 15 minute shortened hybridisation, figure 7.1. The 
removal of the wash buffer step in the process shortened the overall protocol 
turnaround time to approximately 20 minutes. The reduction in turnaround time was 
achieved by removing the need to stringently wash residual unbound probe by 
reformatting the assay to contain quencher-probe complexes, replacing the old format 
of ‘free’ PNA probe. The quencher molecules complex with the PNA probe as the slide 
cools to room temperature. When added to the slide and hybridised at 56ºC the 
quencher dis-associates from the PNA probe allowing the PNA probe to bind to its 
target. After hybridisation the slide cools to room temperature and any unbound probe 
re-forms a complex with its quencher molecule. The quencher molecules neutralize the 
fluorescence emitted from unbound probes and only fluorescence from PNA probes 
bound to their target in-situ can be visualized. The manufacturers also modified the 
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fixation step steps to include two fixative solutions that are applied to the blood culture 
smear prior to probe hybridisation. The modified dual fixative improves the permeability 
of the yeast cell wall to the PNA FISH probes allowing for more rapid and efficient in-
situ hybridisation, shortening hybridisation from 30 to 16 minutes at 56°C. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1.Comparison of PNA-FISH and QuickFISH processing methods. 
 
An additional change was made to the Candida QuickFISH™ assay (AdvanDX, 
Denmark) in that the assay was reformatted to exclude C. tropicalis and C. krusei as 
targets with a streamlined format targeting only three species; C. albicans (green), C. 
parapsilosis (yellow) and C. glabrata (red). The decision to reformat the assay format 
was based on the prevalence of each species in candidemia. In the USA and Europe 
C. albicans accounts for >50% of candidemia and C. glabrata has emerged as an 
important pathogen (Wisplinghoff et al., 2014; Kullberg and Arendrup, 2015). C. 
glabrata is the second most prevalent species accounting for 10-20% (Odds et al., 
2007; Ruan et al., 2008; Kett et al., 2011; Silva et al., 2012; Moretti et al., 2013; 
Deorukhkar, Saini and Mathew, 2014) and finally C. parapsilosis, known to cause 
candidemia in premature neonates accounts for 33.4% of candidemia in the neonatal 
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patient cohort (Singh and Parija, 2012; Pammi et al., 2013) but also 12% in adults 
(Odds et al., 2007). The impact of removing C. tropicalis and C. krusei from the kit 
format may be significant as C. tropicalis is implicated in 3-66% of candidemia, 
frequency varying with geography (Ann Chai, Denning and Warn, 2010) and is known 
to be more virulent than other Candida species, especially in the haemato-oncology 
setting (Kontoyiannis et al., 2001). C. krusei accounts for 2.1% of candidemia (Pfaller 
et al., 2011), therefore not identifying this species may be of less concern. However, C. 
krusei is intrinsically resistant to fluconazole, used as prophylaxis and as first-line 
therapy in some patients. 
The aim of this study was to evaluate the performance of QuickFISH for the 
identification of yeasts direct from positive blood cultures. A retrospective audit of 
fungemia was performed to establish the proportion of yeasts isolated in our setting 
that would have been identified by the new assay format and to assess the impact that 
removing C. tropical and C. krusei would have had on the diagnosis of Candidemia in 
our hospital.  
 
7.2 Methods 
7.2.1 Yeast isolates 
Eighty-one yeast isolates were selected from a clinical archive of isolates retained at 
the Royal Free Hospital microbiology laboratory. Isolates were selected to represent a 
diverse collection of species encountered in fungemia. All isolates were from previous 
cases of fungemia from patients treated at the Royal Free Hospital. Isolates were 
stored in sterile water; away from light at room temperature. Throughout the study all 
prospective blood cultures positive for yeasts by Gram’s stain were also included for 
analysis with QuickFISH.  
7.2.2 Subculture of yeast isolates  
See general methods section 2.1.1 
7.2.3 Simulated blood cultures 
See general methods section 2.1.2 
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7.2.4 Routine blood culture investigation 
Blood smears were prepared from 1 drop of culture and the smears were fixed on a 
heated slide station. Once dried a conventional Gram’s stain method was applied. For 
subculture 2-3 drops of positive blood culture was inoculated onto blood Columbia, 
chocolate and cystine lactose electrolyte deficient agars (Oxoid Wesel, Germany) with 
the addition of a blood agar plate incubated anaerobically. All subcultures were 
incubated at 36°C for 18-24 hours.  
 
7.2.5 MALDI-TOF identification of yeasts 
See general methods section 2.3.1 - 2.3.3 
 
7.2.6 ITS rRNA sequenced based identification of yeasts 
 See general methods 2.2. 
 
7.2.7 Preparation of QuickFISH slides 
All work was performed in a class 2 microbiology safety cabinet. QuickFISH slides 
were pre-warmed for 1 minute on a slide station at 55 ± 1°C. Using a vacutainer blood 
collection device and syringe 0.5mL of blood culture was transferred to a microfuge 
tube. 10μL of the blood culture was pipetted from the microfuge tube to the centre of 
the QuickFISH slide sample area. One drop of QuickFix-1 was immediately added to 
the sample, and the mixture was spread evenly throughout the sample area on the 
slide with an inoculating needle, see figure 7.2. The slide was transferred back to the 
slide station and heat fixed until the smear was visibly dried (1–3 minutes). Two drops 
of QuickFix-2 were added to the centre of the sample area and allowed to dry (1 
minute). One drop of PNA Blue was applied to the centre of a 24 × 50mm coverslip, 
followed by 1 drop of PNA Yellow. The blue and yellow hybridization reagents were 
thoroughly mixed with a mixing stick until a uniform green colour was observed 
(approximately 5–10 seconds). Coverslips were inverted and applied to the QuickFISH 
slides to cover the control wells and the fixed samples with the hybridization reagent 
mixture. Slides were then incubated on a heat block at 55 ± 1°C for 15 minutes. 
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Figure 7.2 QuickFISH slide demonstrating sample preparation area, negative and 
positive control areas on the pre-prepared slide. 
 
7.2.8 Microscopic analysis of QuickFISH slides 
Slides were analysed using an Olympus BX63 fluorescence microscope (objective, 
100×, Olympus BX40; Osram HBO 100 W/2 Hg lamp) equipped with a fluorescein 
isothiocyanate-Texas Red double filter (filter no. AC003, AdvanDx). Slides were 
analysed from the positive control field to ensure hybridisation was successful for all 
yeasts and the negative control (containing a smear of Cryptococcus cells) to ensure 
cross hybridisation did not occurred. The sample section was analysed last for results 
interpretation. All areas of the sample field were examined to ensure mixed yeast 
cultures were not present. Figure 7.3 demonstrates typical fluorescence seen when 
analysing QuickFISH Candida slides with C. albicans (green), C. parapsilosis (yellow) 
and C. glabrata (red) demonstrated. A mixed culture representing a typical image of 
the positive control is also shown.  
 
 
Figure 7.3 Fluorescence signal observed when analysing QuickFISH Candida slides 
with C. albicans (green), C. parapsilosis (yellow) and C. glabrata (red) demonstrated. A 
mixed culture representing a typical image of the positive control is also shown.  
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7.2.9 Fungaemia audit 
A twelve-month retrospective audit, from 1st January 2013 to 31st December 2013, of 
fungaemia episodes documented at our centre was performed. The aim was to 
establish the prevalence of yeast species implicated in fungaemia and the potential 
performance of the QuickFISH assay in our setting. The yeast identification reported 
out from the blood culture was collected on our local WinPath reporting system.  
7.3 Results 
7.3.1 Yeast blood cultures 
In total 96 blood cultures were included in the study. Of the 96 blood cultures, 15 were 
tested in real-time from cases of fungaemia and 81 were spiked blood cultures. Spiked 
yeast cultures included yeasts from 3 genera and 19 species, of which 65.9% (54/82) 
of the isolates were contained within the QuickFISH assay format. A full break down of 
the species distribution is presented in table 7.1. 
 
Table 7.1 Species distribution for yeasts from 96 blood cultures 
analysed using QuickFISH in this study 
Species Spiked Clinical Total 
 n n % n 
Candida albicans 33 11 45.8 44 
Candida glabrata 14 2 16.7 16 
Candida parapsilosis 7  7.3 7 
Candida krusei 5  5.2 5 
Candida tropicalis 3  3.1 3 
Candida dubliniensis 2  2.1 2 
Candida guillermondii 2  2.1 2 
Candida kefyr 2  2.1 2 
Pichia cactophila 2  2.1 2 
Candida sp - 2 2.1 2 
Candida famata 1  1.0 1 
Candida lambica 1  1.0 1 
Candida utilis 1  1.0 1 
Candida lusitaniae 1  1.0 1 
Candida metapsilosis 1  1.0 1 
Candida bracariensis 1  1.0 1 
Trichosporon inkin 1  1.0 1 
Trichosporon mucoides 1  1.0 1 
Cryptoccus neoformans 1  1.0 1 
Saccharomyces cerevisiae 1  1.0 1 
Candida fermentati 1  1.0 1 
Total  81 15 100 96 
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7.3.2 Performance of QuickFISH  
Table 7.2 details the performance characteristics of QuickFISH, overall and by probe 
set. Overall, QuickFISH demonstrated 98.5% (93/96, CI: 91.2, 98.9) diagnostic 
accuracy when compared against the conventional identification method MALDI-TOF 
MS. Sensitivity was 98.5% (66/67 CI: 92.0, 99.7), specificity was 93% (27/29 CI: 78.0, 
98.1), PPV was 97.1% (66/68 CI: 89.9, 99.2) and NPV was 96.4% (27/28 CI: 82.3, 
99.4). 
7.3.2.1 C. albicans probe performance 
 The green QuickFISH C. albicans probe demonstrated 100% (96/96, CI: 96.2, 100) 
diagnostic accuracy when compared against the conventional identification method. 
The sensitivity of the C. albicans probe was 100% (44/44, CI: 91.8, 100), specificity of 
100% (52/52, CI: 93.2, 100), PPV of 100% (44/44, CI: 91.8, 100) and NPV of 100% 
(52/52, CI: 93.2, 100). No incorrect results were recorded for the C. albicans PNA 
probe. 
7.3.2.2 C. parapsilosis probe performance 
The QuickFISH yellow C. parapsilosis probe demonstrated 100% (96/96, CI: 96.2, 100) 
diagnostic accuracy when compared against the conventional identification method. 
The sensitivity of the C. parapsilosis probe was 100% (7/7, CI: 64.6, 100), specificity of 
100% (89/89, CI: 95.6, 100), PPV of 100% (7/7, CI: 64.6, 100) and NPV of 100% 
(89/89, CI: 95.6, 100). No incorrect results were recorded for the C. parapsilosis PNA 
probe. 
7.3.2.3 C. glabrata probe performance 
The QuickFISH red C. glabrata probe demonstrated an overall diagnostic accuracy of 
96.9% (93/96, CI: 91.2, 98.9) when compared to the conventional identification 
method. The sensitivity of the C. glabrata probe was 93.8% (15/16, CI: 71.7, 98.9), 
specificity of 97.5% (78/80, CI: (91.3, 99.3), PPV of 88.2% (15/17 CI: 65.7, 96.7) and 
NPV of 98.7% (78/80, CI: 93.2, 99.8). Three incorrect results were recorded using the 
red C. glabrata probe. One C. glabrata isolate was missed on QuickFISH analysis with 
a report of ‘no colour’ recorded. Two blood cultures containing yeasts other than C. 
glabrata were reported as positive with red fluorescence, table 7.3.  
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7.3.2.4 Performance for the identification of other Yeasts 
For yeasts not targeted by the QuickFISH Candida probes an overall diagnostic 
accuracy of 96.9% (93/96, CI: 93.9, 99.8) was observed when compared to the 
conventional identification method if a result of no colour was considered as the correct 
result. Sensitivity was 92% (23/25, CI: 75.0, 97.8), specificity 98.6% (70/71, CI 94.4, 
100), PPV 95.8% (23/24, CI: 79.8, 99.4) and NPV 97.2% (70/72, CI: 90.4, 99.2).  
 
7.3.3 Assessing assay cost and turn-around-time 
Reagent costs of the QuickFISH assay were £19.50 per test not including ancillary 
consumables): calculated by dividing the cost of the kit by the total number of tests per 
kit. The average turnaround time, measured across the 15 prospective analyses during 
the course of the study, was 21 minutes (range 19-21) per slide for processing and 
23.2 minutes (range 19.8-27.4) per slide including analysis.  
 
 
Table 7.3 Isolates misidentified or unidentified from blood cultures QuickFISH 
compared with the expected result. 
  Misidentifications 
Isolate n Expected result n QuickFISH n 
C. glabrata 1 Red fluorescence 1 Negative 1 
C. braciariensis 1 Negative 1 Red fluorescence 1 
Candida sp. 1 Negative 1 Red fluorescence 1 
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Table 7.2. Performance characteristics of QuickFISH for the identification of yeasts direct from 96 blood cultures, overall performance 
and performance by probe set is represented. 
 Diagnostic accuracy Sensitivity Specificity PPV NPV 
 % 95% CI n % 95% CI n % 95% CI n % 95% CI n % 95% CI n 
Overall 98.5 91.2 98.9 93/96 98.5 92 99.7 66/67 93 78 98.1 27/29 97.1 89.9 99.2 66/68 96.4 82.3 99.4 27/28 
C. albicans 100 96.2 100 96/96 100 91.8 100 44/44 100 93.2 100 52/52 100 91.8 100 44/44 100 932. 100 52/52 
C. parapsilosis 100 96.2 100 96/96 100 64.6 100 7/7 100 95.6 100 89/89 100 64.6 100 7/7 100 95.6 100 89/89 
C. glabrata 96.9 91.2 98.9 93/96 93.8 71.7 98.9 15/16 97.5 91.3 99.3 78/80 88.2 65.7 96.7 15/17 98.7 93.2 99.8 78/80 
Other yeasts 96.9 93.9 99.8 93/96 92 75 97.8 23/25 98.6 94.4 100 70/71 95.8 79.8 99.4 23/24 97.2 90.4 99.2 70/72 
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7.3.4 Fungaemia audit 
Data extracted from the laboratory reporting system (WinPath, Clinisys Group, UK) 
from a 12-month time period of fungaemia from 1st January – 31st of December 2013 
recorded 38 events of yeasts isolated from blood cultures. The blood cultures were 
taken from 23 patients. Figure 7.4 details the frequency of the 10 yeast species 
isolated. QuickFISH would have identified 57.9% (22/38) of the yeast isolates from 
blood culture. ‘Other’ species included; Candida lusitaniae (1), Trichosporon sp (1), 
Candida famata (1) and Candida guillermondii. 
If the PNA-FISH assay format had been available a further 13.2% (5/38) of yeasts from 
blood culture, all C. tropicalis isolates, would have been identified by QuickFISH with a 
total identification rate of 71.1% (27/38), figure 7.4. This difference in the identification 
rate is not significant when compared with the identification rate that would have been 
obtained using the current QuickFISH assay format (p=0.23).  
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Figure 7.4 Histogram displaying the frequency of yeast species isolated from 38 blood 
cultures at the Royal Free Hospital microbiology laboratory over a twelve-month period 
from 1st January – 31st December 2013. The colours demonstrate the colour of the 
QuickFISH probe fluorophores that targets each species.  
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7.4 Discussion 
QuickFISH is the only nucleic-acid based method to date capable of providing a 
species identification in less than 30 minutes direct from a positive blood culture, as 
other approaches such as real-time PCR and DNA microarray require a turnaround 
time of approximately 2 hours for results (Deck et al., 2014). QuickFISH has shown to 
be a rapid, sensitive and specific method, identifying 98.5% (66/67) of the target 
species correctly in this study. This high performance of Candida QuickFISH is 
supported by a multicentre trial, which reported a diagnostic accuracy of 99.3% for the 
identification of the species contained within the assay format, supporting the findings 
of our study (Abdelhamed et al., 2015).  
As QuickFISH was launched in 2012 only a small number of reports have been 
published utilising the assay for the identification of microorganisms from blood culture, 
but all report high sensitivities and specificities (Deck et al., 2012, 2014; Carretto et al., 
2013; Martinez et al., 2014; Salimnia et al., 2014; Abdelhamed et al., 2015; Koncelik 
and Hernandez, 2016). A trial utilising QuickFISH panels for the identification of 
Enterococci, Gram negative bacilli, Staphylococci and Candida reported an overall 
concordance of 98% with conventional identification (Martinez et al., 2014). In the 
respective study four yeasts were isolated from blood culture and 100% concordance 
was observed between QuickFISH Candida and conventional methods of identification 
(Martinez et al., 2014). In a multicentre study Deck et al investigated the Enterococcus 
QuickFISH panel reporting sensitivities of 100% (106) and 97% (65/67) were recorded 
for the green (Enterococcus faecalis) and red PNA (other enterococci) probes 
respectively (Deck et al., 2012, 2014). By far the most investigated QuickFISH panel to 
date is the Staphylococcal panel that determines S. aureus (green probe) from 
coagulase negative staphylococci. A multicentre study, investigating the 
Staphylococcal QuickFISH panel performed by Deck et al reported sensitivities of 
99.5% (217/218) for the green (S. aureus) and 98.8% (487/493) for the red (coagulase 
negative staphylococci) probes (Deck et al., 2012). The success with the 
Staphylococcus QuickFISH kit was also replicated in a further study reporting 100% 
sensitivity and specificity for the identification of S. aureus and a sensitivity of 98.5% 
and specificity of 100% for coagulase negative staphylococci identification (Carretto et 
al., 2013). The successful use of the Staphylococcal QuickFISH was further supported 
in a large multicentre trial reporting concordance with the routine phenotypic testing 
methods of the testing laboratories in 99.1% (1,211/1,221) samples across 5 
laboratories (Salimnia et al., 2014) In the respective studies the performance of 
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QuickFISH was slightly lower with the red PNA probe. This was also an observation in 
our study.  
Three errors were reported using the red PNA probe. Two isolates, C. bracariensis and 
C. nivariensis, were reported as C. glabrata with red fluorescence and one C. glabrata 
was not detected in an analysis. Repeat interrogation of the slide from which C. 
glabrata was missed demonstrated a low quantity of red fluorescent yeast cells 
amongst the background of non-specific (yellow/orange) auto fluorescence from 
erythrocytes within the preparation. In this instance the PNA probe had bound to its 
target but due to a low concentration of yeasts within the blood culture the investigator 
had failed to detect the yeasts. In part, this is a limitation of utilising a red fluorescent 
probe as non-specific auto fluorescence from erythrocytes may in some instances 
mask the specific fluorescence of the bound PNA probe when the quantity of 
organisms is low in a blood culture. Higher than expected levels of background auto 
fluorescence has also been attributed to misidentifications made in a similar study 
evaluation of QuickFISH and was associated with the specification of microscope being 
used for analysis (Martinez et al., 2014). This is an important consideration for 
laboratories choosing to implement PNA FISH methods as the quality of the 
microscope, light source; filter wavelength specifications may impact on the accuracy 
of results (Martinez et al., 2014). Operator variation and error is also a recognised 
limitation in laboratory based microscopy screening and was concluded to be the 
cause of two false negative results reported in a staphylococcal QuickFISH study 
(Deck et al., 2012).  
Two other discrepancies recorded in our study were related to cross reaction of the C. 
glabrata PNA probe with two genotypically closely related species C. nivariensis and C. 
bracariensis. Although these misidentifications have low clinical significance, in our 
setting it would prompt the use of an echinocandin as both C. nivariensis and C. 
bracariensis also have the same inducible mechanism of resistance to fluconazole as 
C. glabrata. Unfortunately the multi-center trial evaluating the Candida QuickFISH 
assay used biochemical profiling for the identification of yeasts. Both C. nivariensis and 
C. bracariensis are indistinguishable from C. glabrata biochemically so any cross-
reaction of the red PNA probe with these cryptic species could not be determined 
(Lockhart et al., 2009). Investigators in the respective study reported cross-reaction of 
the C. parapsilosis probe with two isolates, C. metapsilosis and C. tropicalis, 
(Abdelhamed et al., 2015). The assay manufacturer acknowledges cross-reaction of 
the C. glabrata PNA probe with C. nivariensis and C. bracariensis and the C. 
parapsilosis probe with C. orthopsilosis and C. metapsilosis in the product insert. None 
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of the known cross-reacting misidentifications are considered to be clinically significant 
in our setting, as they would not impact on the therapeutic management of patients. 
What is of some concern is the limited range of species that the Candida QuickFISH 
assay can identify and the uncertainty when a negative result is reported by the assay.  
The three species included in the assay format do represent the three commonest 
Candida species implicated in fungaemia, reportedly responsible for 74%-88.2% of the 
burden of disease (Chalmers et al., 2011; M. A. Pfaller et al., 2011; Orasch et al., 2014; 
Trouvé et al., 2017). As a second-generation assay, the manufacturers determined 
QuickFISH should not include C. tropicalis and C. krusei PNA probes in the assay 
assay format. Whilst C. krusei does not represent a significant proportion of the 
fungaemia burden globally, C. tropicalis is commonly isolated from blood cultures (M. 
A. Pfaller et al., 2011) and accounted for a significant proportion of the blood cultures, 
13.2% (5/38), encountered in our setting. The removal of the C. tropicalis PNA probe 
has had an impact on the overall specificity of the assay. An audit of Candida blood 
cultures processed over a twelve month period from 1st January 2013 to 31st December 
2013 revealed that only 59.5% (22/37) of yeasts would have been identified. The 
addition of a C. tropicalis probe would have increased success to 73% (27/37) in our 
setting. In the multicentre trial investigating the Candida QuickFISH assay 26% of 
yeasts were not identified (8.8% of the isolates being C. tropicalis) (Abdelhamed et al., 
2015).  
The SENTRY antimicrobial surveillance program published data from North and South 
America. C. tropicalis was the fourth most common cause of fungaemia representing 
11% of the burden (Pfaller et al., 2011). In an Indian tertiary care hospital in the 
haemato-oncology setting C. tropicalis was the most common cause of fungaemia 
accounting for 46.7% of the isolates encountered in blood cultures (Kaur et al., 2017). 
The inclusion of a C. tropicalis probe would only have a positive impact on assay 
performance and would benefit in selecting a global population of Candida species, 
suiting a broader array of healthcare environments. The decision to omit the number of 
probes in the assay format for Candida is most likely not based on technical limitations 
but more related to the regulatory claims required to produce an in vitro diagnostic 
assay. The S. aureus panel and the Enterococcus panel has a broad range of species 
included within the assay format. The Staphylococcal QuickFISH assay has been 
shown to detect 28 species of coagulase negative staphylococci in the red probe mix 
(AdvandDX manufacturer’s validation) and the enterococci assay detects 14 non-
faecalis enterococci species (AdvandDX manufacturers validation). PNA as a 
technique can incorporate multiplexed probes within a single mix without impacting on 
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the performance of the test. If differing probe combinations were available for centres 
with a more diverse range of yeast species implicated in fungaemia, where specialist 
patient groups have a reduced incidence of candidemia with the more common species 
contained within the Candida QuickFISH format, this would be of greater benefit to a 
broader range of clinical services. The inability of QuickFISH to identify 40% of yeasts 
from blood cultures in the prospective audit in our study is not adequate for the 
diagnostic service. However, it is also important to acknowledge that a negative result 
is informative as it indicates the presence of a less common species. 
The clinical impact of QuickFISH is yet to be firmly established. In a prospective cohort 
study of patients receiving antifungal therapy for candidemia it was estimated that 
using the first generation PNA FISH Candida assay antifungals could have been 
initiated 24 hours earlier compared with standard microbiological practice for yeast 
identification (Aitken et al., 2014). As the mortality of Candidemia is known to increase 
dramatically over 24 hours, earlier initiation of antifungal therapy could lead to 
decreased mortality for patients (Garey et al., 2006). In an impact study investigating 
the Staphylococcal QuickFISH assay the average length of stay and days on 
vancomycin were all decreased significantly (P = .0484, and P = .0084, respectively) as 
the result of QuickFISH testing; for acute-care patients hospitalized for 10 days or less 
(Koncelik and Hernandez, 2016). This indicates that QuickFISH can have a positive 
impact downstream on outcomes from blood stream infection. As with any new test it is 
important not only to establish clinical impact but also implement an appropriate testing 
rationale, establishing local guidelines to ensure that the test is used in the correct 
setting. In our laboratory an algorithm was developed to screen positive blood cultures 
and only new positive cultures for a patient that had not had a previous blood culture 
tested within a 72 hour window. A similar decision-making strategy was also 
implemented by Almangour et al who developed the strategy for rapid testing, only 
performing QuickFISH in patients where the test would have an impact if a 
staphylococcal isolate was encountered or in a patient whereby a foreign device was In 
situ or was not being treatment with vancomycin. This was a slightly different approach 
to diagnostic implementation, the driver being clinical as opposed to laboratory 
operational. However, this approach maintained a reduction in the number of tests from 
a possible 43 blood cultures to 9, equating to an approximate saving of £3000 in 
reagent costs (Almangour, Alhifany and Tabb, 2017) This highlights the optimal 
implementation strategy of rapid screening tests requires a combined clinical and 
laboratory approach to obtain the best testing strategy. 
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In summary, this study has demonstrated that the Candida QuickFISH assay is an 
accurate and rapid test for the identification of yeasts within minutes from positive 
blood cultures and may contribute to targeted clinical management, antimicrobial 
stewardship and improved patient care whilst benefiting via an improved healthcare 
economic model. Earlier identification has also been associated with decreased costs 
with a delay in antifungal therapy increasing the attributed hospital costs by 
approximately £8000 (Arnold et al., 2010; Taur et al., 2010; Zilberberg et al., 2010). 
Future work should include trials of the assay to ascertain its clinical utility so that the 
additional cost per test added to a blood culture of approximately £20 can be justified.   
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8 Chapter 8 Evaluating the performance of P. jirovecii PCR 
alongside automated DNA extraction; a comparison of the 
MycAssay/Diasorin IXT and the BD MAX™  
8.1 Introduction 
Many laboratories still rely on cytological staining methods to detect and diagnose P. 
jirovecii infection from brochoalveolar lavage (BAL) and sputum specimens (Schelenz 
et al., 2009). The sensitivity of microscopy is known to be suboptimal. Grocott’s 
staining; a methenamine silver stain has reported sensitivities of 50-89.7% and 
immunofluorescence 60-93.1% (Flori, 2004; Procop et al., 2004; Alanio, Desoubeaux, 
et al., 2011). In addition microscopy cannot be used to exclude disease when a test is 
negative. In most patient cohorts the incidence of PCP is relatively low (Kim et al., 
2013; Sarwar et al., 2013; Kostakis, Sotiropoulos and Kouraklis, 2014), in this scenario 
the diagnostic test is used to rule out disease with a high negative predictive value and 
a high sensitivity for detecting P. jirovecii from specimens (White et al., 2017). This in 
turn can result in false positive results as colonising P. jirovecii will be defected (White 
et al., 2017) but positive results can be assessed in the context of the patient and the 
clinical presentation to assess the significance of the result. In a low prevalence setting 
microscopy should not be the primary method of diagnosis as PCP, but rather a more 
sensitive assay such as PCR is better suited (White et al., 2017).  
The use of PCR for the detection of P. jirovecii infection is not a novel approach, with 
many studies detailing the use of PCR for the diagnosis of PCP for over 20 years. In 
three recent meta-analyses the performance of PCR was shown to be highly sensitive 
ranging from 97-99% and the negative predictive value was very high ≥99% for the 
exclusion of PCP (Lu et al., 2011; Fan et al., 2013; Summah et al., 2013). In the 
respective meta-analyses the specificity for the detection of P. jirovecii ranged from 90-
94% with a positive predictive value of 66-85% reflecting the complexities of 
distinguishing infection from colonisation when utilising PCR (Lu et al., 2011; Fan et al., 
2013; Summah et al., 2013). The diagnosis of PCP using PCR is not without 
challenges and most likely explains why some clinical services choose microscopy as 
their method of choice as the limit of detection is lower (poorer) therefore colonisation 
is not detected (Armbruster, Pokieser and Hassl, 1994; Flori et al., 2004; Seah et al., 
2012a; Moodley, Tempia and Frean, 2017).   
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When implementing a PCR based methodology for the diagnosis of PCP the workflow 
of the specimen and its processing are crucial in determining the performance of the 
test. Some diagnostic centres choose to target whole cell DNA by centrifugation of the 
specimen and subsequent extraction from the resulting concentrate (Flori, 2004; Tia et 
al., 2012; Matsumura et al., 2014; Robert-Gangneux et al., 2014; Fauchier T, Hasseine 
L, Gari-Toussaint M, Casanova V, Marty PM, 2016) . An alternative approach is to 
target free nucleic acid within BAL specimens, by extracting direct from the BAL 
supernatant (Samuel et al., 2011; Moodley, Tempia and Frean, 2017). The 
performance of PCP PCR can therefore be heavily influenced by the fraction of sample 
used, but also by the choice of DNA extraction methods used to recover nucleic acid 
from the clinical specimen.  
Efforts to standardise PCR protocols are required to enable the comparison of 
performance across centres using PCR for diagnosis of PCP (Alanio et al., 2012). One 
way to standardise performance is through the use of commercially available workflows 
for the isolation of nucleic acid (Springer et al., 2013). Most commercially available 
extraction platforms utilise solid phase nucleic acid capture base technologies in the 
extraction protocols, see table 8.1. Solid phase capture of nucleic acid is efficient as it 
facilitates physical separation of nucleic acids from other biological components of the 
sample (Archer et al., 2006). The impact of biological inhibitors such as complex 
polysaccharides and mucin are reduced, as they are not carried through the extraction 
process. The most common solid phase mechanism in automated DNA extraction 
systems is magnetic bead based capture, table 8.1. 
 
Table 8.1 Commercially available extraction platforms utilising 
magnetic bead based capture 
Platform Manufacturer 
QiaSymphony Qiagen 
Bullet Pro Diasorin 
Maxwell Promega  
Liaison (Arrow) Diasorin 
EasyMag Biomerieux 
Kingfisher/Magmix Thermofisher 
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Magnetic bead-based capture of nucleic acid was first described in 1988 by Hultman 
and colleagues as a solid phase capture mechanism from which sequencing could be 
performed (Hultman et al., 1989). A review of this technique was published a year later 
in Nature by Uhlen, who highlighted its potential application in DNA extraction from 
bacterial colonies of plasmid purification (Uhlen, 1989). Magnetic beads capable of 
binding DNA are manufactured in a variety of ways, but usually magnetically 
susceptible particles (e.g. iron oxide) are coated with synthetic or biological polymers, 
such as cellulose, polystyrene of silica (Berensmeier, 2006). Figure 8.1 demonstrates 
the basic principle behind magnetic bead based extraction. In summary, cell lysis is 
performed, releasing DNA into the supernatant. Streptavidin coated magnetic beads 
are added to the buffered solution and DNA is captured and immobilised on the beads. 
Using a magnet, beads are then separated from the solution, the supernatant is 
aspirated, and the beads are washed. DNA is then released from the beads through 
the addition of water or a buffered solution (e.g. tris-(hydroxymethyl)-aminomethane). 
 
Figure 8.1 schematic of magnetic bead based DNA extraction (www.fairbiotech.com, 2017) 
The Liaison IXT system (Diasorin) is an automated platform suited to low to medium 
throughput testing such as PCP PCR. The system can extract from 1 to 12 samples 
per run using pre-manufactured reagent cartridges, minimising reagent wastage and 
standardising the extraction process. The total run time for extraction is 45 minutes 
(manufacturers pre-set program). This extraction platform when coupled with a 
commercially available PCR, such as the MycAssay Pneumocystis™, provides a 
turnaround time to result in less than 3 hours. In comparison, a second automated 
system, BD MAX (Becton Dickinson, Fanklin Lakes, New Jersey), advances on the 
respective workflow by utilising a semi-closed system approach with nucleic acid 
extraction which takes place using individual reagent cartridges and is coupled with on-
board PCR set up and processing. The benefits of using a system such as the BD 
MAX are mainly through savings in hands on time for the operator. In 2013 Dalpke and 
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colleagues developed and evaluated a P. jirovecii PCR for use on the BD MAX system 
(Dalpke et al , 2013). The first aim of this study was to investigate and compare the 
IXT/MycAssay and the BD MAX PCP workflows for the detection of P. jirovecii from 
BAL specimens.  
8.2 Methods  
8.2.1 Prospective clinical samples and plasmid control material;  
BAL samples submitted to the Royal Free Hospital microbiology laboratory for the 
investigations of invasive fungal disease were included. 3mL was set as the minimum 
volume required for testing. Samples were stored at 4°C for 72 hours then centrifuged 
and two 1mL aliquots were frozen at -20°C prior to extraction. Plasmid control material 
containing the P. jirovecii large mitochondrial sub-unit (Mit LSU) specific for the 
MycAssay was sourced from Myconostica at a concentration of 1 x 108 copies/mL. For 
the BD MAX assay a positive-control plasmid containing a P. jirovecii HuMSG14 major 
surface glycoprotein gene (GenBank accession number AF033209) cloned into 
pCR2.1 was obtained from the research group of Dalpke et al (2013) at a 
concentration of 8x108 copies/mL. All plasmid was stored at -80°C prior to use in 
extraction studies. 
 
8.2.2 Control samples from patients diagnosed with PCP 
To analyse the sensitivity of the MycAssay Pneumocystis, DNA extracts and paired 
BAL aliquots were supplied by a collaborating centre led by Professor Oliver Schildgen 
at the Klinikum der Privaten Universität Witten-Herdecke mit Sitz in Köln, Institut für 
Pathologie, Cologne, Germany. DNA was extracted from 200µL BAL supernatant using 
the Maxwell RNA cartridge from Promega at the Klinikum der Privaten Universität 
Witten-Herdecke mit Sitz in Köln, Institut für Pathologie, Cologne, Germany. Both the 
extract and the native BAL were shipped on dry ice to the Royal Free microbiology 
laboratory and stored at -80°C until testing was performed.  
 
8.2.3 Preparation of BAL samples obtained from the Royal Free Hospital 
laboratory  
Samples were stored at 4°C for 72 hours then collected for testing. Viscous samples 
were pre-treated by mixing an equal volume of dithiothreitol (Sputasol, 1:1; Oxoid, 
Wesel, Germany) with the sample, followed by incubation at room temperature for 30 
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minutes. BAL samples were then centrifuged (4024g for 30 minutes) and the majority 
of supernatant discarded leaving 1mL to re suspend the pellet in. Samples were 
transferred to a screw cap 2mL tube (Sarstedt). If samples were not processed on the 
day of collection they were stored at -20°C until the day of testing (performed twice 
weekly). On the day of testing (following thawing if the samples were frozen), the 
samples were heat-treated on a dry heating block at 95°C for 30 minutes. After heat 
treating samples were split into two portions, 500μL was analysed using the Diasorin 
LIAISON® Ixt /MycAssay Pneumocystis assay and 500μL by the BD MAX system.  
 
8.2.4 Diasorin LIAISON® Ixt nucleic acid extraction 
Two types of extraction cartridges were used in this study for nucleic acid extraction. 
The first was a specific DNA extraction cartridge. This method of extraction targets 
whole cell DNA and is performed using the spun down pellet of BAL which was then 
re-suspended in lysis buffer specific to the cartridge kit. The second type of extraction 
cartridge targeted total nucleic acid and was designed to extract direct from the whole 
specimen, in this instance the neat BAL supernatant.  
 
For prospective BAL samples obtained through from the Royal Free Hospital routine 
diagnostic laboratory, DNA extraction cartridges were utilised. 500μL of BAL 
concentrate was centrifuged at 8000g for 10 minutes. The supernatant was discarded 
and approximately 50μL of acid washed glass beads were added to the pellet. The 
pellet was disrupted through ribolysis on a FastPrep24 platform for 45 seconds. 240μL 
of lysis buffer 2 (Diasorin DNA extraction kit) was added immediately to the lysate 
along with 10μL of proteinase K. The tube was vortexed for 30 seconds then pulse 
centrifuged. Tubes were incubated for 10 minutes at 56°C on a dry hot block then 
transferred to the Diasorin Liaison IXT platform for extraction. Extraction was 
performed as per manufacturer’s instructions. The program required 43 minutes from 
start to completion. Extracts were eluted into a 50μL volume.  
 
For nucleic extraction from BAL obtained from the Institut für Pathologie, Cologne, 
Germany the total nucleic extraction cartridge was utilised. This method was in line 
with the extraction method used by the collaborating centre, a Promega Maxwell total 
nucleic acid cartridge. The selection of cartridge type was to allow a fair comparison 
across centres. Nucleic acid was extracted directly from the BAL supernatant without 
prior processing and eluted into a 50μL volume.  
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8.2.5 PCP PCR For in vitro Diagnostic Use MycAssay Pneumocystis 
The MycAssay kit is separated into pouches, each pouch is sufficient to run 6 clinical 
samples, one positive and one negative control per run. Extraction was performed as 
per manufacturer’s instructions 
Reagent pouches were removed from the freezer and tubes 1 (master mix 1), 2 
(master mix 2) and 3 (negative control) removed from their respective storage 
packaging. Tube 4 (positive control) was left in the storage pouch until required. The 
reagents were allowed to thaw for 5 minutes and briefly vortexed then pulse 
centrifuged. Smart Cycler reaction tubes (individual reactions) were placed into chilled 
support racks. To each tube 7.5μL of tube 1 and 7.5μL of tube 2 were added. To the 
final tube in sequence 10μL of the negative control was added and sealed. The 
reaction tubes were transferred to the extraction room along with the positive control. 
Each clinical sample extract was added to a single reaction tube for the Smart Cycler 
PCR. Once all clinical samples were added the positive control pouch was unsealed, 
the positive control was lightly vortexed and pulse centrifuged. 10μL of the positive 
control was added to the second to last tube in sequence and sealed. The reaction 
tubes were centrifuged for 10 seconds using a microfuge. A visual check was 
performed to ensure that no bubbles were present in the reaction mixtures. The PCR 
was performed according to the manufacturers cycling condition; 95°C for 10 minutes 
flowed by 39 cycles of 95°C for 15 seconds, 57°C for 50 seconds and 72°C for 20 
seconds. A positive PCR was defined as a sigmoidal amplification curve with a cycle 
threshold value <35. 
8.2.6  BD MAX Primers and Probes 
The MSG primers amplify a 250-bp product from the target gene. The primer 
sequences (5’-3’) for the P. jirovecii PCR were as follows gene MSG: MSG-fw, GAA 
TGC AAA TCC TTA CAG ACA ACA G, and MSG-rv, AAA TCA TGA ACG AAA TAA 
CCA TTG C. For detection, a dual labelled hydrolysis probe was used as follows: MSG 
probe, FAM-AGA CAT CGA CAC ACA CAA GCA CGT CT-BHQ1. Primer and probe 
stock solutions were prepared at 100μmol and stored at -20°C. The sample process 
internal control is included in the BD MAX ExK DNA-2 kit (BD Diagnostics) and carries 
the Drosophila melanogaster scaffold protein gene (GenBank accession number 
AC246497.1) cloned in a pUC119 vector sequence (GenBank accession number 
U07650).  
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8.2.7 Preparation of BD MAX PCR reagents 
Primers and probes were purchased from Eurofins MWG Operon (Ebersberg, 
Germany). Primer and probe stock solutions were dissolved at 100µmol and stored at -
20°C. The P. jirovecii target gene MSG primer sequences were as follows (5’- 3’) MSG-
fw, GAA TGC AAA TCC TTA CAG ACA ACA G, and MSG-rv, AAA TCA TGA ACG 
AAA TAA CCA TTG C (A H Dalpke, Hofko and Zimmermann, 2013). The dually 
labelled hydrolysis probe sequence was as follows: MSG probe, FAM-AGA CAT CGA 
CAC ACA CAA GCA CGT CT-BHQ1. The internal control probe was TET or Texas 
Red-CTA GCA GCA CGC CAT AGT GAC TGG C-BHQ2. 
 
The probe/primer master mix was aliquoted at 12μL directly into conical snap-in tubes 
fitting the BD MAX extraction strip. A total of 200μL of the specimen was pipetted into 
the sample buffer tube (SBT) of the BD MAX ExK DNA-2 kit. The extraction was 
carried out following manufacturer’s instructions. The PCP PCR assay was performed 
with the instrument in research mode using default settings for the extraction and the 
following PCR cycling protocol: 95°C for 60 seconds and 45 cycles of 98°C for 8 
seconds and 58°C for 16.3 seconds. Fluorescence gains and thresholds were set for 
FAM (475/520nm). Quantitation was performed using a plasmid standard that was run 
once and saved as an external standard. For analysis in the PCR-only mode, 12μL of 
DNA or plasmid standard was added to the master mix and 12μL loaded manually into 
the PCR cartridge. 
 
8.2.8 Analytical sensitivity  
The analytical sensitivity of the workflows was determined by testing a tenfold dilution 
series of plasmid DNA of known concentrations from 106-10 copies/μL in 10μL aliquots. 
The plasmid dilutions were analysed through each stage of the PCR workflows as 
follows: 
 
1. Direct analysis through the PCR only. For the MycAssay Pneumocystis we 
were limited to processing three replicates due to the financial constraints of 
the study. For the BD MAX assay, as it was an in-house PCR, we were able to 
perform six replicates. 
2. Spiked into and extracted from TE buffer and analysed by PCR.  
3. Spiked into 1mL of BAL and extracted then analysed by PCR. For Diasorin 
Liaison IXT processing the pellet from the BAL was extracted using the DNA 
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cartridge and the remaining supernatant was extracted from using the total 
nucleic acid cartridge. For BD MAX processing the spiked BAL was inoculated 
directly into the extraction. 
 
To measure reproducibility around the end point detection limit the 103 copy/µL, 102 
copy/µL and 10 copies/µL were measured eight times by direct spiking into the PCR. 
8.2.9 Linearity 
To test the linearity of each PCR assay plasmid copies of 105 to 102 were analysed in 
triplicates through directly spiking the plasmid into the PCR reactions. 
 
8.2.10 Inter-assay repeatability 
To determine repeatability across different days of testing pooled P. jirovecii positive 
BAL in neat, 1:10 and 1:100 dilutions were processed three times on different days. 
The arithmetic mean (x), standard deviation (σ) and coefficient of variation (%CV) 
were calculated.  
 
8.2.11 Evaluation of PCR performance when applied to characterised clinical 
samples   
The performance of each PCR workflow was assessed though the analysis of samples 
from known PCP positive patients, obtained from an external laboratory at the Institute 
of Pathology, Hospital of the Private University Witten/Herdecke, Germany. The 
samples were anonymised at source and had been submitted for the investigation of 
fungal infection; redundant samples were retained under the umbrella of service 
development for which ethical consent was not required. The sample set contained 16 
DNA extracts from BAL samples with 16-paired aliquots of supernatant from the same 
BAL samples. 10μL of the extracts were processed directly into PCR reactions for the 
BD MAX and the MycAssay Pneumocystis PCR. Due to sample volume restrictions the 
BAL supernatants had to be divided with samples 1-8 spiked into the BD MAX sample 
extraction buffer and processed through the BD MAX PCP PCR and samples 9-16 
processed through the Diasorin Liaison IXT MycAssay Pneumocystis PCR workflow 
using the total nucleic acid extraction cartridges on the Diasorin LIAISON® Ixt.  
As an additional measure, where enough volume was available, 13 of the extracts 
were also sent to an external site at NPHS Microbiology (Cardiff Heath Park, Wales) for 
analysis using a 23 rRNA assay specific for P. jirovecii. 
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8.2.12 Evaluation of PCR performance when applied to prospective clinical 
samples   
Prospective analysis of BAL submitted to the Microbiology department was performed 
using the BD MAX and Diasorin LIAISON® Ixt/MycAssay Pneumocystis assays. 
Definitive PCP was diagnosed in the presence of a compatible clinical presentation of 
PCP, using the criteria below, and a positive Grocott’s stain in BALF. To classify acute 
PCP lung disease the following criteria, adapted from those reported by Mühlethaler 
and colleagues (Mühlethaler et al., 2012) 
1. Proven PCP was made in those patient s with microscopy positive BAL (i.e., the 
presence of P. jirovecii trophic forms or cysts detected by MGG).  
2. Possible PCP was diagnosed in deceased patients and/or patients having 
received an active drug against P. jirovecii for 5 days, if the following additional 
four elements were present: 1) compatibility of clinical signs (at least two 
symptoms: fever; dyspnoea; cough); 2) presence of hypoxia (arterial oxygen 
saturation, 93% and/or need for supplementary oxygen of 0.2L/min-1 and/or 
mechanical ventilation); 3) compatible radiological findings (interstitial pattern 
and/or ground glass opacities on computed tomography); and 4) 
immunosuppression.  
3. PCP was excluded in immunocompromised patients with acute lung disease 
compatible with PCP but have good outcome despite not receiving specific P. 
jirovecii therapy. 
 
8.2.13 Statistical analysis  
Linear regression was performed using Prism software, which calculated a correlation 
coefficient for the standard curve generated. The efficiency (E) of PCR is defined as 
the fraction of target molecules that are copied in one PCR cycle. Amplification 
efficiency (E) of the PCR was calculated from the slope of the standard curve obtained 
through processing plasmid dilutions using the following formula. 
E = 10(-1/slope)-1. 
It is possible to have efficiency >100% which most likely reflects the presence of PCR 
inhibitors or an excess in concentrated total nucleic acid within the sample.   
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8.3 Results 
8.3.1 Analytical sensitivity and PCR efficiency 
Analysis of known plasmid concentrations added directly to each PCR in replicates 
demonstrated 100% (3/3) reproducibility for the detection of the MitLSU target using 
the MycAssay Pneumocystis at 100 copies per reaction and 100% (6/6) reproducibility 
for the detection of the MSG target using BD MAX assay at 20 copies per reaction 
(table 8.2). Linear regression analysis, figures 8.2 and 8.3, of CT values obtained 
across the respective analyses demonstrated significant positive correlation 
coefficients for the MycAssay Pneumocystis (r=0.99) figure 8.2, and BD MAX PCP 
assays (r=0.99) figure 8.3. The median differences in CT values across tenfold 
dilutions of the target gene were 3.2 (range 3.5-2.8) for the MycAssay Pneumocystis 
and 2.8 (range 3.1-2.6) for the BD MAX PCP assay. PCR efficiency was calculated to 
be 97.2% for the MycAssay Pneumocystis and 100.5% for the BD MAX PCP PCR.  
Table 8.2 Mean CT values and SD for replicates (n=3) of plasmid dilutions 
spiked directly into MycAssay Pneumocystis PCR and the BD MAX P. 
jirovecii PCR 
c/mL Reproducibility ẋ Σ 
MycAssay Pneumocystis 
1E+8 100% (3/3) 22.1 0.29 
1E+7 100% (3/3) 25.3 0.30 
1E+6 100% (3/3) 28.5 0.28 
1E+5 100% (3/3) 32 0.32 
1E+4 100% (3/3) 34.8 0.40 
1E+3 66.6% (2/3) 36.5 1.63 
 BD MAX P. jirovecii PCR 
5E+8 100% (6/6) 17.2 0.33 
5E+7 100% (6/6) 20 0.26 
5E+6 100% (6/6) 23.1 0.27 
5E+5 100% (6/6) 26.1 0.48 
5E+4 100% (6/6) 28.4 0.57 
5E+3 100% (6/6) 31 0.75 
5E+2 ND - - 
 
When comparing CT values across the two PCR assays, measuring the same log 
concentration of plasmid, a significant difference was observed showing the MycAssay 
Pneumocystis has significantly lower CT values compared with the BD MAX PCR. The 
median CT value was 30.25 (IQR 24.5, 19.3) for the MycAssay and 24.6 (IQR 19.3, 
29.1) for the BD MAX.   
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Figure 8.2 Linear regression of CT values for plasmid dilutions processed through the MycAssay 
Pneumocystis PCR. 
 
Figure 8.3 Linear regression of CT values for plasmid dilutions processed through the BD MAX 
P. jirovecii PCR. 
 
8.3.2 Reproducibility at the limit of detection (LOD) 
Replicate testing at the end point of detection demonstrated 100% reproducibility at the 
lowest input of 20 targets per reaction for the BD MAX PCP assay. The MycAssay 
Pneumocystis demonstrated 100% reproducibility at 1000 copies per reaction and 75% 
(6/8) reproducibility at 100 copies per reaction, table 8.3.  
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8.3.3 Analytical sensitivity of the complete workflows for Diasorin Liaison 
IXT/MycAssay Pneumocystis and BD MAX PCP 
Table 8.4 presents CT values obtained from plasmid dilutions extracted through each 
PCR workflow. When extracted on the Diasorin Liaison IXT plasmid target DNA was 
detected with 100% reproducibility using the MycAssay Pneumocystis PCR at an input 
of 100 copies. Target DNA was undetected at an input of 10 copies per sample. When 
plasmid target DNA was extracted on the BD MAX platform 100% reproducibility was 
observed with a total input of 2000 target copies, which decreased to 66.6% 
reproducibility (2/3) for a total input of 200 target copies.  
 
 
Table 8.4 Mean CT values and SD for replicates of plasmid dilutions processed 
through the BD MAX PCP workflow and the Diasorin Liaison IXT/MycAssay 
Pneumocystis 
Input 
Expected 
tC/rxn 
Reproducibility ẋ Cq Σ 
MycAssay Pneumocystis 
1E+6 2E+5 100% (3/3) 25.6 0.62 
1E+5 2E+4 100% (3/3) 28.7 0.56 
1E+4 2E+3 100% (3/3) 31.27 0.25 
1E+3 2E+2 100% (3/3) 34.37 0.84 
1E+2 20 100% (3/3) 37.37 0.35 
10 2 0% (0/3) - - 
 BD MAX P. jirovecii PCR 
2E+6 1.97E+5 100% (3/3) 21.4 0.72 
2E+5 1.97E+4 100% (3/3) 23.8 0.25 
2E+4 1.97E+3 100% (3/3) 26.9 0.23 
2E+3 1.97E+2 100% (3/3) 30.2 0.29 
200 19.7 66.7 (2/3) 32.8 0.42 
 
Table 8.3 Analytical sensitivity of the BD MAX and MycAssay Pneumocystis PCR 
around the end point detection limit measured using plasmid control dilutions 
 BD MAX PCR MycAssay Pneumocystis 
2E+3 2E+2 20 1E+4 1E+3 1E+2 
100% 8/8 100% 8/8 100% 8/8 100% 8/8 100% 8/8 87.5% 6/8 
26.1 28.4 31 28.7 31.5 34.35 
 181 
8.3.4 Analytical precision  
Tables 8.5 and 8.6 detail CT values and calculated copies/mL for the respective 
conversion into cells/mL obtained from the analysis of a positive BAL serially diluted 
and tested on three different days through both workflows. %CV demonstrates that the 
two assays have a similar degree of variance across measurements from the same 
samples at the three dilutions tested. Quantification of P. jirovecii from the serially 
diluted BAL was linear in concordance with the tenfold dilutions prepared from the 
sample.  
The measured copies per/ml was an average of 7.3 fold (6.3-8.42) higher through the 
IXT/MycAssay workflow compared with the BD MAX workflow. When normalized into 
cells/mL both assays quantified the P. jirovecii burden in the dilutions at the same 
log10 quantities.  
 
8.3.5 Clinical verification - analysis of samples from cases of PCP 
In the first stage of the clinical verification process known positive samples donated by 
HPUW were analysed.  
 
8.3.6 Analysis of DNA extracts 
Concordance between the MycAssay Pneumocystis PCR and the qualitative results 
reported by HPUW from DNA extracts was 87.5% (14/16), table 8.7. The qPCR results, 
measuring copy numbers of target in the specimen, obtained by MycAssay 
Pneumocystis reported significantly lower number of target copy (p<0.01), on average 
2.25x103 fold target copies lower (range 6.6 – 1x104 fold lower), compared with HPUW 
Table 8.5 Mean CT values for dilutions of pooled P. jirovecii positive BAL 
processed through the BD MAX PCP and the Diasorin Liaison IXT/MycAssay 
Pneumocystis workflows on three different days 
Dilution Day 1 Day 2 Day 3 ẋ Σ 
MycAssay Pneumocystis 
Neat 20.6 21.2 20.9 20.5 0.96 
1/10 23.1 24.3 24.1 23.8 0.64 
1/100 26.3 27.2 27.5 27 0.62 
 BD MAX P. jirovecii PCR 
Neat 19.1 18 19.4 18.8 0.74 
1/10 21.3 20.9 21.6 21.3 0.35 
1/100 23.6 24.1 24.5 24.1 0.45 
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qPCR results for DNA extracts, table 8.7 and figure 8.4. Two samples testing negative 
by MycAssay Pneumocystis PCR, were reported to contain 8.14x106 and 8.9x106 
copies/mL by HPUW. 
Concordance between the BD MAX PCP and the qualitative results reported by HPUW 
from DNA extracts was 31.3% (5/16). Significantly lower target copies (p<0.01) were 
detected using the BD MAX P. jirovecii PCR, on average 5.7x103 fold lower (range 8 - 
1.1x104 fold), compared with HPUW qPCR results. P. jirovecii was not detected from 
68.7% (11/16) of the extracts by the BD MAX PCP PCR despite the respective extracts 
measuring positive by HPUW ranging from 1.28x107 to 7.32x1011 copies/mL as 
determined by the referring laboratory. When comparing qPCR results for the BD MAX 
IXT/MycAssay Pneumocystis workflow and converting into representative cells/mL both 
the BD MAX PCR and the MycAssay Pneumocystis demonstrated 80% (4/5) 
agreement for samples 1, 10 and 11 (table 8.7) when measuring the burden of P. 
jirovecii in extracts in the same Log10 concentrations. Measured cells/mL in sample 3 
was discrepant measuring tenfold less by BD MAX PCR at 4.2x105 compared with 
1.31x106-1.3x107 through the MycAssay Pneumocystis PCR, table 8.7).   
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4 CT values obtained across the three methods processing DNA extracts from patients 
with proven PCP. 
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Due to significantly different qPCR results observed between qPCR result from HPUW and the 
two PCRs in this study DNA extracts were referred to a third external laboratory, Bristol, for 
23S rRNA region (mtLSUrRNA) qualitative PCR, which is the same target as the MycAssay 
Pneumocystis. Figure 8.5 demonstrates CT values obtained with the MycAssay and the 23S 
assay. No significant difference (p0.69) was observed between the CT values obtained by these 
two assays, with a median CT of 34.5 (IQR: 27.2, 35.7) by 23S PCR and 33.3 (IQR: 27.2, 35.7) by 
MycAssay Pneumocystis.  
 
 
 
 
 
 
 
 
Figure 8.5 Comparison of CT values obtained from MycAssay and Bristol 23S PCR from DNA 
extracts. 
 
Table 8.6 Quantitation analysis of copies per ml for dilutions of pooled P. 
jirovecii positive BAL processed through the BD MAX PCP and the Diasorin 
Liaison IXT/MycAssay Pneumocystis workflows on three different days 
Dilution Day 1 Day 2 Day 3 ẋ Σ CV Cells/mL 
ẋ fold 
chang
e 
MycAssay Pneumocystis   
Neat 4.2E+8 2.6E+8 3.3E+8 3.34E+8 7.7E+7 0.23 7.7 E+6 1.4 
1/10 6E+7 2.4E+7 2.8E+7 3.7E+7 1.9E+7 0.53 3.7 E+5 2.3 
1/100 5.0E+6 2.5E+6 2.0E+6 3.2E+6 1.6E+6 0.51 3.2 E+4 2.3 
 BD MAX P. jirovecii PCR   
Neat 6.6E+7 4.0E+7 5.2E+7 5.3E+7 1.3E+7 0.24 5.3E+5 1.5 
1/10 8.5E+6 3.2E+6 3.7E+6 5.1E+6 2.9E+6 0.57 5.1E+4 2.5 
1/100 6.1E+5 2.9E+5 2.3E+5 3.8E+5 2.1E+5 0.54 3.8E+3 2.4 
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8.3.7 BAL supernatants 
When analysing BAL samples through the complete assay workflow including DNA 
extraction 87.5% (7/8) qualitative agreement was observed between the MycAssay 
Pneumocystis and HPUW, table 8.8. The IXT/MycAssay Pneumocystis workflow failed 
to detect P. jirovecii in a single BAL supernatant that had measured positive at 2.1x106 
copies/mL by HPUW. The remaining seven BAL supernatant samples all measured 
positive but the quantified target again measured significantly lower through the 
IXT/MycAssay workflow (p<0.05) with an average fold difference of 5.1x103 (9.3x10-
1.7x104 fold lower) compared with the referring laboratory results. When comparing 
qPCR results from extracted BAL supernatant with the original DNA extract results an 
average five-fold (range 1.2-9.4 fold) reduction in the P. jirovecii burden was measured, 
table 8.8. 
The BD MAX PCP demonstrated 50% (4/8) qualitative agreement with HPUW, table 
8.8. The BD MAX workflow measured 50% (4/8) of the BAL supernatant samples as 
negative with quantified target ranging between 9.68x105 - 1.5x108 copies/mL by 
HPUW. The remaining 50% (4/4) measured as positive by the BD MAX workflow, but 
again the quantified target was significantly lower, average 3.33 x103 fold (range 
1.35x10-1.33x106 fold) compared with the quantification results supplied by the 
referring laboratory, table 8.8. Only two BAL samples, 1 and 3, measured positive that 
had positive results from the DNA extracts processed via PCR.  
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Table 8.7 Results for BAL DNA extracts from known P. jirovecii positive tested by Institute of Pathology, Hospital of the Private 
University Witten/Herdecke, Germany then processed through the MycAssay PCR, BD MAX PCP PCR and Bristol 23S PCR 
 
HPUW MycAssay MitLSU  BD MAX  
Bristol 
23S 
Sample c/mL cells/ml CT c/mL cells/mL 
Fold 
difference$ 
CT c/mL Cells/mL 
Fold 
difference$ 
CT 
  100-1000 copies   100-1000 copies 
 
  
Single 
copy 
  
1 7.32E+11 7.32E+08 7.32E+09 21.1 2.80E+08 2.80E+05 2.80E+06 2.61E+03 20.6 3.0E+07 3.0E+05 2.44E+04 NT 
2 8.90E+06 8.90E+03 8.90E+04 ND - - - - ND - - - ND 
3 8.70E+09 8.70E+06 8.70E+07 19.1 1.31E+09 1.31E+06 1.31E+07 6.6 20.3 4.20E+07 4.2E+05 2.07E+02 18.8 
4 1.60E+05 1.60E+02 1.60E+03 34.8 6.90E+03 6.90E+00 6.90E+01 23.2 ND - - - 35.1 
5 2.00E+06 2.00E+03 2.00E+04 34.8 6.90E+03 6.90E+00 6.90E+01 2.90E+02 ND - - - 35.7 
6 9.68E+05 9.68E+02 9.68E+03 34.4 9.40E+03 9.40E+00 9.40E+01 1.03E+02 ND - - - 36.8 
7 1.50E+08 1.50E+05 1.50E+06 32.1 5.60E+04 5.60E+01 5.60E+02 2.68E+03 ND - - - 30.1 
8 2.90E+06 2.90E+03 2.90E+04 38.9 2.90E+02 2.90E-01 2.90E+00 1.00E+04 ND - - - 39.2 
9 1.30E+08 1.30E+05 1.30E+06 27.5 1.90E+06 1.90E+03 1.90E+04 68.4 ND - - - 24.2 
10 1.28E+07 1.28E+04 1.28E+05 26.4 4.60E+06 4.60E+03 4.60E+04 2.7 25.1 8.1E+05 8.1E+03 15.8 27.3 
11 4.70E+08 4.70E+05 4.70E+06 29.4 4.50E+05 4.50E+02 4.50E+03 1.04E+03 29.4 2.3E+04 2.3E+2 2.04E+04 30.2 
12 2.90E+06 2.90E+03 2.90E+04 39 2.60E+02 2.60E-01 2.60E+00 1.12E+04 ND - - - 38.9 
13 8.14E+06 8.14E+03 8.14E+04 ND - - - - ND - - - ND 
14 1.00E+09 1.00E+06 1.00E+07 28.4 9.80E+05 9.80E+02 9.80E+03 1.02E+03 28.1 7.1E+04 7.1E+2 1.41E+04 29.3 
15 1.90E+06 1.90E+03 1.90E+04 35.8 3.10E+03 3.10E+00 3.10E+01 6.13E+02 ND - -  NT 
16 7.00E+06 7.00E+03 7.00E+04 35.6 3.70E+03 3.70E+00 3.70E+01 1.89E+03 ND - -  34.7 
  
 
 
87.5% (14/16) 87.5% (7/8) 
 85.7% 
(12/14) 
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Table 8.8 Results for BAL from known P. jirovecii positive tested by Institute of Pathology, Hospital of the Private University 
Witten/Herdecke, Germany then processed through the IXT/MycAssay and BD MAX PCP PCR complete workflow including extraction 
 HPUW MycAssay MitLSU  BD MAX 
Patient c/mL cells/mL CT c/mL cells/mL 
Fold 
difference$ 
CT c/mL Cells/mL 
Fold 
difference$ 
1 7.32E+11 7.32E+08 7.32E+09 NT NT - -  26.4 3.2E+05 3.2E+03 2.29E+05 
2 8.90E+06 8.90E+03 8.90E+04 NT NT - -  26.2 3.1E+05 3.1E+03 2.87E+00 
3 8.70E+09 8.70E+06 8.70E+07 NT NT - -  22 1.00E+07 1.0E+05 8.70E+01 
4 1.60E+05 1.60E+02 1.60E+03 NT NT - -  32.4 2.00E+03 2.0E+01 8.00E+00 
5 2.00E+06 2.00E+03 2.00E+04 NT NT - -  ND - -  
6 9.68E+05 9.68E+02 9.68E+03 NT NT - -  ND - -  
7 1.50E+08 1.50E+05 1.50E+06 NT NT - -  ND - -  
8 2.90E+06 2.90E+03 2.90E+04 NT NT - -  ND - -  
9 1.30E+08 1.30E+05 1.30E+06 27.9 1.40E+06 1.40E+03 1.40E+04 9.29E+01 NT NT -  
10 1.28E+07 1.28E+04 1.28E+05 29 6.10E+05 6.10E+02 6.10E+03 2.10E+01 NT NT -  
11 4.70E+08 4.70E+05 4.70E+06 31.1 1.20E+05 1.20E+02 1.20E+03 3.92E+03 NT NT -  
12 2.90E+06 2.90E+03 2.90E+04 0 - - -  NT NT -  
13 8.14E+06 8.14E+03 8.14E+04 38.2 4.90E+02 4.90E-01 4.90E+00 1.66E+04 NT NT -  
14 1.00E+09 1.00E+06 1.00E+07 30.9 1.40E+05 1.40E+02 1.40E+03 7.14E+03 NT NT -  
15 1.90E+06 1.90E+03 1.90E+04 38.7 3.30E+02 3.30E-01 3.30E+00 5.76E+03 NT NT -  
16 7.00E+06 7.00E+03 7.00E+04 35.8 3.20E+03 3.20E+00 3.20E+01 2.19E+03 NT NT -  
Total  87.5% (7/8) 50% (4/8) 
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8.3.8 Prospective clinical verification of PCP PCR 
8.3.8.1 Patient demographics  
Table 8.9 and 8.10 detail the patient demographic characteristics for the overall patient 
population. When comparing gender, the ratio of males to females was higher in the 
PCP group. Not surprisingly, oxygen saturation was lower in the PCP group compared 
with the control group. Of note, oxygen saturation data was only available for seven 
patients in the control arm. Only two patients received anti-PCP therapy in the control 
group and only one patient had radiological findings consistent with PCP in the control 
arm but did not receive anti-PCP therapy during the episode around BAL sampling. 
Table 8.9. Patient demographics for BAL samples taken from 54 patients 
tested prospectively through two automated P. jirovecii PCR workflows; 
IXT/MycAssay Pneumocystis and BD MAX PCP PCR 
 Cases Controls 
Demographic % n % n 
% Male 80  4  63.2  31 
Median age 50   56   
Median O2% 88.5  95.3
  
% Radiological evidence  100 5 2 1 
% Anti-PCP therapeutic 100  5 4 2 
 
Table 8.10 Underlying immunosuppressive conditions for 54 patients 
tested prospectively through two automated P. jirovecii PCR workflows; 
IXT/MycAssay Pneumocystis and BD MAX PCP PCR 
Underlying immunosuppressive condition % n 
Haemato-oncology 20.4 11 
HIV (human immune deficiency virus) 16.7  9 
GVHD (graft versus host disease) 5.6  3 
Renal Transplant 9.3  5 
Tuberculosis 12.9  7 
High dose steroids 5.6  3 
Liver Transplant 3.7  2 
Other* 25.9 14 
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8.3.8.2 Clinical samples 
In total, 57 BAL samples from 54 patients were analysed prospectively by both P. 
jirovecii PCR workflows. Three samples were submitted from a second BAL taken from 
three of the patients more than two weeks apart, so were included as independent 
samples.  
When tested by the IXT/MycAssay workflow 10.5% (6/57) samples were positive, 
80.7% (46/57) of samples were negative and 8.8% of samples were inhibited (5/57). 
When tested by the BD MAX workflow 7% (4/57) of samples were positive, 84.2% 
(48.57) of samples were negative and 5.3% (3/57) of samples were inhibited. 
 
8.3.8.3 Classification of patients: Proven, Probable and control  
According to the clinical criteria, detailed in section 8.2.12, for defining PCP infection 
3.7% (2/54) of the patients were classified as probable PCP infection, 5.6% (3/54) as 
proven infection table 8.11. The remaining 90.7% (49/54) patients were classified as 
having no evidence of PCP infection.  
Proven infection: Two patients were defined as having proven infection through the 
positivity of Grocott’s staining on BAL samples positive for Pneumocystis. Patient 1 
was an AML patient with radiology suggestive of PCP, who received anti-PCP therapy 
and had an oxygen saturation of 92% at the time of presentation, table 8.11. The 
measured load of P. jirovecii in the BAL processed for PCR was 1.5-15 cells per mL by 
IXT/MycAssay but was not detected by the BD MAX workflow.  
Patient 2 was an HIV patient presenting with hypoxia, with ground glass changes on 
CT, and who had received anti-PCP therapy. The measured P. jirovecii burden in BAL 
was 3.5 E+05-E+06 by IXT/MycAssay and 7.1 E+05 by the BD MAX workflow table 
8.11.  
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Probable infection: All patients with probable PCP received cotrimoxazole treatment 
around the time of the BAL sampling and all had ground glass opacification consistent 
with PCP infection noted on their radiological reports. All had hypoxia at the time of 
presentation noted in clinical records; oxygen saturation readings were available for 2 
of the three patients as detailed in table 8.11.  
 Patient 3, a renal transplant patient, had a measured burden of 2.3 E+03 – 2.3 
E+04 P. jirovecii cells/mL by IXT/MycAssay Pneumocystis and 1.1 E+05 by BD 
MAX. 
 Patient 4, an HIV patient, had a measured burden of 1.3E+04 – 1.3 E+05 P. 
jirovecii cells/mL by IXT/MycAssay Pneumocystis and 6.2 E+02 by BD MAX. 
 Patient 5, receiving high dose corticosteroids for an underlying condition, had a 
measured burden between 28 - 280 P. jirovecii cells/mL by IXT/MycAssay 
Pneumocystis but no cells were detected by BD MAX. 
 
 
No evidence of PCP infection; The final positive PCR result was measured in patient 
6 who presented with atypical changes on radiology and was not considered to be at 
risk of PCP. Underlying immunosuppression was the administration of high dose 
corticosteroids. No anti-PCP therapy was administered to this patient and P. jirovecii 
microscopy was not requested. The measured burden of P. jirovecii cells/mL by 
IXT/MycAssay Pneumocystis was 8.2 E+04-8.2 E+05 and was 3.4 E+05 by BD MAX, 
table 8.11. 
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GGO= ground glass opacification, O2 = oxygen saturation 
 
 
 
Table 8.11 Summary of clinical criteria and PCP definitions for six patients with positive P. jirovecii PCR results from BAL 
Patient Sex Classification Age O2% Radiology Anti-PCP therapy Immune-suppression Grocott’s IXT/MycAssay  BD MAX 
1 M Proven 56 91 GGO 
Cotrimoxazole 
Pentamidine 
Acute Myeloid 
Leukemia 
Positive 1.5-15 ND 
2 M Proven 30 92 GGO Cotrimoxazole HIV infection Positive 3.5 E+05-3.5E+06 7.1 E+05 
3 M Probable 54 91 GGO Cotrimoxazole Renal Transplant Negative 2.3E+03-2.3E+04 6.2 E+02 
4 M Probable 56 80 GGO Cotrimoxazole HIV infection Negative 1.3 E+04-1.3 E+05 1.1 E+04 
5 F Probable 58 ND* GGO Cotrimoxazole High dose corticosteroids Negative 28-280 ND 
6 M Control 72 ND Atypical changes No High dose corticosteroids ND 8.2 E+04 -2 E+05 3.4 E+05 
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8.3.8.4 Performance of PCP PCR compared with clinical diagnosis as the 
gold standard 
The IXT/MycAssay Pneumocystis workflow demonstrated a sensitivity and NPV of 
100% (5/5, 95% CI: 56.6, 100) and 100% (46/46, 95% CI: 92.3, 100) respectively. 
Specificity was 97.9% (46/47, 95% CI: 88.9, 99.6) and PPV was 83.3% (5/6, 95% CI: 
43.7, 97). Diagnostic accuracy was 98.1% (51/52, 95% CI: 89.9, 99.7) with clinical 
diagnosis as the gold standard; a single false positive result was observed detailed in 
table 8.12. This patient was on high dose corticosteroids and had atypical pneumonia 
on radiology but was not suspected to have PCP, oxygen saturation was unavailable 
and the patient did not receive anti-PCP therapy.   
The BD MAX PCP PCR workflow demonstrated a sensitivity of 60% (3/5, 95% CI: 23.1, 
88.2) and PPV of 75% (3/4, 95% CI: 30, 95.4) and a specificity and negative predictive 
value of 98% (48/49, 95% CI: 89.3, 99.6) and 96% (48/50, 86.5, 98.9) respectively. 
94.4% (51/54, 95% CI: 84.9, 98.1) agreement was achieved with clinical diagnosis as 
the gold standard. The same false positive was detected as with the IXT/MycAssay 
Pneumocystis workflow. Two false negative results were recorded, one in a proven 
case of PCP and one in a probable case of PCP, table 8.12 
 
8.3.8.5 Performance of PCP PCR compared with microscopy as the gold 
standard 
The IXT/MycAssay Pneumocystis workflow demonstrated a sensitivity and NPV of 
100% (2/2, 95% CI: 32.2, 100) and 100% (46/46, 95% CI: 92.3, 100) respectively when 
compared with microscopy. Specificity was 92% (46/50, 81.2, 996.9) and PPV was 
33.3% (2/6, 95% CI: 9.7, 70). Less agreement was achieved with microscopy 
compared to clinical diagnosis 92.3% (48/52, 95% CI: 81.3, 97) Table 8.11. Four false 
positives were observed in three patients with probable infection and one control 
patient detailed in table 8.12. 
The BD MAX PCP PCR workflow demonstrated a sensitivity of 50% (1/2, 95% CI: 9.5, 
90.6) and PPV of 25% (1/4, 95% CI: 4.6, 70) and specificity and negative predictive 
value of 94.2% (49/52, 84.4, 98) and 98% (49/50, 95% CI: 89.5, 99.7) respectively, 
table 8.11. With clinical diagnosis as the gold standard 92.6% (50/54, 95% CI: 82.5, 
97.1) agreement was achieved. Three false positive results were observed, all in 
probable cases of PCP. One false negative result occurred in a microscopy positive 
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proven case of PCP, from which a high CT of 33 was measured by the IXT/MycAssay 
Pneumocystis workflow.  
 
Table 8.12 Performance characteristics of the IXT/MycAssay Pneumocystis and 
BD MAX PCP PCR from clinical specimens when measured against clinically 
defined proven/probable PCP infection and microscopy as gold standards 
 IXT/MycAssay   BD MAX PCP 
 Clinical diagnosis 
 Positive Negative  Positive Negative 
Positive 5 1  3 1 
Negative 0 46  2 48 
 
Accuracy 98.1% 89.9, 99.7  94.4% 84.9, 98.1 
Sensitivity 100% 56.6, 100  60% 23.1, 88.2 
Specificity 97.9% 88.9, 99.6  98 89.3 99.6 
PPV 83.3% 43.7, 97  75 30, 95.4 
NPV 100% 92.3, 100  96 86,5, 98.9 
 
 Microscopy 
 Positive Negative  Positive Negative 
Positive 2 4  1 3 
Negative 0 46  1 49 
 
Accuracy 92 81.8 97  92.6 82.5, 97.1 
Sensitivity 100 32.2, 100  50 9.5, 90.6 
Specificity 92 81.2, 96.9  94.2 84.4, 98 
PPV 33.3 9.7, 70  25 4.6, 70 
NPV 100 92.3, 100  98 89.5, 99.7 
 
 
8.4 Discussion 
The aim of this chapter was to evaluate automated DNA extraction alongside PCR for 
the diagnosis of PCP. Two workflows were investigated. The first was a stand-alone 
automated DNA extraction platform, the IXT, alongside a commercially available 
MycAssay Pneumocystis PCR. The second workflow was a closed system automated 
platform, BD MAX, performing both DNA extraction and PCR on board in a continuous 
workflow. This study has demonstrated that both IXT/MycAssay Pneumocystis had a 
very high specificity and NPV of 97.9 (955 CI: 88.9, 99.6) and 100 (95% CI: 56.6, 100) 
and the BD MAX PCR had a high specificity and NPV of 98% (95% CI: 89.3 99.6) and 
96% (95% CI: 86.5, 98.9) for the exclusion of Pneumocystis pneumonia when 
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compared with clinical diagnosis as the gold standard. The sensitivity and PPV of the 
IXT/MycAssay workflow at 100% (95% CI: 34.2, 100) and 83.3% (95% CI: 43.7, 97) 
was superior to the BD MAX PCR in this study 60% (95% CI: 23.1, 88.2) and 75% 
(95% CI: 30, 95.4). Several studies utilising MycAssay Pneumocystis have supported 
these findings with high NPV ranging between 99-100% and sensitivities ranging 
between 93-100% (Hauser et al., 2011; McTaggart, Wengenack and Richardson, 
2012; Orsi et al., 2012; Seah et al., 2012b). However, the reported specificity and PPV 
across these studies varies considerably ranging between 79.1-100% and 33.3-80% 
respectively (Hauser et al., 2011; McTaggart, Wengenack and Richardson, 2012; Orsi 
et al., 2012; Seah et al., 2012b). There are several contributing factors affecting 
specificity and PPV when using PCR to diagnose PCP.  
 
8.4.1 Verification of the analytical performance of P. jirovecii PCR 
In this study the linearity, sensitivity and the precision (inter and intra assay 
reproducibility) of both PCR workflows were investigated. A high degree of linearity 
was observed across serial dilution of plasmids processed through both assays 
indicating accuracy at the upper and lower detection limits of both assays. The 
calculated PCR efficiencies for both PCR’s were not significantly different, 100% vs 
97.2% for the Myconostica vs the BD MAX respectively. Furthermore both assays 
demonstrated excellent intra and inter-assay reproducibility however, differences in 
performance were observed when assessing the analytical LOD of each PCR the 
MycAssay. 
The MycAssay Pneumocystis PCR was 10-100 fold less sensitive than the BD MAX 
PCP PCR which was reproducibly positive at 20 plasmid copies input, which is similar 
to previous published sensitivities using this assay (Alexander H. Dalpke, Hofko and 
Zimmermann, 2013). In table 8.2 average CT values obtained from the two PCRs 
demonstrate that the BD MAX has earlier CT values compared with the Myconostica 
assay, at 106 copies CT values were 25.3 for the MycAssay v’s 20for the BD MAX. At 
the 103 concentrations the MycAssay CT was 37 reaching the end point of the assay. A 
ten-fold lower plasmid concentration would have had a CT value exceeding the set 
cycling conditions of 40 cycles and was therefore undetected. The differences in PCR 
performance may be a result of the mechanical hardware or the molecular design of 
PCR primers and probes (Reynisson et al., 2006; Buh Gašparič et al., 2010; Navarro et 
al., 2015). 
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The detection system within the hardware of the BD MAX and the Smartcycler used for 
MycAssay are proprietary so comparisons cannot be made but there are some obvious 
differences between the two systems that may contribute to variance in performance. 
The BD MAX system utilizes a microfluidic chamber that performs a PCR from a 
reaction volume of 4µL, (diagram 8.6.b). The Smart cycler PCR tubes contain the 
reaction in a thin window; at 5-6 times the surface area of the BD MAX chamber 
therefore the reaction is spread over a wider surface. The thermal block on the smart 
cycler is also situated underneath the tube compartment rather than in direct contact 
with the reaction window of the tube as with the BD MAX, diagram 8.6.a. The 
differences in the design of the PCR systems could have contributed to the decreased 
sensitivity of the MycAssay when amplifying plasmid copies figure 8.6.a. The 
significance of the difference in PCR sensitivity is normalised through the choice of 
target amplified in each assay. The MycAssay targets the MitLSU, a multicopy target at 
100-1000 copies per cell (as specified by the manufacturer). The BD MAX system 
detects the major surface glycoprotein (MSG) a single copy gene within each cell 
therefore increased sensitivity is required (Alexander H. Dalpke, Hofko and 
Zimmermann, 2013).  
The rate of inhibition on the SmartCycler platform was higher, 8% (7/43) than the 4.7% 
seen using the BD MAX PCR. Chemistry of the Myconostica PCR master mix may 
have impacted on performance of the assays. The BD MAX utilizes a hydrolysis 
TaqMan whereas the Myconostica P. jirovecii utilizes a hairpin molecular beacon. A 
previous study have described comparable results using either probe design (Buh 
Gašparič et al., 2010) providing optimization is performed especially in the instance of 
molecular beacons (Buh Gašparič et al., 2010). A comparative study observed the 
lowest efficiency using the molecular beacon design compared with other probes and it 
was stated that this probe design was more sensitive to changes in the PCR reaction, 
such as inhibitors (Andersen et al., 2006). Freeze thawing the extracts led to a 
reduction in inhibition (due to the known detrimental effect freeze thawing has on an 
residual protein/enzymatic material in the extracts) and could be added to the workflow 
ahead of performing the PCR, but would lead to an extension of the turnaround time, 
which is not desirable considering the extended extraction process of almost 4 hours 
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a)  
b)  
Diagram 8.6 a) design of the smart cycler unit demonstrating the position of the thermal heating 
block b) a BD MAX cartridge demonstrating the cylindrical reaction chambers that hold the 4μL 
reaction.  
 
Plasmid dilutions processed from extraction to PCR allowed the impact of DNA 
extraction on sensitivity of the workflow to be assessed. In contrast to the findings of 
direct PCR analysis, the BD MAX workflow was ten-fold less sensitive than the 
IXT/MycAssay workflow, which includes the extraction component, with an LOD of 
approximately 103 copies per mL compared to 102 for the IXT/MycAssay workflow. 
Dalpke and colleagues observed the same sensitivity using the BD MAX PCR workflow 
with 100% detection at 103 c/mL versus 33% detection at 102 c/mL (Alexander H. 
Dalpke, Hofko and Zimmermann, 2013). The loss in analytical sensitivity when 
processing samples through the entire workflow using the BD MAX is most likely a 
result of the analytical steps built into the extraction process on the BD MAX. Figure 
8.7 details the pipetting steps included in each PCR workflow, highlighted are the steps 
contributing to a dilution effect on the final target extracted from the sample. When 
extracted through the BD MAX system at best only 10% of the target DNA extracted 
from the sample will be transferred to the reaction, compared with 20% using the 
IXT/Myconostica workflow.  
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Figure 8.7. Pipetting workflow for the BD MAX PCP PCR and IXT/Myconostica. 
 
This study clearly demonstrates that when evaluating the performance of PCR for 
diagnostic purposes it is important to evaluate each component of the workflow so that 
it is possible to understand the limitations of each stage of the process. Despite the BD 
MAX PCR being highly sensitive the loss of target through the extraction makes it the 
less sensitive workflow analytically. This is an important factor to consider when 
analysing clinical specimens, so that one can rationalize when difference in 
performance observed from clinical samples. Differences in PCR performance were 
observed when processing extracts from clinical samples and BAL supernatant from 
known positive patients. DNA extracts.  
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8.4.2 Clinical performance of PCP PCR 
This study has demonstrated that both IXT/MycAssay Pneumocystis and the BD MAX 
PCR could be used with confidence for the exclusion of Pneumocystis pneumonia with 
high NPV and sensitivity. Several studies utilising MycAssay Pneumocystis have 
supported these findings with high NPV ranging between 99-100% and sensitivities 
ranging between 93-100% (Hauser et al., 2011; McTaggart, Wengenack and 
Richardson, 2012; Orsi et al., 2012; Seah et al., 2012b).  
The sensitivity and PPV in this study was 100% (CI: 56.6, 100) and 83.3% (43.7, 97) 
for the MycAssay Pneumocystis and for the BD MAX PCP PCR was 60% (23.1, 88.2) 
and 75% (30, 95.4) when compared against clinical diagnosis of proven or probable 
disease as the gold standard. Our study was limited in that only two specimens from 
proven cases of PCP were included, and three cases of probable disease. Reported 
specificity and PPV across studies utilising PCP PCR varies considerably ranging 
between 79.1-100% and 33.3-80% respectively (Hauser et al., 2011; McTaggart, 
Wengenack and Richardson, 2012; Orsi et al., 2012; Seah et al., 2012b). There are 
several contributing factors affecting specificity and PPV when using PCR to diagnose 
PCP. The burden of P. jirovecii in colonisation is poorly defined and may be transient 
with human-to-human transmission occurring (Gigliotti and Wright, 2012). An autopsy 
study using a nested PCR from lung tissue samples reported 64.9% of adults had 
detectable P. jirovecii. For 68% of the samples positive by PCR, colonization with P. 
jirovecii was confirmed by IF microscopy but only with enhanced analysis of the IF 
slides (90 minutes per slide) (Ponce et al., 2010). Distinguishing infection from 
colonization in the laboratory is challenging. Confidently diagnosing PCP infection 
based on laboratory tests alone relies on detecting a significant burden of P. jirovecii 
from clinical specimens. This is the reason why microscopy can be the preferred 
method of detection as IF staining has a LOD of 1.5 x 103 cfu/mL of organisms from 
BAL (Alanio, Desoubeaux, et al., 2011) and Grocott’s staining being less sensitive and 
having a detection limit of 104 - 105 cfu/mL (Baselski and Wunderink, 1994). When P. 
jirovecii is detected using light or fluorescence microscopy a high PPV for infection can 
be expected as a positive result indicates a significant burden of organism in the 
specimen and can be used to definitively diagnose PCP. It is reasonable to 
hypothesise that increased sensitivity using PCR for P. jirovecii detection leads to 
increased laboratory diagnosis of PCP compared with GMS microscopy.  
In our study 40% (2/5) of BAL samples positive by PCR were positive by GMS 
microscopy. PCR results for one of the patients was a very low positive by MycAssay 
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with only 150-1500 copies/mL the equivalent of 1-10 cells/mL of BAL being measured, 
this sample was negative by BD MAX PCR. The second positive patient had a high 
positive PCR result at 3.5 x 106 copies per µL equivalent to 3.5 x 103-3.5 x 104 cells per 
mL by MycAssay and 7 x 105 copies by BD MAX PCR. The remaining three samples 
positive on PCR but negative by GMS microscopy had burdens of P. jirovecii ranging 
from 3 cells per mL to 1 x 103 cells per mL as measured by MycAssay PCR, two of 
which were also positive at the same level by BD MAX PCR. From this limited data 
there doesn’t appear to be a positive correlation with increased burden of P. jirovecii in 
a BAL specimen and detection by GMS stainin as the sample with the lowest PCR 
positive signal was detected by GMS staining. In larger studies PCR has been shown 
to be more sensitive than Grocott’s staining and IF for the detection of P. jirovecii from 
clinical samples (Gupta et al., 2008; Chumpitazi et al., 2011; Hardak et al., 2012; 
Robert-Gangneux et al., 2014). This is particularly the case in the non-HIV patient 
populations (Hardak et al., 2012; Robert-Gangneux et al., 2014). In 2008 Gupta and 
colleagues demonstrated that a conventional single round PCR amplifying the Major 
Surface Glycoprotein (MSG) gene detected P. jirovecii in 11% of patients with a clinical 
suspicion of PCP compared with 4% using GMS (Gupta et al., 2008). In the respective 
study P. jirovecii was not detected in the control group even after the application of a 
highly sensitive nested PCR (Gupta et al., 2008). Similarly Chumpitazi et al 
demonstrated that using a quantitative PCR P. jirovecii could be detected in 95.8% of 
samples from patients with confirmed PCP compared with 66.7% using GMS 
(Chumpitazi et al., 2011). More strikingly it has also been demonstrated that GMS only 
detected P. jirovecii in 20.7% of specimens compared with 96.2% using PCR from 
patients considered having probable PCP infection with a clinical presentation 
consistent with infection (Matsumura et al., 2012). Furthermore, this study 
demonstrated resolution of pulmonary infiltrates after anti-PCP treatment in the PCR 
positive group (Matsumura et al., 2012). Increased sensitivity using PCR for the 
detection of P. jirovecii also leads to increased laboratory diagnosis of PCP compared 
with conventional IF microscopy.  
Muhlethaler et al detected three additional cases of probable PCP as defined by strict 
clinical criteria that tested negative by IF (Mühlethaler et al., 2012). Orsi and colleagues 
demonstrated that the MycAssay Pneumocystis assay detected an additional case of 
PCP in a non-HIV patient negative by IF (Orsi et al., 2012). Increased sensitivity using 
PCR for P. jirovecii detection also leads to increased laboratory diagnosis of PCP in 
the paediatric population. Samuel and colleagues reported a significant increase of 
47.6% (154/323) in the detection of P. jirovecii from upper and lower respiratory tract 
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specimens in a cohort of HIV-infected African children hospitalized with a high clinical 
suspicion of PCP using PCR (noting only 6.6% of controls were positive in this study 
(Samuel et al., 2011). Several other studies have also demonstrated increased 
detection of P. jirovecii from patients diagnosed clinically with PCP using PCR 
compared with microscopy (Hauser et al., 2011; Hardak et al., 2012; Orsi et al., 2012; 
Seah et al., 2012b; Guigue et al., 2014; Maillet et al., 2014; Nakashima et al., 2014) 
However, increased sensitivity can also lead to detection of colonization in patients 
with no attributable symptoms of PCP. 
Across the five studies evaluating PCR the mean PPV was 76.7% (range 59%-95.5%) 
(Chumpitazi et al., 2011; Hauser et al., 2011; Matsumura et al., 2012; Orsi et al., 2012; 
Seah et al., 2012b). In patients with proven PCP usually defined as being positive on 
microscopy in combination with clinical diagnosis the PPV reached 100% across most 
studies (Hauser et al., 2011; Lu et al., 2011; McTaggart, Wengenack and Richardson, 
2012; Fan et al., 2013; Matsumura et al., 2014). Using PCR to distinguish between 
patients with probable PCP and colonisation can be more complicated. Using 
quantitative PCR Matsumara and colleagues demonstrated no significant difference in 
the measured copies/mL from the BAL of patients with probable PCP infection and 
those who were colonized (Matsumura et al., 2012). Using the MycAssay 
Pneumocystis assay Hauser and colleagues observed positivity in seven patients 
without any clinical evidence of PCP (Hauser et al., 2011). In the respective study CT 
values were significantly lower (stronger positive) for the probable PCP group than the 
colonized group (median: 29.4 v’s 34.2). Seah and colleagues chose to define a true 
positive as one that could be confirmed with microscopy or a second P. jirovecii PCR 
when evaluating the MycAssay Pneumocystis assay (Seah et al., 2012b). In the 
respective study the PPV was 70.5% with 17 positive results not confirmed by a 
second assay. The CT values of true positive results confirmed by a second PCR were 
significantly lower (31.79 +/- 2.87) than false positive results that could not be 
confirmed by a second test (36.3 +/- 1.81). Distinguishing between colonisation and 
infection based on a CT threshold cut of ≤25 for infection and 26-36 for colonisation 
was also proposed by Rudramurthy and colleagues, using the major surface 
glycoprotein as a target (Rudramurthy SM, et al 2017). Caution must be used when 
interpreting the strength of a positive result based on the CT values alone as several 
factors can influence the values obtained. CT values on one system can be significantly 
different to those on a differing system at the same log concentrations. This was 
demonstrated in our study. Qualitative PCR is therefore limited by an inability to 
accurately reflect the burden of organisms within specimens. Quantitative PCR 
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addresses this limitation, running standards alongside clinical samples it is possible to 
quantify the target copies detected and quantify the positivity of a sample.  
The use of quantitative PCR for the characterisation of P. jirovecii infection has been 
reported in several studies (Lu et al., 1995; Alanio, Desoubeaux, et al., 2011; 
Chumpitazi et al., 2011; Maillet et al., 2014; Matsumura et al., 2014). By quantifying 
Pneumocystis cells it may allow clinicians to make a decision regarding the 
significance of a positive result (Lu et al., 1995). It presents an opportunity to not only 
define the burden of organisms within a sample but to also define thresholds for 
infection and colonization (Robert-Gangneux et al., 2014). Across published studies 
using quantitative PCR there is a common approach in which a lower threshold is 
established to define colonization and a higher threshold is established to define 
infection, leaving a ‘grey area’ in which a positive result cannot definitively be used to 
classify a patients disease status and needs to be interpreted in the context of a 
patient’s clinical presentation. Table 8.12 details five studies defining thresholds for P. 
jirovecii qPCR interpretation. In study 1 the MSG single copy gene was used and a 
threshold <3160 equivalent to 1E+04 cells per mL was used to define colonisation and 
>31600 copies equivalent to 1E+06 cells per mL used to define infection (Maillet et al., 
2014). In the respective study 25% (9/35) patients fell between the grey zone of > 
1E+04 and 1E+06 with authors stating that these patients needed to be assessed on a 
case by case basis to determine the significance of the positive result (Maillet et al., 
2014). In the respective study the threshold for colonization was also high at <3160 
copies/mL, which is slightly higher that the published LOD for IF microscopy.  
In the majority of published studies a patient with >1 x 103 cfu/mL would be considered 
to have probable PCP. In study 3 (table 8.12) Alanio and colleagues defined thresholds 
for colonisation and infection utilising a multi-copy gene MitLSU and converting the 
results to trophic form equivalents (TFE) for interpretations (Alanio, Desoubeaux, et al., 
2011). This approach is likely to be most accurate as it not only quantifies the amount 
of target being detected but also the standards are extracted through the same 
workflow as the clinical samples and thus any loss of DNA through extraction occurs 
for both the standards and samples. A threshold of <190 TFE/mL defined colonisation 
verses a threshold of >1.9E+4 TFE defining infection (Alanio, Desoubeaux, et al., 
2011). Alanio reported 3.9% of patient for which fungal load was in the grey zone (≥120 
and ≤1900 TFEq/mL), and the infection status of the patient could not be determined. 
Studies 4 and 5 also set thresholds similar to that of Alanio et al with the colonisation 
thresholds close to the 100 cells/mL target copy per/mL mark and infection at >103 
cells/mL. Chumpitazi and colleagues chose to utilise a low threshold of 54 copies/mL 
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for discriminating colonisation with infection, however this study had a high prevalence 
of 27.3% (18/66) which may have biased the calculated performance of the PCR, 
dampening the effects of false positive results (Chumpitazi et al., 2011) (table 8.12). 
However, there is disparity between thresholds set across studies utilising qPCR. In 
80% (4/5) of the studies in table 8.12 the PPV was >95% suggesting that thresholds do 
increase the performance of PCR for the diagnosis of PCP.  
 
In our study the application of thresholds to define infection from colonisation would 
have led to the exclusion of one patient with proven disease with a low positive at 
1.5E+1-1.5E+2 cells/mL and would not have resolved the false positive result tin a 
control patient whose fungal burden was determined to be 8.2 E+4-8.2 E+5 cells/mL. 
Both respective patients were not textbook HIV infected PCP cases and this may be 
the reason for the disparity in performance of PCR in our study.  
The use of thresholds for the interpretation of qPCR results in HIV infected patients is 
more successful that in non-HIV infected patients. In 2008, Hugget and colleagues 
applied qPCR specifically to the detection of P. jirovecii from BAL in HIV infected 
patients. The respective study reported 98% sensitivity and 96% specificity for the 
diagnosis of PCP when using a threshold of >10 copies per reaction, which would have 
equated to approximately 60-120 cfu/mL (Huggett et al., 2008). Teh et al reported no 
clear relationship between qPCR results and clinical features or outcome in the non-
HIV patient cohort and concluded that qualitative PCR and using a negative result to 
exclude PCP was most appropriate (Teh et al., 2014). Furthermore, it was concluded 
Table 8.12 P. jirovecii qPCR studies alongside published thresholds to define 
infection/colonization and performance characteristics. 
Study Author Target 
(copy) 
Threshold Cells 
/mL 
PPV NPV Sens Spec 
1 Maillet  
MSG  
(single) 
<3160 tc/mL 
>31600 tc/mL 
3E+04 
3E+06 
- 
100 
100 
- 
100 
- 
70 
80 
2 Chumpitazi 
MSG  
(single) 
54.3 t/mL 5.4E+01 95.5 100 100 97.7 
3 Alanio 
LmitSU  
(100-1000) 
<120 TFE/mL 
>1900 
TFE/mL 
1.2E+02 
1.9E+03 
- 
100 
100 
- 
100 
85.7 
96.9 
100 
4 Matsumara 
DHPS  
(single) 
<340 tc/mL 
>1300 tc/mL 
3.4 E+02 
1.3E+03 
78.6 100 100 80.0 
5 Muhlethaler 
Unknown 
(single) 
<85 tc/mL 
>1450 tc/mL 
8.5E+01 
1.5E+03 
- 
98 
100 
- 
100 
- 
99.4 
- 
6 Rudramurthy 
MSG 
(single) 
CT ≤25  
CT 26-36 
- 
- 
100 100 100 100 
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that positive results should be interpreted in the clinical context of the patient rather 
than using thresholds to define their significance. This finding is supported by further 
studies (Mühlethaler et al., 2012; Seah et al., 2012a; Robert-Gangneux et al., 2014) 
and by the findings of a meta-analysis that 31% of patients labelled with false positive 
PCR results had or later developed PCP infection (Lu et al., 2011).  
From this study it is clear that the close interaction between the laboratory and 
clinicians in the provision of a molecular diagnostic service for PCP is crucial. Results 
need to be interpreted on a case-by-case basis. The introduction of a new molecular 
diagnostic assay also needs to be appropriately justified; sufficient numbers of samples 
are needed to render it cost effective and also to ensure that the laboratory maintains 
the expertise in interpreting the results. For these reasons National reference 
laboratories should be considered, as the testing provider if the number of samples 
expected to be tested is not significant. Services may be brought in-house following a 
period of parallel testing using specialist referral labs as a benchmark. As induced 
sputum and BAL are acquired through moderately invasive poorly tolerated procedures 
a high clinical suspicion of infection is required to justify collecting these specimens 
and not every patient ill be suitable for these procedures. Therefore relatively few 
samples may be submitted for investigation to an individual laboratory, but for larger 
regional or national reference laboratories serving several hospitals the use of PCR is 
more strongly justified. As the incidence of PCP remains low in the HIV population 
following the advent of anti-retroviral treatment and in the non-HIV patient population 
due to prophylaxis the implementation of a PCR for P. jirovecii as a diagnostic assay 
requires consideration not only in terms of the assay but in the wider context of the 
patient population which in turn influences the performance of the test and how it is 
interpreted and reported to the clinical interface. This study has demonstrated that PCP 
PCR can demonstrate a high NPV and specificity for the exclusion of PCP in at risk 
patients. Further developments in standardising PCR and defining thresholds for 
interpretation are required to achieve a robust positive predicative value that will allow 
clinicians to have the confidence to diagnose disease with accuracy.  
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9 Chapter 9 Evaluation of PCR for screening patients with 
haematological malignancy for the detection of Invasive 
Aspergillosis (IA)   
9.1 Introduction  
The detection and diagnosis of invasive aspergillosis relies heavily on radiological 
imaging by high resolution computer tomography (HRCT) which has a sensitivity of 
96% and specificity of 65.4% respectively for the diagnosis of invasive aspergillosis 
(IA) (Prem et al., 2010) if the characteristic features, including lung nodules with ground 
glass/halo sign are detected (Escuissato et al., 2005; Gasparetto, Escuissato and 
Marchiori, 2008; Qin et al., 2012). The laboratory’s role in the diagnostic pathway 
includes provision of an enzyme immune assay (EIA) that detects circulating 
Galactomannan enzyme immuno assay (GM-EIA). Galactomannan is a cell wall 
lipopolysaccharide of Aspergillus species (Bernard and Latgé, 2001) which serves as a 
cell wall storage polysaccharide but is also a powerful antigen excreted during fungal 
growth (Engel, Schmalhorst and Routier, 2012; Free, 2013). Culture from clinical 
specimens also has some but limited utility. Biopsies for histopathological analysis with 
fungal specific stains are the current gold standard for diagnosis of invasive infection.  
The respective tests, including HRCT and GM-EIA are included in the European 
Organization for Research and Treatment of Cancer (EORTC) Mycoses Study Group 
guidelines for defining invasive fungal disease (IFD) (De Pauw et al., 2008).  
In recent years Aspergillus PCR has been investigated for its utility as a screening tool 
for the detection of invasive aspergillosis. Serological specimens are favoured when 
screening, as high frequency sampling is required. The specimen types most 
commonly analysed being whole blood (Bernal-Martínez et al., 2011; Löffler and 
Kurzai, 2011; Springer et al., 2013) and serum, with improved performance achieved 
when analysing plasma (J. Loeffler et al., 2000; White et al., 2015). The most suitable 
fraction of blood has not definitively been determined to date. A recent meta-analysis 
reported a combined sensitivity of 84% (95% CI 75, 91) and a specificity of 76% (95% 
CI 65, 84) for the performance of PCR in the diagnosis of invasive aspergillosis 
(Arvanitis, Anagnostou and Mylonakis, 2015) with negative PCR results used to 
exclude disease as the combined negative predictive value across 25 studies in this 
analysis was 96% (Arvanitis, Anagnostou and Mylonakis, 2015). However, positive 
results cannot be used to definitively diagnose disease, as the combined PPV was 
reported to be only 38% (Arvanitis, Anagnostou and Mylonakis, 2015). The 
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interpretation of positive results remains the on-going challenge as false positive 
results are frequently encountered, most likely a result of environmental contamination 
or a lack of specificity in the PCR assays being utilized (Alanio, Desoubeaux, et al., 
2011). Recent studies have demonstrated that combining PCR with antigen testing 
(Morrissey et al., 2013; Rogers et al., 2013; Aguado et al., 2015) improves the 
performance of biomarker detection for the diagnosis of IA and may also enable earlier 
detection of disease (Morrissey et al., 2013; Rogers et al., 2013; Aguado et al., 2015).  
With evidence pointing to the use of PCR as one of the primary methods to support the 
diagnosis of invasive aspergillosis there is a question as to why guidelines to date have 
not recommended its use. One of the major factors prohibiting the introduction of PCR 
across laboratories globally for diagnosis of IA is a lack of a standardisation across the 
molecular method employed (De Pauw et al., 2008). Over the last 10 years a multi-
centre collaboration, the European Aspergillus PCR Initiative (EAPCRI) has worked to 
identify the critical steps in standardizing the performance of Aspergillus PCR from 
serological and respiratory specimens (White et al., 2010). The aim was to better 
understand critical factors in the application of PCR in this setting and how best to 
utilize PCR alongside other diagnostic techniques to improve diagnosis. Studies from 
the EAPCRI group have highlighted the importance of the nucleic acid extraction 
protocol in achieving satisfactory analytical sensitivity (White et al., 2010). Input sample 
volume, elution volume and mechanical lysis when extracting from whole blood were 
also critical (White et al., 2010). As DNA extraction from whole blood yields variable 
results serum has emerged as a more optimal sample type for Aspergillus PCR, and 
facilitates dual biomarker testing as it is the sample type also used in GM-EIA analysis 
(White et al., 2010). When considering the performance of Aspergillus PCR a mean 
sensitivity and specificity of 71.8% and 96% were reported from five studies (Bretagne 
et al., 1998; Williamson et al., 2000; Costa et al., 2002; Pham et al., 2003; Halliday et 
al., 2006). 
 
The majority of studies have utilized in-house developed Aspergillus PCR assays and 
in our centre the 28Asp assay, a PCR targeting the 28S ribosomal RNA gene, utilized 
in the EAPCRI studies is the assay of choice (White et al., 2010, 2014; Löffler and 
Kurzai, 2011). As highlighted in previous chapters the use of in house assays can 
contribute to varied performance across centers (Walker and Subasinghe, 1999; 
Burkardt, 2000; Techniques, 2000) centres. One solution is to utilize commercially 
validated assays, which assist with standardizing processes across centres, allowing 
for standardised laboratory methodologies to generate data to compare both disease 
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prevalence and on-going performance. Commercial assays also have the benefit of 
manufacturing and production quality control to national and international 
manufacturing standards. Although in-house assays can be adequately quality 
controlled, often using high yield clinical samples, what they are unable to do as 
material is exhausted is to provide longitudinal quality control over time to monitor for 
assay drift. This is a crucial factor when assessing both assay performance and 
disease prevalence over long periods. At the time of undertaking this research a new 
commercial assay for the detection of Aspergillus from clinical specimens by PCR had 
been developed for diagnostic use. This assay employed a novel approach coupling 
conventional PCR with probe based chemistry and Raman scattering spectra (SERS) 
(White et al., 2014). SERS utilizes sensitive spectroscopic detection to generate 
analyte-specific fingerprint spectra (White et al., 2014), Figure 9.1.  
 
Raman spectroscopy is a detection method that captures molecular vibrations as a 
mass spectrum and is used in many applications for identification and quantitation. The 
vibrations, or Raman scattering, are strongly enhanced as a molecule is bound to a 
metallic surface (Stiles et al., 2008; Schlücker, 2014). In the case of the fungiplex the 
molecule is the species-specific probe and the metalic surface is the metallic capture 
beads. As the electromagnetic wave in the Raman spectroscope interacts with the 
metal surface plasmons, coherent delocalized electron oscillations that exist at the 
interface between any two materials, are excited (Stiles et al., 2008; Schlücker, 2014). 
The magnitude of the electromagnetic fields at the surface is enhanced if the species-
specific probe has adsorbed onto the metal bead. The electronic coupling between the 
metal and the molecule increases its Raman-scattering signal which is then detected 
(Stiles et al., 2008; Schlücker, 2014). In the case of the Fungiplex assay a positive 
PCR will result in probe being adsorbed onto the metal beads whereas a negative 
reaction will only warrant beads with no bound molecule and therefore no Raman 
signal. The method is also claimed to be more sensitive than standard real time PCR 
applications making it suitable for its application in the IA setting (White et al., 2014). 
The aim of this study was to compare an EAPCRI compliant 28Asp real time PCR with 
the RenDX Fungiplex® assay for the detection of Aspergillus DNA from serum as a 
screening approach for the detection of IA in haemato oncology patients.  
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Figure 9.1 Schematic of PCR-SERS amplification and detection. 
 
 
 
 
 
1. PCR amplification of extracted 
DNA. 
 
2. Specific RenDX probes are 
hybridized to biotinylated target 
DNA. 
 
3. Hybridised DNA is captured on 
streptavidin bound magnetic beads 
 
4. Probes eluted from captured DNA 
 
 
5. Eluted probes are adsorbed onto 
silver nano particles and analysed. 
 
 
6. Sample is exposed to a Raman 
laser and a detector receives the 
Raman signal reflected off the 
sample.  
 
 
7. SERS signal detailing an example 
base line spectrum for a negative 
sample (lowest line) with positive 
target signals in the upper three 
lines showing additional peaks for 
the associated bound probes. 
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9.2 Methods 
9.2.1 Clinical Samples 
Sera submitted to the laboratory for the investigation of fungal infection, including 
specifically GM-ELISA testing, from patients undergoing chemotherapy for acute 
myeloid leukaemia (AML), myelodysplastic syndrome, or allogeneic stem cell 
transplantation and receiving itraconazole prophylaxis were included. The samples 
were tested under the umbrella of service development, whereby specimens can be 
utilised for the development of diagnostics tests directly relating to the diagnosis of 
disease that the specimen was originally submitted for, in this case galactomannan 
testing for the investigation of Aspergillosis. Disease status was classified using 
EORTC/MSG (2008) criteria (de Pauw et al., 2008). Table 9.1 shows the EORTC/MSG 
criteria used to classify patients. Those with probable disease require one factor from 
all three categories including: host, clinical and mycological categories. For possible 
disease the mycological criteria is omitted as being essential. 
Table 9.1 EORTC/MSG criteria for defining probable and possible Invasive 
Fungal Disease. 
Host factors 
History of neutropenia (<500 neutrophils/mm3 for >10 days) related 
to the onset of fungal disease. 
Receipt of an allogeneic stem cell transplant. 
Prolonged use of corticosteroids.  
Treatment with other recognized T cell immunosuppressant, such as 
cyclosporine. 
Inherited severe immunodeficiency (such as chronic granulomatous 
disease). 
Clinical criteria 
The presence of 1 of the following 3 signs on CT: 
Dense, well-circumscribed lesions(s) 
With or without a halo sign, air-crescent sign or cavity 
Mycological 
criteria 
Direct microscopy positive for hyphae from BA or sputum. 
Galactomannan antigen detected in serum or bronchoalveolar 
lavage fluid. 
Recovery, by culture, of Aspergillus from BAL or sputum. 
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9.2.2 Culture of Aspergillus fumigatus control strain 
Aspergillus control strain Aspergillus fumigatus ATCC® 1022™ Designation: NRRL 
163 was sub cultured onto Sabouraud's agar, incubated for 2-3 days until colonies had 
developed with fruiting structures. The control strain was then cultured as mycelial 
mats for DNA extraction as detailed in section 2.1.4 
9.2.3 Extraction of DNA from Aspergillus fumigatus control strain;  
See general methods 2.2. In addition extracted DNA was quantified using the 
Nanodrop spectrophotometer and dilutions of genomic DNA were prepared in 1 x (Tris 
Ethylenediaminetetraacetic acid (EDTA) buffer. 
9.2.4 Extraction of genomic DNA from potato (IC SPUD) 
Internal control methodology was adapted from Honeybourne et al (2011). 1cm2 
sections of Solanum tuberosum (potato) tuber were snap frozen in liquid nitrogen and 
ground to powder using a pestle and mortar. Total genomic DNA was extracted from 
100mg of this powder using the GenElute Plant Genomic DNA Miniprep kit, Sigma 
according to the manufacturer’s instructions.  
9.2.5 Generating the SPUD DNA IC control 
A 1957 bp fragment of the tuber gene was amplified using forward primer 5’-
ggttcactcacaatcaaagcattcaaaccc-3’ (Honeyborne et al., 2011) and reverse primer 5’-
ggaagctgtgggtggcggtcgaaattcaa primers3’ (Honeyborne et al., 2011). The PCR 
amplicon was verified as being the correct tuber gene fragment by sequence analysis, 
see general methods 2.2. The product was purified by gel extraction (QIAQuick Gel 
Extraction kit, Qiagen, UK) see general methods 2.2 and then quantified using a 
Nanodrop Spectrophotometer (ThermoFisher, USA) see general methods 2.2.   
 
9.2.6 DNA extraction from serum 
 DNA was extracted from 1mL of serum through the Diasorin IXT automated workflow 
as per manufacturer’s instructions (Diasorin, Ireland). Viral nucleic acid cartridges were 
used to extract DNA from serum. Samples were loaded onto the platform, 10µL 
proteinase K was added and an internal control (10µL 0.002ng SPUD) and the large 
volume extraction protocol was selected, with a run time of approximately 45 minutes. 
The extracted nucleic acid was eluted into a final volume of 50µL of eluate, in line with 
EAPCRI recommendations (White et al., 2010). A negative extraction control was 
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included in every run. A maximum number of 11 samples per extraction run were 
possible.   
9.2.7 28Asp real time PCR 
A previously published Aspergillus real-time PCR (28Asp) targeting the 28S rRNA 
gene was utilized (White et al., 2010). Primers and probes sequences were as follows; 
forward primer ASF1 5’-GCA CGT GAA ATT GTT GAA AGG-3’, reverse primer ADR1 
5’-CAG GCT GGC CGC ATT G-3’ and Taqman probe ASP 28P 5’-FAM- CAT TCG 
TGC CGG TGT ACT TCC CCG-TAMARA-3’. For the inhibition control SPUD PCR 
forward primer IC F 5’-GCACAGGGTTGATGTTGGTATTGTC-3’ Tm 63°C, reverse 
primer IC R 5’-CAAATGAGAAATAGCCCTCACTGCAAG-3’ Tm 63.4°C and probe IC 
Probe 5’-JOE-GCAGGGTCCTCAGTTCTAGCAGGCTCCA-BHQ1-3’ were utilized. 
Aspergillus PCR reactions were run in duplicate with separate internal control reaction 
in third tube. 
The assay was performed for 45 cycles as a single-round assay using a Rotorgene Q 
HRM instrument (Qiagen, United Kingdom). The final reaction composition in a 50 µL, 
reaction contained 0.75µM primers, 0.4µM hydrolysis probe, 4mM MgCl5, Abgene 
QPCR 2 x master mix and 10µL template DNA. PCR plasmid controls were also 
utilized to allow for run verification at 500, 50 and 5 input copies per reaction. For the 
28Asp PCR expected CT values for 300 plasmid copies was 32, 30 plasmid copies 35 
and 3 plasmid copies 39. Control plasmid was supplied by Dr P White, UKCMN 
Regional Mycology Reference Laboratory PHW Microbiology Cardiff Heath Park, 
Cardiff. 
 
9.2.8 PCR amplification and SERS detection 
PCR-SERS testing was performed, according to the manufacturer’s instructions. The 
first stage of the assay was a conventional PCR in a 50µL reaction to which 10µL of 
DNA template was added. The PCR assay targets the 28S rRNA genes, generating an 
amplicon of approximately 200bp in size. A negative test control (NTC) of molecular 
grade water was included in each PCR run and processed from extraction through to 
PCR. An internal amplification control was added prior to extract the amplification 
process. Once the PCR amplification was complete the second stage of processing 
was SERS probe hybridisation. Post amplification steps included transferring 5µL of 
the amplified product to a 96 well microtitre plate containing 15µL of SERS detection 
probe. The probe/amplicon mix was heated to 95°C for 15 minutes to allow for 
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denaturing, annealing and hybridisation. Once complete the hybridised products were 
processed on a RenDX (Renishaw Diagnostics, UK) sample processor where samples 
were passed through a series of wash buffers. Remaining bound probe was released 
into the elution buffer in preparation for detection on the SERS platform. Figure 9.1 
details the process of Fungiplex SERS detection and resulting SERS trace from which 
a result is interpreted.  
The total process, including DNA extraction, was completed within one working day 
(8hours), with the PCR amplification-SERS analysis taking approximately 6hours to 
complete. Operator hands-on time of approximately 2 hours including DNA extraction 
was needed. The Raman spectroscopy instrument software, using a direct classical 
least-squares model of analysis, automatically interpreted results as positive, negative, 
or inhibited. 
 
9.2.9 Determination of the analytical sensitivity of the 28ASP real time PCR 
and Fungiplex workflow;  
Serial dilutions of plasmid DNA containing the 28Asp target were processed through 
the 28Asp PCR, in eight replicates, to assess the analytical sensitivity and 
reproducibility at an input of 2000, 200, 20 and 2 plasmids per reaction. 
 
A. fumigatus genomic DNA sample was diluted into high medium and low 
concentrations.  
 
a) 10µL of each dilution was processed through each PCR in 12 replicates.  
 
b) 20µL of each A. fumigatus genomic DNA dilution was spiked into 2mL 
serum samples in six replicates and extraction performed from 550µL and 
1mL of the spiked serum. 
 
The representative copy number of the A. fumigatus genomic DNA was calculated by 
quantifying the results against a standard curve generated using the control plasmid 
through the 28Asp PCR.  
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9.2.10 Assessing the clinical performance of the 28ASP real time PCR and 
Fungiplex workflow 
Patients were classified into proven, probable or control groups through analysis of 
radiological, laboratory and clinical investigations according to criteria described in 
table 9.1. Classifications were reviewed by two operators, firstly by a senior scientist 
and secondly by a clinical consultant mycologist. Serum submitted for GM-EIA testing 
was processed through DNA extraction and tested using the 28Asp and Fungiplex in 
parallel. Samples were batched into a minimum of 20 samples processed at one time 
to allow for more efficient processing. The investigators were blinded to the EIA testing 
results, which were collected retrospectively after the completion of PCR processing of 
the complete sample set.  
9.2.11 Statistical analysis  
Clinical performance was assessed by calculating sensitivity, specificity, positive and 
negative predictive values for both PCR assays versus the EORTC definitions 
assigned to each patient. Two by two binary concordance tables were constructed, 
using both probable IFD and probable/possible IFD as true cases and NEF patients as 
the control population. A single positive PCR reaction was required to consider a 
patient positive The agreement between the Fungiplex assay and the original 28Asp 
real-time PCR results was determined by calculating the kappa statistic and observed 
agreement. Receiver operating characteristic (ROC) curves were generated using the 
earliest CT value generated per patient to determine whether a particular CT threshold 
provided optimal PCR performance for the 28Asp assay. For this analysis in patients 
negative by PCR, a CT value of 41 cycles was applied, representing the lowest number 
of PCR cycles performed. 
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9.3 Results 
9.3.1 Analytical sensitivity and performance of the 28Asp PCR;  
Table 9.2 details median CT values of 26.1(IQR 25.9, 26.2) for 2000 copies, 30.7 (IQR: 
30.6, 31.1) for 200 copies, 33.9 (IQR: 33.7, 34.2) for 20 copies and 38.9 (IQR: 38.2, 
39.4) for 2 copies per reaction with 100% (10/10) reproducibility across all dilutions. 
Variance in CT values increased slightly for the 2 plasmid copies per reaction dilution, 
figure 9.2, but was not significantly different across any of the plasmid dilutions.  
The calculated efficiency of the 28Asp PCR was 74% (slope -4.16).  
 
 
Figure 9.2 CT values for plasmid dilutions processed through the 28Asp PCR, with median 
values and IQR indicated. 
 
Table 9.2 Reproducibility of 28Asp PCR across serial dilutions of plasmid 
target with median CT values and IQR presented. 
Plasmid copies per 
reaction 
% Reproducibility Median CT IQR 
2000 100% (8/8) 26.1 25.9, 26.2 
200 100% (8/8) 30.7 30.6, 31.1 
20 100% (8/8) 33.9 33.7, 34.2 
2 100% (8/8) 38.9 38.2, 39.4 
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Figure 9.3 Standard curve derived from target plasmid dilutions processed through the 28Asp 
PCR for which the high, medium and low genomic DNA dilutions were measured against to 
estimate the equivalent plasmid copies.  
 
9.3.2 Characterizing Genomic DNA dilutions  
Equivalent plasmid copies for each genomic DNA dilution were calculated by testing 12 
replicates of each DNA dilution through the 28Asp PCR and measuring the CT result 
against a standard curve generated from plasmid dilutions, see figure 9.3 and table 
9.3. The high genomic concentration of approximately 1pg/µL was equivalent to CT 
43.2 (95% CI: 31.1 to 57.9) plasmid copies input, the medium DNA concentration of 
approximately 100fg/µL was equivalent to CT 6.5 (95% CI: 2.8 to 14.4) plasmid copies 
and the low DNA concentration of approximately 10fg/µL was equivalent to CT 0.74 
(95% CI: 0.03 to 5.6) plasmid copies input per reaction, see figure 9.3. 
 
Table 9.3 Equivalent plasmid copies per mL for A. fumigatus genomic DNA 
dilutions. 
Plasmid copies 
per reaction 
% reproducibility Median CT PC eq 95%CI 
High 100% (12/12) 33.1 43.2 31.1, 57.9 
Medium 100% (12/12) 36.5 6.5 2.8, 14.4 
Low 62.5% (5/12) 40.4 0.7 0.03, 5.6 
PC eq = plasmid copy equivalent 
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9.3.3 Analytical performance of the Fungiplex PCR-SERS assay compared 
with the 28Asp real time PCR assay  
100% (12/12 95%CI: 70.1, 100) reproducibility was observed through each PCR for the 
detection of the high and medium DNA dilutions. For the low concentration of genomic 
DNA reproducibility was 55.6% (5/9, 95%CI: 26.7, 81.1) for the Fungiplex PCR SERS 
assay and 66.7% (6/9, 95%CI: 35.42, 87.94) reproducibility for the 28Asp qPCR, table 
9.4. 
 
9.3.4 Determination of the limit of detection of the complete workflow; 
extraction to PCR detection 
When analysing extracts from 1mL of serum spiked with the high and medium 
concentrations of genomic DNA both the 28Asp and Fungiplex PCR detected A. 
fumigatus from 100% (6/6) of the extracts with a mean CT values of 33.1 (33.7-35.2) 
and 38.6 (37.6-39) respectively for the 28Asp PCR. When analysing extracts from 1mL 
of serum spiked with the low concentration of genomic DNA (representing 0.7 plasmid 
copies/uL) 83.3% (5/6) of the extracts were positive for A. fumigatus by the 28ASP 
PCR with a mean CT of 40 (38.5-41.4) and 50% (3/6) for the Fungiplex PCR, table 9.5.  
 When analysing extracts from 550μL of serum both the 28ASP, with a median CT of 
35.8 (34.8-36.5) and Fungiplex PCR detected A. fumigatus from 100% of the extracts. 
For the medium spiked serum the 28ASP PCR detected A. fumigatus for 66.7% (4/6) 
of the extracts with a mean CT of 39.3 (38.9-39.7) and the Fungiplex from 83.3% (5/6) 
of the extracts. For the low spiked serum the 28ASP PCR was positive from a single 
sample with a CT of 40.5, whereas the Fungiplex failed to detect A. fumigatus from all 6 
extracts, table 9.5.  
Table 9.4 Reproducibility of detection of the Fungiplex PCR-SERS assay and 28Asp 
PCR for high, medium and low genomic DNA dilutions processed directly through 
each PCR. 
 High 1pg/µL 
(43.2 Pc) 
Medium 100fg/µL 
(6.5 Pc) 
Low 10fg/µL 
(0.7 Pc) 
 % (95% CI) n % (95% CI) n % (95% CI) N 
Fungiplex 100%  
(70.1, 100) 
12/12 100%  
(70.1, 100) 
12/12 55.6%  
(26.7, 81.1) 
5/12 
28Asp qPCR 100%  
(70.1, 100) 
12/12 100%  
(70.1, 100) 
12/12 66.7% 
(35.4, 87.9) 
6/12 
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Figure 9.4 demonstrates CT values for the A. fumigatus high and medium genomic DNA dilutions directly spiked into the 28Asp PCR 
assay, extracted from 1mL and 550µL of serum, demonstrating the loss in sensitivity when extracting DNA from lower volumes of serum. 
Table 9.5 CT values and reproducibility of 28Asp PCR and Fungiplex for the detection of Aspergillus fumigatus genomic DNA extracted 
from 550µL and 1mL of serum on the Diasorin IXT platform compared with direct PCR. 
 
Direct 1mL 550µL 
 28ASP PCR RENDX PCR 28ASP PCR RENDX PCR  28Asp PCR RENDX PCR  
 
CT 
Dynamic 
Range 
Reproducibility % CT 
Dynamic 
Range 
Reproducibility % CT 
Dynamic 
Range 
Reproducibility % 
High 
(43.2 Pc/µL) 
 
33.1 
31.4-35.7 100 (12/12) 100 (12/12) 34.3 33.7-35.2 100 6/6) 100 6/6) 35.8 34.8-36.5 100 (6/6) 100 (6/6) 
Med 
(6.5 Pc/µL) 
36.5 33.6-37.8 100 (12/12) 100 (12/12) 38.6 37.6-39 100 (6/6) 100 (6/6) 39.3 38.9-39.7 66.7 (4/6) 83.3 (5/6) 
Low 
0.7 Pc/µL) 
40.4 38.2-41.3 41.7 (5/12) 50 (6/12) 40 38.5-41.4 83.3 (5/6) 50 (3/6) 40.5 - 13 (1/6) 0 (0/6) 
High Medium  
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Figure 9.4 demonstrates a scatter plot of CT values, with the median and IQR ranges 
shown, for the high and medium A. fumigatus genomic DNA concentrations processed 
through the 28Asp PCR. There was no significant difference in CT values when testing 
the high concentration directly spiked into the PCR and when extracted from 1mL of 
serum (p<0.09), whereas when the high concentration was extracted from 550µL of 
serum the CT values were significantly higher than the direct and 1mL analysis. When 
testing the medium concentration of A. fumigatus genomic DNA the CT values were 
significantly higher than the direct analysis (p<0.01), but no significant difference 
(p=0.07) was observed in the CT values when extracting from 1mL and 550µL volumes 
of serum for the medium concentration of genomic DNA, figure 9.4.  
 
9.3.5 Clinical performance of the 28Asp and Fungiplex PCR  
Utilising methodological data generated from previous analytical investigations, 
analysis of clinical specimens was performed from 1mL of serum, as this specimen 
volume had been previously shown to provide optimal performance through both PCR 
assays.  
 
Patient demographics; in total 83 patients were screened for fungal infection during 
the time frame of this study. Table 9.6 demonstrates the demographics for patients 
included. The median age was 52 years (range 24-85). Of the underlying 
haematological conditions acute myeloid leukaemia (AML) accounted for 51.8% 
(43/83), acute lymphoblastic leukaemia (ALL) accounted for 18.1% (15/82). Lymphoma 
accounted for 16.9% (14/83) and Myeloma 9.6% (8/83). Two patients were categorised 
in the other haematological malignancy subgroups, with one patient diagnosed with a 
RAEB1 with monosomy 7 immunodeficiency and the second with Wiskott - Aldrich 
syndrome. 
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Table 9.6. Patient demographics with EORTC/MSG definitions of IFD. 
 Mean Range  M F   
Age 52 24-85 Sex 58% 42%   
 EORTC definition  
 Probable (2) Possible (11) NEF (70) Overall 
Underlying condition  % n % n % n % n 
ALL   1.2 1 16.9 14 18.1 15 
AML 2.4 2 8.4 5 43.4 36 51.8 43 
CLL     1.2 1 1.2 1 
Myeloma/lymphoma    2 24.1 20 26.5 22 
Other     2.4 2 2.4 2 
HRCT  2.4 2 13.3 11 32.5 27 51.8 43 
NEF = no evidence of fungal disease 
 
9.3.6 Screening characteristics 
In total 343 samples were submitted to the laboratory for investigation, Sample 
frequencies sent during neutropenic episodes were 1 sample for 25.3% (22/83) 
patients, 2.4% (2/83) samples for 18.1% (15/83) patients, 3 samples for 20.5 (17/83) 
patients and ≥4 samples for 48.2% (30/83) patients.  
9.3.6.1 Classification of disease status according to EORTC criteria 
From the cohort of 83 patients none were classified as having proven invasive fungal 
disease.  
9.3.6.2 Control patients ‘No evidence of fungal disease ‘NEF’ 
Seventy-three patients were classified as having no evidence of fungal infection on 
HRCT 32.5% (27/83) or did not undergo HRCT scanning, as fungal infection was not 
clinically suspected 51.8% (43/83).   
9.3.6.3 Possible invasive fungal disease 
Eight patients were classified as having a possible fungal disease. HRCT 
demonstrated pulmonary lesions consistent with invasive aspergillosis described as 
defined nodules and ground glass shadowing. All 8 patients had a period of profound 
neutropenia >10 days meeting the clinical criterion required for possible infection. For 
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all 8 patients GM EIA analysis was negative and cultures from clinical specimens did 
not grow Aspergillus sp. Of note 50% (4/8) patients had >4 samples submitted for GM 
EIA during their neutropenic episode. The remaining 50% (4/8) had 2 (2) or 3 (2) 
samples submitted for screening.  
9.3.6.4 Probable invasive fungal disease 
Two patients were classified as having probable invasive fungal disease with HRCT 
features consistent with invasive aspergillosis, a neutropenic episode >10 days but 
also mycological criterion of a positive GM EIA during their neutropenic episode. 
Patient 1 had a single sample submitted for GM EIA analysis with an index of 2.184, 
which on repeat measured at 0.84. Patient 2 had 10 samples submitted for GM EIA 
analysis. One sample submitted for patient 2 was positive measuring an index value of 
0.989 and 0.86 on repeat, two equivocal samples measuring 0.516 and 0.636 on initial 
testing but on repeat measured 0.11 and 0.10 and 7 samples all measuring negative 
on initial testing with index values <0.5.   
 
9.3.7 Performance of Galactomannan EIA for the detection of IA  
The overall performance of GM EIA for probable patients was a sensitivity of 100% 
(32.2, 100), specificity of 97.5% (91.3, 99.3), PPV of 50% (15, 85) and NPV of 100% 
(95.3, 100). Overall diagnostic accuracy was 97.6% (91.5, 99.3). Performance of GM 
EIA in probable/possible patients had a sensitivity of 22.2% (6.3, 54.7), specificity of 
97.3% (90.7, 99.3, PPV of 50% (15, 85) and NPV of 91.1% (82.8, 95.6). Overall 
diagnostic accuracy was 89.2% (80.7, 94.2).   
Table 9.7 details the four patients with positive GM EIA results. Patient 1 with probable 
IA had two equivocal GM results measuring 0.636/0.11 and 0.516/0.10 and one 
positive result measuring 0.99/0.86 over a four-month neutropenic period. Patient 2 
with probable IA had a single sample submitted to the laboratory, which was positive 
by GM EIA, measuring 2.184/0.82. Patients 3 had a positive GM EIA result for the only 
sample submitted to the laboratory measuring 3.744/1.60, but was not suspected to 
have IA and no HRCT was not requested on this patient. The final Patient 4 had four 
samples submitted to the laboratory, with three positive GM EIA results in succession 
0.853/0.675, 0.86/1.271 and 1.01/0.64 however, the HRCT demonstrated no evidence 
of invasive aspergillosis.  
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Table 9.7 Patients positive by GM EIA with corresponding PCR results for the 28Asp and the Fungiplex assay. 
Patient 
Underlying  
Disease 
Radiology  
HRCT 
EORTC 
Sample 
date 
GMI 1 GMI 2 
GM EIA 
Result 
28Asp 
(1) 
28Asp  
(2) 
28Asp 
Result 
Fungiplex 
Result 
1 AML Positive Probable 
10/04/14 0.636 0.11 Equivocal 38.43 36.61 Positive Negative 
14/04/14 NT  - NT 40.83 40.91 Positive Negative 
17/04/14 0.12  - Negative 0 0 Negative Negative 
21/04/14 0.13  - Negative 40.29 0 PNC Negative 
26/05/14 0.10  - Negative 0 0 Negative Negative 
09/06/14 0.989 0.86 Positive 37.93 40.52 Positive Negative 
14/06/14 NT  - NT 39.91 40.25 Positive Negative 
21/07/14 0.516 0.10 Equivocal 0 0 Negative Negative 
31/07/14 0.16  - Negative 0 0 Negative Negative 
13/08/14 0.18  - Negative 40.15 41.5 Positive Positive 
13/08/14 NT  - NT 38.21 0 PNC Negative 
2 AML Positive Probable 
        
07/02/14 2.184 0.82 Positive 32.1 31.69 POS Positive 
        
3 ALL 
Not  
requested 
NEF 
        
17/02/14 3.744 1.60 Positive 44.26 0 NEG Negative 
        
4 
Wiskott-Aldrich 
Syndrome 
No evidence  
of fungal 
disease 
NEF 
16/10/14 0.20 -  Negative 0 0 NEG Negative 
22/01/15 0.853 0.675 Positive 0 0 NEG Negative 
29/01/15 0.86 1.271 Positive 0 0 NEG Negative 
26/01/15 1.01 0.646 Positive 0 0 NEG Negative 
GMI = galactomannan index, CT positive threshold for 28Asp PCR = 41,  AML = acute myeloid leukemia,  ALL = acute lymphoblastic leukemia,  
NEF = No evidence of fungal disease. 
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9.3.8 Clinical Performance of Aspergillus PCR  
Performance of the 28Asp and the Fungiplex PCR was measured against the clinical 
definition of IFI as the gold standard. The first analysis only considered probable 
patients as those with a diagnosis of IFI (table 9.8). The second analysis included 
possible and probable patients as those with a diagnosis of IFI (table 9.9).  
Performance of the 28Asp PCR assay was assessed using two definitions of a positive 
result. A single positive PCR reaction (out of two replicates) was termed positive non-
confirmed (PNC) and when the two replicate PCR reactions were positive the result 
was termed POS. Performance of the 28Asp PCR was undertaken to include and 
exclude PNC results. The Fungiplex PCR was performed as a single reaction 
therefore; a single positive was considered as positive.  
9.3.9 PCR performance for patients with a diagnosis of probable IFI  
9.3.9.1 POS/PNC 28Asp PCR performance 
28Asp PCR demonstrated a sensitivity of 100% (2/2, CI: 34.2, 100), specificity of 
69.2% (56/81 CI: 58.4, 78.1), PPV 7.4 (2/27, CI: 2, 23.4) and NPV of 100% (56/56, CI: 
93.6, 100) for the diagnosis of IA in probable patients when considering POS and PNC 
results as positive. The overall diagnostic accuracy was 69.9% (58/83, CI: 59.3 78.7) 
and the positive likelihood ratio was 3.2 (CI: 3-3.5). 
9.3.9.2 POS 28Asp PCR performance 
28Asp PCR demonstrated a sensitivity of 100% (2/2, CI: 34.2, 100), specificity of 
92.6% (76/81 CI: 86.4, 97.3), PPV 28.6% (2/7, CI: 8.2, 64.1) and NPV of 100% (76/76, 
CI: 95.2 100) for the diagnosis of IA in probable patients when considering only POS 
results as positive. The overall diagnostic accuracy was 94% (77/83, CI: 86.7, 97.4) 
and the positive likelihood ratio was 16.2 (CI: 11-24). 
9.3.9.3 Fungiplex PCR 
Fungiplex PCR demonstrated a sensitivity of 100% (2/2, CI: 34.2, 100), specificity of 
61.7% (50/81, CI 50.8, 71.6), PPV 6.1% (2/33, CI: 1.7, 19.6) and NPV of 100% (50/50, 
CI: 92.9, 100) for the diagnosis of IA in probable patients. The overall diagnostic 
accuracy was 62.7% (52/83, CI: 51.9, 72.2) and the positive likelihood ratio was 2.6 
(CI: 2.4, 2.8). 
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*POS = two positive PCR replicates $PNC = Positive not confirmed with one positive 
reaction.  
 
9.3.10 PCR performance for patients with a diagnosis of probable or possible 
IFI  
9.3.10.1 POS/PNC 28Asp PCR performance 
28Asp PCR demonstrated a sensitivity of 50% (5/10, CI: 23.7, 76.3), specificity of 
69.9% (51/73 CI: 58.6, 79.2), PPV 18.5% (5/27, CI: 8.1, 36.7) and NPV of 91.2% 
(51/56, CI: 80.7, 96.1) for the diagnosis of IA in probable/possible patients when 
considering POS and PNC results as positive. The overall diagnostic accuracy was 
67.5% (56/83 CI: 56.8, 76.6) and the positive likelihood ratio was 1.7 (CI: 1, 2.7). The 
negative likelihood ratio was 0.7 (CI: 0.5, 1.1). 
9.3.10.2 POS 28Asp PCR performance 
28Asp PCR demonstrated a sensitivity of 20% (2/10, CI: 5.7, 51), specificity of 93.2% 
(68/73 CI: 85, 97), PPV 28.6% (2/7 CI: 8.2, 64.1) and NPV of 89.5% (68/76, CI: 80.5, 
94.6) for the diagnosis of IA in probable/possible patients when considering only POS 
results as positive. The overall diagnostic accuracy was 84.3% (70/83, CI: 75, 90.6) 
and the positive likelihood ratio was 2.9 (CI: 0.03-217.8). The negative likelihood ratio 
was 0.85 (CI: 0.7, 1.1). 
Table 9.8. Overall performance of the Fungiplex PCR-SERS and 28Asp qPCR for 
the diagnosis of invasive Aspergillosis in 83 patients with Probable IA. 
 28Asp 
PNC$/POS* 
28Asp 
POS 
Fungiplex 
 % 95% CI % 95% CI % 95% CI 
Sensitivity 100 34.2, 100 100  34.2, 100 100 34,2, 100 
Specificity 69.2 58.4, 78.1 93.8 86.4, 97.3 61.7 50.8, 71.6 
NPV 100 93.6, 100 100 95.2, 100 100 92.9, 100 
PPV 7.4 2, 23.4 28.6 8.2, 64.1 6.1 1.7, 19.6 
Diagnostic accuracy 69.9 59.3, 78.7 94 86.7, 97.4 62.7 51.9, 72.2 
LHR+ 3.24 3 – 3.5 16.2 11, 24 2.6 2.4, 2.8 
LHR- 0 0.0 - ? 0 0.0 – ? 0.0 0.0 – ? 
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9.3.10.3 Fungiplex PCR 
Fungiplex PCR demonstrated a sensitivity of 50% (5/10 CI: 23.6, 76.3), specificity of 
61.6% (45/73 CI: 50.2, 72), PPV 15.5 (5/27 CI: 6.7, 30.9) and NPV of 90% (51/56, CI: 
78.6, 95.7) for the diagnosis of IA in probable/possible patients when considering only 
POS results as positive. The overall diagnostic accuracy was 60.2% (56/83 CI: 49.5, 
70.1) and the positive likelihood ratio was 1.3 (CI: 0.8-2.1). The negative likelihood ratio 
was 0.8 (CI: 0.5 1.2). 
 *POS = two positive PCR replicates $PNC = Positive not confirmed with one positive 
reaction.  
 
9.3.11 Comparison of PCR positivity by Fungiplex PCR-SERS and 28Asp 
qPCR  
In total 14.3% (49/342) of samples were positive by 28Asp PCR and (43/342) as 
detailed in table 9.10. Overall agreement between the two assays was seen for 79.9% 
of the samples. Out of 85 samples positive by either assay only 8.2% (7/85) were 
positive by both assays. This agreement is considered to be poor between the two 
assays. 
 
 
 
Table 9.9 Overall performance of the Fungiplex PCR-SERS and 28Asp qPCR for the 
diagnosis of invasive aspergillosis in patients with Probable or Possible IA. 
 28Asp 
PNC
$
/POS* 
28Asp 
POS 
Fungiplex 
 % 95% CI % 95% CI % 95% CI 
Sensitivity 50 23.7, 76.3 20 5.7, 51.0 50 23.6, 76.3 
Specificity 69.9 58.6, 79.2 93.2 85, 97 61.6 50.2, 72 
NPV 91.2 80.7, 96.1 89.5 80.5, 94.6 90 78.6, 95.7 
PPV 18.5 8.1, 36.7 28.6 8.2, 64.1 15.5 6.7, 30.9 
Diagnostic 
accuracy 
67.5 56.8, 76.6 84.3 75, 90.6 60.2 49.5, 70.1 
LHR+ 1.7 1, 2.7 2.9 0.03, 217.8 1.3 0.8, 2.1 
LHR- 0.7 0.5, 1.1 0.85 0.7, 1.1 0.8 0.5, 1.2 
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9.3.12 Performance of combined biomarker testing; Fungiplex PCR-SERS 
and 28Asp qPCR alongside GM EIA in patients with Probable IA 
The performance of combined biomarker testing for the detection of IA in patients with 
probable disease is detailed in table 9.11. When combining a positive PCR result with 
either Fungiplex PCR-SERS or 28Asp qPCR with a positive GM EIA result for probable 
patients the sensitivity was 100% (34.2, 100), specificity was 100% (95.5, 100), PPV 
100% (34.2, 100) and NPV 100% (95.5, 100).  
 
 
 
 
 
 
Table 9.10 Comparison of Fungiplex and qPCR results per sample. 
 
qPCR Positive 
(+ve) 
qPCR Negative 
(-ve) 
Fungiplex Positive (+ve) 6 37 
Fungiplex Negative (-) 32 268 
Agreement 79.9%  - 
Kappa  0.035 (-0.08-0.149) 
Table 9.11 Overall performances of the Fungiplex PCR-SERS and 28Asp 
qPCR assays in combination with Galactomannan EIA for the diagnosis of 
IA in probable and NEF patients. 
 Fungiplex PCR-SERS + 
GM 
28ASP 
PNC$/POS* + GM 
 % 95% CI % 95% CI 
Sensitivity 100 34.2, 100 100 34.2, 100 
Specificity 100 95.47, 100 100 95.47, 100 
NPV 100 95.47, 100 100 95.47, 100 
PPV 100 34.2, 100 100 34.2, 10O 
Diagnostic 
accuracy 
100 95.6, 100 100 95.58, 100 
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9.3.13 ROC analysis of CT values from the 28Asp PCR 
Receiver operator characteristic (ROC) curves were plotted for four scenarios, POS 
PCR and probable disease figure 9.5 a), POS or PNC PCR with probable disease 
figure 9.5 b), POS PCR with possible/probable disease figure 9.5 c) and POS/PNC 
PCR with probable or possible disease classifications figure 9.5 d). The area under the 
curve was poor at 0.65 and 0.70 for POS 28Asp PCR and probable disease and POS 
or PNC 28Asp PCR with probable disease respectively. For the remaining two 
analyses the area under the curve of 0.55 and 0.57 indicated ‘failed’ performance of 
PCR in the POS 28Assp PCR with possible/probable disease and 28Asp POS/PNC 
PCR with probable or possible disease. Table 9.12 demonstrates the performance 
parameters of the 28Asp PCR in the four categories at the analytically determined LOD 
of the PCR, a CT of 41 cycles. Again this analysis supports the use of duplicate PCR 
reactions (POS) to be a true positive result for the diagnosis of IA with a sensitivity of 
32% (CI: 15, 54), specificity of 97% (CI: 94, 98). 
 
   
   
Figure 9.5 ROC curve analysis for 28Asp PCR for a) POS PCR (using an average CT) and 
probable disease, b) POS (using an average CT) /PNC PCR with probable disease c) POS 
PCR (using an average CT) and probable/possible disease and d) POS (using an average CT) 
/PNC PCR and probable/possible disease. 
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Acc = accuracy, POS = two positive reactions, PNC = positive non-confirmed with one positive reaction 
 
 
 
Table 9.12 Overall performance of the 28Asp PCR at the positive CT threshold of 41 for PCR classifications against disease 
classification. 
PCR EORTC Sens % CI Spec % CI PPV NPV LR+ LR- TP TN FP FN Acc 
POC Probable 0.32 0.15 0.54 0.97 0.94 0.98 0.35 0.96 9.3 0.7 6 313 11 13 0.93 
POS/PNC Probable 0.42 0.23 0.64 0.92 0.88 0.94 0.23 0.96 5.2 0.62 8 298 26 11 0.89 
POS Probable/possible 0.13 0.06 0.27 0.96 0.93 0.98 0.35 0.87 3.4 0.90 6 285 11 41 0.84 
POS/PNC Probable/possible 0.21 0.12 0.35 0.92 0.88 0.95 0.29 0.88 2.6 0.86 10 272 24 37 0.82 
 
 226 
9.4 Discussion 
This study has demonstrated the challenges of utilising PCR for the diagnosis of 
invasive aspergillosis in the haemato-oncology setting. Both PCR assays 
demonstrated the ability to exclude disease with NPV of 100% (56/56, 95% CI: 95.2, 
100) for the 28Asp PCR (POS only) and 100% (50/50, 95% CI: 92.9, 100) for the 
Fungiplex PCR. Both assays detected Aspergillus sp in patients with probable disease, 
with a sensitivity of 100% (2/2, 95% CI: 34.2, 100). However, Aspergillus DNA was also 
detected from serum samples of patients without disease, and both assays 
demonstrated very low PPV, 28.6% (2/7, 95% CI: 8.2, 64.1) for the 28Asp assay 
(accepting POS only) and 6.1% (2/33, 95% CI: 1.7, 19.6) for the Fungiplex assay 
(when accepting only patient with probable disease). Specificity was improved for the 
28Asp assay 93.8% (56/81 95% CI: 86.4, 97.3) by accepting duplicate PCR reactions 
as a true positive (POS) versus 61.7% (50/81 95% CI: 50.8, 71.6) for the Fungiplex 
assay that could only be performed as a single reaction. This study has demonstrated 
that Aspergillus PCR can be used to rule out Invasive aspergillosis but cannot be used 
to accurately detect disease as a stand-alone test. When combined with a second 
biomarker, in this case GM-EIA, PCR shows better statistical significance for 
diagnosing invasive aspergillosis infection.  
Both PCR assays show promise for the accurate inclusion and exclusion of invasive 
aspergillosis when used in combination with a second biomarker such as GM-EIA. In 
this study 100% (83/83 95% CI: 95.6, 100) diagnostic accuracy for the detection of 
invasive aspergillosis, during the ‘at risk’ neutropenia window was demonstrated by the 
28Adp and the Fungiplex PCR assays. These findings are supported by several other 
studies that also demonstrated increased accuracy of diagnosis when combining 
biomarkers along with clinical findings on CT (Rogers et al., 2013; Johnson et al., 
2015; Paholcsek et al., 2015; Eigl et al., 2016). This discussion aims to consider the 
analytical performance of Aspergillus PCR and highlight the factors impacting on the 
clinical performance that contribute to lack of accuracy of PCR as a standalone test in 
the diagnosis of IA. 
 
9.4.1 Analytical performance of Aspergillus PCR 
It is important to implement a highly sensitive PCR strategy for the detection of 
Aspergillus DNA from serum. Free circulating DNA is known to be present in low 
quantities during the disease process (J Loeffler et al., 2000; Challier et al., 2004). In 
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2002 Loeffler and colleagues demonstrated through analysis of serum from mice 
models that the detection of Aspergillus in mice known to have invasive pulmonary 
disease was only 25%, and that the fungal load in blood was relatively low (101 – 102 
cfu/mL), in blood despite the mice having significant pulmonary infection (Loeffler et al., 
2002). It was also demonstrated that the quantities of DNA detected by PCR in the 
murine model of invasive aspergillosis were proportional to the amount of fungal 
biomass present in the mouse lung (Morton et al., 2010), suggesting that in early 
infection the burden of DNA in blood would be low and corresponding to low burden in 
the lung. The observation made in the mouse model studies have correlated with 
observations made when testing blood samples from patients also known to have 
invasive aspergillosis (Oliver Morton et al., 2011). As the diagnostic aim is to apply 
PCR to detect the early stages of infection it is essential to employ a highly sensitive 
PCR to detect these low levels of circulating DNA. 
 
The first step of this study was to demonstrate that both PCR assays evaluated were 
sensitive enough to detect low quantities of DNA from serum. Using control plasmid for 
the 28Asp assay sensitivity down to 20 plasmid copies per reaction equivalent to 1 
genome copy per reaction was demonstrated. In a previous study the LOD of 
Fungiplex was reportedly 20 plasmid copies per reaction with 95% reproducibility 
(White et al., 2014). However, for this study plasmid was not available to assess the 
Fungiplex sensitivity. The comparison of sensitivity of the two PCR assays evaluated 
was achieved through dilutions of genomic DNA, which were analysed. Absolute 
reproducibility was demonstrated at concentrations equivalent to 6.5 (CI: 2.8, 14.4) 
plasmid copies copies/µL for both assays, equivalent to between 1 and 7 genome 
copies per reaction. The detection of Aspergillus DNA was possible at the lowest 
concentration of genomic DNA equivalent to between 0.3 and 3 genome copies per µL, 
but was not 100% reproducible at this dilution for both assays, most likely reflecting the 
variability in the lowest genomic DNA concentration. These observations are supported 
by work published by the EAPCRI working party which demonstrated 97% 
reproducibility at a concentration of 10 genomes per mL of serum, equivalent to 2 
genome copies per reaction (White et al., 2011). As comparable sensitivity was 
observed across both assays it can be concluded that if any differences in performance 
were observed it is unlikely that this would be due to differences in sensitivity. A 
limitation of this study was not to investigate dilutions between the medium and low 
concentrations therefore, one can only state that the LOD lies between 1-7 genome 
copies per reaction. As both assays demonstrate the sensitivity required follow-up 
investigations were required to assess the impact of DNA extraction and sample input 
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volume to ensure the DNA extraction process did not negatively impact on the 
sensitivity of the workflow. The extraction methods in this study followed the guidance 
published by the EAPCRI working party.  
 
9.4.2 EAPCRI compliant DNA extraction  
Over the past decade the EAPCRI working party have worked to develop guidelines 
that can be used across clinical centres to standardize Aspergillus PCR (White et al., 
2010, 2011, 2012). Work conducted to date has identified the critical factors influencing 
the performance of Aspergillus PCR through the distribution of blinded quality control 
(QC) panels to international centres. The results from the working party identified that 
DNA extraction was the critical component of the PCR process that affected the 
performance of Aspergillus PCR. The recommendations made by EAPCRI are to use a 
commercial extraction method, preferably automated extracting from a minimum of 
500µL of sample and elute into less than 100µL of elution buffer (White et al., 2010, 
2011, 2012). To ensure optimal performance of both PCRs being investigated in this 
study we chose to investigate the impact of extracting from two sample volumes, 
550μL and 1mL, whilst maintaining the eluate to a 50µL volume on the automated 
extraction platform Diasorin IXT.  
 
9.4.3 Impact of sample volume DNA extraction  
By spiking serum with the genomic DNA dilutions previously characterized through 
direct PCR analysis it was possible to demonstrate the impact of the extraction process 
and input sample volume on recovery of DNA. No loss in sensitivity was observed 
when analysing extracts from 1mL of serum for high concentrated samples, whereas 
CT values were significantly higher when extracting from 550µL of serum, indicating a 
loss in sensitivity. A significant loss in sensitivity was observed when extracting DNA 
from 1mL of serum at the medium concentration but 100% reproducibility was still 
maintained, whereas from the 550µL serum extract the detection of Aspergillus was no 
longer 100% reproducible. It is expected that some loss in DNA will occur through 
extraction; this observation was demonstrated by White et al whereby DNA that was 
extracted and quantified revealed losses of at least 102 copies during manual 
extraction. Minimising the loss of DNA during extraction through the use of novel 
automated extraction technology has been recommended by leading groups 
investigating the performance of Aspergillus PCR (White, Linton, et al., 2006).  
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This study aimed to minimize the impact by utilising automated extraction with 
paramagnetic bead-based capture of DNA. The Diasorin IXT (Nordiag Arrow) has been 
shown to be highly efficient nucleic acid platform when extracting from blood cultures, 
stool and spiked blood samples (Laakso et al., 2011; Laakso and Mäki, 2013; Kalina et 
al., 2014; Forsell et al., 2015). When extracting DNA from whole cell bacteria spiked 
into blood the method was shown to be sensitive at 11cfu/mL for Escherichia coli. To 
date there are no comparative studies published using this exact method of extraction 
for Aspergillus DNA from serum but other similar platforms utilising paramagnetic bead-
based DNA capture have been shown to be superior to column based and manual 
extraction techniques through increased yield of nucleic acid from paraffin embedded 
tissue (Ribeiro-Silva, Zhang and Jeffrey, 2007). When extracting 4-5 A. fumigatus 
genome copies from 1mL of serum ultimately equating to 1-2 genomes copies input 
per reaction this study demonstrated that 100% reproducibility through both PCR 
assays. It can be concluded that the Diasorin IXT extraction platform used in 
conjunction with both PCR assays combined to produce a laboratory workflow met the 
required performance characteristics expected of a diagnostic assay in the clinical 
setting of invasive aspergillosis.   
 
9.4.4 Clinical performance of PCR 
The gold standard for comparison of PCR performance in this study was the 
classification of patients according to 2008 EORTC/MSG criteria (De Pauw et al. 2008) 
into categories of proven, probable, possible disease or control cases. The primary 
analysis was assessing the performance of PCR for the diagnosis of IA in patients with 
proven/probable IA. Patients classified as having possible disease were included 
alongside those without evidence of disease in the control group. This is the approach 
recommended by the Cochrane group (Leeflang et al., 2013) as possible IA should not 
be considered as positive for treatment purposes. In clinical practice many patients are 
classified as possible cases of IA, therefore a secondary analysis was performed to 
assess PCR performance for the diagnosis of patients classified as probable and 
possible cases of IA versus control patients.  
 
9.4.5 Prevalence of Invasive Aspergillosis according to EORTC MSG criteria  
In this study the prevalence of probable and probable/possible invasive aspergillosis 
was 2.4% (2/83) and 12% (10/83) respectively. We did not experience a case of 
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proven invasive aspergillosis. In a recent meta-analysis evaluating the performance of 
Aspergillus PCR the mean incidence of proven/probable diseases across the 13 
published studies was 22.5% (range 6.5%-66.7%) (Arvanitis, Anagnostou and 
Mylonakis, 2015). The mean number of patients included in the respective studies was 
118 (range 25-549) with 8 studies having less than 100 patients. The sample size of 
these studies is not too dissimilar from this study therefore; one can conclude that in 
this study the prevalence of invasive aspergillosis is low in comparison to other 
published work. The use of mould active antifungals as prophylaxis or empirically in 
patients at high risk of invasive fungal disease in our centre is most likely the cause of 
this observation, resulting most likely resulted in the low prevalence of disease. This is 
supported by a study by Cordonnier et al who demonstrated that patients receiving 
empirical antifungal therapy the prevalence of disease was lower at 2.7% versus 9.1% 
in the pre-emptive study arm who did not receive mould active treatment empirically 
(Cordonnier et al., 2009). The prevalence of disease is important when assessing the 
performance of diagnostic assays, in low prevalence disease settings the specificity 
and PPV of diagnostic tests is reduced (Leeflang et al., 2013). The performance 
characteristics of a diagnostic test determine how the test is utilized in the 
management of patients. If the test is highly specific with a high PPV then it may be 
used to confirm the presence of disease, whereas tests with high NPV and sensitivity 
can be used, when negative, to rule out disease (diagnostic tests 2: predictive values 
bland). In this study Aspergillus PCR demonstrated the latter attribute.   
 
9.4.6 Negative predictive value of Aspergillus PCR 
This study has demonstrated that the strength of Aspergillus PCR is in its ability to rule 
out disease in patients at risk of invasive aspergillosis with NPV of 100% (76/76, CI: 
95.2 100) for the 28Asp PCR (POS) and 100% (50/50, CI: 92.9, 100) for the Fungiplex 
PCR when considering patients with probable disease only. High NPV for the diagnosis 
of proven/probable IA is a finding replicated in many studies investigating Aspergillus 
PCR for the diagnosis of IA (Mengoli et al., 2009; Arvanitis, Anagnostou and 
Mylonakis, 2015). When considering patients with probable/possible disease the NPV 
was reduced to approximately 93.2% in our study. A definition of possible IA does not 
rely on the inclusion of a fungal biomarker leading to a less stringently defined cohort of 
patents, in which patients without disease will almost definitely be included as cases. It 
is generally accepted that when using PCR assays in clinical practice disease cannot 
be conclusively ruled out in a small proportion of patients. However, the NPV of PCR 
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remains the leading attribute suggesting PCR as an ideal Candidate as a diagnostic 
test to drive pre-emptive strategies when prescribing antifungal agents in clinical 
practice.  
The use of PCR to rule out invasive aspergillosis or to withhold unnecessary use 
antifungal agents is referred to as a targeted pre-emptive approach to antifungal 
therapy. A clear definition of a ‘pre-emptive antifungal strategy’ has not been 
established in national or international guidelines, but commonly the aim is to restrict 
the use of empirical antifungal therapy to those who have an indication of early stage 
antifungal disease. This would reduce the overall use of antifungals and their 
associated costs. Furthermore it would lessen the attributed mortality from toxicity. 
Antifungal therapy may then be administered when either radiologically or a biomarker 
positive (PCR or GM EIA) results are suggestive (Maertens et al., 2006; Cordonnier et 
al., 2009; Barnes et al., 2013; Knitsch et al., 2015). This approach is increasingly 
necessary as the use of antifungals in healthcare is disproportionate to the incidence of 
invasive fungal disease. It is estimated that over 50% of antifungals are inappropriately 
administered (J Loeffler et al., 2000; Sutepvarnon et al., 2008; Nivoix et al., 2012). 
Antifungal agents are toxic to certain patients as many of the molecular targets for 
antifungal drugs are eukaryotic molecules synonymous with those within the human 
body, in particular those resulting in hepatic and renal toxicity. Moreover, antifungal 
agents can be expensive, with the annual UK antifungal spend exceeding £112 million 
alone in 2013 (PHE, 2014). There are also only four main classes of antifungal agents 
used empirically and with antifungal resistance increasing and multi-drug resistant 
(MDR) fungi such as C. auris, are emerging globally under the selective pressure of 
antifungal overuse (Chowdhary et al., 2014; Morales-López et al., 2017). Selective use 
of antifungal agents and antifungal stewardship is now a healthcare directive from the 
PHE with the increased risk of MDR yeast species such as C. auris (PHE, 2016). 
One limitation of this study was that data relating to antifungal administration to 
patients was not collected so for our patient cohort not allowing estimates are made as 
to how PCR may have affected antifungal use in a targeted approach. However, our 
management strategy for haemato-oncology patients is to use Itraconazole prophylaxis 
(or liposomal Amphotericin B when Itraconazole is contraindicated) during their period 
of neutropenia to protect against IA. In this study using the 28Asp PCR or the 
Fungiplex PCR with two positive reactions 62.7% (52/83) patients tested negative for 
Aspergillus sp and according to EORTC/MSG criteria were classified as control 
patients unlikely of ever having Invasive Aspergillosis. Prophylaxis could have been 
withheld in a significant proportion of these patients based on biomarker use. This is 
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supported by findings in published studies utilising a pre-emptive approach to 
antifungal therapy (Maertens et al., 2005; Girmenia et al., 2010; Tan et al., 2011; 
Barnes et al., 2013).  
In 2013, Barnes and colleagues published their findings when assessing a pre-emptive 
pathway of twice weekly antigen and PCR screening for the management of invasive 
fungal disease (Barnes et al., 2013). In this study 549 high-risk haematology and stem 
cell transplantation patients were enrolled over a 5-year period. Both GM-EIA and PCR 
showed optimal performance as screening tests when used in combination with high 
sensitivity (98%) and negative predictive value (99.6%). Using a pre-emptive strategy a 
£100,000 decrease in antifungal spends over a six month period was observed 
(Barnes et al., 2013). These savings were approximately double the cost of 
implementing the biomarker screening (Barnes et al., 2013). Using a pre-emptive 
approach through a diagnostic driven strategy also resulted in a significant decrease 
(p=0·002) in antifungal use in a randomized control trial (Morrissey et al., 2013).  
Caution must be taken when implementing any diagnostic driven strategy, incorrect 
implementation may result in overuse of antifungal agents. In 2009 Herbert and 
colleagues utilized a pan fungal PCR to drive pre-emptive use of antifungal agents 
compared with a fever based driven strategy in the empirical group (Hebart et al., 
2009). An increase in antifungal usage was observed in the pre-emptive arm as the 
investigators chose to administer antifungals after 5 days of fever despite obtaining 
negative PCR results, disregarding the NPV of fungal PCR (Hebart et al., 2009). It is 
also important to acknowledge that if empirical treatment is withheld in patients at risk 
of invasive aspergillosis and a pre-emptive approach is used to drive antifungal therapy 
an increase in the prevalence of aspergillosis may be observed. Whereas work 
performed by Cordonier and colleagues observed significantly increased prevalence 
(p<0.02) of aspergillosis of 9.1% compared with 2.7% in the preemptive arm, but also 
observed a reduction in the use of antifungals in the preemptive arm (Cordonnier et al., 
2009). It may be the case that removing empirical therapy enables the performance of 
the diagnostic assays to improve. Antifungal treatment has been shown to affect the 
performance of PCR in early stages of disease, reducing sensitivity of detection in 
animal models (McCulloch et al., 2012) and in patients at risk of invasive aspergillosis 
(Marr et al., 2004). The reduction in biomarker availability when using antifungal 
prophylaxis with a background of low disease prevalence requires the use of a highly 
sensitive PCR assay. In this setting the effects of false positivity in the diagnostic 
workflow are enhanced, as was observed in this study.  
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9.4.7 Positive predictive value and specificity of Aspergillus PCR 
The quantity of fungal nucleic acid in serum is low (J Loeffler et al., 2000; Challier et 
al., 2004) and is most likely very close to the limit of PCR detection (LOD) (Springer et 
al., 2013). Previous studies have recommended that a single positive reaction should 
be accepted as positive, even when performing PCR in duplicate reactions (Millon et 
al., 2005; Springer et al., 2012). In this study, when accepting a single positive PCR 
reaction as a true positive, the performance of the two PCR assays was comparable 
with a very low PPV of 7.4% (2/27, CI: 2, 23.4) for the 28Asp PCR and 6.1% (2/33, CI: 
1.7, 19.6) for the Fungiplex assay. Specificity was also low at 69.2% and 61.7% for the 
28Asp and Fungiplex assays respectively. If the positive acceptance criteria were 
restricted to only accept a true positive result as a sample that is reproducibly positive 
(two positive PCR reactions) performance of the 28Asp PCR was improved to a PPV 
and specificity of 28.6% (2/7, CI: 8.2, 64.1) and 92.6% (76/81 CI: 86.4, 97.3). This 
performance is comparable to that of the meta-analysis published by Arvantis and 
colleagues (Arvanitis, Anagnostou and Mylonakis, 2015). This study has demonstrated 
that applying PCR in a very low disease prevalence setting, with only two cases of 
probable disease more stringent criteria are required to obtain the performance 
expected of PCR as a diagnostic assay. The same analysis could not be performed for 
the Fungiplex as the study was limited by the cost at £45 per single reaction. It is 
possible that the performance of the Fungiplex assay would have also been improved 
by performing PCR in duplicates. The performance of the Fungiplex PCR was 
previously shown to be 85.7% and specificity of 87.5% with single reactions which 
increased to a specificity of 97.5% when testing in duplicate (White et al., 2014).  
Performance of PCR can also be enhanced by combination with a second biomarker 
for the detection of Aspergillus. 
The combination of Galactomannan and PCR for the diagnosis of IA in probable 
patients was shown to be 100% accurate in this study, although was limited by only 
two patients being classified as having probable IA. Galactomannan and PCR were 
only positive in combination for patients with radiological evidence of disease. The 
impact is slightly biased as a probable case of IA is defined as being a patient with a 
positive GM EIA, but no patients were positive by both biomarkers in the absence of 
radiological evidence of disease. The combined biomarker approach has been shown 
to be successful in other studies. In 2008 Botterel and colleagues demonstrated 
improved specificity for the diagnosis of IA when performing PCR on the first GM 
positive sample when screening liver transplant patient at risk of IA (Botterel et al., 
2008). Aguado et al demonstrated that earlier diagnosis could be achieved using PCR 
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and GM when compared with GM alone with a median time to diagnosis of 13 days 
versus 20 days respectively (Aguado et al., 2015). Furthermore survival was 
statistically higher in the PCR-GM group in this study (p<0.05) (Aguado et al., 2015). 
Combined use of GM and PCR could neutralize the effects of false positivity when 
using PCR as a stand-alone assay.  
The risk is that a false positive result could lead to the administration of unnecessary 
antifungal therapy. In this study if a pre-emptive approach had been driven by one 
positive PCR reaction 32.5% (27/83) of patients would have been administered 
targeted antifungal therapy and 39.8% (33/83) if the Fungiplex assay had been utilized. 
This echoes the findings of the study by Hebart [discussed previously] who observed 
the use of antifungal agents in the pre-emptive fever plus PCR arm increase by 20.4% 
(Hebart et al., 2009). The high rate of positive results when using Aspergillus PCR 
diagnostically is a concern and the environment in which the PCR is performed 
undoubtedly is a key factor. False positivity when utilising a highly sensitive PCR is 
almost unavoidable in this setting as Aspergillus is ubiquitous in the environment. As 
saprophytic fungi, Aspergillus sp are found in soil and detritus material and is freely 
cultured from the environment through an abundance of conidia dispersed though the 
aerodynamic structure of spores. As a consequence via both conidia but also free DNA 
in the environment PCR reaction processes can be readily contaminated. A. fumigatus 
has been found to contaminate extraction reagents in commercially available kits and 
blood vacutainers used to collect blood specimens (Rimek et al., 1999; Harrison et al., 
2010; Perry, White and Barnes, 2014). A further reported source of false positivity is a 
lack of fungal specificity in the design of PCR assays which may result in the 
amplification human DNA, which has also been previously reported (White and Barnes, 
2006; White,et al., 2006). To reduce the impact of false positivity this study a cut off of 
41 cycles was selected. The rationale for this threshold was that an input of 3 plasmid 
copies into the reaction resulted in a median CT of 40.8 that was equivalent to the LOD 
of our assay at evaluation. Any positivity beyond a cycle threshold of 41 most likely 
does not represent true amplification but late false amplification in the assay. One 
further complication experienced in this study which almost certainly contributed to the 
high rate of false positivity was in the design of the assays. The 28Asp PCR targets the 
gene encoding 28S ribosomal RNA (White et al, 2011). The Fungiplex PCR also 
targets this same region. When running these two workflows in parallel it became clear 
that the rate of false positively was higher than would have been expected.  
The root cause of the increased false positivity was poor control of cross contamination 
in the environment in which the assays were being performed in, resulting in carry over 
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contamination. The Fungiplex workflow requires amplification tubes to be opened for 
the addition of the amplification product into the hybridization reaction. This action is a 
high risk process that should ideally be performed in a post-PCR environment, i.e. a 
room dedicated for the handling of amplicon manipulation, completely isolated from 
reagent preparation (pre-PCR) and other sample (DNA extraction) working 
environments. Furthermore, once this task has been performed the operator should not 
enter a clean environment until the next day once clothing has been changed as 
amplicons can be carried into clean environments (this process is similar to other high 
risk work flows in molecular pathology in areas such as pre-natal diagnostics). This 
study was conducted in a shared university research department where the control of 
amplicon spread was challenging due to lack of segregated molecular infrastructure. 
The correct molecular infrastructure in the clinical setting is crucial to establishing a 
robust service. The lack of a second open tube amplicon manipulation post-PCR room 
controlling for both movement of people and sample through the PCR workflow led to 
amplicon contamination being detected in the clean room. When testing the amplicon 
of the Fungiplex assay in the 28Asp PCR it was realized that the same target region 
was being amplified as positive reactions were obtained.   
9.4.8 Conclusions 
In conclusion, this study has demonstrated the challenges faced when using 
Aspergillus PCR for the diagnosis of IA in the haemato-oncology setting. Prophylaxis 
impacts on the performance of an assay already challenged by a low prevalence of 
disease. Environmental false positivity is a significant risk that could contribute to the 
over use of antifungal agents and misdiagnosis of infection. The 28Asp assay 
demonstrated the most successful approach when used in combination with GM, for 
diagnosis of IA. The Fungiplex PCR did not demonstrate any increased performance 
when compared with the 28Asp assay, despite its use of SERS technology. The assay 
setup process presents a significant risk when establishing Aspergillus PCR as a 
diagnostic test with high risk of cross contamination during post-PCR amplicon 
manipulation phase, therefore limiting its practicality in the diagnostic setting. In 
summary Aspergillus PCR remains a controversial test for diagnosis of IA and a 
multicentre trial investigating a pre-emptive strategy is most likely required to 
definitively answer the question as to whether this could be an effective approach.  
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10 Chapter 10 Conclusion and Future Developments 
Our research has demonstrated that it is possible to improve the diagnosis of invasive 
fungal disease by utilising molecular methods in the clinical diagnostic laboratory. At 
the outset of this research our routine diagnostic workflows relied heavily on culture 
based investigation and the detection of antigen using the GM–EIA. The aim of this 
research was to replace or supplement the existing testing strategy with molecular 
based techniques that could improve diagnosis of invasive fungal infection. Figure 10.2 
details what is now the outputs of this research and is new our workflow for diagnosis 
of invasive fungal disease within our clinical service. Whilst, in some instances, the 
assays utilised in the respective research did not conclusively improve the diagnosis of 
IFI as stand-alone tests, their use in testing strategies has aided in informing how 
molecular tests can be utilised appropriately. One molecular method that has met the 
criteria required to be a stand-alone assay for diagnosis is MALDI-TOF MS for the 
identification of fungi.  
10.1 Improving the identification of fungi from culture  
The introduction of MALDI-TOF MS for the identification of yeasts from clinical 
specimens has undoubtedly revolutionised our approach to diagnosing invasive 
candidiasis. One of the main advantages of MALDI-TOF MS is an increased specificity 
in identifying rare yeast species from infections. After the introduction of MALDI-TOF 
MS based diagnosis of invasive candidiasis we diagnosed a rare infection of                 
C. nivariensis in a renal patient with persistent Candiduria (Gorton et al., 2013). In 
immunocompetent patients Candida in the urine is often considered insignificant, but in 
a renal patient cohort the isolation of Candida from urine warrants further investigation 
as ascending or descending renal infection post-transplant can be a major cause of 
morbidity and mortality (Safdar. et al., 2005). The history of this patient when using 
AuxaColor (BIORAD) testing up to this point had been clinically confusing, as C. 
nivariensis isolates had been identified as two closely related species Candida glabrata 
(3/5) and Candida inconspicua (2/5) (Gorton et al., 2013). This had led to the isolation 
of these yeasts being considered insignificant for over a year after the patient’s 
admission to hospital. Current guidelines from the British Society of Medial Mycology 
strongly recommend that all Candida isolates from urine in the transplant setting are 
fully identified (Schelenz et al., 2009, 2015). Biochemical profiling is currently the 
primary method for yeast identification in most diagnostic laboratories. As a result, 
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cryptic de novo species such as C. nivarensis are not incorporated into databases for 
commercially available biochemical assays and clinically significant yeasts are 
misidentified (Posteraro et al., 2015). C. nivariensis is now a recognised cause of 
vaginal thrush and resistant to fluconazole, therefore demonstrating the impact of 
MALDI-TOF MS in benefiting routine clinical infection in addition to IFI. To date, several 
other case reports have detailed the impact of MALDI-TOF MS in the identification of 
rare yeast infection. These include the isolation of Kodamaea ohmeri in a case of 
fungemia which was correctly identified by MALDI-TOF MS (Valenza et al., 2006; 
Distasi et al., 2015; Aznar-Marin et al., 2016). This reinforces the fact that MALDI-TOF 
MS is equivalent to gold standard methods such as ribosomal sequenced based 
identification (Borman et al., 2008, 2010). 
Perhaps the most important event to have occurred in the last 5 years from a clinical 
mycology perspective is the global emergence of the multi drug resistant species 
Candida auris (Chowdhary et al., 2014; Clancy and Nguyen, 2017). In the UK, the 
emergence of C. auris is linked to carriage of the yeast into the UK through travel, as 
strains have been shown to have wide geographic origins (Borman, Szekely and 
Johnson, 2017). Intrinsically resistant to fluconazole, this species also has 
demonstrated high MICs to other antifungal agents such as amphotericin B and 
caspofungin (Arendrup and Patterson, 2017). Strains from India were reportedly fully 
resistant to all antifungal drug classes (Chowdhary et al., 2014). C. auris now presents 
as a major infection control concern, as the opportunistic pathogen is able to colonise 
and cause invasive infection in vulnerable patients, most commonly in the ICU (Shetty 
et al., 2016; Clancy and Nguyen, 2017). In a similar way to Staphylococcus aureus and 
MRSA, C. auris has resulted in large outbreaks and attributed deaths in healthcare 
systems globally. Biochemical methods, including CHROMagar and reaction test strips, 
are unable to distinguish this species from C. haemulonii or C. duboshealulonii  
(Kathuria et al., 2015). MALDI-TOF MS is capable of identifying C. auris with a high 
degree of accuracy (Grenfell et al., 2016). In the infection control setting, this 
technology now sits at the front line in the laboratory for the rapid identification of 
yeasts from cultures and has been essential in the control of clinical outbreaks. In 
centers where MALDI-TOF MS is not available, referral to recognised mycology 
reference services or implementation of molecular sequenced based identification 
techniques is the only other robust mechanism for identification. Both of these 
scenarios come with limitations in terms of both TAT and cost (Kordalewska et al., 
2017). Conclusively MALDI-TOF has strengthened the diagnostic laboratories ability to 
identify yeasts from clinical culture specimens. 
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10.2 Filamentous mould identification  
The identification of filamentous moulds using MALDI-TOF MS in the clinical laboratory 
has also had success, with large multicentre efforts to establish a comprehensive 
databases that can be used with high degrees of accuracy (Lima, Santos and Vena, 
2010; Del Chierico et al., 2012; Kondori et al., 2014; Ranque et al., 2014). However, 
standardisation across processing methods used across centres has become an issue 
with deviation from manufacturer’s recommended methods when establishing in-house 
databases (Lima, Santos and Vena, 2010; Del Chierico et al., 2012; Kondori et al., 
2014; Ranque et al., 2014). For our local clinical service we have decided to develop 
the existing Bruker filamentous mould database, in real time, using the manufacturer’s 
recommended preparation methods. This maintains the validation criteria performed by 
the manufacturer and builds on the quality and breadth of the reference spectra. The 
implementation of MALDI-TOF MS alongside microscopic culture strengthens the 
laboratories ability to have confidence in identifications returned by less experienced 
scientists and if discordance is observed between the scientist and the MALDI-TOF MS 
identification the isolate can then be processed using molecular sequencing methods 
to allow for resolution of the species identification. In turn, this enables our service to 
develop the database by creating spectral profiles for unidentified or discrepant fungi 
using the ITS rRNA sequenced based identification as the gold standard.  
Optimisation of the MALDI-TOF MS process could improve success. Normand and 
colleagues investigated a decision-base strategy against an in-house developed 
database and the commercially available filamentous mould dataset from Bruker. 
Across both databases they demonstrated that improved identification could be 
achieved by accepting that the highest score of four spots was taken into account with 
a 1.7 log (score) threshold (Normand et al., 2013). Using the in house database 
87.41% of isolates were identified compared to 35.15% using the Bruker database, 
with a positive predictive value (PPV) of 1 at the genus level for both databases as well 
as 0.89 PPV (in-house database) and 0.72 PPV (Bruker database) at the species level 
(Normand et al., 2013). These efforts have contributed significantly to the knowledge 
base of filamentous mould diagnosis. In support of, but potentially superseding this, we 
have seen this year [2017] the release of a free open access MALDI-TOF MS 
database for filamentous fungi which aims to address the challenges discussed 
throughout this research.  
https://biological-mass-spectrometry-identification.com/msi/ 
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The database was the effort of a multicentre working party, the BCCM/IHEM collection 
in Brussels, whose aims were to build a database for fungi as robust as bacterial 
databases that currently exist in routine clinical diagnostics. Comprised of 11,851 
spectra (938 fungal species and 246 fungal genera), the size of the database is 
significantly larger than commercial databases, which currently contain less than 150 
reference spectra. The database has ISO:9001 certification and therefore is suitable for 
use in routine diagnostic laboratories and also supports commercial developments. A 
recent study evaluated the performance of the database against a collection of >600 
isolates (Normand et al., 2017). A total of 87.4% were correctly identified at the species 
level, while 5.21% were assigned to the correct genus but the incorrect species. Only 
7.4% of the isolates were not identified as the defined threshold of 20 was not reached 
(Normand et al., 2017). This approach is building on the success of the GenBank 
database for the identification of fungi through sequence-based analysis of unknown 
strains against an extensive database of characterized genomic sequences. However, 
like with all databases the strength of their accuracy is in the gold standard reference 
point used to create the database. The potential impact of the new web based 
databases will undoubtedly be far reaching with global implementation in the routine 
setting and will be one of the next objectives of our diagnostic laboratory and clinical 
service to introduce the new database into routine use.  
10.3 Direct identification of yeasts from blood cultures  
The limitation of MALDI-TOF for the identification of yeasts direct from blood culture 
specimens was the principal finding of our analysis using this technology, lacking 
specificity in its pan detection of proteins from clinical specimens. In a similar manner 
to the filamentous mould database, optimization for successful identification of yeasts 
direct from blood cultures using MALDI-TOF MS could be achieved by further 
investigating the process of sample preparation. In our study we utilized the Sepsityper 
kit. This was a limiting factor as the method was restricted in the processing steps that 
could be optimized. Ironically this was the most crucial element to the success of the 
technique. In a recent publication Jeddi and colleagues (2017) have demonstrated that 
an alternative method can significantly improve the success of MALDI-TOF MS for 
yeast species (Jeddi et al., 2016). The method utilized by the group in brief involved 
processing 1.8mL of positive blood culture, which was first centrifuged for 13,000g for 2 
minutes, the supernatant was removed, and the pellet was suspended in 1.8mL of 
sterile distilled water and centrifuged again at 13,000g for 2 minutes. The supernatant 
was removed and the pellet was suspended in 1.8mL of 0.1% SDS in sterile distilled 
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water and incubated for 10 minutes (Jeddi et al., 2016). This contrasts with previous 
methods, as there is an initial centrifugation at high speed prior to processing the blood 
culture specimen through red cell lysis and wash steps, which was not investigated in 
our research. The difference in performance to the standard Sepsityper protocol was 
98.9 v 66.6% success. As the QuickFISH assay is limited in its assay format this new 
method for yeast processing most likely requires some consideration when QuickFISH 
in our laboratory returns a result of no identification, figure 10.2.  
To date, no further studies have been published using QuickFISH for the identification 
of yeasts direct from blood culture specimens. The test is fully implemented into our 
work streams for gram-positive bacteria and yeasts as a rapid method for identification. 
The results are being returned in real time along with the gram stain to clinicians and 
used for the antifungal decision-making process in patients with candidemia. The 
implementation of QuickFISH is a perfect example of a molecular test that was 
designed from the outset to complement the workflow of the clinical diagnostic 
laboratory without impact of staffing resource. Some of the most successful molecular 
diagnostic assays also follow this principle, including the GeneXpert (Cepheid, USA) 
range of NAAT assays in cartridge based format used widely in most tuberculosis 
laboratories globally (McNerney and Zumla, 2015). Expansion of the second 
generation QuickFISH assay will inevitably improve the assay and the next generation 
of the test will incorporate new species within the assay format, perhaps even a 
Candida auris probe.  
The next frontier in the diagnosis of invasive candidiasis is undoubtedly the 
implementation of Candida PCR direct from blood alongside BDG testing for the 
detection of invasive Candidiasis. At the time of starting this research the BDG assay 
was confined to reference laboratory testing services. However, with the increasing use 
of the assay and the final implementation in our clinical laboratory, we are now starting 
to further investigate patients’ who are positive by BDG. In these patients, for whom a 
clear diagnosis for IFI cannot be made, IC is the IFI for which we are lacking in a clear 
laboratory strategy and provides the next challenge diagnostically. The introduction of 
real-time PCR for Candida and the T2MR system (T2 Biosystems, MA, USA) in the 
future months will allow for a prospective evaluation of Candida PCR from blood 
alongside BDG for the diagnosis of invasive candidiasis (Mylonakis et al., 2015; Pfaller, 
Wolk and Lowery, 2016). The T2MR has demonstrated excellent performance in 
studies to date reporting sensitivity and specificity of 91.1% and 92.3% respectively for 
the diagnosis of IC (Mylonakis et al., 2015). Commercially available PCR kits are also 
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now available as real-time qualitative assays (Bruker Daltonics, Germany). The same 
principles and methods presented in the Aspergillus chapter will be applied to Candida 
PCR. This work is being undertaken as part of the efforts of the fungal PCR Initiative 
(FPCRI). With the use of PCR alongside the second biomarker BDG, which is not in 
itself a unique approach to invasive candidiasis is the approach we have implemented 
for the diagnosis of PCP in our clinical laboratory. 
 
10.4 Diagnosis of PCP 
GMS staining from BAL has been replaced by PCR as the front line test for the 
diagnosis of PCP. As demonstrated in this research, PCR can be limited in its 
specificity as colonisation of the lungs with P. jirovecii leads to false positive results. To 
resolve the lack of correlation between atypical clinical presentation for PCP and a low 
positive PCP PCR result we chose to adopt a dual biomarker testing strategy for 
improved clinical performance utilising the β-D-Glucan (BDG) assay (Fungitell, Cape 
Cod). The approach of dual biomarker testing is steadily increasing in adoption 
throughout centers using PCP PCR (Borstnar et al., 2013; Wood et al., 2013; White, 
Backx and Barnes, 2017). 
In 2012 Matsumura and colleagues reported the first study to investigate the utilisation 
of dual biomarkers in patients being investigated for PCP (Matsumura et al., 2012). A 
cut off of 1300 copies/mL of a single copy PCR targeting the dihydrophate synthase 
gene was established to discriminate between definite PCP with a specificity of 80.0%. 
A threshold of 340 copies/mL was used to discriminate between probable PCP and 
colonization (Matsumura et al., 2012). Matsumura and colleagues measured BDG in 
the same patients and reported significantly higher BDG levels in the definite group 
(median 39.5pg/mL, range 15.7–352.7pg/mL) than in the colonized group (median 4.3, 
range 4.3–61.5, p < 0.001) (Matsumura et al., 2012). In a similar investigation Damiani 
and colleagues demonstrated PCR had a PPV of 100% when the P. jirovecii DNA copy 
numbers were greater than 2 × 104 copies/μL (Damiani et al., 2011). The negative 
predictive value of the assay was 100% when the P. jirovecii DNA copy numbers were 
less than 1.6 × 103 copies/μL (Damiani et al., 2011). In figure 10.1 taken from 
Matsumara et al 2012 they correlated the BDG pg/mL results with the PCR copy 
numbers for each patient tested in the study. The authors demonstrated a clear 
relationship between low positive PCR results and positive BDG results (>100pg/mL) 
and suspected PCP infection. Where PCP infection was not suspected but the PCP 
reported a low positive result the BDG test was negative (<100pg/mL).  
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Figure 10.1 Correlation of β- D-glucan (pg/mL) and PCP qPCR (copies per µL) for the diagnosis 
of PCP in cases and controls (Damiani et al., 2011). 
Two further studies have since demonstrated that BDG levels are significantly different 
patients across the different classifications of disease made by incorporating PCR in 
the decision-making processes. Tasaka and colleagues reported β-D-glucan in the 
negative, colonization, probable PCP, and definite PCP subgroups as 20.2 ± 6.3, 48.8 
± 15.9, 89.9 ± 20.2, 224.9 ± 25.9 pg/mL (Tasaka, 2015). Lahmer reported BDG levels 
were significantly lower in patients with no PCP (86; 30–315 pg/ml) than in patients 
with a high positive PCP PCR (589; 356–1000 pg/mL; p =0.001) and low positive PCP 
(398; 297–516 pg/mL; p=0.004) (Lahmer et al., 2017). This approach enhances the 
diagnosis of PCP in non-HIV patients and may offer clinicians the confidence to treat or 
withhold treatment in patients where the clinical diagnosis is unclear.  
 
10.5 Combined biomarkers for diagnosis of invasive aspergillosis  
In our research we demonstrated 100% performance in the use of combined 
Galactomannan and PCR for the diagnosis of invasive aspergillosis in haemato-
oncology patients. The strategy of combined GM-EIA has also been demonstrated to 
have high performance in other studies on blood and BAL specimens (Bellanger et al., 
2011; Torelli et al., 2011; Eigl et al., 2015; Boch et al., 2016). Aspergillus PCR and GM-
EIA from serum have equivalent performance (Pini et al., 2014). Therefore combining 
the two tests and applying criteria of one of the two tests being positive when screening 
patients for IA is effective at detecting biomarkers of disease. Bellanger and colleagues 
reported the use of PCR and GM-EIA from serum in 16 cases of proven and probable 
IA. For 56.3% (9/16) of the samples both tests were simultaneously positive, all in 
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probable patients (Bellanger et al, 2011). Therefore this could have supported the 
diagnosis by providing increased confidence in the positivity of each test. For 18.8% of 
the samples PCR was positive without GM-EIA positivity and 25% were GM-EIA 
positive without PCR positivity at the same time (Bellanger et al, 2011).  
The complicating issue when utilising dual biomarkers for the diagnosis of IA, is that 
only one positive test still leaves a degree of uncertainty in the significance of the 
result. In a multicentre study by Boch and colleagues it was demonstrated that a single 
positive test when using GM and PCR on blood had a sensitivity of 22%, specificity of 
97% a PPV of 89% but an NPV of 49% (Boch et al., 2016). In an animal model study 
utilising PCR and GM-EIA for the detection of Aspergillus from blood the highest 
performance was obtained when using the two tests in combination with an AUC of 
0.95, however authors reported that no dual combination could entirely exclude 
disease but accepting one of two tests as positive had a sensitivity of 100% (White et 
al., 2016). The cost effectiveness of utilising two biomarkers for screening patients at 
risk of IA needs to be considered, as twice-weekly screening with the two assays will 
contribute to an increase in the cost per test. In a randomised control trial Macesic 
demonstrated no significant difference between the control group and the intervention 
group receiving GM-PCR screening (Macesic et al., 2017). There was a reduction in 
mortality from 14.7% to 10.1% (p=0.57) that was close to, but showed no statistical 
significance. In the cost analysis the authors estimated a cost per lifesaving of 
£242,661 at 180 days (Macesic et al., 2017). The utilisation of biomarkers for screening 
does not reduce the overall cost burden but does have an impact on survival and 
attributed cost per life year. The authors concluded the GM-PCR testing is not cost 
sparing but cost effective (Macesic et al., 2017). In an open label controlled trial across 
13 centers using GM-PCR based strategy the time to diagnosis was significantly 
reduced (p=0.027) from 20 to 13 days using biomarkers compared within the control 
arm (Aguado et al., 2015). 
There is clear evidence that a dual biomarker diagnostic strategy would be beneficial 
for the screening and diagnosis of patients at high risk of IA, however, implementation 
of this process in the current clinical environment is challenging from budgetary and 
logistical standpoints. In our centre we chose to utilise an alternate strategy, using PCR 
on BAL alongside GM-EIA testing from BAL and serum. This is a similar approach to 
one investigated by Boch and colleagues who demonstrated the optimal combination 
of biomarker performance being PCR and GM-EIA from BAL and BDG from blood 
(Boch et al., 2016). Boch demonstrated sensitivity, specificity, PPV and NPV of 92, 93, 
94 and 90% respectively with this triple testing strategy (Boch et al., 2016). This 
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approach is limited by the fact that a BAL sample is required as part of the testing 
algorithm but does target the use of biomarkers to specific specimens based on test 
performance and in combination offers a profile for the diagnosis of IA. Torelli and 
colleagues reported 94.1% concordance for positive results from BAL for PCR and 
GM-EIA and 98.6% concordance for negative results (Torelli et al., 2011). Therefore 
employing a testing strategy for BAL with two biomarkers and maintaining the use of 
BDG or GM-EIA from serum appears to be a reserved but suitable alternative 
approach until a time at which the use of PCR can be introduced. Our future aims are 
to audit our local service and summarise performance of this testing strategy following 
one year of established clinical testing. 
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INTRODUCTION 
Conventional methods for yeast identification, including culture and 
biochemical profiling, have a turn around time of 24-72 hours. 
Commercially available biochemical assays have restricted 
databases leading to misidentification of rarer cryptic species 1,2.  
The recent introduction of MALDI-TOF mass spectrometry (MS) 
into the routine diagnostic setting has enabled yeast identification in 
under 10 minutes from culture. This study aimed to evaluate three 
culture processing methods and the Bruker BioTyper™ 3 database, 
compared with conventional  phenotypic and ITS1&2 rRNA 
sequencing methods for yeast identification. Once validated 
prospective MALDI-TOF yeast identifications were collected over a 
one year period.  
MATERIALS & METHODS 
Yeast isolates; n = 488 including; 191 retrospective isolates 
(validation) and 297 prospective isolates. 
Conventional identification  
191 validation isolates; Sub-culture on CHROMagar™ Candida 
followed by Auxacolor™ 2 (BIORAD) and cornmeal agar 
phenotyping for non-albicans species.  
ITS rRNA genotypic identification (Gold standard);  
DNA extraction – mechanical lysis and Promega Wizard kit. ITS 
amplification performed using primers ITS1 (5' TCC GTA GGT GAA 
CCT GCG G 3') and ITS4 (5' TCC TCC GCT TAT TGA TAT GC 3'). 
Sequencing; BigDye® Terminator v3.1 Cycle Sequencing method on 
an Applied Biosystems 3130 platform.  
MALDI-TOF pre-processing;  
• Direct smear analysis - small amount of biomass smeared onto 
the target. 
• Direct on plate FA extraction -1µl 100% formic acid (FA) added 
to direct smear and allowed to dry prior to matrix. 
• Conventional FA extraction – as per standard protocol.  
MALDI-TOF analysis.  
1µl α-Cyano-4-hydroxy-cinnamic-acid  matrix, Microflex™ LT 
platform (Bruker Daltonics) analysing spectra in the 2000-20,000 m/
z range standard settings. Bruker Biotyper™ log score thresholds 
for secure species >2.0. Re-analysis of spectra was also performed 
lowering the species acceptable threshold to >1.9.  
 
 
 
 
 
RESULTS 
MALDI-TOF validation. The Bruker Biotyper™ identified 
96.5%(184/191) of isolates, demonstrating 100% agreement 
(184/184) with ITS rRNA sequencing. 3.5% (7/191) of isolates were 
not identified despite acquiring good MS spectra (Table 1). 
 
 
 
CONCLUSIONS 
MALDI-TOF MS and the Bruker BioTyper™ 3 software is an accurate 
method for the identification of clinically relevant yeasts. The Bruker 
BioTyper™ 3 database contains >100 yeast species and is capable of 
identifying cryptic species such as C. orthopsilosis where current 
conventional phenotypic methods cannot. Misidentification did not 
occur. If the Bruker Biotyper™ cannot identify a yeast genotypic 
methods should be used, as conventional phenotypic methods will give 
an incorrect result. In routine practice this is a rare occurrence. 
FA extraction of proteins is crucial and conventional FA extraction is 
recommended for yeasts, although some success is possible with 
direct on plate FA extraction. With an estimated reagent cost of £0.30 
per sample MALDI-TOF contributes to considerable cost savings and 
reduces the turn-around time for yeast identification by up to 72 hours. 
Acknowledgments: National Institute for Health Research NIHR (PhD funding)  
1. Massonet, C., E. J. Van, M. Vaneechoutte, B. T. De, J. Verhaegen, and K. 
Lagrou. 2004. Comparison of VITEK 2 with ITS2-fragment length polymorphism 
analysis for identification of yeast species. J. Clin. Microbiol. 42:2209-2211. 
2. Verweij, P. E., I. M. Breuker, A. J. Rijs, and J. F. Meis. 1999. Comparative study 
of seven commercial yeast identification systems. J. Clin. Pathol. 52:271-273. 
Table 2. Yeast species identified by the Bruker Biotyper ™ 
Species n Species n 
Candida albicans 192 Cryptococcus neoformans 5 
Candida glabrata 91 Candida dubliniensis  5 
Candida parapsilosis 84 Candida lusitaniae 4 
Candida tropicalis 36 Candida lipolytica 2 
Candida guilliermondii 17 Candida nivariensis 2 
Candida krusei 11 Magnusiomyces capitatus 1 
Saccharomyces cerevisiae  11 Pichia cactophila 1 
Candida kefyr 8 Candida pelliculosa 1 
Candida orthopsilosis 5 Trichosporon beigelii 1 
Candida famata 1 Candida lambica 1 
Table 1. Conventional misidentifications and MALDI-TOF ‘No 
identification’ compared to ITS rRNA results  
Conventional  n MALDI-TOF ITS rRNA 
C. parapsilosis 3 C. orthopsilosis C. orthopsilosis 
C. krusei 1 C. lambica C. lambica 
C. albicans 1 C. dubliniensis C. dubliniensis 
C. tropicalis 1 Pichia cactophila Pichia cactophila 
C. glabrata 1 C. nivariensis C. nivariensis 
C. guilliermondii 4 NO ID Candida fermentati 
C. pelliculosa 1 NO ID Candida fabianii 
G. candidum 1 NO ID Unresolved 
C. famata 1 NO ID D. nepalensis 
Conventional method evaluation. Conventional methods identified 
93% (177/191) of isolates correctly compared to ITS rRNA sequencing. 
7% (14/191) were misidentified by conventional methods (Table 1).  
 
Pre-processing methods; On the first attempt at identification the 
following MALDI-TOF success rates were observed ; 
(>2.0 />1.9 log score) 
• Direct  smear analysis - 0% (0/184) /both thresholds 
• Direct on plate FA - 42% (78/184)/66% (121/184) 
• Conventional FA extraction - 86% (158/184)/92% (170/184) 
Prospective evaluation of MALDI-TOF Between January 2012- 
January 2013 297 yeast isolates were identified by the diagnostic 
service using MALDI-TOF. 99.7% (296/297) isolates identified 
successfully using a log score >1.9. One isolate, Pichia fabianii, did not 
identify using MALDI-TOF MS requiring reference laboratory testing.  
Table 2. details the yeast species identified by the Bruker Biotyper™ in 
this study including retrospective and prospective isolates.  
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INTRODUCTION 
Early onset of appropriate antifungal treatment is associated with a reduction in 
morbidity and mortality in patients with Candidemia1. Reducing the time to 
identification of yeasts from blood cultures, currently 24-72 hours, could improve 
clinical outcome by influencing accurate choice of antifungal therapy earlier. 
The aim of this comparative study was to investigate three rapid laboratory 
techniques for the identification of yeasts directly from blood cultures in less than 
4 hours.  
Gram’s stain - Unique morphological characteristics of yeasts, e.g. true hyphae 
with C. albicans (Figure A), seen within gram’s stained blood films may be used to 
identify species. 
Peptide Nucleic Acid Fluorescent In – Situ Hybridisation (PNA-FISH) - PNA 
probes labelled with different fluorescent dyes complement species specific rRNA 
sequences for C. albicans, C. parapsilosis, C. glabrata, C. tropicalis and    C. 
krusei (Figure B).  
Matrix-assisted  laser desorption/ionization  time-of-flight  mass spectrometry 
(MALDI-TOF) is a technique measuring biomolecules, including proteins, from 
samples (Figure C). Spectra are matched against a library of reference spectra to 
identify unknown  organisms. 
METHODS 
Yeast Isolates; 50 yeast isolates previously implicated in Candidemia were 
selected and sub-cultured onto CHROMagar™ Candida (BD)  Identified was 
achieved by biochemical profiling using the Auxacolor2 system (BioRad). 
Simulated Blood Cultures; ~200 cfu inoculated into five-day negative blood 
culture bottles, were incubated until flagged positive (BD BacTec™). Sub-culture 
and Gram’s stain confirmed growth and purity.  
Gram’s stain; Blood smears were fixed and standard gram’s stain method was 
applied. Slides were analysed by a health care scientist experienced in examining 
yeast blood culture slides (4 months). An image gallery of 7 yeasts species was 
used as an identification aid.  
MALDI-TOF; Blood culture bottles were vortexed, 1ml aspirated and vortexed for 
5 minutes. Bruker Sepsityper™ kit was used for blood culture processing as per 
manufacturer’s instructions. The Bruker formic acid (FA) extraction protocol was 
used for protein extraction with a 15 minute FA incubation step. 1µl of analyte, 
inoculated onto the target in triplicates was overlaid with 1µl α-Cyano-4-hydroxy-
cinnamic-acid matrix. Spectra acquisition was performed on a Microflex™ LT 
platform (Bruker Daltonics) with FlexControl software (version 3.0) using default 
settings. Spectra analysis was performed using MALDI Flex analysis™ software 
analysing spectra in the 5000-15000 m/z range. Score thresholds; no reliable ID 
0.0-1.599, probable genus 1.6-1.8, secure genus, probable species 1.8 - 2.0, 
highly probable species >2.0.          
PNA FISH: The AdvanDX PNA Traffic Light™ assay was used as per 
manufacturers instructions. Green fluorescence - C. albicans/C. parapsilosis, red 
fluorescence - C. glabrata /C .krusei and yellow fluorescence  - C. tropicalis. 
(Figure B)  
*where	confidence	scores	secured	genus	iden fica on,	1.600-1.799,	the	correct	species	was	indicated	for	all	isolates.	
Table	2.	Isolates	missed	or	misiden fied	by	Gram’s	stain,	PNA-FISH	and	MALDI-TOF	
Yeast	species	 n	 Gram’s	stain										n	 PNA-FISH	 n	 MALDI-TOF					n	
C.	albicans		 17	 C.	tropicalis	 2	 -	 Missed		 4	
C.	parapsilosis	 1	 -	 Genus		 5	
Missed	 1	 -	
C.	tropicalis	 4	 C.	albicans	 1	 -	 Genus	 2	
C.	glabrata	 9	 C.	parapsilosis	 1	 -	 Missed		 3	
C.	krusei	 4	 C.	parapsilosis	 3	 -	
			C.	parapsilosis	 9	 C.	albicans	 1	 -	 Missed		 2	
C.	guillermondii	 2	 C.	glabrata	 1	 -	 Genus		 2	
C.	lusitaniae	 1	 C.	glabrata	 1	 -	 Missed	 1	
C.	pelliculosa	 1	 C.	glabrata	 1	 -	 Missed		 1	
C.	neoformans	 2	 -	 C.	glabrata	 1 Missed		 2	
B.	capitatus	 1 - C.	glabrata	 1 Genus		 1	
RESULTS 
Table 1 details the frequencies of classification, misclassification and non-
recognition for Gram’s stain, MALDI-TOF and PNA-FISH. Table 2 presents isolates 
missed or misidentified by Gram’s stain, PNA-FISH and MALDI-TOF 
CONCLUSIONS 
Gram’s stain is inexpensive, rapid and relatively successful. However, almost 25% 
of isolates were misidentified, including three C. krusei identified as C. parapsilosis, 
which would have had a significant impact on treatment choice.  
MALDI-TOF is cost effective, rapid and requires minimal technical ability. The assay 
also has the most extensive database including >100 species. Yet this approach 
lacks the sensitivity required from a diagnostic assay, most likely associated with 
inadequate protein extraction from yeasts.  
PNA-FISH was very successful at detecting yeast species targeted by the assay 
and requires little technical expertise. The assay is limited by the range of species it 
detects and at £70.00 per test is the most expensive.  
Until protein extraction methods are improved for MALDI-TOF, PNA-FISH is the 
most applicable method for rapid identification of yeasts from blood cultures.  
1) Tortorano AM et al Epidemiology of candidaemia in Europe: results of 28-month European Confederation of 
Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 23: 317-322. 2004 
Species	names	indicate	misiden fica ons,	‘Missed’		isolates	contained	within	the	database	but	not	
recognised,	‘Genus’		score	confirmed	genus	iden fica on	only	but	correct	species	were	indicated	for	all.	
Figure	A)	C.	albicans	gram	stain,	Figure	B)	PNA-FISH	with	C.	albicans,	C.	tropicalis	and	C.	
glabrata,	Figure	C)		MALDI-TOF	spectra	for	C.	glabrata.	
Table	3.	Cost,	turn	around	 me	and	technical	requirement	for	Gram’s	stain,	PNA-FISH	
and	MALDI-TOF	
Gram’s	stain	 PNA-FISH	 MALDI-TOF	
Cost	per	test	 £0.10*	 £70.00*	 £1.30*	
Turnaround	 me	 15	minutes	 90	minutes	 90	minutes	
Technical		requirement	 Experienced$	 Inexperienced&	 Inexperienced		
A	comparison	of	three	rapid	iden fica on	techniques	for	the	
iden fica on	of	yeasts	from	posi ve	blood	cultures:	Gram’s	
stain,	PNA-FISH	and	MALDI-TOF	
*Not	including		HCS	salary	costs,	$	Required	>	1	weeks	training,	&	Requires	≤	1	week	training.	
  
Table 3 details cost, turn around time and technical requirement for Gram’s stain, 
PNA-FISH and MALDI-TOF 
Table	2.	Frequencies	of	classifica on,	misclassifica on	and	non-recogni on	for	Gram’s	stain,	MALDI-TOF	and	PNA-FISH	
Subset	descrip on	 Classifica on	results	
Species	(n)	 Isolates	(n)	 %	of	total	 Correct	 Misclassified	 Unknown	 Success	rate	(%)	
(a)	Performance	total	
Gram’s		stain	 10	 50	 100.0	 36	 13	 1	 72	
PNA-FISH	 10	 50	 100.0	 43	 2	 5	 86	
MALDI-TOF	 10	 50	 100.0	 28	(38)*	 0	 12	 56	(76)*	
(b)	Performance	only	on	species	in	respec ve	method	database	
Gram’s		stain	 7	 47	 94	 36	 10	 1	 76.6	
PNA-FISH	 5	 43	 86	 43	 0	 0	 100	
MALDI-TOF	 10	 50	 100	 28	(38)*	 0	 9	 56	(76)*	
(c)	Performance	only	on	species	contained	in	all	three	databases	
Gram’s		stain	 5	 43	 86	 34	 8	 1	 79	
PNA-FISH	 5	 43	 86	 43	 0	 0	 100	
MALDI-TOF	 5	 43	 86	 26	(35)*	 0	 8	 60.4	(81.4)*	
(d)	Performance	total	(including	‘unknown’	as	the	correct	iden fica on	for	isolates	absent	from	the	database)	
Gram’s		stain	 10	 50	 100.0	 36	 13	 1	 72	
PNA-FISH	 10	 50	 100.0	 48	 2	 0	 96	
MALDI-TOF	 10	 50	 100.0	 28	(39)*	 0	 11	 56	(78)*	
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